Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors

ABSTRACT

Novel compounds of formula (I): 
                         
or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.

The present invention relates to novel pyrrolo(2,3-b)pyridinederivatives, to a process for preparing them, to their use as medicinalproducts, to pharmaceutical compositions containing them and to thepharmaceutical use of such derivatives for preventing and treatingconditions that may be modulated by inhibiting the activity of proteinkinases.

The present invention relates to novel pyrrolo(2,3-b)pyridinederivatives that have inhibitory effects on protein kinases.

The compounds of the present invention may thus be used in particularfor preventing or treating conditions that may be modulated byinhibiting the activity of protein kinases.

The inhibition and regulation of protein kinases in particularconstitute a powerful new mechanism of action for treating a largenumber of solid tumors.

Such conditions that can be treated by the compounds of the presentapplication are therefore most particularly solid tumors.

Such protein kinases belong in particular to the following group:

-   IGF1, Raf, EGF, PDGF, VEGF, Tie2, KDR, Fltl-3, FAK, Src, Abl, cKit,    cdk1-9, Aurora 1-2, cdc7, Akt, Pdk, S6K, Jnk, IR, FLK-1, FGFR1,    FGFR2, FGFR3, FGFR4, FGFR5, PLK, Pyk2

Such protein kinases belong more particularly to the following group:IGF1, cdc7, Aurora 1-2, Src, Jnk, FAK, KDR, IR, Tie2

The protein kinase IGF1 (Insulin Growth Factor-1) is particularlyindicated.

The present invention thus relates particularly to novel inhibitors ofthe IGF-1R receptor which can be used for oncology treatments.

Cancer remains a disease for which the existing treatments are clearlyinsufficient. Certain protein kinases play an important role in manycancers. The inhibition of such protein kinases is potentially importantin the chemotherapy of cancers, in particular for suppressing tumorgrowth or survival. The present invention therefore relates to theidentification of novel compounds which inhibit such protein kinases.

Protein kinases participate in signaling events that control theactivation, growth and differentiation of cells in response either toextracellular mediators or to changes in the environment. In general,these kinases belong to two groups: those which preferentiallyphosphorylate serine and/or threonine residues and those whichpreferentially phosphorylate tyrosine residues [S. K. Hanks and T.Hunter, FASEB, J., 1995, 9, pages 576-596]. Serine/threonine kinasesare, for example, the isoforms of the protein kinases C [A. C. Newton,J. Biol. Chem., 1995, 270, pages 28495-28498] and a group ofcycline-dependent kinases, such as cdc2 [J. Pines, Trends in BiochemicalSciences, 1995, 18, pages 195-197]. Tyrosine kinases comprise growthfactor receptors, such as the epidermal growth factor (EGF) receptor [S.Iwashita and M. Kobayashi, Cellular Signalling, 1992, 4, pages 123-132],and cytosolic kinases such as p56tck, p59fYn, ZAP-70 and the csk kinases[C. Chan et al., Ann. Rev. Immunol., 1994, 12, pages 555-592].

Abnormally high levels of protein kinase activity have been implicatedin many diseases, resulting from abnormal cellular functions. This mayarise either directly or indirectly from a dysfunction in the mechanismscontrolling the kinase activity, linked, for example, to a mutation, anoverexpression or an inappropriate activation of the enzyme, or an over-or underproduction of cytokines or of growth factors, also involved intransduction of the signals upstream or downstream of the kinases. Inall these cases, selective inhibition of the action of the kinasesoffers hope of a beneficial effect.

The type 1 receptor for insulin-like growth factor (IGF-I-R) is atransmembrane receptor with tyrosine kinase activity which binds firstlyto IGFI, but also to IGFII and to insulin with lower affinity. Thebinding of IGFI to its receptor results in oligomerization of thereceptor, activation of the tyrosine kinase, intermolecularautophosphorylation and phosphorylation of cell substrates (mainsubstrates: IRS1 and Shc). The receptor activated by its ligand inducesmitogenic activity in normal cells. However, IGF-I-R plays an importantrole in “abnormal” growth.

Several clinical reports underline the important role of the IGF-Ipathway in the development of human cancers:

IGF-I-R is often found to be overexpressed in many tumor types (breast,colon, lung, sarcoma, etc.) and its presence is often associated with amore aggressive phenotype.

High concentrations of circulating IGF1 are strongly correlated with arisk of prostate cancer, lung cancer and breast cancer.

In addition, it has been widely documented that IGF-I-R is necessary forestablishing and maintaining the transformed phenotype in vitro as invivo [Baserga R, Exp. Cell, Res., 1999, 253, 253, pages 1-6]. The kinaseactivity of IGF-I-R is essential to the transforming activity of severaloncogenes: EGFR, PDGFR, SV40 virus large T antigen, activated Ras, Raf,and v-Src. The expression of IGF-I-R in normal fibroblasts induces aneoplastic phenotype, which may then result in the formation of a tumorin vivo. The expression of IGF-I-R plays an important role insubstrate-independent growth. IGF-I-R has also been shown to be aprotector in chemotherapy-induced and radiation-induced apoptosis, andcytokine-induced apoptosis. In addition, the inhibition of endogenousIGF-I-R by means of a dominant negative, the formation of a triple helixor the expression of an antisense brings about suppression of thetransforming activity in vitro and reduction of tumor growth in animalmodels.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 (Scheme 1) describes a pathway “A” for obtaining the compounds offormula (I): 2-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine.

FIG. 2 (Scheme 2) describes a pathway “B” for obtaining the compounds offormula (I): 2-(indol-3-yl)-1H-pyrrolo[2,3-b]pyridine.

FIG. 3 (Scheme 3) describes pathways for introducing substituents in theR1 position, in the synthesis of the compounds of formula (I) of thepresent invention.

FIG. 4 (Scheme 4) describes pathways for introducing substituents in theR3 position, in the synthesis of the compounds of formula (I) of thepresent invention.

FIG. 5 (Scheme 5) describes a synthetic route for gaining access to the2-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carboxaldehydederivatives.

FIG. 6 (Scheme 6) describes a synthetic route for introducingsubstituents R4 into the compounds of formula (I).

A subject of the present invention is the compounds of formula (I):

in which:

-   R represents hydrogen or is selected from the values of R2 and R3,-   R1 represents alkenyl or alkyl optionally substituted with    —CO—NR7R8, —NR7R8, free or esterified carboxyl, hydroxyl, alkoxy or    a halogen atom,-   R2 and R3, which may be identical or different, represent alkyl or    —O-alkyl optionally substituted with —CO—NR7R8,-   —NR7R8, alkoxy, alkoxy-NR7R8, free or esterified carboxyl, or    phenyl, which is itself optionally substituted,-   R4, R5 and R6, which may be identical or different, are selected    from a hydrogen atom, halogen atoms and cyano, amino, and optionally    substituted alkoxy or alkyl radicals, R4 also possibly being    selected from the following values: carboxaldehyde —CH═O,    formaldoxime —CH═N—OH and methylhydroxylamine —CH2NHOH;-   R7 and R8, which may be identical or different, are selected from    hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl,    heterocycloalkyl, aryl and heteroaryl, which may be monocyclic or    bicyclic, all these radicals being optionally substituted, or    alternatively R7 and R8 form, with the nitrogen atom to which they    are attached, an unsaturated or partially or totally saturated 3- to    10-membered heterocyclic radical containing one or more hetero atoms    selected from O, S, N and NR14, this radical being optionally    substituted,-   all the above alkyl, alkenyl, cycloalkyl, cycloalkenyl,    heterocycloalkyl, aryl and heteroaryl radicals, which may be    monocyclic or bicyclic, and also the heterocyclic radical formed by    R7 and R8 with the nitrogen atom to which they are attached, being    optionally substituted with one or more radicals, which may be    identical or different, selected from halogen atoms and cyano,    hydroxyl, alkyl, alkoxy, alkylthio, nitro, oxo, cycloalkyl,    heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,    heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, —C(═O)—R9,    —C(═O)—OR10,-   —N(R11)-C(═O)—R9, —N(R11)-C(═O)—OR10, —NR12R13, —C(═O)—NR12R13,    —N(R11)-C(═O)—NR12R13, —S(O)n-R9, —N(R11)-S(O)n-R9, —S(O)n-NR12R13    and —N(R11)-S(O)n-NR12R13 radicals,-   n represents an integer from 0 to 2,-   the latter alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl,    heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl and    heteroarylalkyl radicals themselves being optionally substituted    with one or more radicals, which may be identical or different,    selected from halogen atoms and hydroxyl, alkyl, alkoxy, —NR12R13,    free or esterified carboxyl, CF3, nitro, cyano, phenyl and    phenylalkyl radicals in which the phenyl radical is itself    optionally substituted with one or more radicals, which may be    identical or different, selected from halogen atoms and hydroxyl,    alkyl, alkoxy, free or esterified carboxyl, CF3, nitro, cyano and    pyridyl radicals;-   R9 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl,    heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl and    heteroarylalkyl, all these radicals being optionally substituted,-   R10 represents the values of R9 and hydrogen,-   R11 represents hydrogen or optionally substituted alkyl,-   R12 and R13, which may be identical or different, represent    hydrogen, acyl, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl,    SO2-heteroaryl, —SO2-alkyl, —SO2-phenyl, —CO—NH-phenyl and phenyl    radicals, all these radicals being optionally substituted,-   or alternatively R12 and R13 form, with the nitrogen atom to which    they are attached, an unsaturated or partially or totally saturated    3- to 10-membered heterocyclic radical containing one or more hetero    atoms selected from O, S, N and NR14, this radical being optionally    substituted,-   R14 represents the values of R9 and hydrogen, acyl and free and    esterified carboxyl,-   the radicals R9, R10, R11, R12, R13 and R14 above, and also the    cyclic radical that may be formed by R12 and R13 with the nitrogen    atom to which they are attached, being optionally substituted with    one or more radicals, which may be identical or different, selected    from halogen atoms and alkyl, alkyl-NH2, alkyl-NHCO2alkyl, NH2,    NHCO2alkyl, hydroxyl, alkoxy, hydroxyalkoxy, free or esterified    carboxyl, CF3, SCF3, OCF3, OCHF2, SO2CF3, nitro, cyano,    heterocycloalkyl, heteroaryl and phenyl radicals, the latter cyclic    radicals themselves being optionally substituted with one or more    radicals, which may be identical or different, selected from halogen    atoms and alkyl, hydroxyl, alkoxy, free or esterified carboxyl, CF3,    SCF3, OCF3, OCHF2, SO2CF3, NH2, NHCO2alkyl, nitro and cyano    radicals,-   all the above aryl, heteroaryl and heterocycloalkyl radicals    moreover being optionally substituted with an alkylenedioxy radical,-   all the above alkyl, alkenyl, alkoxy or —O-alkyl and alkylthio    radicals being linear or branched and containing no more than 6    carbon atoms,-   all the above cycloalkyl radicals containing no more than 7 carbon    atoms,-   all the above aryl, heteroaryl and heterocycloalkyl radicals    containing no more than 10 carbon atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which:

-   R represents hydrogen or is selected from the values of R2 and R3,-   R1 represents alkenyl or alkyl optionally substituted with    —CO—NR7R8, —NR7R8, free or esterified carboxyl, hydroxyl, alkoxy or    a halogen atom,-   R2 and R3, which may be identical or different, represent alkyl or    —O-alkyl optionally substituted with —CO—NR7R8,-   —NR7R8, alkoxy, alkoxy-NR7R8, free or esterified carboxyl, or    phenyl, which is itself optionally substituted,-   R4, R5 and R6, which may be identical or different, are selected    from a hydrogen atom, halogen atoms and cyano, amino, and optionally    substituted alkoxy or alkyl radicals, R4 also possibly being    selected from the following values: carboxaldehyde —CH═O,    formaldoxime —CH═N—OH and methylhydroxylamine —CH2NHOH;-   R7 and R8, which may be identical or different, are selected from    hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl,    heterocycloalkyl, aryl and heteroaryl, which may be monocyclic or    bicyclic, all these radicals being optionally substituted, or    alternatively R7 and R8 form, with the nitrogen atom to which they    are attached, an unsaturated or partially or totally saturated 3- to    10-membered heterocyclic radical containing one or more hetero atoms    selected from O, S, N and NR14, this radical being optionally    substituted,-   all the above alkyl, alkenyl, cycloalkyl, cycloalkenyl,    heterocycloalkyl, aryl and heteroaryl radicals, which may be    monocyclic or bicyclic, and also the heterocyclic radical formed by    R7 and R8 with the nitrogen atom to which they are attached, being    optionally substituted with one or more radicals, which may be    identical or different, selected from halogen atoms and cyano,    hydroxyl, alkyl, alkoxy, alkylthio, nitro, oxo, cycloalkyl,    heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,    heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, —C(═O)—R9,    —C(═O)—OR10, —N(R11)-C(═O)—R9, —N(R11)-C(═O)—OR10, —NR12R13,    —C(═O)—NR12R13, —N(R11)-C(═O)—NR12R13, —S(O)n-R9, —N(R11)-S(O)n-R9,    —S(O)n-NR12R13 and —N(R11)-S(O)n-NR12R13 radicals,-   n represents an integer from 0 to 2,-   the latter alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl,    heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl and    heteroarylalkyl radicals themselves being optionally substituted    with one or more radicals, which may be identical or different,    selected from halogen atoms and hydroxyl, alkyl, alkoxy, —NR12R13,    free or esterified carboxyl, CF3, nitro, cyano, phenyl and    phenylalkyl radicals in which the phenyl radical is itself    optionally substituted with one or more radicals, which may be    identical or different, selected from halogen atoms and hydroxyl,    alkyl, alkoxy, free or esterified carboxyl, CF3, nitro, cyano and    pyridyl radicals;-   R9 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl,    heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl and    heteroarylalkyl, all these radicals being optionally substituted,-   R10 represents the values of R9 and hydrogen,-   R11 represents hydrogen or optionally substituted alkyl,-   R12 and R13, which may be identical or different, represent    hydrogen, acyl, alkyl, cycloalkyl, piperidyl, piperazinyl,    pyrrolidinyl, azetidinyl, pyrazolyl, pyridyl, imidazolyl, pyrimidyl,    thiazolyl, thiazolidinyl, —SO2-thienyl, —SO2-pyridyl, —SO2-alkyl,    —SO2-phenyl, —CO—NH-phenyl and phenyl radicals, all these radicals    being optionally substituted,-   or alternatively R12 and R13 form, with the nitrogen atom to which    they are attached, an unsaturated or partially or totally saturated    3- to 10-membered heterocyclic radical containing one or more hetero    atoms selected from O, S, N and NR14, this radical being optionally    substituted,-   R14 represents the values of R9 and hydrogen, acyl and free and    esterified carboxyl,-   the radicals R9, R10, R11, R12, R13 and R14 above, and also the    cyclic radical that may be formed by R12 and R13 with the nitrogen    atom to which they are attached, being optionally substituted with    one or more radicals, which may be identical or different, selected    from halogen atoms and alkyl, —CH2-NH2, —CH2-NHCO2alkyl, NH2,    NHCO2alkyl, hydroxyl, alkoxy, hydroxyalkoxy, free or esterified    carboxyl, CF3, SCF3, OCF3, OCHF2, SO2CF3, nitro, cyano, piperidyl,    morpholinyl, piperazinyl, thienyl, pyridyl, imidazolyl, thiazolyl,    thiazolidinyl and phenyl radicals, the latter cyclic radicals    themselves being optionally substituted with one or more radicals,    which may be identical or different, selected from halogen atoms and    alkyl, hydroxyl, alkoxy, free or esterified carboxyl, CF3, SCF3,    OCF3, OCHF2, SO2CF3, NH2, NHCO2alkyl, nitro and cyano radicals,-   all the above aryl, heteroaryl and heterocycloalkyl radicals    moreover being optionally substituted with an alkylenedioxy radical,-   all the above alkyl, alkenyl, alkoxy or —O-alkyl and alkylthio    radicals being linear or branched and containing no more than 6    carbon atoms,-   all the above cycloalkyl radicals containing no more than 7 carbon    atoms,-   all the above aryl, heteroaryl and heterocycloalkyl radicals    containing no more than 10 carbon atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is the compounds of formula (I):

in which:

-   R represents hydrogen or is selected from the values for R2 and R3,-   R1 represents alkenyl or alkyl optionally substituted with    —CO—NR7R8, —NR7R8, free or esterified carboxyl, hydroxyl, alkoxy or    a halogen atom,-   R2 and R3, which may identical or different, represent alkyl or    —O-alkyl optionally substituted with —CO—NR7R8, —NR7R8, hydroxyl,    alkoxy, alkoxy-NR7R8, free or esterified carboxyl, or phenyl which    is itself optionally substituted,-   R4, R5 and R6, which may be identical or different, are selected    from the hydrogen atom, the halogen atoms and the radicals: cyano,    amino, alkoxy or alkyl, which is optionally substituted,-   R7 and R8, which may be identical or different, are selected from    hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl,    heterocycloalkyl, aryl and heteroaryl, which may be monocyclic or    bicyclic, all these radicals being optionally substituted, or    alternatively R7 and R8 form, with the nitrogen atom to which they    are attached, an unsaturated or partially or totally saturated    heterocyclic radical consisting of 3 to 10 ring members and    containing one or more hetero atoms selected from O, S, N and NR14,    this radical being optionally substituted,-   all the above radicals: alkyl, alkenyl, cycloalkyl, cycloalkenyl,    heterocycloalkyl, aryl and heteroaryl, which may be monocyclic or    bicyclic, and also the heterocyclic radical formed by R7 and R8 with    the nitrogen atom to which they are attached, being optionally    substituted with one or more radicals, which may be identical or    different, selected from the halogen atoms and the radicals: cyano,    hydroxyl, alkyl, alkoxy, alkylthio, nitro, oxo, cycloalkyl,    heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,    heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, —C(═O)—R9,    —C(═O)—OR10, —N(R11)-C(═O)—R9, —N(R11)-C(═O)—OR10, —NR12R13,    —C(═O)—NR12R13, —N(R11)-C(═O)—NR12R13, —S(O)n-R9, —N(R11)-S(O)n-R9,    —S(O)n-NR12R13 and —N(R11)-S(O)n-NR12R13,-   n represents an integer from 0 to 2,-   the latter alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl,    heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl and    heteroarylalkyl radicals themselves being optionally substituted    with one or more radicals, which may be identical or different,    selected from the halogen atoms and the radicals: hydroxyl, alkyl,    alkoxy, —NR12R13, free or esterified carboxyl, CF₃, nitro, cyano,    pyrrolidinyl, and phenyl and phenylalkyl in which the phenyl radical    is itself optionally substituted with one or more radicals, which    may be identical or different, selected from the halogen atoms and    the radicals: hydroxyl, alkyl, alkoxy, free or esterified carboxyl,    CF₃, nitro, cyano and pyridyl,-   R9 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl,    heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and    heteroarylalkyl, all these radicals being optionally substituted,-   R10 represents the values of R9 and hydrogen,-   R11 represents hydrogen or optionally substituted alkyl,-   R12 and R13, which may be identical or different, represent    hydrogen, acyl, alkyl, cycloalkyl and phenyl, these radicals being    optionally substituted,

or alternatively R12 and R13 form, with the nitrogen atom to which theyare attached, an unsaturated or partially or totally saturatedheterocyclic radical consisting of 3 to 10 ring members and containingone or more hetero atoms selected from O, S, N and NR14, the radicalbeing optionally substituted,

-   R14 represents the values for R9 and hydrogen, acyl and free and    esterified carboxyl,-   the radicals R9, R10, R11, R12, R13 and R14 above being optionally    substituted with one or more radicals, which may be identical or    different, selected from the halogen atoms and the radicals: alkyl,    hydroxyl, alkoxy, hydroxyalkoxy, free or esterified carboxyl, CF₃,    nitro, cyano and phenyl, itself optionally substituted with one or    more radicals, which may be identical or different, selected from    the halogen atoms and the radicals: alkyl, hydroxyl, alkoxy, free or    esterified carboxyl, CF₃, nitro and cyano,-   all the aryl, heteroaryl and heterocycloalkyl radicals above being,    in addition, optionally substituted with an alkylenedioxy radical,-   all the alkyl, alkenyl, alkoxy or —O-alkyl and alkylthio radicals    above being linear or branched and containing no more than 6 carbon    atoms,-   all the cycloalkyl radicals above containing no more than 7 carbon    atoms,-   all the aryl, heteroaryl and heterocycloalkyl radicals above    containing no more than 10 carbon atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R2 and R3, whichmay be identical or different, represent —O-alkyl containing no morethan 4 carbon atoms, optionally substituted with —CO—NR7R8, —NR7R8,alkoxy, alkoxy-NR7R8 or free or esterified carboxyl,

-   the other substituents of said compounds of formula (I) having the    values defined above in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R2 and R3, whichmay be identical or different, represent —O-alkyl containing no morethan 4 carbon atoms, optionally substituted with —CO—NR7R8, —NR7R8,alkoxy, alkoxy-NR7R8,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R2 and R3, whichmay be identical or different, represent —O-alkyl containing at most 4carbon atoms, optionally substituted with —CO—NR7R8 or —NR7R8,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R1 representsalkyl optionally substituted with —CO—NR7R8, —NR7R8, free or esterifiedcarboxyl, hydroxyl, alkoxy, or a halogen atom,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R1 representsalkyl containing no more than 4 carbon atoms, optionally substitutedwith —CO—NR7R8, —NR7R8, free or esterified carboxyl, or hydroxyl,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R1 representsalkyl containing no more than 4 carbon atoms, optionally substitutedwith —CO—NR7R8, —NR7R8 or hydroxyl,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined in any one of the other claims, in which R1 represents alkylcontaining no more than 4 carbon atoms, optionally substituted with—CO—NR7R8 or —NR7R8, the other substituents of said compounds of formula(I) having the values defined above and in the present invention,

-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R1 representsalkyl containing no more than 4 carbon atoms, optionally substitutedwith NR7R8,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which:

-   R4, R5 and R6 are such that one represents hydrogen and the others,    which may be identical or different, are selected from the hydrogen    atom, the halogen atoms and the radicals: cyano, amino or alkyl    which may be optionally substituted,-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4, R5 and R6are such that R5 and R6, which may be identical or different, areselected from a hydrogen atom and halogen atoms,

and R4, which may be identical to or different from R5 and R6, isselected from halogen atoms and amino, carboxaldehyde —CH═O,formaldoxime —CH═N—OH, methylhydroxylamine —CH2NHOH and alkyl radicals,optionally substituted with one or more radicals, which may be identicalor different, selected from halogen atoms and cyano, hydroxyl, alkoxy,cycloalkyl, heterocycloalkyl, phenyl, heteroaryl and —NR12R13 radicals;

-   R, R1, R2, R3, R12 and R13 having the values defined in any one of    the other claims,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which:

-   R4, R5 and R6 represent hydrogen or are such that two of them    represent hydrogen and the third represents a halogen atom or the    cyano radical,-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4, R5 and R6represent hydrogen, the other substituents of said compounds of formula(I) having the values defined above and in the present invention,

-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4, R5 and R6are such that two of them represent hydrogen and the third represents ahalogen atom or the cyano radical,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4, R5 and R6are such that two of them represent hydrogen and the third represents ahalogen atom,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4, R5 and R6are such that two of them represent hydrogen and the third represents achlorine or fluorine atom,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4, R5 and R6are such that two of them represent hydrogen and the third representsthe cyano radical,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R6 representshydrogen,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R5 and R6represent hydrogen and R4 represents a halogen atom or the cyanoradical,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R4 and R6represent hydrogen and R5 represents a fluorine atom,

-   the other substituents of said compounds of formula (I) having the    values defined above and in the present invention,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

In the compounds of formula (I) and in the following text, the termsindicated have the following meanings:

-   -   the term “Hal”, “Halo” or “halogen” denotes fluorine, chlorine,        bromine or iodine atoms;    -   the term “alkyl radical” or “alk radical” denotes a linear or        branched radical containing no more than 12 carbon atoms,        selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl,        sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl,        tert-pentyl, neopentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl        and also heptyl, octyl, nonyl, decyl, undecyl and dodecyl        radicals, and also the linear or branched positional isomers        thereof.

Mention is made more particularly of alkyl radicals having no more than6 carbon atoms, and in particular methyl, ethyl, propyl, isopropyl,n-butyl, isobutyl, tert-butyl, linear or branched pentyl and linear orbranched hexyl radicals;

-   -   the term “alkylene radical”, denotes a linear or branched        radical containing no more than 12 carbon atoms, and preferably        4 carbon atoms, selected, for example, from the following        values: ethenyl or vinyl, propenyl or allyl, 1-propenyl,        n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, hexenyl,        heptenyl, octenyl, cyclohexylbutenyl and decenyl, and also the        linear or branched positional isomers thereof.

Among the alkenyl values, mention may be made more particularly of theallyl or butenyl values:

-   -   the term “alkoxy radical” or “O-alkyl radical” denotes a linear        or branched radical containing no more than 12 carbon atoms, and        preferably 6 carbon atoms, selected, for example, from methoxy,        ethoxy, propoxy, isopropoxy, linear, secondary or tertiary        butoxy, pentoxy, hexoxy and heptoxy radicals, and also the        linear or branched positional isomers thereof;    -   the term “alkoxycarbonyl radical”, or “alkyl-O—CO— radical”,        denotes a linear or branched radical containing no more than 12        carbon atoms, in which the alkyl radical has the meaning given        above; mention may be made, for example, of methoxycarbonyl and        ethoxycarbonyl radicals;    -   the term “alkylenedioxy radical” or “—O-alkylene-O— radical”        denotes a linear or branched radical containing no more than 12        carbon atoms, in which the alkylene radical has the meaning        given above; mention may be made, for example, of methylenedioxy        and ethylenedioxy radicals;    -   the term “alkylsulfinyl” or “alkyl-SO—” denotes a linear or        branched radical containing no more than 12 carbon atoms, in        which the alkyl radical has the meaning given above and        preferably contains 4 carbon atoms;    -   the term “alkylsulfonyl” or “alkyl-SO₂-” denotes a linear or        branched radical containing no more than 12 carbon atoms, in        which the alkyl radical has the meaning given above and        preferably contains 4 carbon atoms;    -   the term “alkylsulfonylcarbamoyl” or “alkyl-SO₂—NH—C(═O)-”        denotes a linear or branched radical containing no more than 12        carbon atoms, in which the alkyl radical has the meaning given        above and preferably contains 4 carbon atoms;    -   the term “alkylthio” or “alkyl-S-” denotes a linear or branched        radical containing no more than 12 carbon atoms and represents        in particular methylthio, ethylthio, isopropylthio and        heptylthio radicals;    -   the term “cycloalkyl radical” denotes a 3- to 10-membered        monocyclic or bicyclic carbocyclic radical and denotes in        particular cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl        radicals;    -   the term “—O-cycloalkyl radical” denotes a radical in which the        cycloalkyl radical has the meaning given above;    -   the term “cycloalkenyl radical” denotes a monocyclic or bicyclic        nonaromatic carbocyclic radical containing at least one double        bond and having from 3 to 10 ring members, and denotes in        particular cyclobutenyl, cyclopentenyl or cyclohexenyl radicals;    -   the term “cycloalkylalkyl radical” denotes a radical in which        the cycloalkyl and alkyl are selected from the values indicated        above; this radical thus denotes, for example,        cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and        cycloheptylmethyl radicals;    -   the term “acyl radical” or “r-CO— radical” denotes a linear or        branched radical containing no more than 12 carbon atoms, in        which the radical r represents a hydrogen atom or an alkyl,        cycloalkyl, cycloalkenyl, cycloalkyl, heterocycloalkyl, aryl or        heteroaryl radical, these radicals having the optionally        substituted values indicated above and hereinafter; thus, the        acyl radical represents in particular CO-alkyl, CO-aryl or        CO-heteroaryl. Mention may be made, for example, of formyl,        acetyl, propionyl, butyryl or benzoyl radicals, or else valeryl,        hexanoyl, acryloyl, crotonoyl, carbamoyl, pyrrolidinylcarboxyl        or furylcarboxyl radicals;    -   the term “acyloxy radical” is intended to mean acyl-O-radicals        in which acyl has the meaning given above; mention may be made,        for example, of acetoxy or propionyloxy radicals;    -   the term “acylamino radical” is intended to mean acyl-NH        radicals in which acyl has the meaning given above;    -   the term “aryl radical” denotes unsaturated monocyclic radicals        or unsaturated radicals consisting of fused carbocyclic rings.        As examples of such aryl radicals, mention may be made of phenyl        or naphthyl radicals.

Mention is more particularly made of the phenyl radical.

-   -   The term “arylalkyl” is intended to mean radicals resulting from        the combination of the optionally substituted alkyl radicals        mentioned above and the optionally substituted aryl radicals        also mentioned above; mention may be made, for example, of        benzyl, phenylethyl, 2-phenylethyl, triphenylmethyl or        naphthalenemethyl radicals;    -   the term “heterocyclic radical” denotes a saturated carbocyclic        radical (heterocycloalkyl) or unsaturated carbocyclic radical        (heteroaryl) which is at most 6-membered, interrupted with one        or more hetero atoms, which may be identical or different,        selected from oxygen, nitrogen and sulfur atoms.

Heterocycloalkyl radicals which may be in particular be mentionedinclude dioxolane, dioxane, dithiolane, thiooxolane, thiooxane,oxiranyl, oxolanyl, dioxolanyl, piperazinyl, piperidyl, pyrrolidyl,imidazolidinyl, pyrazolidinyl, morpholinyl, or tetrahydrofuryl,tetrahydrothienyl, chromanyl, dihydrobenzofuranyl, indolinyl, piperidyl,perhydropyranyl, pyrindolinyl, tetrahydroquinolyl, tetrahydroisoquinolylor thio-azolidinyl, piperidyl, tetrahydrofuran-2-yl, imidazolinyl,dihydropyrrolyl, tetrahydropyrrolyl, diazepine, perhydro-1,4-diazepine,tetrahydropyrrolo[3,4-c]pyrrol-2-one,tetrahydropyrrolo[3,4-c]pyrrol-1,3-dione and1,4-dioxa-8-azaspiro[4.5]decane radicals, all these radicals beingoptionally substituted.

Among the heterocycloalkyl radicals, mention may in particular be madeof piperazinyl, piperidyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl,morpholinyl, thioazolidinyl, piperidyl radicals; tetrahydrofuran-2-yl,imidazolinyl, dihydropyrrolyl, tetrahydropyrrolyl, diazepine,perhydro-1,4-diazepine, tetrahydropyrrolo[3,4-c]pyrrol-2-one,tetrahydropyrrolo-[3,4-c]pyrrol-1,3-dione and1,4-dioxa-8-azaspiro[4.5]decane radicals, all these radicals beingoptionally substituted.

-   -   The term “heterocycloalkylalkyl radical” is intended to mean        radicals in which the heterocycloalkyl and alkyl residues have        the above meanings.

Among the 5-membered heteroaryl radicals, mention may be made of furylradicals such as 2-furyl, thienyl radicals such as 2-thienyl and3-thienyl, and pyrrolyl, diazolyl, thiazolyl, thiadiazolyl,thiatriazolyl, isothiazolyl, oxazolyl, oxadiazolyl, 3- or 4-isoxazolyl,imidazolyl, pyrazolyl and isoxazolyl radicals.

Among the 6-membered heteroaryl radicals, mention may in particular bemade of pyridyl radicals such as 2-pyridyl, 3-pyridyl and 4-pyridyl, andpyrimidyl, pyrimidinyl, pyridazinyl, pyrazinyl and tetrazolyl radicals.

As fused heteroaryl radicals containing at least one hetero atomselected from sulfur, nitrogen and oxygen, mention may be made, forexample, of benzothienyl such as 3-benzothienyl, benzofuryl,benzopyranyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl,thionaphthyl, indolyl, purinyl, quinolyl, isoquinolyl andnaphthyridinyl.

Among the fused heteroaryl radicals, mention may be made moreparticularly of benzothienyl, benzofuranyl, indolyl, quinolyl,benzimidazolyl, benzothiazolyl, furyl, imidazolyl, indolizinyl,isoxazolyl, isoquinolyl, isothiazolyl, oxadiazolyl, pyrazinyl,pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl,1,3,4-thiadiazolyl, thiazolyl, and thienyl radicals and triazolylgroups, these radicals being optionally substituted as indicated for theheteroaryl radicals.

-   -   the term “cyclic amine” denotes 3- to 8-membered cycloalkyl        radical in which one carbon atom is replaced with a nitrogen        atom, the cycloalkyl radical having the meaning given above and        also possibly containing one or more other hetero atoms selected        from O, S, SO₂, N or NR9 with R9 as defined above; as examples        of such cyclic amines, mention may be made, for example, of        pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, indolinyl,        pyrindolinyl and tetrahydroquinolyl radicals, these radicals        being optionally substituted.

The term “patient” denotes human beings, but also other mammals.

The term “prodrug” denotes a compound which may be converted in vivo viametabolic mechanisms (such as hydrolysis) into a compound of formula(I). For example, an ester of a compound of formula (I) containing ahydroxyl group may be converted by hydrolysis in vivo into its parentmolecule. Alternatively, an ester of a compound of formula (I)containing a carboxyl group may be converted by hydrolysis in vivo intoits parent molecule.

Examples of esters of compounds of formula (I) containing a hydroxylgroup which may be mentioned include the acetates, citrates, lactates,tartrates, malonates, oxalates, salicylates, propionates, succinates,fumarates, maleates, methylenebis-beta-hydroxynaphthoates, gentisates,isethionates, di-p-tolyltartrates, methanesulfonates, ethanesulfonates,benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates andquinates.

Esters of compounds of formula (I) which are particularly useful,containing a hydroxyl group, may be prepared from acid residues such asthose described by Bundgaard et al., J. Med. Chem., 1989, 32, page2503-2507; these esters include in particular substituted(aminomethyl)benzoates, dialkylaminomethylbenzoates in which the twoalkyl groups may be linked together or may be interrupted with an oxygenatom or with an optionally substituted nitrogen atom, i.e. an alkylatednitrogen atom, or alternatively (morpholinomethyl)benzoates, e.g. 3- or4-(morpholinomethyl)benzoates, and (4-alkylpiperazin-1-yl)benzoates,e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

The carboxyl radical(s) of the compounds of formula (I) may be salifiedor esterified with various groups known to those skilled in the art,among which mention may be made, as non-limiting examples, of thefollowing compounds:

-   -   among the salification compounds, mineral bases such as, for        example, one equivalent of sodium, potassium, lithium, calcium,        magnesium or ammonium, or organic bases such as, for example,        methylamine, propylamine, trimethylamine, diethylamine,        triethylamine, N,N-dimethylethanolamine,        tris(hydroxymethyl)-aminomethane, ethanolamine, pyridine,        picoline, dicyclohexylamine, morpholine, benzylamine, procaine,        lysine, arginine, histidine or N-methylglucamine,    -   among the esterification compounds, alkyl radicals to form        alkoxycarbonyl groups such as, for example, methoxycarbonyl,        ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these        alkyl radicals possibly being substituted with radicals        selected, for example, from halogen atoms, and hydroxyl, alkoxy,        acyl, acyloxy, alkylthio, amino or aryl radicals, such as, for        example, in chloromethyl, hydroxypropyl, methoxymethyl,        propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl        or phenethyl groups.

The term “esterified carboxyl” is intended to mean, for example,radicals such as alkyloxycarbonyl radicals, for example methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, butyl or tert-butyloxycarbonyl,cyclobutyloxycarbonyl, cyclopentyloxycarbonyl or cyclohexyloxycarbonyl.

Mention may also be made of radicals formed with readily cleavable esterresidues, such as methoxymethyl or ethoxymethyl radicals; acyloxyalkylradicals such as pivaloyloxymethyl, pivaloyloxyethyl, acetoxymethyl oracetoxyethyl; alkyloxycarbonyloxy alkyl radicals such asmethoxycarbonyloxy methyl or ethyl radicals, and isopropyloxycarbonyloxymethyl or ethyl radicals.

A list of such ester radicals may be found, for example, in Europeanpatent EP 0 034 536.

The term “amidated carboxyl” is intended to mean radicals of the type—CONR7R8 as defined above or hereinafter.

The term “alkylamino radical” or “dialkylamino radical” is intended tomean radicals in which the alkyl radical(s) preferably contain(s) 1 to 4carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl or tert-butyl radicals; this gives, for example, methylamino,ethylamino, propylamino or butylamino radicals, which may be linear orbranched, and dimethylamino, diethylamino and methylethylamino radicals.

The amino radicals may also contain one or two heterocycles which mayoptionally contain an additional hetero atom. Mention may be made, forexample, of pyrrolyl, imidazolyl, indolyl, piperidyl, morpholinyl andpiperazinyl radicals, and particularly piperidyl, morpholinyl orpiperazinyl radicals.

The term “salified carboxyl” is intended to mean the salts formed, forexample, with one equivalent of sodium, potassium, lithium, calcium,magnesium or ammonium. Mention may also be made of the salts formed withorganic bases such as methylamine, propylamine, trimethylamine,diethylamine or triethylamine. The sodium salt is preferred.

When the compounds of formula (I) comprise an amino radical that may besalified with an acid, it is clearly understood that these acid saltsalso form part of the invention. Mention may be made of the saltsobtained, for example, with hydrochloric acid or methanesulfonic acid.

The addition salts with mineral or organic acids of the compounds offormula (I) may be, for example, the salts formed with hydrochloricacid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid,phosphoric acid, propionic acid, acetic acid, trifluoroacetic acid,formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid,tartaric acid, citric acid, oxalic acid, glyoxylic acid, aspartic acid,ascorbic acid, alkylmonosulfonic acids such as, for example,methanesulfonic acid, ethanesulfonic acid or propanesulfonic acid,alkyldisulfonic acids such as, for example, methanedisulfonic acid, oralpha,beta-ethanedisulfonic acid, arylmonosulfonic acids such asbenzenesulfonic acid, and aryldisulfonic acids.

It may be recalled that the stereoisomerism may be defined in its broadsense as the isomerism of compounds having the same structural formulaebut whose various groups are arranged differently in space, especiallysuch as in monosubstituted cyclohexanes whose substituent may be in theaxial or equatorial position, and the various possible rotationalconformations of ethane derivatives. However, there is another type ofstereoisomerism, due to the different spatial arrangements of fixedsubstituents, either on double bonds or on rings, which is oftenreferred to as geometrical isomerism or cis-trans isomerism. The term“stereoisomer” is used in the present patent application in its broadestsense and thus relates to all the compounds indicated above.

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which the substituentsR, R1, R2, R3, R4, R5 and R6 of said compounds of formula (I) have thevalues defined above and in the present invention, in which the radical—NR12R13 is such that R12 and R13, which may be identical or different,represent a hydrogen atom; and acyl, alkyl, cycloalkyl, piperidyl,piperazinyl, pyrrolidinyl, azetidinyl, pyrazolyl, pyridyl, imidazolyl,pyrimidyl, thiazolyl, thiazolidinyl, —SO2-thienyl, —SO2-pyridyl,—SO2-alkyl, —SO2-phenyl, —CO—NH-phenyl and phenyl radicals,

-   all these radicals being optionally substituted with one or more    radicals, which may be identical or different, selected from halogen    atoms and the following radicals: alkyl; CH2-NH2; CH2—NHCO2alkyl;    NH2; NHCO2alkyl; hydroxyl; alkoxy; hydroxyalkoxy; free or esterified    carboxyl; CF3; SCF3; OCF3; OCHF2; SO2CF3; nitro; cyano; thienyl;    piperidyl; morpholino, which is itself optionally substituted with    one or two alkyl radicals; and phenyl, which is itself optionally    substituted with one or more radicals, which may be identical or    different, selected from halogen atoms and alkyl, hydroxyl, alkoxy,    free or esterified carboxyl, CF3, SCF3, OCH3, OCHF2, SO2CF3, NH2,    NHCO2alkyl, nitro and cyano radicals;-   or alternatively R12 and R13 form, with the nitrogen atom to which    they are attached, an unsaturated or partially or totally saturated    3- to 10-membered heterocyclic radical containing one or more hetero    atoms selected from O, S, N and NR11, this radical being optionally    substituted with one or more radicals, which may be identical or    different, selected from halogen atoms and the following radicals:    alkyl; —CH2-NH2; CH2-NHCO2alkyl; NH2; NHCO2alkyl; hydroxyl; alkoxy;    hydroxyalkoxy; free or esterified carboxyl; CF3; SCF3; OCF3; OCHF2;    SO2CF3; nitro; cyano; and piperidyl; morpholinyl; piperazinyl;    thienyl; pyridyl, imidazolyl, thiazolyl, thiazolidinyl and phenyl    radicals, which are themselves optionally substituted with one or    more radicals, which may be identical or different, selected from    halogen atoms and alkyl, hydroxyl, alkoxy, free or esterified    carboxyl, CF3, SCF3, NH2, NHCO2alkyl, nitro and cyano radicals,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

In particular, R12 and R13, which may be identical or different, mayrepresent hydrogen; acyl, for instance alkyl-CO—,phenyl-CO-pyrazolyl-CO—, pyridyl-CO—, imidazolyl-CO—, pyrimidyl-CO— orthiazolyl-CO—; alkyl optionally substituted with thienyl, alkoxy orphenyl, which is itself optionally substituted with OCH3, SCF3, NHCO2ALKor NH2; cycloalkyl; piperidyl optionally substituted with alkyl;piperazinyl, pyrrolidinyl, azetidinyl; pyrazolyl optionally substitutedwith alkyl; pyridyl, imidazolyl, pyrimidyl, thiazolyl, thiazolidinyl;—SO2-thienyl; —SO2-pyridyl; —SO2-alkyl; —SO2-phenyl optionallysubstituted with OCF3; —CO—NH-phenyl optionally substituted with OCF3;and phenyl, which is itself optionally substituted with OCH3, SCF3,piperidyl or morpholino, the latter radical itself being optionallysubstituted with one or two alkyl radicals.

A subject of the present invention is thus the compounds of formula (I)as defined above and in the present invention, in which R, R1, R2, R3,R4, R5 and R6 have the meanings given above and in the presentinvention, and R7 and R8, which may be identical or different, areselected from hydrogen, alkyl, cycloalkyl, phenyl, heterocycloalkyl andheteroaryl, which may be monocyclic or bicyclic, all these radicalsbeing optionally substituted, or alternatively R7 and R8 form, with thenitrogen atom to which they are attached, an unsaturated or partially ortotally saturated heterocyclic radical consisting of 3 to 10ring-members and containing one or more hetero atoms selected from O, S,N and NR14, this radical being optionally substituted,

-   all the above radicals: alkyl, cycloalkyl, phenyl, heterocycloalkyl    and heteroaryl, which may be monocyclic or bicyclic, and also the    heterocyclic radical formed by R7 and R8 with the nitrogen atom to    which they are attached, being optionally substituted with one or    more radicals, which may be identical or different, selected from    the halogen atoms and the radicals hydroxyl, oxo, nitro, alkyl,    alkoxy, alkylthio, cycloalkyl, phenyl, heterocycloalkyl, heteroaryl,    —C(═O)—R9, —C(═O)—OR10, —N(R11)-C(═O)—R9, —N(R11)-C(═O)—OR10,    —NR12R13, —C(═O)—NR12R13, and —N(R11)-C(═O)—NR12R13,-   the latter alkyl, alkoxy, cycloalkyl, phenyl, heterocycloalkyl and    heteroaryl radicals themselves being optionally substituted with one    or more radicals, which may be identical or different, selected from    the halogen atoms and the radicals: hydroxyl, alkyl, alkoxy,    —NR12R13, free or esterified carboxyl, pyrrolidinyl, and phenyl and    phenylalkyl in which the phenyl radical is itself optionally    substituted with one or more radicals, which may be identical or    different, selected from the halogen atoms and the radicals:    hydroxyl, alkyl, alkoxy, free or esterified carboxyl, CF₃, nitro,    cyano and pyridyl,-   R9 represents alkyl, cycloalkyl, phenyl, heterocycloalkyl and    heteroaryl, all these radicals being optionally substituted,-   R10 represents the values for R9 and hydrogen,-   R11 represents hydrogen or optionally substituted alkyl,-   R12 and R13, which may be identical or different, represent    hydrogen, acyl, alkyl, cycloalkyl and phenyl, these radicals being    optionally substituted,-   or alternatively R12 and R13 form, with the nitrogen atom to which    they are attached, an unsaturated or partially or totally saturated    heterocyclic radical consisting of 3 to 10 ring members and    containing one or more hetero atoms selected from O, S, N and NR11,    this radical being optionally substituted,-   R14 represents hydrogen, acyl, free and esterified carboxyl, alkyl,    cycloalkyl and phenyl, which may be optionally substituted,-   the radicals R9, R10, R11, R12, R13 and R14 above being optionally    substituted with one or more radicals, which may be identical or    different, selected from the halogen atoms and the radicals: alkyl,    hydroxyl, alkoxy, hydroxyalkoxy, free or esterified carboxyl, CF₃,    nitro, cyano and phenyl, itself optionally substituted with one or    more radicals, which may be identical or different, selected from    the halogen atoms and the radicals: alkyl, hydroxyl, alkoxy, free or    esterified carboxyl, CF₃, nitro and cyano,-   all the phenyl and heteroaryl radicals above being, in addition,    optionally substituted with a dioxol radical,-   all the alkyl, alkenyl, alkoxy or —O-alkyl and alkylthio radicals    above being linear or branched and containing no more than 4 carbon    atoms,-   all the cycloalkyl radicals above containing no more than 7 carbon    atoms,-   all the heteroaryl and heterocycloalkyl radicals above containing no    more than 10 carbon atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

For example, R14 may represent a hydrogen atom; a cycloalkyl radical; analkyl radical optionally substituted, for example, with hydroxyl,alkoxy, hydroxyalkoxy or phenyl, itself optionally substituted with oneor more radicals selected from the halogen atoms and CF₃, alkoxy anddioxol radicals; a heterocyclic radical such as, for example, piperidylor pyridyl; a phenyl radical, itself optionally substituted with alkoxy,CF₃ or halogen; a free or esterified carboxyl radical; an acyl radicalsuch as, for example, —CO—CH₃ or —CO-furyl.

Examples of heterocyclic radicals that the above radicals may representare given hereinafter: among these heterocyclic radicals hereinafter,those comprising at least one nitrogen atom constitute examples ofradicals that R7 and R8 may form with the nitrogen atom to which theyare attached and also that R12 and R13 may form with the nitrogen atomto which they are attached. Mention may thus be made, in a nonlimitingmanner, of the following radicals:

pyrrolidinyl, piperidyl, pyrimidinyl, thienyl, thiazolyl, pyran, furyl,tetrahydrofuryl, tetrahydrofur-2-yl, imidazolinyl, imidazolyl,piperazinyl, indolyl, pyrrole, benzopyran, quinolyl, pyridyl, purinyl,morpholinyl, thiomorpholinyl, azetidinyl, azepanyl, diazepine,spiro[4.5]decane, pyrrolyl, 2H-pyrrolyl, piperidyl, indolinyl,pyrindolinyl, tetrahydroquinolyl, thiazolidinyl, naphthyridyl,quinazolinyl, dihydropyrrolyl, 1,4-dioxa-8-azaspiro[4.5]decane andtetrahydropyrrolo[3,4-c]-pyrrolyl, all these radicals being optionallysubstituted.

More particularly, when R12 and R13 form a cyclic radical with thenitrogen atom to which they are attached, this cyclic radical may beselected from pyrrolidinyl, morpholinyl, piperazinyl, piperidyl andazetidinyl radicals, all these radicals being optionally substituted asindicated above.

In particular when R12 and R13 form a cyclic radical with the nitrogenatom to which they are attached, this cyclic radical may be selectedfrom the following radicals: piperidyl, which is itself optionallysubstituted with a piperidyl radical or a hydroxyl radical; azetidinyl,which is itself optionally substituted with NH—CO2alk, CH2-NH2-CO2alk,CH2-NH2 and NH2; and piperazinyl, which is itself optionally substitutedwith an alkyl, phenylalkyl or phenyl radical, in which the phenylradical is itself optionally substituted with one or more radicalsselected from OCF3, OCHF2, SCF3 and SO2CF3.

A subject of the present invention is particularly the compounds offormula (I) as defined above and in the present invention, in which R,R1, R2, R3, R4, R5 and R6 have the meanings given above and in thepresent invention, and

-   R7 and R8, which may be identical or different, are selected from    hydrogen, cycloalkyl, optionally substituted alkyl, optionally    substituted phenyl, heterocycloalkyl and monocyclic or bicyclic    heteroaryl, which may be optionally substituted,-   or alternatively R7 and R8 form, with the nitrogen atom to which    they are attached, an optionally substituted heterocyclic radical    containing one or more hetero atoms,-   all the alkyl, phenyl and heterocyclic radicals above, and also the    heterocyclic radical that R7 and R8 may form with the nitrogen atom    to which they are attached, being optionally substituted with one or    more radicals selected from the halogen atoms and the radicals:    hydroxyl; oxo; nitro; cycloalkyl; alkoxy; OCF₃; hydroxyalkoxy;    alkylthio; acyl; free or esterified carboxyl; optionally substituted    phenyl; optionally substituted amino; alkyl optionally substituted    with one or more radicals selected from the halogen atoms and the    radicals: hydroxyl, alkoxy, pyrrolidinyl, phenyl and amino,    themselves optionally substituted; and pyrrolidinyl, piperidyl,    pyridyl and piperazinyl, themselves optionally substituted with one    or more radicals selected from the radicals: hydroxyl, alkyl,    alkoxy, free or esterified carboxyl, phenyl and phenylalkyl,    themselves optionally substituted,-   the amino radicals being optionally substituted with one or two    radicals, which may be identical or different, selected from alkyl,    hydroxyalkyl, alkoxyalkyl, acyl, phenyl and phenylalkyl, themselves    optionally substituted,-   the phenyl and phenylalkyl radicals being optionally substituted    with one or more radicals selected from the halogen atoms and-   the radicals: hydroxyl, alkyl, alkoxy, CF₃, free or esterified    carboxyl, pyridyl and dioxol,-   all the alkyl and alkoxy radicals being linear or branched and    containing no more than 4 carbon atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

The radicals R7 and R8, which may be identical or different, may thus inparticular represent hydrogen and optionally substituted alkyl,cycloalkyl, phenyl radicals and an optionally substituted heterocyclicradical: among the values for R7 and R8, mention may be made, forexample, of pyrimidinyl; thienyl; pyridyl; quinolyl; thiazolyloptionally substituted with one or two halogen atoms; pyran optionallysubstituted with one or more OCOAlk; phenyl optionally substituted withone or more radicals selected from the halogen atoms and the radicals:alkyl, alkoxy, amino, alkylamino, dialkylamino and free carboxyl orcarboxyl esterified with an alkyl radical; alkyl substituted withphenyl, itself optionally substituted with one or more radicals selectedfrom the halogen atoms, alkyl, alkoxy, amino, alkylamino, dialkylamino,and free carboxyl or carboxyl esterified with an alkyl radical; alkylsubstituted with piperazinyl, itself optionally substituted with one ormore radicals selected from Alk, Alk-OH and pyridyl; alkyl substitutedwith imidazolyl; alkyl substituted with one or more radicals selectedfrom NH₂, NHAlk, N(Alk)₂, N(Alk) (phenylalkyl), N(Alk) (aminoalkyl),N(Alk)-(alkylaminoalkyl) and N(Alk)(dialkylaminoalkyl); alkylsubstituted with morpholinyl optionally substituted with one or two Alk;alkyl substituted with pyrrolidinyl; alkyl substituted with piperidyl,itself optionally substituted with one or two Alk; alkyl substitutedwith thiomorpholinyl; alkyl substituted with azetidinyl; alkylsubstituted with azepanyl optionally substituted with oxo.

As radical that R7 and R8 may form with the nitrogen atom to which theyare attached, mention may also be made of dihydropyrrolyl,1,4-dioxa-8-azaspiro[4.5]decane or tetrahydropyrrolo[3,4-c]pyrrolylradicals, these radicals all being optionally substituted.

The radical that R7 and R8 may form with the nitrogen atom to which theyare attached can in particular be optionally substituted with one ormore radicals, which may be identical or different, selected from thehalogen atoms and the radicals: alkyl, hydroxyl, alkoxy and phenyl,itself optionally substituted with one or more radicals selected fromthe halogen atoms and alkyl and alkoxy radicals.

The pyrrolidinyl and quinazolinyl radicals may in particular beoptionally substituted with oxo or thioxo.

The piperazinyl radical may in particular be optionally substituted withone or more radicals selected from Alk, Alk-OH and pyridyl.

The acyl radical represents in particular the —CO-alkyl radicals withalkyl containing no more than 4 carbon atoms, the —CO-furyl radical orthe —CO-pyrrolidinyl radical.

A subject of the present invention is more particularly the compounds offormula (I) as defined above and in the present invention, in which R,R1, R2, R3, R4, R5 and R6 have the meanings given above and in thepresent invention, and

-   R7 and R8, which may be identical or different, are selected from    hydrogen and alkyl, cycloalkyl, phenyl and heterocyclic radicals,    such as pyrrolidinyl, piperidyl, pyrimidinyl, thienyl, thiazolyl,    pyran, furyl, tetrahydrofuryl, tetrahydrofur-2-yl, imidazolinyl,    piperazinyl, indolyl, pyrrole, benzopyran, quinolyl, pyridyl,    purinyl and morpholinyl, these radicals being optionally    substituted,-   or alternatively R7 and R8 form, with the nitrogen atom to which    they are attached, a heterocyclic radical selected from    pyrrolidinyl, imidazolyl, morpholinyl, piperazinyl, piperidyl,    thiazolyl, diazepine, spiro[4.5]decane, pyrrolyl, dihydropyrrolyl,    tetrahydropyrrolyl, tetrahydropyrrolo[3,4-c]pyrrolyl, piperidyl,    indolinyl, pyrindolinyl, tetrahydroquinolyl, thiazolidinyl,    naphthyridyl, azetidine or quinazolinyl radicals, these radicals all    being optionally substituted,-   all the above alkyl, phenyl and heterocyclic radicals being    optionally substituted with one or more radicals selected from the    halogen atoms and the radicals: hydroxyl; oxo; nitro; cycloalkyl;    alkoxy; OCF₃; hydroxyalkoxy; alkylthio; acyl; free or esterified    carboxyl; optionally substituted phenyl; optionally substituted    amino; alkyl optionally substituted with one or more radicals    selected from halogen atoms and the radicals: hydroxyl, alkoxyl,    pyrrolidinyl, phenyl and amino, themselves optionally substituted;    and pyrrolidinyl, piperidyl, pyridyl and piperazinyl, themselves    optionally substituted with one or more radicals selected from the    radicals: hydroxyl, alkyl, alkoxy, free or esterified carboxyl,    phenyl and phenylalkyl, themselves optionally substituted,-   the amino radicals being optionally substituted with one or two    radicals, which may be identical or different, selected from alkyl,    hydroxyalkyl, alkoxyalkyl, acyl, phenyl and phenylalkyl, themselves    optionally substituted,-   the phenyl and phenylalkyl radicals being optionally substituted    with one or more radicals selected from the halogen atoms and-   the radicals: hydroxyl, alkyl, alkoxy, CF₃, free or esterified    carboxyl, pyridyl and dioxol,-   all the alkyl and alkoxy radicals being linear or branched and    containing no more than 4 carbon atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is in particular the compounds; offormula (I) as defined above and in the present invention, in which R,R1, R2, R3, R4, R5 and R6 have the meanings given above and in thepresent invention, and

-   R7 and R8, which may be identical or different, are selected from    hydrogen, cycloalkyl radicals and alkyl, phenyl and heterocyclic    radicals such as pyrrolidinyl, piperidyl, furyl, tetrahydrofuryl,    tetrahydrofur-2-yl, imidazolinyl, piperazinyl, indolyl, pyrrolyl,    benzopyranyl, benzopyran-8-carboxylic, pyridyl, purinyl and    morpholinyl, all these radicals being optionally substituted,-   or alternatively R7 and R8 form, with the nitrogen atom to which    they are attached, a heterocyclic radical selected from    pyrrolidinyl, imidazolyl, morpholinyl, piperazinyl, piperidyl,    thiazolyl, diazepine, spiro[4.5]decane, pyrrolyl, dihydropyrrolyl,    tetrahydropyrrolyl and tetrahydropyrrolo[3,4-c]pyrrolyl radicals,    all these radicals being optionally substituted,-   all the above alkyl, phenyl and heterocyclic radicals that R7 and R8    represent or that R7 and R8 may form with the nitrogen atom to which    they are attached being optionally substituted with one or more    radicals selected from the radicals: oxo; cycloalkyl; CO-alkyl;    —CO-furyl; hydroxyl; alkoxy; hydroxyalkoxy; alkylthio; free or    esterified carboxyl; optionally substituted phenyl; alkyl optionally    substituted with a radical selected from hydroxyl, alkoxyl,    pyrrolidinyl, optionally substituted phenyl and amino optionally    substituted with one or two radicals selected from alkyl and    optionally substituted phenyl; amino optionally substituted with one    or two radicals, which may be identical or different, selected from    alkyl, hydroxyalkyl, alkoxyalkyl, CO-alkyl and phenyl, itself    optionally substituted; pyrrolidinyl, piperidyl, pyridyl and    piperazinyl, optionally substituted with one or more radicals    selected from free or esterified carboxyl, alkyl, alkoxy, hydroxyl,    phenylalkyl and optionally substituted phenyl,-   all the phenyl radicals being optionally substituted with one or    more radicals, which may be identical or different, selected from    the halogen atoms and the radicals: hydroxyl, alkyl, alkoxy, CF₃,    free or esterified carboxyl, pyridyl and dioxol,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

Thus, R7 and R8 form in particular, with the nitrogen atom to which theyare attached, a radical selected from the following radicals:pyrrolidinyl; imidazolyl; dihydropyrrolyl;1,4-dioxa-8-azaspiro[4.5]decane; morpholinyl; piperazinyl; piperidyl;thiazolyl; diazepine; perhydro-1,4-diazepine;4-methylperhydro-1,4-diazepin-1-yl;tetrahydropyrrolo[3,4-c]pyrrol-2-one;tetrahydropyrrolo[3,4-c]pyrrol-1,3-dione, these radicals beingoptionally substituted with one or more radicals: as indicated above orelse illustrated in the experimental section.

A subject of the present invention is more particularly the compounds offormula (I) as defined above and in the present invention, in which R,R1, R2, R3, R4, R5 and R6 have the meanings given above and in thepresent invention, and

-   R7 and R8, which may be identical or different, are selected from    the following radicals:    -   hydrogen;    -   benzopyran;    -   pyridyl itself optionally substituted with hydroxyl;    -   piperidyl optionally substituted with alkyl, itself optionally        substituted with phenyl;    -   purinyl;    -   alkyl optionally substituted with one or more radicals selected        from hydroxyl; alkoxy; alkylthio; pyridyl; imidazolinyl,        indolyl; pyrrolyl; furyl; tetrahydrofuryl; amino optionally        substituted with one or two radicals, which may be identical or        different, selected from alkyl, hydroxyalkyl, alkoxyalkyl and        phenyl, itself optionally substituted with alkyl; pyrrolidinyl,        itself optionally substituted with an alkyl radical; piperidyl,        itself optionally substituted with alkyl or phenylalkyl;        piperazinyl, itself optionally substituted with alkyl; phenyl        optionally substituted with dioxol or free or esterified        carboxyl;    -   phenyl optionally substituted with one or more radicals selected        from alkoxyl, piperidyl and piperazinyl, itself optionally        substituted with an alkyl radical;-   or alternatively R7 and R8 form, with the nitrogen atom to which    they are attached, a heterocyclic radical selected from the    following radicals:    -   imidazolyl;    -   dihydropyrrolyl;    -   1,4-dioxa-8-azaspiro[4.5]decane;    -   thiazolyl;    -   tetrahydropyrrolo[3,4-c]pyrrol-2-one;    -   tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione;    -   pyrrolidinyl optionally substituted with a radical selected from        pyridyl; amino, itself optionally substituted with an alkyl        radical and an acyl radical; and alkyl, itself optionally        substituted with a radical selected from hydroxyl, alkoxy,        pyrrolidinyl and amino, itself optionally substituted with a        phenyl radical;    -   morpholinyl optionally substituted with one or more alkyl        radicals;    -   piperazinyl optionally substituted with one or more radicals,        which may be identical or different, selected from the radicals:        oxo; cycloalkyl; acyl; carboxyl; pyridyl; alkyl containing no        more than 4 carbon atoms, itself optionally substituted with a        radical: hydroxyl, alkoxy, hydroxyalkoxy containing no more than        4 carbon atoms and phenyl, itself optionally substituted with a        dioxol radical; phenyl, itself optionally substituted with one        or more radicals selected from the halogen atoms and hydroxyl,        alkoxy and CF₃ radicals;    -   piperidyl optionally substituted with one or more substituents        selected from hydroxyl, alkyl, hydroxyalkyl and piperidyl;    -   diazepine or perhydro-1,4-diazepine optionally substituted with        an alkyl radical; itself optionally substituted with        pyrrolidinyl;-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is more particularly the compounds offormula (I) as defined above and in the present invention, in which R,R1, R2, R3, R4, R5 and R6 have the meanings given above and in thepresent invention, and

-   R7 and R8, which may be identical or different, are selected from    the radicals: hydrogen, alkyl, itself optionally substituted with a    pyrrolidinyl or piperidyl radical and phenyl, itself optionally    substituted with one or more radicals selected from the piperazinyl    radical, itself optionally substituted with an alkyl radical, or    alternatively R7 and R8 form, together with the nitrogen atom to    which they are attached, a radical selected from the following    radicals: morpholinyl; thiazolyl; diazepine or    perhydro-1,4-diazepine optionally substituted with an alkyl radical;    1-tetrahydropyrrolo[3,4-c]pyrrol-2-one; piperazinyl optionally    substituted with one or more radicals, which may be identical or    different, selected from the radicals: oxo and alkyl, itself    optionally substituted with a hydroxyl, alkoxy or hydroxyalkoxy    radical; piperidyl optionally substituted with hydroxyl, alkyl,    hydroxyalkyl or piperidyl;-   the alkyl and alkoxy radicals containing no more than 4 carbon    atoms,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is more particularly the compounds offormula (I) as defined above, in which:

-   R and R6 represent a hydrogen atom,-   R1 represents alkyl containing no more than 2 carbon atoms,    optionally substituted with —CO—NR7R8 or —NR7R8,-   R2 and R3, which may be identical or different, represent —O-alkyl    containing no more than 3 carbon atoms, optionally substituted with    —CO—NR7R8 or —NR7R8,-   R4 and R5 are such that one represents hydrogen and the other    represents a halogen atom or a cyano radical,-   R7 and R8 having the meanings given above,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is more particularly the compounds offormula (I) as defined above and in the present invention, in which R,R1, R2, R3, R4, R5, R6, R7 and R8 have the meanings given above and inthe present invention,

it being understood that R7 and R8 do not both represent hydrogen,

-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is more particularly the compounds offormula (I) as defined above and in the present invention, in which:

-   R, R1, R2, R3, R4, R5 and R6 have the meanings given in any one of    the other claims, and R7 and R8 are such that either one of R7 and    R8 represents hydrogen or alkyl and the other is selected from the    values for R7 and R8 as defined in any one of the other claims, or    R7 and R8 form, with the nitrogen atom to which they are attached, a    heterocyclic radical as defined in any one of the other claims,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

Among the preferred compounds of the invention, mention may be made moreparticularly of the compounds of formula (I) as defined above, the namesof which are given below:

-   2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-(4-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperazin-1-yl)ethanol-   2-(1-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperid-4-yl)ethanol-   1′-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}-[1,4′]bipiperidyl-   1-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperid-3-ol-   2-{5,6-dimethoxy-1-[2-(4-methylperhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]-1-(4-hydroxypiperid-1-yl)ethanone-   2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone-   4-{[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one-   4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-   2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   4-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine-   2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyrid-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperid-4-yl)ethanol-   4-chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-morpholin-4-ylethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-(4-methyl[1,4]diazepan-1-yl)ethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]acetamide-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)ethanone-   1-{4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl}-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]ethanone-   3aS,6aS)-5-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]acetyl}hexahydropyrrolo[3,4-c]pyrrol-1-one    trifluoroacetate-   2-{5-Methoxy-1-methyl-6-[3-(4-methylperhydro-1,4-diazepin-1-yl)propoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperid-1-yl)    ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{5-Methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids, or with mineral and organic    bases of said compounds of formula (I).

Among the preferred compounds of the invention, mention may moreparticularly be made of the compounds of formula (I) as defined above,the names of which are given below:

-   2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-(4-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperazin-1-yl)ethanol-   2-(1-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-4-yl)ethanol-   1′-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-[1,4′]bipiperidinyl-   1-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-3-ol-   2-{5,6-Dimethoxy-1-[2-(4-methylperhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(4-hydroxypiperidin-1-yl)ethanone-   2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone-   4-{[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one-   4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-   2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   4-Chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine-   2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperidin-4-yl)ethanol-   4-Chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   2-{5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-Dimethoxy-1-[2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-morpholin-4-ylethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methyl-[1,4]diazepan-1-yl)ethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]acetamide-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)ethanone-   1-{4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl}-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethanone-   (3aS,6aS)-5-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetyl}hexahydropyrrolo[3,4-c]pyrrol-1-one    trifluoroacetate-   2-{5-Methoxy-1-methyl-6-[3-(4-methylperhydro-1,4-diazepin-1-yl)propoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperidin-1-yl)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine,-   said compounds of formula (I) being in any possible racemic,    enantiomeric or diastereoisomeric isomer form, and also the addition    salts with mineral and organic acids or with mineral and organic    bases of said compounds of formula (I).

A subject of the present invention is also a process for preparing thecompounds of formula (I) as described above.

The compounds of formula (I) of the present invention as described abovecan be prepared as indicated in Schemes 1 to 6 (FIGS. 1 to 6) describedhereinafter; these schemes thus describe stages for synthesizing thecompounds of formula (I) of the present invention and are part of thepresent invention.

The 1H-pyrrolo[2,3-b]pyridines of formula 1 according to the presentinvention:

in which R1, R2, R3, R4, R5, R6 and R are defined as above, can beprepared according to schemes 1 to 4 in FIGS. 1 to 4; these schemes arepart of the present invention.

In scheme 1 (FIG. 1), more particularly, the treatment of the2-aminopyridines of formula (A) with R₅≠H, with N-iodosuccinimide orN-bromosuccinimide in a solvent such as acetic acid at a temperature ofbetween 20° C. and 80° C., for instance under the conditions describedby A. Fuss and V. Koch (Synthesis, 1990, 8, 681-5), results in the3-halo-2-aminopyridines of formula (B).

More particularly, the 3-trimethylsilanylethynylpyridin-2-ylamines offormula (C) can be obtained by Sonogashira-type coupling withethynyltrimethylsilane, for instance under the conditions described byP. Knochel et al., (Tetrahedron, 2003, 59, 1571-1587) using the3-halo-2-aminopyridines of formula (B) in the presence of catalysts suchas [1,1′-bis(diphenylphosphino)ferrocene] palladium(II) chloride orbis(triphenylphosphine) palladium(II) chloride, of copper iodide, of abase such as triethylamine and, optionally, of lithium chloride in asolvent such as dimethylformamide at a temperature of between 20° C. and120° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (D) may beobtained by cyclization of the derivatives of formula (C) in thepresence of a strong base such as potassium tert-butoxide or potassiumhydride, in a solvent such as 1-methyl-2-pyrrolidinone at a temperaturebetween 20° C. and 120° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridine 7-oxides of formula (E)may be obtained by treating the derivatives of formula (D1) with3-chloroperoxybenzoic acid in an ethereal solvent such as1,2-dimethoxyethane at a temperature in the region of 20° C. under theconditions described in patent WO 03/000688 A1; the1H-pyrrolo[2,3-b]pyridines of formula (D) with R₄═Cl may be obtainedfrom the 1H-pyrrolo[2,3-b]pyridine 7-oxides of formula (E) by treatmentwith phosphorus oxychloride at a temperature of between 20° C. and 50°C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (F) may beobtained under the conditions described in patent WO 03/000688 A1 byprotection of the nitrogen atom of the derivatives of formula (D) with agroup such as, for example, p-toluenesulfonyl or benzenesulfonyl bytreatment with the corresponding sulfonyl chlorides in the presence of astrong base such as sodium hydroxide and of a quaternary ammonium saltsuch as tetrabutylammonium hydrogen sulfate in a mixture of water and asolvent such as toluene at a temperature in the region of 20° C.

The 1H-pyrrolo[2,3-b]pyridines of formula (G) may be obtained as underthe conditions described in the patent mentioned above, by treatment ofthe derivatives of formula (F) with a strong base such as N-butyllithiumor tert-butyllithium in an ethereal solvent such as tetrahydrofuran,followed by the addition of iodine in solution in a solvent such astetrahydrofuran, at a temperature in the region of −78° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (F), withR₄═I and GP=acetyl may be prepared from the 1H-pyrrolo[2,3-b]pyridinesof formula (D) with R₄═Cl, as under the conditions described by M.Allegretti et al., (Synlett, 2001, 5, 609-612) by treatment with acetylchloride in the presence of sodium iodide in a solvent such asacetonitrile at a temperature between 20° C. and the reflux temperatureof the solvent.

The 1H-pyrrolo[2,3-b]pyridines of formula (F), with R₄═I and GP=acetyl,can result in the derivatives of formula (D) with R₄═I by treatment in asolvent such as methanol at a temperature of between 20° C. and thereflux temperature of the solvent, under the conditions described in theabove-mentioned reference.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (F) may beprepared from the derivatives of formula (F) with R₄═I by Stillecoupling as under the conditions described by Javier Form et al., (SynthCommun, 23(21), 2965, 1993) by treatment with a stannic derivative, suchas, for example, tetramethyl tin, in the presence of a catalyst such asbis(triphenylphosphine) palladium(II) chloride, of lithium chloride, ofa phosphine such as triphenylphosphine in a solvent such asdimethylformamide at a temperature of between 20° C. and 120° C.

More particularly, the 1H-indoles of formula (I) may be obtained fromthe derivatives of formula (H) as under the conditions described inpatent WO 03/000688 A1 by treatment with iodine in the presence of astrong base such as, for example, potassium hydroxide and of an organicbase such as, for example, 4-(dimethylamino)pyridine, followed by theaddition of di-tert-butyl dicarbonate in a solvent such asdimethylformamide at a temperature of between 20° C. and 60° C.

More particularly, the 1H-indoles of formula (J) may be prepared fromthe derivatives of formula (I) as under the conditions described inpatent WO 03/000688 A1 by treatment with a strong base such as, forexample, N-butyllithium and a boronic ester such as, for example,tributyl borate in an ethereal solvent such as tetrahydrofuran at atemperature of between −100° C. and 20° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (K) may beobtained by Suzuki-type coupling between the derivatives of formula (J)and the derivatives of formula (G), as, for example, under theconditions described in patent WO 03/000688 A1, in the presence of acatalyst such as tetrakis(triphenylphosphine)palladium, and of a basesuch as sodium hydrogen sulfate in aqueous solution, in a solvent suchas dimethylformamide at a temperature of between 20° C. and the refluxtemperature of the solvent.

In scheme 2 (FIG. 2), more particularly, treatment of the 1H-indoles offormula (H) with a strong base such as, for example, potassium hydroxidein a solvent such as dimethylformamide, followed by the addition ofiodine or of bromine and then, for example, of an alkyl halide(preferably methyl iodide), at a temperature in the region of 20° C.,results in the 3-halo-1H-indoles of formula (N) as under the conditionsdescribed by Gordon W. Gribble (J. Nat. Prod, 2002, 65, 748-749).

The 3-(trimethylsilanylethynyl-1H-indoles of formula (O) may be preparedfrom the derivatives of formula (N) by Sonogashira-type coupling asunder the conditions described above for the derivatives of formula (C).

The 3-ethynyl-1H-indoles of formula (P) are obtained by treatment of thederivatives of formula (O) by treatment with a fluoro derivative suchas, for example, potassium fluoride in a solvent such as methanol ortetrabutylammonium fluoride in a solvent such as tetrahydrofuran, at atemperature of between 20° C. and the reflux temperature of the solvent.

More particularly, the 3-ethynylpyridin-2-ylamines of formula (L) may beobtained, as under the conditions described above for the derivatives offormula (P), from the derivatives of formula (C).

More particularly, the 3-(1H-indol-3-ethynyl)pyridin-2-ylamines offormula (M) may be obtained by Sonogashira-type coupling under theconditions described above:

-   -   either between the 3-halo-2-aminopyridines of formula (B) and        the 3-ethynyl-1H-indoles of formula (P)    -   or between the 3-halo-1H-indoles of formula (N) and the        3-ethynylpyridin-2-ylamines of formula (L).

The 1H-pyrrolo[2,3-b]pyridines of formula 1 may be prepared by treatmentof the derivatives of formula (M) with a strong base such as, forexample, potassium tert-butoxide or potassium hydride, in a solvent suchas 1-methyl-2-pyrrolidinone, at a temperature of between 20° C. and 120°C. as under the conditions described by P. Knochel et al., (Tetrahedron,2003, 59, 1571-1587).

In scheme 3 (FIG. 3), more particularly, the 1H-pyrrolo[2,3-b]pyridinesof formula (Q) may be obtained by alkylation of the derivatives offormula (K) with an alkyl halide optionally substituted at the endposition with:

-   -   a cyclic or acyclic, optionally substituted amine,    -   a halogen so as to give the derivatives of formula (Q2),    -   an alkoxy group so as to give the derivatives of formula (Q3),    -   an alkoxycarbonyl group so as to give the derivatives of formula        (Q4),

as, for example, under the conditions described by D. Oelgen et al.,(Pharmazie, 57(4), 238, 2002), in the presence of a base such as sodiumhydride, in a solvent such as dimethylformamide, at a temperaturebetween 20° C. and the reflux temperature of the solvent.

In the case of the derivatives of the formula (Q2), the conditionsdescribed by D. Bogdal et al., (Synthetic Communication, 30 (18),3341-3352, 2000) in dichloroethane in the presence of bases such aspotassium hydroxide, potassium carbonate, a quaternary ammonium such astetrabutylammonium bromide, at a temperature in the region of 20° C.,may optionally be used.

Alternatively, the 1H-pyrrolo[2,3-b]pyridines of formula (Q4), withR′₁=2-(CH₂)₂CO₂tBu may be obtained by alkylation of the derivatives offormula (K) with a tert-butyl acrylate, as, for example, under theconditions described by M. V. R. Reddy et al., (J. Org. Chem, 67(15),5382, 2002), in the presence of a base such as potassium carbonate, in asolvent such as dimethylformamide, at a temperature between 20° C. andthe reflux temperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1a) may beobtained by simultaneous deprotection of the p-toluenesulfonyl group andof the ester of the derivatives of formula (Q4), as, for example, underthe conditions described by A. V. Samet et al., (Synth Commun, 31(9),1441, 2001), in the presence of a base such as potassium hydroxide, in asolvent such as methanol, at a temperature of between 20° C. and thereflux temperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1), whereR₁═(CH₂)_(n)CONR₇R₈, may be obtained by amidation of the derivatives offormula (1a) with amines HNR₇R₈, using peptide coupling agents such as,for example, O-benzotriazolyl-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HBTU) orO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HAUT), under the conditions described by V.Dourtoglou and B. Gross (Synthesis, 572, 1984), in a solvent such asdimethylformamide, at a temperature of between 20° C. and the refluxtemperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (R) may beobtained by reaction of the derivatives of formula (Q2) with sodiumiodide or potassium iodide, as, for example, under the conditionsdescribed by C. F. H. Allen et al., (J. Org Chem, 14, 754, 1949), in asolvent such as methyl ethyl ketone, at a temperature of between 20° C.and the reflux temperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (S) may beobtained by reaction of the derivatives of formula (R) with aminesHNR₇R₈, as, for example, under the conditions described by M. D. Pujolet al., (Eur. J. Med. Chem., 31(11), 889, 1996), in the presence of abase such as potassium carbonate, in a solvent such as methyl ethylketone, at a temperature of between 20° C. and the reflux temperature ofthe solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of the formula (U) or(T) may be obtained from the 4-chloro-1H-pyrrolo[2,3-b]pyridines offormula (Q1) or (S1) by means of the action of zinc cyanide, in thepresence of zinc, and of a catalyst such as, for example,1,1′-bis(diphenylphosphino)ferrocene palladium(II) dichloride in asolvent such as, for example, dimethylacetamide, at a temperature ofbetween 20 and 150° C., for instance under the conditions described byFuqiang Jin et al., (Tetrahedron Letters 41, 2000, 3271-3273).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (V) may beobtained from the derivatives of formula (Q1) by Buchwald-type couplingwith benzophenone imine in the presence of a base such as cesiumcarbonate, of a catalyst such as palladium(II) acetate, and of a ligand,such as, for example, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, in asolvent such as toluene, at a temperature of between 20° C. and thereflux temperature of the solvent, for instance under the conditionsdescribed by L. Buchwald et al., (J. Org. Chem, 61, 1996, 7240-7241).

The 1H-pyrrolo[2,3-b]pyridines of formula (W) may be obtained from thederivatives of formula (V) under conventional conditions described byGreene and Wuts in Protective Groups in Organic Synthesis, 3rd edition,Wiley-Interscience, by hydrolysis of the imine in acid medium, forinstance in aqueous hydrochloric acid in a solvent such astetrahydrofuran, at a temperature of between 20° C. and the refluxtemperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (X) withΦ=OH, may be obtained from the derivatives of formula (Q3) withR′₁═(CH₂)_(n)OSiMe₂tBu [(CH₂)_(n)OTBDMS], for instance under theconditions described by E. J. Corey and A. Venkateswarlu (J Am Chem Soc,94, 6190, 1972), by reaction with a fluoro derivative such as, forexample, tetrabutylammonium fluoride, in a solvent such astetrahydrofuran, at a temperature of between 20° C. and the refluxtemperature of the solvent. During this reaction, the derivatives offormula (X) with Φ=F are also obtained.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1) may beobtained by deprotection of the derivatives of formulae (S), (T), (U),(W), (X) and (Q) under conventional conditions described by Greene andWuts in Protective Groups in Organic Synthesis, 3rd edition,Wiley-Interscience, 1999.

When the protective group is a p-toluenesulfonyl group, theN-deprotection of the derivatives of formulae (S), (T), (U), (W), (X)and (Q) is carried out for instance under the conditions described abovefor the derivatives of formula (1a) or else, for example, in thepresence of tetrabutylammonium fluoride in a solvent such astetrahydrofuran at a temperature of between 20° C. and the refluxtemperature of the solvent.

In scheme 4 (FIG. 4), more particularly, the 1H-pyrrolo[2,3-b]pyridinesof formula (Q5) may be obtained from the derivatives of formula (K1) asdescribed above for the derivatives of formula (Q).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (Y) may beobtained by debenzylation of the derivatives of formula (Q5), forexample under the conditions described by M. E. Jung and M. A. Lyster (JOrg Chem, 42, 3761, 1977), in the presence of trimethylsilane iodide ina solvent such as acetonitrile at a temperature of between 20° C. andthe reflux temperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines derivatives of formula(Z) with Σ=CO-alkyl may be obtained by reaction of the derivatives offormula (Y) with a substituted alkyl halide such as X(CH₂)_(n)OCO-alkyl,for instance under the conditions described by J. C. Gonzalez-Gomez etal., in (Bioorg Med. Chem. Letters, 12, (2), 175, 2003), in the presenceof a base such as sodium hydride, in a solvent such asdimethylformamide, at a temperature of between 20° C. and the refluxtemperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1) withΣ=H may be obtained by simultaneous deprotection of thep-toluenesulfonyl and ester group of (Y) with Σ=CO-alkyl, for instanceunder the conditions described above for the derivatives of formula(1a).

Alternatively, the 1H-pyrrolo[2,3-b]pyridines of formula (Z) withΣ=alkyl may be obtained by reaction of the derivatives of formula (Y)with an alkyl ether halide such as X(CH₂)_(n)O-alkyl, for instance underthe conditions described by A. Leschot et al., (Synth Commun, 32(20),3219, 2002), in the presence of a base such as cesium carbonate orpotassium carbonate, in a solvent such as acetone, acetonitrile ordimethylformamide, at a temperature of between 20° C. and the refluxtemperature of the solvent.

Alternatively, the 1H-pyrrolo[2,3-b]pyridines of formula (Z) withΣ=(CH₂)_(n)Cl may be obtained by reaction of the derivatives of formula(Y) with a dialkyl ether dihalide such as X(CH₂)_(n)O—(CH₂)_(n)X, forinstance under the conditions above for the derivatives of formula (Z)with Σ=CO-alkyl.

Alternatively, the 1H-pyrrolo[2,3-b]pyridines of formula (Z) withΣ=(CH₂)^(n)NR₇R₈ may be obtained by reaction of the derivatives offormula (Z) with Σ=(CH₂)_(n)Cl, with amines HNR₇R₈, for instance underthe conditions described above for the derivatives of formula (S).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AA) withGP=p-toluenesulfonyl may be obtained by alkylation of the derivatives offormula (Y) with an alkyl acetate halide, for instance under theconditions described above for the derivatives of formula (Z) withΣ=CO-alkyl.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1b) may beobtained by simultaneous deprotection of the p-toluenesulfonyl and estergroup of (AA), for instance under the conditions described above for thederivatives of formula (1a).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1) withR₃═OCH₂CONR₇R₈ may be obtained by amidation of the derivatives offormula (1b), with amines HNR₇R₈, for instance under the conditionsdescribed in “Practical Guide to Combinatorial Chemistry”, ISBN0-8412-3485-x, p-51-97, in the presence of dicyclohexylcarbodiimide, orhydroxyazabenzotriazole and of a base in a solvent such asdimethylformamide at a temperature of between 20° C. and the refluxtemperature of the solvent.

More particularly, the 6-hydroxy-1H-pyrrolo[2,3-b]pyridines of formula(AB) may be obtained by debenzylation of the derivatives of formula(K1), for instance under the conditions described above for thederivatives of formula (Y).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AC) withGP=p-toluenesulfonyl may be obtained by bisalkylation of the derivativesof formula (AB) with an alkyl acetate halide, for instance under theconditions described above for the derivatives of formula (AA).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AD) may beobtained by reaction of the derivatives of formula (Y) with triflicanhydride, for instance under the conditions described by K. A. Parkerand Q. J. Ding (Tetrahedron, 56(52), 10249, 2000), in the presence of abase such as pyridine, in a solvent such as dichloromethane, at atemperature of between 0° C. and the reflux temperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AE) may beobtained by Suzuki-type coupling between the derivatives of formula (AD)and alkyl boronic acids, for instance under the conditions described byG. S. Cockerill (J Chem Soc, Perkin Trans. 1, 2591, 2000) in thepresence of a catalyst such as tetrakis(triphenylphosphine)palladium,and of a base such as sodium hydrogen carbonate in aqueous solution, ina solvent such as dimethylformamide, at a temperature of between 20° C.and the reflux temperature of the solvent.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AF) may beobtained by alkylation of the derivatives of formula (Y) with an alkyldihalide, for instance under the conditions described above for thederivatives of formula (AA).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AG) may beobtained by halogen exchange from the derivatives of formula (AF), forinstance under the conditions described above for the derivatives offormula (R).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (AH) may beobtained by reaction of the derivatives of formula (AG) with aminesHNR₇R₈, for instance under the conditions described above for thederivatives of formula (S).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of formula (1) may beobtained by deprotection of the derivatives of formulae (AC), (AE), (AH)and (Z), under conventional conditions described by Greene and Wuts inProtective Groups in Organic Synthesis, 3rd edition, Wiley-Interscience,1999.

When the protective group is a p-toluenesulfonyl group, the deprotectionof the derivatives of formulae (AC), (AE), (AH) and (Z) is carried out,for instance, under the conditions described above for the derivativesof formula (1a).

Scheme 5 (FIG. 5) describes a synthetic route for gaining access to the2-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carboxaldehydederivatives.

More particularly, treatment of the 4-cyano-1H-pyrrolo[2,3-b]pyridinesof general formula (AI) with a reducing agent such as diisobutylaluminumhydride (DIBAH), in an aprotic solvent such as toluene, at a temperatureof between −30° C. and 20° C., for instance under the conditionsdescribed by Anderson, B. A. et al. (J. Org. Chem., 1997, 62(25),8634-8639), leads to the 4-carboxaldehyde-1H-pyrrolo[2,3-b]pyridines ofgeneral formula (AJ).

More particularly, the 4-(1,3-dioxolan)-1H-pyrrolo[2,3-b]pyridines ofgeneral formula (AK) may be obtained by reaction of the derivatives ofgeneral formula (AJ) with ethylene glycol in a solvent such as toluene,in the presence of an acidic catalyst such as para-toluenesulfonic acid,at a temperature of between 80° C. and 120° C., for instance under theconditions described by Pasto M. et al. (Tetrahedron: Asymmetry, 1995,6(9), 2329-2342).

The 4-(1,3-dioxolan)-2-iodo-1H-pyrrolo[2,3-b]pyridines of generalformula (AL) may be obtained as under the conditions described in patentWO 03/000688 A1, by treatment of the derivatives of general formula (AK)with a strong base, for instance n-butyllithium or tert-butyllithium, inan ether solvent such as tetrahydrofuran, followed by the addition ofiodine as a solution in a solvent such as tetrahydrofuran, at atemperature in the region of −78° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AM) may be obtained via a Suzuki coupling between the derivatives ofgeneral formula (J) and the derivatives of general formula (AL) asdescribed above for the derivatives of general formula (K).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AN) may be obtained from the derivatives of general formula (AM) asdescribed above for the derivatives of general formula (Q).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AO) may be obtained by treatment of the derivatives of general formula(AN) in the presence of an acid such as hydrochloric acid, in a solventsuch as tetrahydrofuran at a temperature of between 20° C. and 60° C.,for instance under the conditions described by Ishimaru K. et al.(Heterocycles, 2001, 55(8), 1591-1597).

Scheme 6 (FIG. 6) describes a synthetic route for introducingsubstituents R4 into the compounds of formula (I).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AP) and (AP2) may be obtained by treatment of the derivatives ofgeneral formula (AO) with an amine, in the presence of a hydride such assodium borohydride and a dehydrating agent such as magnesium sulfate, ina solvent such as methanol or ethanol, at a temperature in the region of20° C., for instance under the conditions described by Patra, P. K. etal. (Eur. J. Org. Chem., 2001, 22, 4195-4206).

These 1H-pyrrolo[2,3-b]pyridines of general formula (AP) may also beobtained either:

by treatment of the derivatives of general formula (AR) with a halide ora mesylate, in the presence of a base such as sodium carbonate, in asolvent such as acetonitrile, at a temperature of between 20° C. and theboiling point of the solvent, for instance under the conditionsdescribed by Kaneko, T. et al. (Chem. Pharm. Bull., 2002, 50(7),922-929);

-   or by treatment of the derivatives of general formula (AU) with an    amine, in the presence of a base such as sodium carbonate, in a    solvent such as acetonitrile, at a temperature of between 20° C. and    the boiling point of the solvent, for instance under the conditions    described above.

The 1H-pyrrolo[2,3-b]pyridines of general formula (AQ) may be obtainedfrom the 1H-pyrrolo[2,3-b]pyridines of general formula (AO) by treatmentwith hydroxylamine hydrochloride, in a solvent such as pyridine, at atemperature of between 20° C. and 50° C., for instance under theconditions described by Schroeder, M. C. et al. (J. Heterocyclic Chem.,1992, 29(6), 1481-1498).

More particularly, the 4-aminomethyl-1H-pyrrolo[2,3-b]pyridines ofgeneral formula (AR) may be obtained by reduction of the oxime (AQ) witha metal such as zinc, in the presence of an acid such as acetic acid orformic acid, in a solvent such as water and/or ethanol and at atemperature in the region of 20° C., for instance under the conditionsdescribed by Prasitpan, N. et al. (Synth. Commun., 1990, 20(22),3459-3466).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AS) may be obtained by treatment of the derivatives of general formula(AR) with substituted sulfonyl chlorides, substituted isocyanates orsubstituted acid chlorides, in the presence of a base such astriethylamine, in an aprotic solvent such as dichloromethane, at atemperature of between 0 and 20° C., as under the conditions describedby Metz, P. et al. (Synlett, 1996, (8), 741-742), by Hergueta, A. R. etal. (Chem. Pharm. Bull., 2002, 50(10), 1379-1382) and by Coelho, P. J.et al. (Synlett, 2001, (9), 1455-1457).

The 1H-pyrrolo[2,3-b]pyridine-4-methanol compounds of general formula(AT) may be obtained by reduction of the derivatives of general formula(AO) with a hydride such as sodium borohydride, in an ether solvent suchas tetrahydrofuran, at a temperature in the region of 20° C., forinstance under the conditions described by Wang, E. C. et al.(Heterocycles, 2002, 57(11), 2021-2033).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AU), with X═Cl, may be obtained from the1H-pyrrolo[2,3-b]pyridine-4-methanol compounds of general formula (AT),as under the conditions described by Fucase K. et al. (TetrahedronLett., 1991, 32(32), 4019-4022), by treatment with thionyl chloride inthe presence of DMF in a solvent such as dichloromethane, at atemperature of between 0° C. and 20° C.

The 1H-pyrrolo[2,3-b]pyridines of general formula (AU), with X═OSO2Me,may be obtained from 1H-pyrrolo[2,3-b]pyridine-4-methanol compounds ofgeneral formula (AT), as under the conditions described by Altamura M.et al. (J. Org. Chem., 1993, 58(1), 272-274), by treatment withmethanesulfonic anhydride in the presence of a base such as pyridine, ina solvent such as dichloromethane, at a temperature of between −10° C.and 20° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AV) may be obtained by treatment of the derivatives of general formula(AO) with Grignard reagents in a solvent such as tetrahydrofuran at atemperature of between 0 and 20° C., as under the conditions describedby Labrosse, J. R. et al. (Synth. Commun., 2002, 32(23), 3667-3674).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AW), with B═CORa, CONHRb, SO2Rc), may be obtained from the derivativesof general formula (AP2) as described above for the derivatives ofgeneral formula (AS).

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula(AX) may be obtained by deprotection of the derivatives of generalformula (AW) under standard conditions described by Greene and Wuts inProtective Groups in Organic Synthesis, 3rd edition, Wiley-Interscience,1999.

More particularly, the 1H-indoles of general formula (1) may be obtainedfrom the derivatives of general formula (AX) as under the conditionsdescribed by Madar, D. J., et al. (Tetrahedron Lett., 2001, 42,3681-3684), by treatment with an acid, for instance trifluoroacetic acidor para-toluenesulfonic acid, in a solvent such as dichloromethane ortoluene, at a temperature of between 20° C. and 100° C.

More particularly, the 1H-pyrrolo[2,3-b]pyridines of general formula (1)may be obtained by deprotection of the derivatives of general formula(AP), (AQ), (AR), (AS) or (AV) under standard conditions described byGreene and Wuts in Protective Groups in Organic Synthesis, 3rd edition,Wiley-Interscience, 1999.

A subject of the present invention is also processes for preparing:

-   -   the compounds of general formula (D) and most particularly the        reactions using the 2-aminopyridines (A) according to scheme 1;    -   the compounds of general formula (1) and most particularly the        reactions according to scheme 2.

It may be noted that, in the reactions for preparing the compounds offormula (I) according to the present invention, and in particular in thereactions indicated in the schemes, the intermediate compounds or thecompounds of formula (I) may, if necessary, be in protected form, thepossible reactive functions being optionally protected with protectivegroups.

The intermediate compounds or the compounds of formula (I), which may ormay not be in protected form, may be subjected, if desired and ifnecessary, in order to obtain compounds of formula (I) or othercompounds of formula (I), to one or more of the following conversionreactions, in any order:

-   a) a reaction consisting of esterification of an acid function,-   b) a reaction consisting of saponification of an ester function to    an acid function,-   c) a reaction consisting of oxidation of an alkylthio to a    corresponding sulfoxide or sulfone,-   d) a reaction consisting of conversion of a ketone function to an    oxime function,-   e) a reaction consisting of reduction of the free or esterified    carboxyl function to an alcohol function,-   f) a reaction consisting of conversion of an alkoxy function to a    hydroxyl function, or alternatively of a hydroxyl function to an    alkoxy function,-   g) a reaction consisting of oxidation of an alcohol function to an    aldehyde, acid or ketone function,-   h) a reaction consisting of conversion of a nitrile radical to a    tetrazolyl radical,-   i) a reaction consisting of reduction of the nitrogenous compounds    to amino compounds,-   j) a reaction consisting of elimination of the protective groups    that the protected reactive functions may bear,-   k) a reaction consisting of salification with an mineral or organic    acid or with a base in order to obtain the corresponding salt,-   l) a reaction consisting of resolution of the racemic forms into    resolved compounds,-   said compounds of formula (I) thus obtained being in any possible    racemic, enantiomeric or diastereoisomeric isomer form.

It may be noted that such reactions for conversion of substituents toother substituents can also be carried out on the starting compounds andalso on the intermediate compounds as defined above, before continuingthe synthesis according to the reactions indicated in the processdescribed above.

The compounds of formula (I) according to the present invention couldalso be prepared by applying or adapting known methods, and inparticular the methods described in the literature, for instance thosedescribed by R. C. Larock in: Comprehensive Organic Transformations, VCHpublishers, 1989.

In order to prepare the compounds of formula (I), it may therefore benecessary to protect reactive functional groups such as, for example,hydroxyl, amino, imino, thio or carboxyl groups, when these groups aredesired in the final product but when their participation in thereactions to synthesize the compounds of formula (I) is not desired. Usemay in particular be made of conventional protective groups in agreementwith usual standard practices such as those described, for example, byT. W. Greene and P. G. M. Wuts in “Protective Groups in OrganicChemistry” John Wiley and Sons, 1991.

The various reactive functions that may be borne by certain compounds ofthe reactions defined above may, if necessary, be protected. These are,for example, free carboxyl, acyl or hydroxyl radicals, or else amino andmonoalkylamino radicals, which can be protected with appropriateprotective groups.

The following nonexhaustive list of examples of protection of reactivefunctions may be mentioned:

-   -   the hydroxyl groups can be protected, for example, with alkyl        radicals such as tert-butyl, trimethylsilyl,        tert-butyldimethylsilyl, methoxymethyl, tetrahydropyrannyl,        benzyl or acetyl,    -   the amino groups can be protected, for example, with acetyl,        trityl, benzyl, tert-butoxycarbonyl, benzyloxycarbonyl or        phthalimido radicals or other radicals known in peptide        chemistry,    -   the acyl groups, such as the formyl group, can be protected, for        example, in the form of cyclic or noncyclic acetals or        thioacetals such as dimethyl or diethyl acetal or ethylene        dioxyacetal, or diethyl thioacetal or ethylene dithioacetal,    -   the acid functions of the compounds described above can, if        desired, be amidated with a primary or secondary amine, for        example in methylene chloride in the presence, for example, of        1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride at        ambient temperature.    -   the acid functions can be protected, for example, in the form of        esters formed with readily cleavable esters such as benzyl        esters or tert-butyl esters or esters known in peptide        chemistry.

These reactions a) to k) indicated above can be carried out, forexample, as indicated hereinafter.

-   a) The compounds described above can, if desired, be the subject, on    the possible carboxyl functions, of esterification reactions which    can be carried out according to the usual methods known to those    skilled in the art.-   b) The optional conversions of an ester function to an acid function    in the compounds described above can, if desired, be carried out    under the usual conditions known to those skilled in the art, in    particular by acid or alkaline hydrolysis, for example with sodium    hydroxide or potassium hydroxide in alcoholic medium such as, for    example, in methanol, or else with hydrochloric or sulfuric acid.-   c) The possible alkylthio groups of the compounds described above,    in which the alkyl radical is optionally substituted with one or    more halogen atoms, in particular fluorine atoms, can, if desired,    be converted into the corresponding sulfoxide or sulfone functions    under the usual conditions known to those skilled in the art, such    as, for example, with peracids, for instance peracetic acid or    meta-chloroperbenzoic acid, or else with ozone, oxone, sodium    periodate in a solvent such as, for example, methylene chloride, or    dioxane, at ambient temperature.

Obtaining of the sulfoxide function can be promoted with an equimolarmixture of the compound containing an alkylthio group and of the reagentsuch as, in particular, a peracid.

Obtaining of the sulfone function can be promoted with a mixture of thecompound containing an alkylthio group with an excess of the reagentsuch as, in particular, a peracid.

-   d) The reaction consisting of conversion of a ketone function to an    oxime can be carried out under the usual conditions known to those    skilled in the art, such as, in particular, action in the presence    of an optionally O-substituted hydroxylamine in an alcohol such as,    for example, ethanol, at ambient temperature or by heating.-   e) The possible free or esterified carboxyl functions of the    compounds described above can, if desired, be reduced to an alcohol    function by the methods known to those skilled in the art; the    possible esterified carboxyl functions can, if desired, be reduced    to an alcohol function by the methods known to those skilled in the    art, and in particular with lithium aluminum hydride in a solvent    such as, for example, tetrahydrofuran or else dioxane or ethyl    ether.

The possible free carboxyl functions of the compounds described abovecan, if necessary, be reduced to an alcohol function in particular withboron hydride.

-   f) The possible alkoxy functions, such as in particular methoxy    functions, of the compounds described above can, if necessary, be    converted into hydroxyl function under the usual conditions known to    those skilled in the art, for example with boron tribromide in a    solvent such as, for example, methylene chloride, with pyridine    hydrobromide or hydrochloride or else with hydrobromic or    hydrochloric acid in water or trifluoroacetic acid at reflux.-   g) The possible alcohol functions of the compounds described above    can, if desired, be converted into an aldehyde or acid function by    oxidation under the usual conditions known to those skilled in the    art, such as, for example, by the action of manganese oxide in order    to obtain aldehydes, or of Jones reagent in order to obtain acids.-   h) The possible nitrile functions of the compounds described above    can, if desired, be converted into a tetrazolyl function under the    usual conditions known to those skilled in the art, such as, for    example, by cycloaddition of a metal azide such as, for example,    sodium azide or a trialkyl tin azide, on the nitrile function as is    indicated in the method described in the article mentioned below:

J. Organometallic Chemistry, 33, 337 (1971) S. Kozima et al.

It may be noted that the reaction for conversion of a carbamate to urea,and in particular of a sulfonyl carbamate to sulfonylurea, can becarried out, for example, at the reflux of the solvent such as, forexample, toluene, in the presence of the appropriate amine.

It is understood that the reactions described above can be carried outas indicated or alternatively, where appropriate, according to otherusual methods known to those skilled in the art.

-   i) The elimination of protective groups such as, for example, those    indicated above can be carried out under the usual conditions known    to those skilled in the art, in particular by acid or basic    hydrolysis carried out with an acid such as hydrochloric acid,    benzenesulfonic or para-toluenesulfonic acid, formic acid or    trifluoroacetic acid, or else by catalytic hydrogenation or using a    base such as potassium hydroxide, sodium hydroxide or    tetrabutylammonium fluoride.

The phthalimido group can be eliminated with hydrazine.

A list of various protective groups which can be used will be found, forexample, in patent BF 2 499 995.

-   j) The compounds described above can, if desired, be the subject of    salification reactions, for example with an mineral or organic acid    or with a mineral or organic base according to the usual methods    known to those skilled in the art.-   k) The possible optically active forms of the compounds described    above can be prepared by resolution of the racemic mixtures    according to the usual methods known to those skilled in the art.

The possible reactive functions may be hydroxyl or amino functions; theusual protective groups are used to protect these functions. Mention maybe made, for example, of the following amino radical-protecting groups:tert-butyl, tert-amyl, trichloroacetyl, chloroacetyl, benzhydryl,trityl, formyl, benzyloxycarbonyl, para-toluenesulfonyl, acetyl,benzenesulfonyl or benzoyl.

As hydroxyl radical-protecting group, mention may be made of theradicals such as formyl, benzyl, acetyl, chloroacetyl,tetrahydropyranyl, trimethylsilyl and tert-butyldimethylsilyl.

It is clearly understood that the list above is not limiting and thatother protective groups, for example known in peptide chemistry, can beused. A list of such protective groups can be found, for example, inFrench patent BF 2 499 995, the content of which is incorporated hereinby way of reference.

The optional reactions for eliminating the protective groups are carriedout as indicated in said patent BF 2 499 995. The preferred method ofelimination is acid hydrolysis by means of acids selected fromhydrochloric acid, benzenesulfonic acid or para-toluenesulfonic acid,formic acid or trifluoroacetic acid. Hydrochloric acid is preferred.

The optional reaction for hydrolysis of the group >C═NH to a ketonegroup is also preferably carried out by means of an acid, such asaqueous hydrochloric acid, for example at reflux.

The tert-butyldimethylsilyl protective group can be eliminated, forexample, by means of hydrochloric acid.

The optional esterification of a free OH radical is carried out underconventional conditions. Use may be made, for example, of an acid or ofa functional derivative, for example an anhydride such as aceticanhydride in the presence of a base such as pyridine.

The optional esterification or salification of a COOH group is carriedout under the conventional conditions known to those skilled in the art.

The optional amidation of a COOH radical is carried out underconventional conditions. Use may be made of a primary or secondary amineon a functional derivative of the acid, for example a symmetric or mixedanhydride.

The compounds which are the subject of the present invention haveadvantageous pharmacological properties: it has been noted that they inparticular possess protein kinase-inhibiting properties.

Among these protein kinases, mention may in particular be made of IGF1R.

Tests given in the experimental section hereinafter illustrate theinhibitory activity of the compounds of the present invention withrespect to such protein kinases.

These properties therefore make the compounds of formula (I) of thepresent invention usable as medicinal products for the treatment ofmalignant tumors.

The compounds of formula (I) can also be used in the veterinary field.

A subject of the invention is therefore the application, as medicinalproducts, of the pharmaceutically acceptable compounds of formula (I).

A subject of the invention is particularly the application, as medicinalproducts, of the compounds of formula (I), the names of which are givenbelow:

-   2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-(4-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperazin-1-yl)ethanol-   2-(1-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperid-4-yl)ethanol-   1′-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}-[1,4′]bipiperidyl-   1-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperid-3-ol-   2-{5,6-dimethoxy-1-[2-(4-methylperhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]-1-(4-hydroxypiperid-1-yl)ethanone-   2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone-   4-{[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one-   4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-   2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   4-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine-   2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyrid-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperid-4-yl)ethanol-   4-chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-morpholin-4-ylethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-(4-methyl[1,4]diazepan-1-yl)ethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]acetamide-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)ethanone-   1-{4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl)-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]ethanone-   (3aS,6aS)-5-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]acetyl}hexahydropyrrolo[3,4-c]pyrrol-1-one    trifluoroacetate-   2-{5-Methoxy-1-methyl-6-[3-(4-methylperhydro-1,4-diazepin-1-yl)propoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperid-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-[(1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine,

and also the prodrugs thereof, said compounds of formula (I) being inany possible racemic, enantiomeric or diastereoisomeric isomer form, andalso the pharmaceutically acceptable addition salts with mineral andorganic acids or with mineral and organic bases of said compounds offormula (I).

A subject of the invention is particularly the application, as medicinalproduct, of the compounds of formula (I), the names of which are givenbelow:

-   2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-   2-(4-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperazin-1-yl)ethanol-   2-(1-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-4-yl)ethanol-   1′-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-[1,4′]bipiperidinyl-   1-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-3-ol-   2-{5,6-Dimethoxy-1-[2-(4-methylperhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(4-hydroxypiperidin-1-yl)ethanone-   2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone-   4-{[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one-   4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-   2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   4-Chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine-   2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperidin-4-yl)ethanol-   4-Chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile-   2-{5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5,6-Dimethoxy-1-[2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridine-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-morpholin-4-ylethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methyl-[1,4]diazepan-1-yl)ethanone-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]acetamide-   2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)ethanone-   1-{4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl}-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethanone-   (3aS,6aS)-5-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetyl}hexahydropyrrolo[3,4-c]pyrrol-1-one    trifluoroacetate-   2-{5-methoxy-1-methyl-6-[3-(4-methylperhydro-1,4-diazepin-1-yl)propoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro    2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperidin-1-yl)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-(5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-   4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine,

and also the prodrugs thereof, said compounds of formula (I) being inany possible racemic, enantiomeric or diastereoisomeric isomer form, andalso the pharmaceutically acceptable addition salts with mineral andorganic acids or with mineral and organic bases of said compounds offormula (I).

The compounds can be administered parenterally, orally, perlingually,rectally or topically.

A subject of the invention is also the pharmaceutical compositions whichcontain, as active principle, at least one of the medicinal compounds offormula (I).

These compositions can be provided in the form of injectable solutionsor suspensions, of tablets, of coated tablets, of capsules, of syrups,of suppositories, of creams, of ointments and of lotions. Thesepharmaceutical forms are prepared according to the usual methods. Theactive principle can be incorporated into excipients usually used inthese compositions, such as aqueous or nonaqueous vehicles, talc, gumarabic, lactose, starch, magnesium stearate, cocoa butter, fattysubstances of animal or plant origin, paraffin derivatives, glycols,various wetting agents, dispersants or emulsifiers, preserving agents.

The usual dose, which is variable according to the individual treatedand the condition in question, can, for example, be from 10 mg to 500 mgper day in humans, given orally.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I) for preparing medicinal products intended toinhibit the activity of protein kinases, and in particular of a proteinkinase.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I) in which the protein kinase is a tyrosineprotein kinase.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I) in which the protein kinase is selected fromthe following group:

IGF1, Raf, EGF, PDGF, VEGF, Tie2, KDR, Flt1-3, FAK, Src, Abl, cKit,cdk1-9, Aurora1-2, cdc7, Akt, Pdk, S6K, Jnk, IR, FLK-1, FGFR1, FGFR2,FGFR3, FGFR4, FGFR5, PLK and Pyk2.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I), in which the protein kinase is moreparticularly selected from the following group: IGF1, cdc7, Aurora1-2,Src, Jnk, FAK, KDR, IR and Tie2.

The present invention thus relates particularly to the use of compoundsof formula (I) as defined above, or of pharmaceutically acceptable saltsof said compounds of formula (I), in which the protein kinase is IGF1R.

The present invention also relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I), in which the protein kinase is in a cellculture, and also to this use in a mammal.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I), for preparing a medicinal product intended toprevent or treat a disease characterized by a disturbance of theactivity of a protein kinase, and in particular such a disease in amammal.

The present invention relates to the use of compounds of formula (I) asdefined above, or of pharmaceutically acceptable salts of said compoundsof formula (I), for preparing a medicinal product intended to prevent ortreat a disease belonging to the following group: blood vesselproliferation disorders, fibrotic disorders, mesangial cellproliferation disorders, metabolic disorders, allergies, asthma,thromboses, nervous system diseases, retinopathies, psoriasis,rheumatoid arthritis, diabetes, muscle degeneration, diseases inoncology, and cancers.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I), for preparing a medicinal product intended totreat diseases in oncology.

The present invention relates particularly to the use of compounds offormula (I) as defined above, or of pharmaceutically acceptable salts ofsaid compounds of formula (I), for preparing a medicinal productintended to treat cancers.

Among these cancers, the present invention focuses most particularly onthe treatment of solid tumors and on the treatment of cancers that areresistant to cytotoxic agents.

Among these cancers, the present invention relates most particularly tothe treatment of breast cancer, stomach cancer, colon cancer, lungcancer, ovarian cancer, uterine cancer, brain cancer, kidney cancer,cancer of the larynx, cancer of the lymphatic system, thyroid cancer,cancer of the urogenital tract, cancer of the tract including thebladder and prostate, bone cancer, pancreatic cancer, and melanomas.

The present invention focuses even more particularly on the treatment ofbreast cancer, colon cancer and lung cancer.

The present invention thus relates to the use of compounds of formula(I) as defined above, or of pharmaceutically acceptable salts of saidcompounds of formula (I), for preparing a medicinal product intended forcancer chemotherapy.

As medicinal products according to the present invention, intended forcancer chemotherapy, the compounds of formula (I) according to thepresent invention can be used alone or in combination with chemotherapyor radiotherapy, or alternatively in combination with other therapeuticagents.

The present invention thus relates in particular to the pharmaceuticalcompositions as defined above, containing, in addition to the activeprinciples, other medicinal products for chemotherapy against cancer.

Such therapeutic agents may be commonly used antitumor agents.

As examples of known inhibitors of protein kinases, mention may inparticular be made of butyrolactone, flavopiridol,2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine, olomucine, Glivecand Iressa.

The compounds of formula (I) according to the present invention may thusalso advantageously be used in combination with antiproliferativeagents; by way of examples of such antiproliferative agents, butwithout, however, being limited to this list, mention may be made ofaromatase inhibitors, antiestrogens, topoisomerase I inhibitors,topoisomerase II inhibitors, agents that are active on microtubules,alkylating agents, histone deacetylase inhibitors, farnesyl transferaseinhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors,antineoplastic antimetabolites, platinum compounds, compounds whichdecrease protein kinase activity and also anti-angiogenic compounds,gonadorelin agonists, anti-androgens, bengamides, bisphosphonates andtrastuzumab.

Mention may thus be made, by way of examples, of anti-microtubule agentssuch as taxoids, vinca alkaloids, alkylating agents such ascyclophosphamide, DNA-intercalating agents such as cis-platinum, agentsthat are interactive on topoisomerase, such as camptothecin andderivatives, anthracyclines such as adriamycin, antimetabolites such as5-fluorouracil and derivatives, and the like.

The present invention therefore relates to compounds of formula (I) asprotein kinase inhibitors, said compounds of formula (I) being in anypossible racemic, enantiomeric or diastereoisomeric isomer form, andalso the pharmaceutically acceptable addition salts with mineral andorganic acids or with mineral and organic bases of said compounds offormula (I) and also the prodrugs thereof.

The present invention relates particularly to compounds of formula (I)as defined above, as IGF1R inhibitors.

The starting compounds for synthesizing the compounds of formula (I)according to the invention may be known, described in the documents ofthose skilled in the art or commercially available, or may be preparedaccording to usual methods known to those skilled in the art or elseaccording to the methods described in the attached schemes.

The experimental section hereinafter gives, more particularly, anillustration of the syntheses described in the schemes of the presentinvention, with the preparation of examples 1 to 175 of the presentapplication. The examples whose preparation follows, whether thisinvolves preparations of compounds or preparations of pharmaceuticalcompositions, illustrate the present invention without, however,limiting it.

In the preparations which follow, the analytical methods andpurification methods used to characterize the compounds are as follows:

Mass Spectrometry:

The spectra were produced by electron impact (EI) and/or by chemicaldesorption-ionization (CI) (reactant gas: ammonia) on a Finnigan SSQ7000 spectrometer.

Analytical Methods: Method A

Unless explicitly otherwise indicated, the reverse-phase liquidchromatography mass spectrometry (LC/MS) analyses were carried out on aMicromass model LCT device connected to an HP 1100 device. The abundanceof the compounds was measured by means of an HP G1315A diode arraydetector over a wavelength of 200-600 nm (DAD) and a Sedex 65 lightscattering detector. Acquisition of the mass spectra was carried outover a range of 180 to 800. The data were analyzed using the MicromassMassLynx software. Separation was carried out on a Hypersil BDS C18, 3μm (50×4.6 mm) column, elution being carried out with a linear gradientof 5 to 90% of acetonitrile containing 0.05% (v/v) of trifluoroaceticacid (TFA) in water containing 0.05% (v/v) TFA, over 3.5 min at a flowrate of 1 cm³/min. The total time for analysis, including the columnre-equilibration period, is 7 min.

Purification Methods: Method B

In general, the compounds obtained were purified by reverse-phase liquidchromatography mass spectrometry (LC/MS) using a Waters FractionLynxsystem composed of a Waters model 600 gradient pump, a Waters model 515regeneration pump, a Waters Reagent Manager dilution pump, a Watersmodel 2700 autoinjector, two Rheodyne LabPro model valves, a Watersmodel 996 diode array detector, a Waters model ZMD mass spectrometer anda Gilson model 204 fraction collector. The system was controlled by theWaters FractionLynx software. The separation was performed alternatelyon two Waters Symmetry columns (C₁₈, 5 μm, 19×50 mm, catalogue reference186000210), one column undergoing regeneration with a 95/5 (v/v)water/acetonitrile mixture containing 0.07% (v/v) of trifluoroaceticacid, while the other column was used for separation. The columns wereeluted using a linear gradient of acetonitrile containing 0.07% (v/v) oftrifluoroacetic acid in water containing 0.07% (v/v) of trifluoroaceticacid, at a flow rate of 10 cm³ min. At the separation column outlet, athousandth of the effluent was separated out using an LC PackingAccurate device, diluted with methanol at a flow rate of 0.05 cm³/minand sent to the detectors, in a proportion of 75% to the diode arraydetector and the remaining 25% to the mass spectrometer. The rest of theeffluent (999/1000) was sent to the fraction collector, where the flowwas discarded as long as the mass of the expected compound was notdetected by the FractionLynx software. The molecular formulae of theexpected compounds are supplied to the FractionLynx software, whichinitiates collection of the compound when the detected mass signalcorresponds to the [M+H]⁺ and/or [M+Na]⁺ ion. In certain cases,depending on the analytical LC/MS results, when an intense ioncorresponding to (M+2H]⁺⁺ was detected, the value corresponding to halfthe calculated molecular mass (MW/2) is also supplied to theFractionLynx software. Under these conditions, the collection is alsoinitiated when the mass signal for the [M+2H]⁺⁺ ion and/or the[M+Na+H]⁺⁺ ion is (are) detected. The compounds were collected in taredglass tubes.

The solutions having a volume greater than 0.5 cm³ are purified in twostages, the others in a single stage. The fractions are collected inpre-labeled and pre-tared hemolysis tubes, and only the tubes containingthe compound of expected molecular mass are used.

Unless explicitly otherwise indicated, the binary elution gradient usedfor these purifications is as follows:

Concentration gradient chromatographic method B Time (min) 0 0.5 9.5 1212.5 MeCN % 5 5 95 95 5

In the text, the method referred to as “method D” uses the sameequipment as that described above, but with the elution gradient below.

Concentration gradient chromatographic method C Time (min) 0 5 9 12 12.5MeCN % 5 5 95 95 5

In the text, the method referred to as “method E” uses the sameequipment as that described above, but with the elution gradient below.

Concentration gradient chromatographic method E Time (min) 0 1 8 9 1111.5 12 % 2 2 75 98 98 2 2 Acetonitrile

In the text, the method referred to as “method F” uses the sameequipment as that described above, but with the elution gradient below.

Concentration gradient chromatographic method F Time (min) 0 1 8 9 1111.5 12 MeCN % 5 5 75 95 95 5 5

In the text, the method referred to as “method G” uses the sameequipment as that described above, but with the elution gradient below.

Concentration gradient chromatographic method G Time (min) 0 1.5 8 10 1212.5 MeCN % 1 1 50 95 95 5

EXAMPLE 12-(5,6-Dimethoxy-1-vinyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridinetrifluoroacetate

The 2-(5,6-Dimethoxy-1-vinyl-1H-indol-3-yl)-1H-pyrrolo-[2,3-b]pyridinetrifluoroacetate can be prepared in the following way:

A solution of2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.5 g; 1.117 mmol) in dimethylformamide (5 ml) is placed in a 10 mlround-bottomed flask closed with a septum, and then1-bromo-2-chloroethane is added (0.865 g; 0.5 ml; 6.032 mmol). Thereaction mixture is stirred at ambient temperature and then sodiumhydride (0.1 g; 3.35 mmol) is added by means of 33 successive portions.When the reaction mixture becomes green, 1-bromo-2-chloroethane (0.865g; 0.5 cm³; 6.03 mmol) is added. The reaction is monitored by TLC (50/50cyclohexane/ethyl acetate) until the starting compound disappears. Thereaction mixture is run into a mixture of 20 ml of water and a saturatedammonium chloride solution (20 ml). Ethyl acetate (50 ml) is added, andthen separation by settling out and extraction with ethyl acetate (30ml) are performed. The combined extracts are washed with a saturatedammonium chloride solution (30 ml), dried over magnesium sulfate andevaporated under reduced pressure. The evaporation product is taken upin a 50/50 cyclohexane/ethyl acetate mixture and then left at ambienttemperature for 24 hours. The solid formed is filtered off, rinsed witha 72/25 cyclohexane/ethyl acetate mixture (15 ml), and then dried underreduced pressure. The compound obtained is purified by LCMS (method B).

2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.33 g) is isolated, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.30 (s: 3H); 3.73 (s:3H); 3.90 (s: 3H); 4.09 (t, J=6 Hz: 2H); 4.63 (t, J=6 Hz: 2H); 6.76 (s:1H); 6.95 (s: 1H); 7.26 (d, J=8.5 Hz: 2H); 7.27 (s: 1H); 7.32 (dd, J=8and 5 Hz: 1H); 7.55 (s: 1H); 7.58 (d, J=8.5 Hz: 2H); 7.96 (dd, J=8 and1.5 Hz: 1H); 8.38 (dd, J=5 and 1.5 Hz: 1H).

Mass spectrum: (EI): m/z=509 [M]⁺; m/z=354 [M-C₇H₇NSO₂]+(base peak)

2-(5,6-Dimethoxy-1-vinyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridinetrifluoroacetate (0.042 g) is also isolated, the characteristics ofwhich are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.89 (s: 3H); 3.93 (s:3H); 4.86 (broad d, J=8.5 Hz: 1H); 5.32 (broad d, J=15.5 Hz: 1H); 6.97(d, J=2 Hz: 1H); 7.11 (dd, J=8 and 5 Hz: 1H); 7.46 (s: 1H); 7.47 (s:1H); 7.63 (dd, J=15.5 and 8.5 Hz: 1H); 7.99 (broad d, J=8 Hz: 1H); 8.21(dd, J=5 and 1.5 Hz: 1H); 8.34 (s: 1H); 11.96 (unresolved peak: 1H).

Mass spectrum: (EI): m/z=319 [M]⁺ (base peak)

2-(5,6-Dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained as described in patent WO 03/0006881A1.

EXAMPLES 2 TO 79

A) Preparation:2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A solution of2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.331 g; 649 μmol), described in example 1, and sodium iodide (0.195 g;1.298 mmol) in methyl ethyl ketone (5 ml) is placed in a 10 mlround-bottomed flask. The reaction mixture is brought to reflux for 16hours. After evaporation, the product is taken up in a mixture of water(15 ml) and ethyl acetate (15 ml). After separation by settling out andextraction with ethyl acetate (2×15 ml), the organic extracts arecombined, dried over magnesium sulfate, and then evaporated underreduced pressure. The evaporation residue is chromatographed on silicagel, elution being carried out with a mixture of cyclohexane and ethylacetate (50/50). The fractions containing the expected compound arecombined and evaporated, giving2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.24 g; 69%), the characteristics of which are as follows:

LC/MS analysis: tr=3.9 min, m/z 601.99 [M+H]⁺

b) Alkylation of Examples 2 to 79

The amines below, in solution in dimethylformamide at a concentration of90 μmol per 0.5 ml of dimethylformamide, are placed in tared and labeledglass tubes (1.2×10 cm).

The compound2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis dissolved in dimethylformamide at a concentration of 30 μmol per 0.5ml of solvent.

MW Weight Ex Name or reagent Formula (g/mol) (mg) 22-(2-aminoethyl)-1-methylpyrrolidine C7H16N2 128.22 11.540 32-(aminomethyl)-1-ethylpyrrolidine C7H16N2 128.22 11.540 4n-(2-aminoethyl)pyrrolidine C6H14N2 114.19 10.280 5 furfurylamine C5H7NO97.12 8.741 6 I-methioninol C5H13NOS 135.23 12.170 7 imidazole C3H4N268.08 6.127 8 3-pyrroline C4H7N 69.11 6.220 9 pyrrolidine C4H9N 71.126.401 10 tetrahydrofurfurylamine C5H11NO 101.15 9.104 111-piperonylpiperazine C12H16N2O2 220.27 19.820 123,4-methylenedioxybenzylamine C8H9BO2 151.17 13.610 132-methylpiperazine C3H12N2 100.16 9.014 14 1-phenylpiperazine C10H14N2162.24 14.600 15 1-(2-methoxyphenyl)piperazine C11H16N2O 192.26 17.30016 n-(3-trifluoromethylphenyl)piperazine C11H13F3N2 230.23 20.720 171-(4-fluorophenyl)piperazine C10H13FN2 180.23 16.220 181-ethoxycarbonylpiperazine C7H14N2O2 158.2 14.240 19 1-methylpiperazineC5H12N2 100.16 9.014 20 1-benzylpiperazine C11H16N2 176.26 15.860 21n-(2-hydroxyethyl)piperazine C6H14N2O 130.19 11.720 222,6-dimethylmorpholine C6H13NO 115.18 10.370 231,4-dioxa-8-azaspiro[4.5]decane C7H13NO2 143.19 12.890 24 piperidineC5H11N 85.15 7.664 25 2-piperidineethanol C7H15NO 129.2 11.630 263,3-dimethylpiperidine C7H15N 113.2 10.190 27 3,5-dimethylpiperidineC7H15N 113.2 10.190 28 4-hydroxy-4-phenylpiperidine C11H15NO 177.2515.950 29 4-methylpiperidine C6H13N 99.18 8.926 30 4-piperidineethanolC7H15NO 129.2 11.630 31 1-(2-pyridyl)piperazine C9H13N3 163.22 14.690 324-piperidinopiperidine C10H20N2 168.28 15.150 3340-amino-1-benzylpiperidine C12H18N2 190.29 17.130 341-(2-aminoethyl)piperidine C7H16N2 128.22 11.540 352-amino-2-methyl-1-propanol C4H11NO 89.14 8.023 362-amino-5-diethylaminopentane C9H22N2 158.29 14.250 37 benzylamine C7H9N107.16 9.644 38 N,N-diethylethylenediamine C6H16N2 116.21 10.460 39ethanolamine C2H7NO 61.08 5.497 40 N,N-dimethyl-1,3-propanediamineC5H14N2 102.18 9.196 41 1-(3-aminopropyl)imidazole C6H11N3 125.17 11.27042 (s)-(+)-2-(methoxymethyl)pyrrolidine C6H13NO 115.18 10.370 43(s)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine C9H18N2 154.26 13.880 443-hydroxypiperidine C5H11NO 101.15 9.104 451-(3-aminopropyl)-4-methylpiperazine C8H19N3 157.26 14.150 46N1,N1-dimethyl-1,2-propanediamine C5H14N2 102.18 9.196 47N,N-diisopropylethylenediamine C8H20N2 144.26 12.980 483-(2-methylpiperidin-1-yl)propylamine C9H20N2 156.27 14.06 49dl-2-amino-1-propanol C3H9NO 75.11 3.756 50 tryptamine hydrochlorideC10H13ClN2 196.68 9.834 51 (s)-(+)-2-(anilinomethyl)pyrrolidine C11H16N2176.26 8.813 52 (+/−)-nornicotine C9H12N2 148.21 7.411 532-(2-aminoethyl)pyridine C7H10N2 122.17 6.109 544-benzyl-4-hydroxypiperidine C12H17NO 191.28 9.564 55N-aminopropylpiperidine C8H18N2 142.25 7.112 56N-(2-aminoethyl)-n-ethyl-m-toluidine C11H18N2 178.28 8.914 571-(4-methoxyphenyl)piperazine C11H16N2O 192.26 9.613 581-(2-phenylethyl)piperazine C12H18N2 190.29 9.515 591-(4-pyridyl)piperazine C9H13N3 163.22 8.161 601-(2-hydroxyphenyl)piperazine 2 HBr C10H16Br2N2O 340.06 17.00 61 adenineC5H5N5 135.13 6.757 62 N,N-2,2-tetramethyl-1,3-propanediamine C7H18N2130.23 6.512 63 1-cyclohexylpiperazine C10H20N2 168.28 8.414 64N-methylhomopiperazine C6H14N2 114.19 5.710 65 d-prolinol C5H11NO 101.155.058 66 (s)-(+)-2-amino-1-butanol C4H11NO 89.14 4.457 67 dimethylamineC2H7N 45.08 1.352 68 diethylamine C4H11N 73.14 2.194 691-(3-pyrrolidinopropyl)homopiperazine C12H25N3 211.35 6.340 702-(1H-pyrrol-1-yl)-1-ethanamine C6H10N2 110.16 3.305 712-(1-benzyl-piperidinyl)ethylamine C14H22N2 218.34 6.550 72diethanolamine C4H11NO2 105.14 12.620 73 2-(2-methylaminoethyl)pyridineC8H12N2 136.2 16.340 74 N-ethylmethylamine C3H9N 59.11 7.093 75N,N,N′-trimethylethylenediamine C5H14N2 102.18 12.260 76N-methylisobutylamine C5H13N 87.17 10.460 774-(ethylaminomethyl)pyridine C8H12N2 136.2 16.340 78bis(2-methoxyethyl)amine C6H15NO2 133.19 15.980 793-methylamino-1,2-propanediol C4H11NO2 105.14 12.6200.5 ml of each of the solutions prepared above is distributed intoreactors suitable for parallel synthesis, along with 0.5 ml per well ofthe solution of2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein dimethylformamide described above, and then from 0.01 to 0.015 g ofpotassium carbonate is added. Since the reactors are closed by means ofa septum, they are placed at 80° C. for 16 hours, with orbital shaking.After returning to ambient temperature, the content of the reactors isfiltered and then purified by reverse-phase liquid chromatography massspectrometry (method B). After evaporation of the fractions, weighingand analysis of the results of preparative reverse-phase liquidchromatography mass spectrometry, the intermediate compounds areisolated and identified, and are used in the following step.c) Detosylation of Examples 2 to 79

Each compound isolated above is dissolved in a methanolic potassiumhydroxide solution at 0.1 g/ml (0.5 ml), and each tube is then stopperedand shaken at ambient temperature for 60 hours. The content of each tubeis evaporated under reduced pressure, diluted with distilled water (1.5ml) and extracted with dichloromethane (3×0.9 ml). The organic extractsare combined, dried over magnesium sulfate, filtered in tared andlabeled glass tubes (1.2×10 cm), and then evaporated. The compoundsisolated after evaporation are weighed and diluted with dimethylsulfoxide (0.5 ml) and are then subjected to purification byreverse-phase liquid chromatography mass spectrometry in preparativemode (method B). The fractions containing the compounds of expectedmolar mass are evaporated, weighed and diluted to a concentration of 10mM in dimethyl sulfoxide. The expected compounds are identified andcharacterized by reverse-phase liquid chromatography mass spectrometryanalysis (method A). The results obtained are reported in the tablebelow.

IUPAC EF MW RT Ex (Parent) (parent) (parent) (min.) m/z % TRACE 2{2-[5,6-Dimethoxy-3-(1H- C26H33N5O2 447.58 2.51 448.43 79 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-[2-(1-methylpyrrolidin-2-yl)ethyl]amine 3 {2-[5,6-Dimethoxy-3-(1H- C26H33N5O2 447.58 2.48 448.4383 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(1-ethylpyrrolidin-2- ylmethyl)amine 4{2-[5,6-Dimethoxy-3-(1H- C25H31N5O2 433.56 2.50 434.43 82 DADpyrrolo[2,3-b]pyridin-2-yl)- 3alambda7-indol-1-yl]ethyl}-(2-pyrrolidin-1-yl-ethyl)amine 5 {2-[5,6-Dimethoxy-3-(1H- C24H24N4O3 416.482.71 417.35 88 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}furan-2-ylmethylamine 6 2-{2-[5,6-Dimethoxy-3-(1H- C24H30N4O3S454.59 2.71 455.38 91 DAD pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]ethylamino}-4-methylsulfanyl- butan-1-ol 72-[1-(2-Imidazol-1-yl-ethyl)-5,6- C22H21N5O2 387.44 2.54 388.36 84 DADdimethoxy-1H-indol-3-yl]-1H- pyrrolo[2,3-b]pyridine 82-{1-[2-(2,5-Dihydropyrrol-1-yl)- C23H24N4O2 388.47 2.61 389.37 96 DADethyl]-5,6-dimethoxy-1H-indol-3- yl}-1H-pyrrolo[2,3-b]pyridine 92-[5,6-Dimethoxy-1-(2-pyrrolidin- C23H26N4O2 390.49 2.61 391.39 100 DAD1-ylethyl)-1H-indol-3-yl]-1H- pyrrolo[2,3-b]pyridine 10{2-[5,6-Dimethoxy-3-(1H- C24H28N4O3 420.51 2.64 421.39 94 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]-ethyl}(tetrahydro-furan-2-ylmethyl)amine 11 2-{1-[2-(4-Benzo[1,3]dioxol-5- C31H33N5O4 539.64 2.84540.39 100 DAD ylmethylpiperazin-1-yl)ethyl]-5,6-dimethoxy-1H-indol-3-yl}-1H- pyrrolo[2,3-b]pyridine 121,3-Benzodioxol-5-ylmethyl-{2- C27H26N4O4 470.53 2.83 471.38 100 DAD[5,6-dimethoxy-2-(1H-pyrrolo- [2,3-b]pyridin-3-yl)indol-1-yl]-ethyl}amine 13 2-{5,6-Dimethoxy-1-[2-(2-methyl- C24H29N5O2 419.53 2.58420.41 94 DAD piperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 14 2-{5,6-Dimethoxy-1-[2-(4-phenyl-C29H31N5O2 481.60 2.95 482.42 100 DAD piperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 15 2-(5,6-Dimethoxy-1-{2-[4-(2- C30H33N5O3511.63 2.94 512.43 100 DAD methoxyphenyl)piperazin-1-yl]-ethyl}-1H-indol-3-yl)-1H- pyrrolo[2,3-b]pyridine 162-(5,6-Dimethoxy-1-{2-[4-(3- C30H30F3N5O2 549.60 3.22 550.36 97 DADtrifluoromethylphenyl)piperazin-1- yl]-ethyl}-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine 17 2-(1-{2-[4-(4-Fluorophenyl)- C29H30FN5O2499.59 2.99 500.39 100 DAD piperazin-1-yl]ethyl}-5,6-dimethoxy-1H-indol-3-yl)-1H- pyrrolo[2,3-b]pyridine 184-{2-[5,6-Dimethoxy-3-(1H- C26H31N5O4 477.56 2.69 478.41 100 ELSpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}piperazine-1-carboxylicacid ethyl ester 19 2-{5,6-Dimethoxy-1-[2-(4-methyl- C24H29N5O2 419.532.58 420.40 90 DAD piperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 20 2-{1-[2-(4-Benzylpiperazin-1-yl)-C30H33N5O2 495.63 2.83 496.43 100 DAD ethyl]-5,6-dimethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 21 2-(4-{2-[5,6-Dimethoxy-3-(1H-C25H31N5O3 449.55 2.57 450.44 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]-ethyl}piperazin-1-yl)ethanol 222-{1-[2-(2,6-Dimethylmorpholin-4- C25H30N4O3 434.54 2.68 435.42 100 DADyl)ethyl]-5,6-dimethoxy-1H-indol- 3-yl}-1H-pyrrolo[2,3-b]pyridine 238-{2-[5,6-Dimethoxy-3-(1H- C26H30N4O4 462.55 2.68 463.40 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-1,4-dioxa-8-aza-spiro[4,5]decane 24 2-[5,6-Dimethoxy-1-(2-piperidin- C24H28N4O2 404.512.64 405.39 95 DAD 1-yl-ethyl)-1H-indol-3-yl]-1H- pyrrolo[2,3-b]pyridine25 2-(1-{2-[5,6-Dimethoxy-3-(1H- C26H32N4O3 448.57 2.63 449.44 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]-ethyl}piperidin-2-yl)ethanol 262-{1-[2-(3,3-Dimethylpiperidin-1- C26H32N4O2 432.57 2.81 433.44 100 DADyl)ethyl]-5,6-dimethoxy-1H-indol- 3-yl}-1H-pyrrolo[2,3-b]pyridine 272-{1-[2-(3,5-Dimethylpiperidin-1- C26H32N4O2 432.57 2.85 433.44 100 DADyl)ethyl]-5,6-dimethoxy-1H-indol- 3-yl}-1H-pyrrolo[2,3-b]pyridine 281-{2-[5,6-Dimethoxy-3-(1H- C30H32N4O3 496.61 2.84 497.41 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]-ethyl}-4-phenylpiperidin-4-ol 292-{5,6-Dimethoxy-1-[2-(4-methyl- C25H30N4O2 418.54 2.74 419.42 100 DADpiperidin-1-yl)ethyl]-1H-indol-3- yl}-1H-pyrrolo[2,3-b]pyridine 302-(1-{2-[5,6-Dimethoxy-3-(1H- C26H32N4O3 448.57 2.59 449.43 95 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}piperidin-4-yl)ethanol 312-{5,6-Dimethoxy-1-[2-(4-pyridin- C28H30N6O2 482.59 2.55 483.42 100 DAD2-ylpiperazin-1-yl)ethyl]-1H-indol- 3-yl}-1H-pyrrolo[2,3-b]pyridine 321′-{2-[5,6-Dimethoxy-3-(1H- C29H37N5O2 487.65 2.51 488.46 100 DADpyrrolo[2,3-b]pyridin-2-yl)-indol-1- yl]ethyl}-[1,4′]bipiperidinyl 33(1-Benzylpiperidin-4-yl)-{2-[5,6- C31H35N5O2 509.65 2.64 510.42 100 DADdimethoxy-3-(1H-pyrrolo- [2,3-b]pyridin-2-yl)-indol-1-yl]- ethyl}-amine34 {2-[5,6-Dimethoxy-3-(1H- C26H33N5O2 447.58 2.54 448.43 91 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-(2-piperidin-1-ylethyl)-amine 35 2-{2-[5,6-Dimethoxy-3-(1H- C23H28N4O3 408.50 2.50 409.41 96 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethylamino}-2-methyl-propan- 1-ol36 N4-{2-[5,6-Dimethoxy-3-(1H- C28H39N5O2 477.65 2.53 478.49 92 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-N1,N1-diethylpentane-1,4-diamine 37 Benzyl-{2-[5,6-dimethoxy-3-(1H- C26H26N4O2 426.52 2.82427.38 100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}amine 38N′-{2-[5,6-Dimethoxy-3-(1H- C25H33N5O2 435.57 2.52 436.45 92 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-N,N-diethylethane-1,2-diamine 39 2-{2-[5,6-Dimethoxy-3-(1H- C21H24N4O3 380.45 2.57 381.36 91DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethylamino}ethanol 40N′-{2-[5,6-Dimethoxy-3-(1H- C24H31N5O2 421.54 2.47 422.42 86 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-N,N-dimethylpropane-1,3-diamine 41 {2-[5,6-Dimethoxy-3-(1H- C25H28N6O2 444.54 2.47 445.41 92DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(3-imidazol-1-ylpropyl)- amine 42 2-{5,6-Dimethoxy-1-[2-(5-C25H30N4O3 434.54 2.66 435.42 95 DAD methoxymethylpyrrolidin-1-yl)-ethyl]-1H-indol-3-yl}-1H- pyrrolo[2,3-b]pyridine 432-{5,6-Dimethoxy-1-[2-(5- C28H35N5O2 473.62 2.53 474.47 92 DADpyrrolidin-1-ylmethylpyrrolidin-1- yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 44 1-{2-[5,6-Dimethoxy-3-(1H- C24H28N4O3 420.512.57 421.40 97 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-3-ol 45 {2-[5,6-Dimethoxy-3-(1H- C27H36N6O2 476.622.46 477.46 95 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-[3-(4-methylpiperazin-1- yl)propyl]amine 46N2-{2-[5,6-Dimethoxy-3-(1H- C24H31N5O2 421.54 2.49 422.42 84 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-N1,N1-dimethylpropane-1,2-diamine 47 N′-{2-[5,6-Dimethoxy-3-(1H- C27H37N5O2 463.63 2.54 464.47100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-N,N-diisopropylethane- 1,2-diamine 48 {2-[5,6-Dimethoxy-3-(1H-C28H37N5O2 475.63 2.53 476.48 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-[3-(2-methylpiperidin-1-yl)propyl]amine 49 2-{2-[5,6-Dimethoxy-3-(1H- C22H26N4O3 394.47 2.54395.38 96 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethylamino}propan-1-ol 50 {2-[5,6-Dimethoxy-3-(1H- C29H29N5O2 479.582.95 480.41 100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethy}-[2-(1H-indol-3-yl)ethyl]- amine 51 (1-{2-[5,6-Dimethoxy-3-(1H-C30H33N5O2 495.63 2.98 496.44 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}pyrrolidin-2-ylmethyl)-phenylamine 52 2-{5,6-Dimethoxy-1-[2-(5-pyridin- C28H29N5O2 467.57 2.57468.41 97 DAD 3-yl-pyrrolidin-1-yl)ethyl]-1H- indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 53 {2-[5,6-Dimethoxy-3-(1H- C26H27N5O2 441.532.55 442.41 95 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(2-pyridin-2-ylethyl)- amine 544-Benzyl-1-{2-[5,6-dimethoxy-3- C31H34N4O3 510.64 2.89 511.41 100 DAD(1H-pyrrolo[2,3-b]pyridin-2-yl)- indol-1-yl]ethyl}piperidin-4-ol 55{2-[5,6-Dimethoxy-3-(1H- C27H35N5O2 461.61 2.51 462.46 94 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-(3-piperidin-1-yl-propyl)amine 56 N′-{2-[5,6-Dimethoxy-3-(1H- C30H35N5O2 497.64 3.11498.43 100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-N-ethyl-N-m-tolylethane- 1,2-diamine 572-(5,6-Dimethoxy-1-{2-[4-(4- C30H33N5O3 511.63 2.96 512.43 100 DADmethoxyphenyl)piperazin-1-yl]- ethyl}-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine 58 2-{5,6-Dimethoxy-1-[2-(4- C31H35N5O2 509.652.91 510.42 100 DAD phenethylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo- [2,3-b]pyridine 592-{5,6-Dimethoxy-1-[2-(4-pyridin- C28H30N6O2 482.59 2.48 483.42 94 ELS4-ylpiperazin-1-yl)ethyl]-1H-indol- 3-yl}-1H-pyrrolo[2,3-b]pyridine 602-(4-{2-[5,6-Dimethoxy-3-(1H- C29H31N5O3 497.60 2.85 498.39 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}piperazin-1-yl)phenol 61{2-[5,6-Dimethoxy-3-(1H- C24H22N8O2 454.49 2.55 455.36 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}purin-6-ylamine 62N′-{2-[5,6-Dimethoxy-3-(1H- C26H35N5O2 449.60 2.49 450.47 92 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}-2,2,N,N-tetramethyl-propane-1,3-diamine 63 2-{1-[2-(4-Cyclohexylpiperazin-1- C29H37N5O2487.65 2.77 488.45 100 DAD yl)ethyl]-5,6-dimethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine 64 2-{5,6-Dimethoxy-1-[2-(4-methyl-C25H31N5O2 433.56 2.49 434.43 94 DAD perhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H- pyrrolo[2,3-b]pyridine 65 (1-{2-[5,6-Dimethoxy-3-(1H-C24H28N4O3 420.51 2.56 421.40 97 DADpyrrolo[2,3-b]pyridin-2-yl)-indol-1- yl]ethyl}pyrrolidin-2-yl)methanol66 2-{2-[5,6-Dimethoxy-3-(1H- C23H28N4O3 408.50 2.60 409.40 97 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethylamino}butan-1-ol 67{2-[5,6-Dimethoxy-3-(1H- C21H24N4O2 364.449 2.70 365.30 100 DADpyrrolo[2,3-b]pyridin-2-yl)-indol-1- yl]ethyl}dimethylamine 68{2-[5,6-Dimethoxy-3-(1H- C23H28N4O2 392.503 2.78 393.30 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}diethylamine 692-(5,6-Dimethoxy-1-{2-[4-(3- C31H42N6O2 530.717 2.66 531.34 100 DADpyrrolidin-1-yl-propyl)perhydro- 1,4-diazepin-1-yl]ethyl}-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine 70 {2-[5,6-Dimethoxy-3-(1H- C25H27N5O2429.524 2.94 430.26 100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(2-pyrrol-1-ylethyl)amine 71[2-(1-Benzylpiperidin-4-yl)ethyl]- C33H39N5O2 537.708 2.83 538.29 100DAD {2-[5,6-dimethoxy-3-(1H- pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}amine 72 2-[{2-[5,6-Dimethoxy-3-(1H- C23H28N4O4 424.501 2.54425.65 100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(2-hydroxyethyl)amino]- ethanol 73 {2-[5,6-Dimethoxy-3-(1H-C27H29N5O2 455.562 2.63 456.70 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}methyl-(2-pyridin-2-yl-ethyl)amine 74 {2-[5,6-Dimethoxy-3-(1H- C22H26N4O2 378.476 2.61 379.59100 DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}ethylmethylamine 75N-{2-[5,6-Dimethoxy-3-(1H- C24H31N5O2 421.545 2.53 422.2 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]-ethyl}-N,N′,N′-trimethylethane-1,2-diamine 76 {2-[5,6-Dimethoxy-3-(1H- C24H30N4O2 406.53 2.75 407.21 96DAD pyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}isobutylmethylamine 77{2-[5,6-Dimethoxy-3-(1H- C27H29N5O2 455.562 2.62 456.13 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}ethylpyridin-4-ylmethylamine 78 {2-[5,6-Dimethoxy-3-(1H-C25H32N4O4 452.555 2.71 453.26 100 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}bis(2-methoxyethyl)- amine79 3-({2-[5,6-Dimethoxy-3-(1H- C23H28N4O4 424.501 2.54 425.59 94 DADpyrrolo[2,3-b]pyridin-2-yl)indol-1- yl]ethyl}methylamino)propane-1,2-diol

EXAMPLE 80{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(2-methoxyethyl)methylaminetrifluoroacetate

-   a)    {2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl)ethyl}-(2-methoxyethyl)methylamine    trifluoroacetate can be prepared in the following way:

(2-{5,6-Dimethoxy-3-(1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]-pyridin-2-yl)indol-1-yl}ethyl)-(2-methoxyethyl)methylaminetrifluoroacetate (0.0152 g; 22.46 μmol) is dissolved in a methanolicpotassium hydroxide solution (0.5 ml; 0.1 g of potassium hydroxide/mlmethanol) and then agitated at ambient temperature for 48 hours. Afterevaporation, the residue is taken up, with agitation, in 0.7 ml of adimethyl sulfoxide and 12N aqueous hydrochloric acid (50/50 v/v). Afterreturning to ambient temperature, dimethyl sulfoxide (0.35 ml) is addedand then purification is carried out by reverse-phase liquidchromatography mass spectrometry (method B). The fractions containingthe expected compound are combined and evaporated.

{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-(2-methoxyethyl)methylaminetrifluoroacetate (0.0094 g; 80%) is isolated, the characteristics ofwhich are as follows:

LC/MS analysis: tr=2.4 min, m/z=409.24 [M+H}⁺

-   b)    (2-{5,6-Dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl}ethyl)-(2-methoxyethyl)methylamine    trifluoroacetate can be prepared in the following way:

A solution of2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.021 g; 50 μmol) in N-methylpyrrolidine (0.5 ml) is placed in a 5 mlconical-bottomed Wheaton reactor, and then 2-methoxy-N-methylamine(0.013 g; 150 μmol) and potassium carbonate (0.021 g; 150 μmol) areadded. The reaction mixture is agitated and heated at 70° C. overnight.After returning to ambient temperature, the mixture is filtered andevaporated to dryness and the residue is then taken up in dimethylsulfoxide and purified by reverse-phase liquid chromatography massspectrometry (method B). After treatment and evaporation of thefractions,(2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl}ethyl)-(2-methoxyethyl)methylaminetrifluoroacetate (0.015 g; 45%) is isolated, the characteristics ofwhich are as follows:

LC/MS analysis (method B): tr=5.6 min, m/z=563.35 [M+H}⁺

EXAMPLE 812-[(3-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethylamino}propyl)(2-hydroxyethyl)amino]ethanoltrifluoroacetate

-   a)    2-[(3-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethylamino}propyl)(2-hydroxyethyl)amino]ethanol    trifluoroacetate can be prepared in the following way:

(2-[[3-(2-{5,6-Dimethoxy-3-(1-[toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl)ethylamino}propyl](2-hydroxyethyl)amino]ethanoltrifluoroacetate (0.013 g; 17.6 μmol) is dissolved in a methanolicpotassium hydroxide solution (0.5 ml; 0.1 g of potassium hydroxide perml methanol) and then agitated at ambient temperature for 48 hours.After evaporation, the residue is taken up, with agitation, in 0.7 ml ofa mixture of dimethyl sulfoxide and 12N aqueous hydrochloric acid (50/50v/v). After returning to ambient temperature, 0.35 ml of dimethylsulfoxide are added and then purification is carried out byreverse-phase liquid chromatography mass spectrometry (method B). Thefractions containing the expected compound are combined and evaporated,resulting in2-[(3-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethylamino}propyl)(2-hydroxyethyl)amino]ethanoltrifluoroacetate (0.005 g; 39%), the characteristics of which are asfollows:

LC/MS analysis: tr=3.1 min, m/z=482.02 [M+H]⁺

-   b)    2-[[3-{5,6-Dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}ethylamino)propyl](2-hydroxyethyl)amino]ethanol    trifluoroacetate can be prepared in the following way:

A solution of2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.02 g; 50 μmol) in N-methylpyrrolidone (0.5 ml) is placed in a 5 mlconical-bottomed Wheaton reactor, and thenN-(3-aminopropyl)diethanolamine (0.024 g; 150 μmol) and potassiumcarbonate (0.021 g; 150 μmol) are added. The reaction mixture is stirredand heated at 70° C. overnight. After returning to ambient temperature,the mixture is filtered and evaporated to dryness and the residue isthen taken up in dimethyl sulfoxide and purified by reverse-phase liquidchromatography mass spectrometry (method B). After treatment andevaporation of the fractions,2-[[3-(2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-indol-1-yl}ethylamino)propyl]-(2-hydroxyethyl)amino]ethanoltrifluoroacetate is isolated (0.013 g, 35%), the characteristics ofwhich are as follows:

LC/MS analysis (method B): tr=5 min, m/z=636.43 [M+H]⁺

EXAMPLE 822-(4-{3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propyl}piperazin-1-yl)ethanoltrifluoroacetate

-   a)    2-(4-{3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propyl}piperazin-1-yl)ethanol    trifluoroacetate can be prepared in the following way:

A solution of2-[4-(3-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}propyl)piperazin-1-yl]ethanoltrifluoroacetate (0.038 g; 52.2 μmol) in a methanolic potassiumhydroxide solution (3 ml, 0.1 g of potassium hydroxide per ml ofmethanol) is placed in a hemolysis tube (1.3×10 cm) and is agitated at20° C. for 72 hours. The solid form is filtered off and then purified byreverse-phase liquid chromatography mass spectrometry (method E). Thefractions containing the expected compound are combined and thenevaporated under reduced pressure, giving2-(4-{3-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propyl}piperazin-1-yl)ethanoltrifluoroacetate (0.022 g; 90%), the characteristics of which are asfollows:

LC/MS analysis: tr=2.7 min., m/z=464.29 [M+H]⁺

b)2-[4-(3-[5,6-Dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl]propyl)piperazin-1-yl]ethanoltrifluoroacetate can be prepared in the following way:

A solution of2-[1-(3-iodopropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.04 g; 65 μmol) in dimethylformamide (0.5 ml) is placed in a hemolysistube (1.3×10 cm) and then potassium carbonate (0.027 g; 195 μmol) andN-(2-hydroxyethyl)piperazine (0.025 g; 195 μmol) are successively added.The reactor is agitated at 60° C. for 16 hours. After returning to 21°C. and filtration, the solution obtained is purified by reverse-phaseliquid chromatography mass spectrometry (method B). The fractionscontaining the expected compound are combined and then evaporated underreduced pressure, giving2-[4-(3-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}propyl)piperazin-1-yl]ethanoltrifluoroacetate (0.038 g, 69%), used as it is in the following step.

c)2-[1-(3-Iodopropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

2-[1-(3-Chloropropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)—1H-pyrrolo[2,3-b]pyridine(0.395 g; 753.8 μmol) and sodium iodide (0.169 g; 1.13 mmol) in methylethyl ketone (10 ml) are placed in a 50 ml single-necked flask, atreflux. After 16 hours, sodium iodide (0.169 g; 1.13 mmol) is added andreflux is maintained for a further 5 hours. The reaction mixture isevaporated under reduced pressure and the residue is then dissolved in50 ml of ethyl acetate, transferred into a separating funnel and washedwith 2 times 30 ml of distilled water. The organic extract is dried overmagnesium sulfate, filtered and evaporated under reduced pressure, togive the crude compound, which is purified by chromatography on silicagel (10 μg, silica 20-40 μm), elution being carried out at 10 ml/minwith a mixture of cyclohexane and ethyl acetate (70/30; v/v). Thefractions containing the expected compound are combined and evaporatedto give2-[1-(3-iodopropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein the form of an amorphous solid (0.287 g, 62%), the characteristics ofwhich are as follows:

Mass spectrum (EI): m/z=615 [M]⁺; m/z=460 [M-C₇H₇NSO₂]⁺; m/z=333[460-I]⁺ (base peak)

d)2-[1-(3-Chloropropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A solution of2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b](0.447g; 998 μmol) in solution in dimethylformamide (10 ml) is placed in 25 mlthree-necked flask maintained under argon, and then sodium hydride(0.0898 g; 2.99 mmol) is added. The mixture is agitated at 21° C. for 10minutes and then 1-bromo-3-chloropropane (0.514 g; 2.99 mmol) is added.The reaction is carried out at this temperature for 1 hour 30 min. Thereaction mixture is run into 100 ml of water and then extracted threetimes with 50 ml of ethyl acetate. The organic extracts are combined,washed with 50 ml of a saturated ammonium chloride solution, dried overmagnesium sulfate and then evaporated. An oil is isolated, which istriturated in diisopropyl ether. The solid formed is filtered off.2-[1-(3-Chloropropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis isolated in the form of a white solid (0.395 g; 75.5%), thecharacteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.30 (s: 3H); 2.31(mt: 2H); 3.66 (t, J=6.5 Hz: 2H); 3.74 (s: 3H); 3.90 (s: 3H); 4.41(broad t, J=6.5 Hz: 2H); 6.79 (s: 1H); 6.96 (s: 1H); 7.21 (s: 1H); 7.26(broad d, J=8.5 Hz: 2H); 7.32 (dd, J=8 and 5 Hz: 1H); 7.51 (s: 1H); 7.58(d, J=8.5 Hz: 2H); 7.96 (dd, J=8 and 1.5 Hz: 1H); 8.37 (dd, J=5 and 1.5Hz: 1H).

Mass spectrum (EI): m/z=523 [M]⁺; m/z=368 [M-C₇H₇NSO₂]⁺ (base peak)

2-(5,6-Dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinewas prepared as described in patent WO 03/000688 A1.

EXAMPLE 832-{5,6-Dimethoxy-1-[3-(4-methylperhydro-1,4-diazepin-1-yl)propyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridinetrifluoroacetate

a)2-{5,6-Dimethoxy-1-[3-(4-methylperhydro-1,4-diazepin-1-yl)propyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridinecan be prepared in the same way as above (example 82a), but using2-{5,6-dimethoxy-1-[3-(4-methylperhydro-1,4-diazepin-1-yl)propyl]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinetrifluoroacetate, (0.053 g, 63.9 μmol).2-{5,6-dimethoxy-1-[3-(4-methylperhydro-1,4-diazepin-1-yl)propyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridinetrifluoroacetate (0.023 g, 45%) is thus obtained, the characteristics ofwhich are as follows:

LC/MS analysis: tr=2.8 min. m/z=448.30 [M+H]⁺

b)2-{5,6-Dimethoxy-1-[3-(4-methylperhydro-1,4-diazepin-1-yl)propyl]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinetrifluoroacetate can be prepared in the same way as above (example 82b),but using2-[1-(3-iodopropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.04 g, 65 μmol), potassium carbonate (0.027 g; 195 μmol) and1-methylhomopiperazine (0.022 g; 195 μmol);2-{5,6-dimethoxy-1-[3-(4-methylperhydro-1,4-diazepin-1-yl)propyl]-1H-indol3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine trifluoroaceate(0.053 g; 98%) is obtained, which is used as it is in the followingstep.

c)2-[1-(3-Iodopropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared according to example 82c.

EXAMPLES 84 to 87

Step 1: alkylation

The amines specified in the table below are weighed out and solubilizedin dimethylformamide (concentration of 120 μmol in 0.5 ml ofdimethylformamide).

Empirical MW Weight Example Name formula (g/mol) (mg) 84 morpholineC4H9NO 87.12 10.450 85 4-piperidinopiperidine C10H20N2 168.28 20.190 864-piperidineethanol C7H15NO 129.2 15.500 87 3-hydroxypiperidine C5H11NO101.15 12.140

0.5 ml of each amine solution is distributed into reactors suitable forparallel synthesis, then potassium carbonate (0.017 g per well) is addedand, finally, 40 μmol of2-[1-(3-iodopropyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(example 82c) in solution in dimethylformamide (0.5 ml) is distributedper reactor. The calypso reactor is closed and then placed at 50° C. for16 hours with orbital shaking. After returning to 20° C., the solutionsobtained above are purified by reverse-phase liquid chromatography massspectrometry (method B). After evaporation, weighing, dilution andanalysis by reverse-phase liquid chromatography mass spectrometry(method A), the expected compounds are isolated, which are used in thefollowing step.

Step 2: Deprotection

Each compound obtained above is treated with 1 ml of a methanolicpotassium hydroxide solution (0.1 g of potassium hydroxide per ml ofmethanol) for 48 hours at 21° C. The solutions are evaporated underreduced pressure and the solids obtained are then dissolved in dimethylsulfoxide (0.5 ml). 0.5 ml of 1M aqueous hydrochloric acid is then addedto the solution thus obtained and the compounds obtained are thenpurified by means of two successive rounds of reverse-phase liquidchromatography mass spectrometry (method E). After treatment of thefractions and analysis by reverse-phase liquid chromatography massspectrometry (method A), the following compounds are identified andcharacterized:

Ex NAME EF MW (g/mol) RT (min) m/z % 84 2-[5,6-Dimethoxy-1-(3-C24H28N4O3 420.51 2.66 421.69 100 morpholin-4-ylpropyl)-1H-indol-3-yl]-1H- pyrrolo[2,3-b]pyridine 85 1′-{3-[5,6-Dimethoxy-3-C30H39N5O2 501.67 2.56 502.14 96 (1H-pyrrolo[2,3-b]-pyridin-2-yl)indol-1- yl]-propyl}- [1,4′]bipiperidyl 862-(1-{3-[5,6-Dimethoxy- C27H34N4O3 462.59 2.64 463.08 1003-(1H-pyrrolo[2,3-b]- pyridin-2-yl)indol-1- yl]propyl}piperidin-4-yl)ethanol 87 1-{3-[5,6-Dimethoxy-3- C25H30N4O3 434.54 2.61 435.12 100(1H-pyrrolo[2,3-b]- pyridin-2-yl)indol-1- yl]propyl}piperidin-3-ol

EXAMPLE 882-[5,6-Dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine

a)2-[5,6-Dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.080 g of2-[5,6-dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis added, at a temperature in the region of 20° C., to a solution of 3.1ml of methanolic potassium hydroxide (0.1 g/ml; 1.78M). The reactionmedium is agitated at this same temperature for 5 hours. The reactionmedium is then heated at 50° C. for 4 hours. After cooling, the solidformed is filtered off through sintered glass, washed twice with 3 ml ofmethanol, and then 5 times with 5 ml of water. The solid is dried in anoven (35° C.) under vacuum. 0.019 g of2-[5,6-dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.29 (s: 3H); 3.73 (t,J=5 Hz: 2H); 3.87 (s: 3H); 3.90 (s: 3H); 4.37 (broad t, J=5 Hz: 2H);6.79 (broad s: 1H); 7.03 (dd, J=8 and 5 Hz: 1H); 7.22 (s: 1H); 7.44 (s:1H); 7.87 (broad d, J=8 Hz: 1H); 7.87 (s: 1H); 8.03 (dd, J=5 and 1.5 Hz:1H); 11.79 (broad s: 1H).

Mass spectrum (EI): m/z 351 [M+H]⁺ (base peak)

b)2-[5,6-Dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.01 g of sodium hydride (60%) is added to a solution of 0.1 g of2-[5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 2.5 ml of anhydrous dimethylformamide, under an inert argonatmosphere at a temperature in the region of 20° C. Agitation ismaintained at this temperature for 30 minutes. 0.023 ml of bromoethylmethyl ether is added. The reaction medium is agitated at the sametemperature for 16 hours. 3 ml of water and 3 ml of ethyl acetate areadded. After separation by settling out, the organic phase is dried oversodium sulfate, filtered, and then concentrated under reduced pressure.The residue obtained is purified on a flash-pack chromatographycartridge (silica, dichloromethane as eluent). The fractions containingthe product are concentrated under reduced pressure. 0.082 g of2-[5,6-dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=505 [M]⁺; m/z=350 (base peak)

The compound2-(5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)—1H-pyrrolo[2,3-b]pyridineis prepared according to the process described in patent WO 03/000688A1.

EXAMPLE 892-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanol

a) 2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanolis prepared in the following way:

1.65 ml of a 5N aqueous potassium hydroxide solution are added to asolution of 0.18 g of2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}ethanolin 10 ml of methanol, at a temperature in the region of 20° C. Thereaction medium is refluxed for 4 hours. After cooling, the solid formedis filtered off through sintered glass, and washed twice with 3 ml ofmethanol and then five times with 5 ml of water. The solid is purifiedby flash-pack chromatography (silica, 95/05 by volumedichloromethane/methanol as eluents). 0.045 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanol isobtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.80 (unresolved peak:2H); 3.87 (s: 3H); 3.91 (s: 3H); 4.26 (broad t, J=5.5 Hz: 2H); 5.00(unresolved peak: 1H); 6.78 (d, J=2 Hz: 1H); 7.03 (dd, J=8 and 5 Hz:1H); 7.19 (s: 1H); 7.45 (s: 1H); 7.87 (broad d, J=8 Hz: 1H); 7.89 (s:1H); 8.13 (dd, J=5 and 1.5 Hz: 1H); 11.78 (broad s: 1H).

Mass spectrum (EI): m/z=337 [M]⁺ (base peak)

b)2-{5,6-Dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}ethanolis prepared in the following way:

1.52 ml of tetrabutylammonium fluoride (TBAF) are added, dropwise, to asolution of 0.46 g of2-[5,6-dimethoxy-1-(2-tert-butyldimethylsilyloxyethyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 9.5 ml of anhydrous tetrahydrofuran, under an inert argon atmosphereat a temperature in the region of 20° C. The reaction medium is agitatedat the same temperature for 6 hours. The reaction medium is concentratedunder reduced pressure. The residue obtained is purified by flashchromatography (silica, 98/02 by volume dichloromethane/methanol aseluents, argon). The fractions containing the product are concentratedunder reduced pressure. 0.187 g of2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-indol-1-yl}ethanol,the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.30 (s: 3H); 3.74 (s:3H); 3.83 (mt: 2H); 3.88 (s: 3H); 4.30 (t, J=6 Hz: 2H); 5.00 (unresolvedpeak: 1H); 6.75 (s: 1H); 6.95 (s: 1H); 7.20 (s: 1H); 7.25 (broad d, J=8Hz: 2H); 7.31 (dd, J=8 and 5 Hz: 1H); 7.50 (s: 1H); 7.58 (d, J=8 Hz:2H); 7.95 (dd, J=8 and 1.5 Hz: 1H); 8.37 (dd, J=5 and 1.5 Hz: 1H).

c)2-[5,6-Dimethoxy-1-(2-tert-butyldimethylsilyloxyethyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine)is prepared in the following way:

0.049 g of sodium hydride (at 60%) is added to a solution of 0.5 g of2-(5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 12.5 ml of anhydrous dimethylformamide, under an inert argonatmosphere at a temperature in the region of 20° C. Agitation ismaintained at this temperature for 30 minutes. 0.264 ml of2-tert-butyldimethylsilyloxyethyl bromide is added. The reaction mediumis agitated at the same temperature for 16 hours. 25 ml of water and 20ml of ethyl acetate are added. After separation by settling out, theorganic phase is dried over sodium sulfate, filtered, and thenconcentrated under reduced pressure. The residue obtained is purified byflash chromatography (silica, 98/02 by volume dichloromethane/methanolas eluents, argon). The fractions containing the product areconcentrated under reduced pressure. 0.47 g of2-[5,6-dimethoxy-1-(2-tert-butyldimethylsilyloxyethyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=605 [M]⁺; m/z=450 (base peak)

The compound2-(5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-pyridineis prepared according to the process described in patent WO 03/000688A1.

EXAMPLE 90 3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanol

a) 3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanolis prepared by following the procedure described in example 88a, butusing 0.24 g of3-[5,6-dimethoxy-3-(1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanoland a solution of 9.3 ml of methanolic potassium hydroxide (0.1 g/ml;1.78M). After purification by flash-pack chromatography (silica, 98/02by volume dichloromethane/methanol as eluents), 0.103 g of3-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanol isobtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.99 (mt: 2H); 3.48(mt: 2H); 3.88 (s: 3H); 3.92 (s: 3H); 4.27 (broad t, J=7 Hz: 2H); 4.66(broad t, J=5 Hz: 1H); 6.78 (d, J=2 Hz: 1H); 7.03 (dd, J=8 and 5 Hz:1H); 7.17 (s: 1H); 7.45 (s: 1H); 7.87 (s: 1H); 7.87 (dd, J=8 and 1.5 Hz:1H); 8.13 (dd, J=5 and 1.5 Hz: 1H); 11.73 (unresolved peak: 1H).

Mass spectrum (EI): m/z=351 [M]⁺ (base peak)

b)3-{5,6-Dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}propanoland2-[5,6-dimethoxy-1-(3-fluoropropyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare prepared by following the procedure described in example 89b, butusing 0.605 g of2-[5,6-dimethoxy-1-(3-tert-butyldimethylsilyloxypropyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.95 ml of tetrabutylammonium fluoride (TBAF). After purification byflash chromatography (silica, 98/02 by volume dichloromethane/methanolas eluents, argon), 0.243 g of3-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}propanolis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=505 [M]⁺ (base peak) and 0.046 g of2-[5,6-dimethoxy-1-(3-fluoropropyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=507 [M]⁺ (base peak)

c)2-[5,6-Dimethoxy-1-(3-tert-butyldimethylsilyloxypropyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89c, butusing 0.285 ml of 2-tert-butyldimethylsilyloxypropyl bromide and 0.5 gof2-[5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.049 g of sodium hydride (at 60%). After purification by flashchromatography (silica, 98/02 by volume dichloromethane/methanol aseluents, argon), 0.605 g of2-[5,6-dimethoxy-1-(3-tert-butyldimethylsilyloxypropyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=619 [M]⁺ (base peak)

The compound2-(5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared according to the process described in patent WO 03/000688A1.

EXAMPLE 912-[1-(3-Fluoropropyl)-5,6-dimethoxy-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine

2-[1-(3-fluoropropyl)-5,6-dimethoxy-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 88a, butusing 0.042 g of2-[5,6-dimethoxy-1-(3-fluoropropyl)indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.63 ml of a 5N aqueous potassium hydroxide solution. Afterpurification by flash-pack chromatography (silica, 98/02 by volumedichloromethane/methanol as eluents), 0.008 g of2-[1-(3-fluoropropyl)-5,6-dimethoxy-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, d in ppm): 2.22 (dt, J=26 and 6.5Hz: 2H); 3.88 (s: 3H); 3.91 (s: 3H); 4.33 (t, J=6.5 Hz: 2H); 4.52 (dt,J=48 and 6.5 Hz: 2H); 6.80 (broad d, J=2 Hz: 1H); 7.04 (dd, J=8 and 5Hz: 1H); 7.18 (s: 1H); 7.45 (s: 1H); 7.88 (broad dd, J=8 and 1.5 Hz:1H); 7.89 (s: 1H); 8.14 (dd, J=5 and 1.5 Hz: 1H); 11.78 (broad s: 1H).

Mass spectrum (EI): m/z=353 [M]⁺ (base peak)

EXAMPLE 923-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propionicacid

a)3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridine-2-yl)indol-1-yl]propionicacid is prepared by following the procedure described in example 88a,but using 1 g of methyl3-[5,6-dimethoxy-3-(1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propionateand a solution of 74 ml of methanolic potassium hydroxide (0.1 g/ml;1.78M). 0.601 g of3-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propionicacid is obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, d in ppm): 2.82 (t, J=6.5 Hz:2H); 3.88 (s: 3H); 3.90 (s: 3H); 4.44 (t, J=6.5 Hz: 2H); 6.78 (broad d,J=2 Hz: 1H); 7.03 (dd, J=8 and 5 Hz: 1H); 7.22 (s: 1H); 7.44 (s: 1H);7.86 (broad d, J=8 Hz: 1H); 7.87 (s: 1H); 8.13 (broad dd, J=5 and 1.5Hz: 1H); 11.78 (broad s: 1H).

Mass spectrum (EI): m/z=365 [M]⁺ (base peak)

b) Methyl3-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}propionateis prepared in the following way:

0.34 g of potassium carbonate and 0.243 ml of methyl acrylate are added,dropwise, to a solution of 1 g of2-(5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 20 ml of anhydrous dimethylformamide, under an inert argon atmosphereat a temperature in the region of 20° C. The reaction medium is agitatedat the same temperature for 16 hours. 20 ml of water and 20 ml of ethylacetate are added. After separation by settling out, the organic phaseis dried over sodium sulfate, filtered, and then concentrated underreduced pressure. After purification by flash chromatography (silica,dichloromethane as eluent, argon), the fractions containing the productare concentrated under reduced pressure. 1 g of methyl3-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}propionateis thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): EI: m/z=533 [M]⁺ (base peak), m/z=378

The compound2-[5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared according to the process described in patent WO 03/000688A1.

EXAMPLE 93 3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-yl-propan-1-one

3-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]-1-morpholin-4-ylpropan-1-oneis prepared in the following way:

0.036 g of O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate is added to a solution of 0.035 g of3-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propionicacid in 3 ml of dimethylformamide, under an inert argon atmosphere at atemperature in the region of 20° C. The reaction medium is agitated atthis temperature for 1 hour. 0.01 ml of morpholine and then 0.017 ml ofdiisopropylethylamine are added. After agitation at the same temperaturefor 3 hours, 10 ml of water and 10 ml of ethyl acetate are added. Afterseparation by settling out, the organic phase is dried over sodiumsulfate, filtered, and then concentrated under reduced pressure. Theresidue obtained is purified by flash-pack chromatography (silica, 98/02by volume dichloromethane/methanol as eluents). The fractions containingthe product are concentrated under reduced pressure. 0.025 g of3-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylpropan-1-oneis thus obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.90 (t, J=6.5 Hz:2H); from 3.30 to 3.55 (mt: 8H); 3.88 (s: 3H); 3.90 (s: 3H); 4.47 (broadt, J=6.5 Hz: 2H); 6.78 (d, J=2 Hz: 1H); 7.03 (dd, J=8 and 5 Hz: 1H);7.19 (s: 1H); 7.44 (s: 1H); 7.86 (s: 1H); 7.87 (broad d, J=8 Hz: 1H);8.13 (dd, J=5 and 1.5 Hz: 1H); 11.78 (broad s: 1H).

Mass spectrum (EI): m/z=434 [M]⁺ (base peak)

EXAMPLE 942-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(4-hydroxypiperidin-1-yl)-ethanone

a)2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]-1-(4-hydroxypiperidin-1-yl)ethanoneis prepared by following the procedure described in example 93, butusing 0.2 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acidand 0.07 g of 4-hydroxypiperidine. After purification by flash-packchromatography (silica, 98/02 by volume dichloromethane/methanol aseluents), 0.096 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]-1-(4-hydroxypiperidin-1-yl)ethanoneis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 1.20 to 1.55 (mt:2H); from 1.70 to 1.95 (mt: 2H); 3.12 and from 3.20 to 3.45(respectively broad t, J=11 Hz and mt: 2H in total); from 3.75 to 4.00(mt: 2H); 3.78 (mt: 1H); 3.84 (s: 3H); 3.91 (s: 3H); 4.81 (d, J=3.5 Hz:1H); 5.21 (limited AB, J=16.5 Hz: 2H); 6.79 (d, J=2 Hz: 1H); 7.03 (dd,J=8 and 5 Hz: 1H); 7.10 (s: 1H); 7.46 (s: 1H); 7.76 (s: 1H); 7.88 (dd,J=8 and 1.5 Hz: 1H); 8.13 (dd, J=5 and 1.5 Hz: 1H); 11.76 (broad s: 1H).

Mass spectrum (EI): m/z=434 [M]⁺ (base peak)

b) 2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]aceticacid is prepared by following the procedure described in example 88a,but using 1 g of tert-butyl2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}acetateand a solution of 73 ml of methanolic potassium hydroxide (0.1 g/ml;1.78M). 0.701 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acidis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=351 [M]⁺ (base peak)

c) tert-Butyl2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl)-acetateis prepared by following the procedure described in example 89c, butusing 1.91 g of tert-butyl bromoacetate and 4 g of2-(5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.4.5 g of tert-butyl2-{5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]indol-1-yl}acetateare obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=562 [M+H]⁺ (base peak)

EXAMPLE 952-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone

2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]-1-thiazolidin-3-ylethanoneis prepared by following the procedure described in example 93, butusing 0.2 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acidand 0.061 g of thiazolidine. 0.133 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanoneis obtained, the characteristics of which are as follows:

¹H NMR spectrum (400 MHz, (CD₃)₂SO d6, at a temperature of 373 K, δ inppm): 3.16 (unresolved peak: 2H); from 3.85 to 3.95 (mt: 2H); 3.86 (s:3H); 3.90 (s: 3H); 4.66 (broad s: 2H); 5.16 (s: 2H); 6.72 (d, J=1.5 Hz:1H); 7.01 (dd, J=8 and 4.5 Hz: 1H); 7.11 (s: 1H); 7.49 (s: 1H); 7.76 (s:1H); 7.86 (dd, J=8 and 1.5 Hz: 1H); 8.13 (dd, J=4.5 and 1.5 Hz: 1H);11.45 (unresolved peak: 1H).

Mass spectrum (EI): m/z=422 [M]⁺ (base peak)

EXAMPLE 964-{[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one

4-{[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-indol-1-yl]acetyl}-1-methylpiperazin-2-oneis prepared by following the procedure described in example 93, butusing 0.1 g of2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acidand 0.039 g of 1-methylpiperazin-2-one. 0.088 g of4-{[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-oneis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm). At ambienttemperature, a 50/50 mixture of rotamers is observed.

2.94 and 2.96 (2 s: 3H in total); 3.39 and 3.54 (2 mts: 2H in total);3.75 and 3.91 (2 mts: 2H in total); 3.85 (s: 3H); 3.91 (s: 3H); 4.07 and4.34 (2 broad s: 2H in total); 5.25 and 5.30 (2 broad s: 2H in total);6.79 (d, J=1.5 Hz: 1H); 7.04 (dd, J=8 and 5 Hz: 1H); 7.13 and 7.15 (2broad s: 1H in total); 7.46 (s: 1H); 7.71 and 7.74 (2 s: 1H in total);7.88 (broad d, J=8 Hz: 1H); 8.14 (dd, J=5 and 1.5 Hz: 1H); 11.79(unresolved peak: 1H).

Mass spectrum (EI): m/z=447 [M]⁺ (base peak)

EXAMPLE 974-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine

a)4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 2.8 g of4-chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 25.5 ml of a 5N aqueous potassium hydroxide solution. 1.81 g of4-chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.86 (s: 3H); 3.89 (s:3H); 3.92 (s: 3H); 6.73 (s: 1H); 7.16 (d, J=5 Hz: 1H); 7.17 (s: 1H);7.46 (s: 1H); 7.86 (s: 1H); 8.09 (d, J=5 Hz: 1H); 12.16 (unresolvedpeak: 1H).

Mass spectrum (EI): m/z=341 [M]⁺ (base peak)

b)4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89c, butusing 7.1 g of4-chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.10 ml of methyl iodide. After purification by flash chromatography(silica, 40/60 by volume ethyl acetate/cyclohexane as eluents, argon),5.69 g of4-chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=495 [M]⁺ m/z=340 (base peak)

c)4-Chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

67 ml of a saturated aqueous sodium bicarbonate solution and 1.34 g oftetrakis(triphenylphosphine)palladium are added to a solution of 10 g of1-(toluene-4-sulfonyl)-1H-2-iodo-4-chloropyrrolo[2,3-b]pyridine, 245 mlof anhydrous dimethylformamide and 7.42 g of1-tert-butyloxycarbonyl-5,6-dimethoxyindol-3-boronic acid, under aninert argon atmosphere at a temperature in the region of 20° C. Thereaction medium is heated at 130° C. for 45 minutes. After cooling, thereaction medium is concentrated under reduced pressure. The oil obtainedis taken up with 300 ml of water and 300 ml of ethyl acetate. Afterseparation by settling out, the organic phase is dried over sodiumsulfate, filtered, and then concentrated under reduced pressure. Theresidue obtained is purified by flash chromatography (silica, 40/60 byvolume ethyl acetate/cyclohexane as eluents, argon). The fractionscontaining the product are concentrated under reduced pressure. 7.52 gof4-chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=481 [M]⁺; m/z=326 (base peak)

The compounds1-(toluene-4-sulfonyl)-1H-2-iodo-4-chloropyrrolo[2,3-b]pyridine and1-tert-butyloxy-carbonyl-5,6-dimethoxyindol-3-boronic acid are preparedaccording to the process described in patent WO 03000688 A1.

EXAMPLE 982-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

a)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrilecan be prepared in the following way:

A suspension of 0.14 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrilein 1.3 ml of a 5 N aqueous potassium hydroxide solution and 5 ml ofmethanol is brought to a temperature in the region of 60° C. forapproximately 30 minutes. After returning to around 20° C., theinsoluble material is filter-dried, and washed with water until aneutral pH is obtained. The insoluble material is purified by flashchromatography on a silica column [eluent: dichloromethane/methanol(98/2 by volume)]. 0.05 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrileis obtained in the form of a solid, the characteristics of which are asfollows:

Silica TLC [eluent: dichloromethane/methanol (98/2 by volume)] Rf=0.17

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.87 (s: 3H); 3.89 (s:3H); 3.92 (s: 3H); 6.87 (broad s: 1H); 7.17 (s: 1H); 7.44 (broad d, J=5Hz: 1H); 7.49 (broad s: 1H); 7.95 (s: 1H); 8.25 (d, J=5 Hz: 1H); 12.44(unresolved peak: 1H).

Mass spectrum (EI): m/z=332 [M]⁺ (base peak); m/z=317 [M-CH₃]⁺; m/z=289;[m/z=317-CO]⁺

b)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrilecan be prepared in the following way:

0.029 g of [1,1′-bis(diphenylphosphino)ferrocene] palladium(II) is addedto a suspension, degassed with argon for approximately 15 minutes, of0.2 g of 4-chloro-2-(5,6-dimethoxy-1-methyl1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine, 0.084 gof zinc cyanide and 0.013 g of zinc powder in 20 ml ofN,N-dimethylacetamide. The reaction mixture is brought to a temperaturein the region of 150° C. for approximately 2 hours 30 minutes. Afterreturning to around 20° C., the reaction mixture is filtered throughcelite and the insoluble material is washed with 100 ml ofdichloromethane. The filtrate is washed with three times 100 l of water,dried in the magnesium sulfate, filtered and concentrated to drynessunder reduced pressure (13 kPa). The residue is purified by flashchromatography on a silica column [eluent: cyclohexane/ethyl acetate(50/50 by volume)]. 0.14 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrileis obtained in the form of a lake, the characteristics of which are asfollows:

Silica TLC [eluent: cyclohexane/ethyl acetate (50/50 by volume)]=Rf 0.40

Mass spectrum (EI): m/z=486 [M]⁺; m/z=331 [M-C₇H₇O₂S]⁺ (base peak);m/z=316 [331-CH₃]⁺.; m/z=155 [C₇H₇O₂S⁺]; m/z=91 [C₇H₇+]

4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared as described in example 97b.

EXAMPLE 994-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine

a)4-Chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A solution of 0.54 g of4-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.8 g of potassium hydroxide in 18 ml of methanol is brought toaround 60° C. for approximately 2 hours. After cooling to approximately20° C., the precipitate is filter-dried, washed with two times 3 ml ofmethanol and three times 5 ml of water, and then dried in an oven underreduced pressure (13 kPa) at a temperature in the region of 40° C. forapproximately 8 hours. 0.241 g of4-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained in the form of a solid, the characteristics of which are asfollows:

Melting point: 240° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.48 (t, J=4.5 Hz:4H); 2.74 (t, J=6.5 Hz: 2H); 3.49 (t, J=4.5 Hz: 4H); 3.87 (s: 3H); 3.89(s: 3H); 4.32 (broad t, J=6.5 Hz: 2H); 6.71 (s: 1H); 7.14 (d, J=5 Hz:1H); 7.20 (s: 1H): 7.42 (s: 1H); 7.92 (s: 1H); 8.07 (d, J=5 Hz: 1H);12.13 (unresolved peak: 1H).

Mass spectrum (EI): m/z=440 [M]⁺ (base peak); m/z=340 [M-C₅H₁₀NO]⁺;m/z=100 [C₅H₁₀NO]⁺

b)4-Chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A suspension of 1 g of4-chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.655 g of 4-(2-chloroethyl)morpholine hydrochloride and 1.11 g ofpotassium carbonate in 10 ml of dimethylformamide is heated at around95° C. for approximately 3 hours. After cooling to a temperature in theregion of 20° C., the reaction mixture is run into 20 ml of water, andextracted with three times 100 ml of ethyl acetate. The combined organicphases are washed with 100 ml of a saturated aqueous sodium chloridesolution, dried over magnesium sulfate, filtered and concentrated todryness under reduced pressure (13 kPa). The residue is purified byflash chromatography on a silica column [eluent: cyclohexane/ethylacetate (90/10 by volume)]. 0.54 g of4-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained in the form of a solid, the characteristics of which are asfollows:

Silica TLC [eluent: dichloromethane/methanol (98/2 by volume)] Rf=0.18

Mass spectrum (EI): m/z=594 [M]⁺; m/z=481 [M-C₆H₁₁NO]⁺;m/z=439[M-C₇H₇O₂S]⁺; m/z=326 [m/z=481-C₇H₇O₂S]⁺; m/z=100[C₅H₁₀NO⁺] (basepeak)

4-Chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared as described in example 97c.

EXAMPLE 1002-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperidin-4-yl)ethanol

a)2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperidin-4-yl)ethanolcan be prepared as in example 99a:

But using 0.160 g of2-[1-(2-{3-[4-chloro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxyindol-1-yl}ethyl)piperidin-4-yl]ethanoland 0.58 g of potassium hydroxide in 10 ml of methanol. After flashchromatography on a silica column [eluent: dichloromethane/methanol(80/20 by volume)], 0.078 g of2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperidin-4-yl)ethanolis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 200° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 1.00 to 1.25 (mt:2H); from 1.25 to 1.40 (mt: 3H); 1.63 (very broad d, J=13 Hz: 2H); 1.99(broad t, J=11.5 Hz: 2H); 2.70 (t, J=6.5 Hz: 2H); 2.93 (broad d, J=11.5Hz: 2H); 3.43 (unresolved peak: 2H); 3.88 (s: 3H); 3.90 (s: 3H); 4.32(mt: 3H); 6.71 (broad s: 1H); 7.15 (d, J=5 Hz: 1H); 7.20 (s: 1H); 7.42(s: 1H); 7.92 (s: 1H); 8.07 (d, J=5 Hz: 1H); 12.16 (unresolved peak:1H).

Mass spectrum (EI): m/z=482 [M]⁺; m/z=142 [C₈H₁₆NO]⁺ (base peak)

b)2-[1-(2-{3-[4-Chloro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxyindol-1-yl}ethyl)piperidin-4-yl]ethanolcan be prepared in the following way:

A suspension of 0.280 g of4-chloro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.061 g of potassium carbonate and 0.114 g of 2-piperidin-4-ylethanol in30 ml of acetonitrile is brought to a temperature in the region of 60°C. After heating at this temperature for approximately 5 hours, 0.061 gof potassium carbonate and 0.114 g of 2-piperidin-4-ylethanol are againadded and the mixture is agitated at this temperature for approximately2 hours. After returning to a temperature in the region of 20° C., themixture is concentrated to dryness under reduced pressure (13 kPa), andthen taken up with 50 ml of water and extracted with three times 40 mlof dichloromethane. The combined organic phases are dried over magnesiumsulfate, filtered and concentrated to dryness under reduced pressure (13kPa). The residue is purified by flash chromatography on a silica column[eluent: dichloromethane/methanol (95/5 by volume)]. 0.16 g of2-[1-(2-{3-[4-chloro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxyindol-1-yl}ethyl)piperidin-4-yl]ethanolis obtained in the form of an oil, the characteristics of which are asfollows:

Mass spectrum (EI): m/z=636 [M]⁺; m/z=481 [M-C₇H₇O₂S]⁺; m/z=142[C₈H₁₆NO]⁺ (base peak)

c)4-Chloro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A suspension of 0.760 g of4-chloro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.315 g of sodium iodide in 70 ml of 2-butanone is brought to refluxfor approximately 24 hours. The reaction mixture is evaporated todryness under reduced pressure (13 kPa), taken up with 50 ml of water,and extracted with three times 50 ml of ethyl acetate. The combinedorganic phases are dried over magnesium sulfate, filtered andconcentrated to dryness under reduced pressure (13 kPa). 0.98 g of4-chloro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained in the form of a yellow oil, the characteristics of whichare as follows:

Silica TLC [eluent: dichloromethane/ethyl acetate (90/10 by volume)]

-   Rf=0.71

Mass spectrum (EI): m/z=635 [M]⁺ (base peak); m/z=480 [M-C₇H₇O₂S]⁺;m/z=353 [480-I]⁺; m/z=338 [353-CH₃]⁺; m/z=91 [C₇H₇]⁺

d)4-Chloro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

0.79 g of potassium hydroxide and 0.61 g of potassium carbonate areadded to a solution of 1 g of4-chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.013 g of tetrabutylammonium bromide in 25 ml of1,2-dichloroethane. The suspension obtained is brought to around 50° C.for approximately 5 hours. After returning to a temperature in theregion of 20° C. and agitating at this temperature for approximately 16hours, the reaction mixture is filtered through celite; the insolublematerial is washed with three times 10 ml of dichloromethane. Thefiltrate is washed with three times 50 ml of water, dried over magnesiumsulfate, filtered, and concentrated to dryness under reduced pressure.The residue is purified; by flash chromatography on a silica column[eluent: cyclohexane/ethyl acetate (75/25 by volume)]. 0.62 g of4-chloro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained in the form of a solid, the characteristics of which are asfollows:

Silica TLC [eluent: cyclohexane/ethyl acetate (50/50 by volume)]

-   Rf=0.41

Mass spectrum (EI): m/z=543 [M]⁺; m/z=388 [M-C₇H₇O₂S]⁺ (base peak);m/z=91 [C₇H₇]⁺

4-Chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared as described in example 97c.

EXAMPLE 1014-chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine

a)4-Chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 100a:

But using 0.2 g of4-chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.65 g of potassium hydroxide in 7 ml of methanol. After flashchromatography on a silica column [eluent: dichloromethane/methanol(80/20 by volume)], 0.05 g of4-chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 192° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.16 (s: 3H); 2.33(unresolved peak: 4H); from 2.40 to 2.55 (mt: 4H); 2.74 (broad t, J=6.5Hz: 2H); 3.88 (s: 3H); 3.91 (s: 3H); 4.30 (broad t, J=6.5 Hz: 2H); 6.71(broad s: 1H); 7.15 (d, J=5 Hz: 1H); 7.20 (s: 1H); 7.43 (s: 1H); 7.93(s: 1H); 8.08 (d, J=5 Hz: 1H); 12.14 (unresolved peak: 1H).

Mass spectrum (EI): m/z=453 [M]⁺; m/z=113 [C₆H₁₃N₂]⁺; (base peak) m/z=70[C₄H₈N]⁺

b)4-Chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 100b:

But using 0.98 g of4-chloro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.21 g of potassium carbonate and 0.31 g of 1-methylpiperazine in 100 mlof acetonitrile. After flash chromatography on a silica column [eluent:dichloro ethane/methanol (90/10 by volume)], 0.52 g of4-chloro-2-(5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of an oil, the characteristics of which areas follows:

Mass spectrum (EI): m/z=607 [M]⁺; m/z=452 [M-C₇H₇O₂S]⁺; m/z=113[C₆H₁₃N₂]⁺ (base peak); m/z=70 [C₄H₈N]⁺

EXAMPLE 1022-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrilecan be prepared in the following way:

0.036 g of [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) is addedto a suspension, degassed with argon for approximately 15 minutes, 0.3 gof4-chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.104 g of zinc cyanide and 0.016 g of zinc powder in 20 ml ofN,N-dimethylacetamide. The reaction mixture is brought to a temperaturein the region of 150° C. for approximately 1 hour. After returning toaround 20° C. and agitation of the mixture for 18 hours, the reactionmixture is filtered through celite and the insoluble material is washedwith 100 ml of dichloromethane. The filtrate is washed twice with 100 mlof water and then with 100 ml of a saturated aqueous sodium chloridesolution, dried over magnesium sulfate, filtered, and concentrated todryness under reduced pressure (13 kPa). The residue is purified byflash chromatography on a silica column [eluent:dichloromethane/methanol (90/10 by volume)]. 0.08 g of2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrileis obtained in the form of a solid, the characteristics of which are asfollows:

Melting point: 196° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.17 (s: 3H); 2.34(unresolved peak: 4H); from 2.40 to 2.55 (mt: 4H); 2.75 (t, J=6.5 Hz:2H); 3.89 (s: 3H); 3.92 (s: 3H); 4.33 (broad t, J=6.5 Hz: 2H); 6.98 (d,J=1.5 Hz: 1H); 7.23 (s: 1H); 7.45 (d, J=5 Hz: 1H); 7.49 (s: 1H); 8.03(s: 1H); 8.26 (d, J=5 Hz: 1H); 12.43 (broad s: 1H).

Mass spectrum (EI): m/z=444 [M]⁺; m/z=113 [C₆H₁₃N₂]⁺ (base peak); m/z=70[C₄H₈N]⁺

EXAMPLE 1035-chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine

a)5-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A suspension of 0.44 g of5-chloro-3-(5,6-dimethoxy-1-methyl-1H-indol-3-ylethynyl)pyridin-2-ylamineand 0.58 g of potassium tert-butoxide in 25 ml of1-methylpyrrolidin-2-one is heated at a temperature in the region of 70°C. for approximately 4 hours 30 minutes. The mixture is concentrated todryness under reduced pressure (13 kPa). The residue is taken up with 40ml of water and the pH of the suspension obtained is brought toapproximately 4-5 by adding glacial acetic acid. After agitation forapproximately 10 minutes, the solid is filter-dried, washed with threetimes 5 ml of water and then air-dried. After recrystallization from 160ml of propan-1-ol, 0.28 g of5-chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridineis obtained in the form of a beige solid, the characteristics of whichare as follows:

Melting point: 282° C. (Büchi capillary)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.84 (s: 3H); 3.88 (s:3H); 3.89 (s: 3H); 6.76 (broad s: 1H); 7.14 (s: 1H); 7.42 (s: 1H); 7.81(s: 1H); 7.91 (d, J=3 Hz: 1H); 8.09 (d, J=3 Hz: 1H); 11.99 (unresolvedpeak: 1H).

Mass spectrum (EI): m/z=341 [M]⁺ (base peak); m/z=326 [M-CH₃]⁺

b)5-Chloro-3-(5,6-dimethoxy-1-methyl-1H-indol-3-ylethynyl)pyridin-2-ylaminecan be prepared in the following way:

A suspension of 0.43 g of 5-chloro-3-ethynylpyridin-2-ylamine, 0.6 g of3-iodo-5,6-dimethoxy-1-methyl-1H-indole (example 103-f), and 0.072 g ofcopper iodide, in a mixture of 60 ml of triethylamine and 30 ml ofdimethylformamide, is degassed with argon for 15 minutes. 0.066 g ofbis(triphenylphosphine) palladium(II) chloride is added to the abovesuspension. The mixture is agitated at around 20° C. for approximately 6hours; 0.075 g of 5-chloro-3-ethynylpyridin-2-ylamine is added and themixture is agitated at this same temperature for 2 days. The mixture isconcentrated to dryness under reduced pressure (13 kPa). The residue istaken up with 100 ml of water and extracted with three times 100 ml ofdichloromethane. The organic phases are combined, dried over magnesiumsulfate, filtered, and concentrated under reduced pressure (13 kPa). Theresidue is purified by flash chromatography on a silica column [eluent:cyclohexane/ethyl acetate (50/50 by volume)]. 0.44 g of5-chloro-3-(5,6-dimethoxy-1-methyl-1H-indol-3-ylethynyl)pyridin-2-ylamineis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 192° C. (Köfler bench)

Mass spectrum (EI): m/z=341 [M]⁺ (base peak); m/z=326 [M-CH₃]⁺

c) 5-Chloro-3-ethynylpyridin-2-ylamine can be prepared in the followingway:

A suspension of 1.6 g of5-chloro-3-trimethylsilanylethynylpyridin-2-ylamine and 1.24 g ofpotassium fluoride in 80 ml of methanol is brought to reflux forapproximately 3 hours 30 minutes. After returning to a temperature inthe region of 20° C., the mixture is filtered through celite, and theinsoluble material is washed three times with 50 ml of methanol. Thefiltrate is concentrated to dryness under reduced pressure (13 kPa). Theresidue is taken up with 100 ml of dichloromethane. The solutionobtained is washed with three times 60 ml of water, dried over magnesiumsulfate, filtered, and concentrated to dryness under reduced pressure(13 kPa). 0.97 g of 5-chloro-3-ethynylpyridin-2-ylamine is thus obtainedin the form of a solid, the characteristics of which are as follows:

Silica TLC [eluent: cyclohexane/ethyl acetate (50/50 by volume)]

-   Rf=0.72

Mass spectrum (CI): m/z=153 [M+H]⁺ (base peak)

d) 5-Chloro-3-trimethylsilanylethynylpyridin-2-ylamine can be preparedin the following way:

A suspension of 2.54 g of 5-chloro-3-iodopyridin-2-ylamine, 2.12 ml ofethynyltrimethylsilane, 0.38 g of copper iodide and 0.47 g of lithiumchloride in 7 ml of triethylamine and 75 ml of dimethylformamide isdegassed under argon for approximately 15 minutes. 0.408 g of[1,1′-bis(diphenylphosphino)ferrocene] palladium(II) chloride is addedto the above suspension. The mixture is heated at around 40° C. forapproximately 19 hours and then concentrated to dryness under reducedpressure (13 kPa). The residue is taken up with 50 ml of water, andextracted with three times 100 ml of ethyl acetate. The combined organicphases are dried over magnesium sulfate, filtered, and concentrated todryness under reduced pressure (13 kPa). The residue is purified byflash chromatography on a silica column [eluent: cyclohexane/ethylacetate (70/30 by volume)]. 1.63 g of5-chloro-3-trimethylsilanylethynylpyridin-2-ylamine are obtained in theform of a solid, the characteristics of which are as follows:

Melting point: 108° C. (Köfler bench)

Mass spectrum (CI): m/z=225 [M+H]⁺ (base peak)

e) 5-Chloro-3-iodopyridin-2-ylamine can be prepared in the followingway:

A mixture of 6.43 g of 5-chloropyridin-2-ylamine and 12.38 g ofN-iodosuccinimide in 300 ml of glacial acetic acid is heated at around55° C. for 6 hours. After returning to a temperature of approximately20° C., the mixture is agitated for approximately 18 hours and thenconcentrated to dryness under reduced pressure (13 kPa). The residue istaken up with 400 ml of water; the pH of the suspension obtained isbrought back to approximately 8 by adding a saturated aqueous sodiumhydrogen carbonate solution. The precipitate is filter-dried, washedwith water, and dried at 40° C. under reduced pressure (13 kPa) forapproximately 3 hours. 12.35 g of 5-chloro-3-iodopyridin-2-ylamine areobtained in the form of a solid, the characteristics of which are asfollows:

Silica TLC [eluent: cyclohexane/ethyl acetate (50/50 by volume)]

-   Rf 0.68

Mass spectrum (EI): m/z=254 [M]⁺ (base peak); m/z=127 [M-I]⁺; m/z=100[127-HCN]⁺; m/z=92 [127-Cl]⁺

f) 3-Iodo-5,6-dimethoxy-1-methyl-1H-indole can be prepared in thefollowing way:

0.465 g of powdered potassium hydroxide is added to a solution of 0.5 gof 5,6-dimethoxy-1H-indole in 15 ml of dimethylformamide. A solution of0.725 g of bisublimated iodine in 15 ml of dimethylformamide is addeddropwise to the above mixture. After agitation of the reaction mediumfor approximately 3 hours at a temperature in the region of 20° C., 0.21ml of iodomethane is added dropwise, maintaining the mixture at thissame temperature by cooling using a water bath. After agitation ataround 20° C. for 1 hour 30 minutes, the mixture is run into a solutionof 1.5 g of sodium thiosulfate in 150 ml of water cooled to around 5°C., and agitated for approximately 10 minutes. The precipitate isfilter-dried, washed with five times 5 ml of water cooled to around 5°C., and then dried under vacuum (13 kPa) over phosphorus pentaoxide.0.78 g of 3-iodo-5,6-dimethoxy-1-methyl-1H-indole is obtained in theform of a solid, the characteristics of which are as follows:

Melting point: 80-90° C. with decomposition (Köfler bench)

Mass spectrum (EI): m/z=317 [M]⁺ (base peak); m/z=302 [M-CH₃]⁺; m/z=190[M-I]

EXAMPLE 1042-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine

a)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 103a:

But using 0.19 g of3-(5,6-dimethoxy-1-methyl-1H-indol-3-ylethynyl)-5-fluoropyridin-2-ylamineand 0.263 g of potassium tert-butoxide in 15 ml of1-methylpyrrolidin-2-one. After flash chromatography on a silica column[eluent: dichloromethane/ethyl acetate (90/10 by volume)], 0.046 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 283° C. (Büchi capillary)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.83 (s: 3H); 3.87 (s:3H); 3.89 (s: 3H); 6.76 (broad s: 1H); 7.13 (s: 1H); 7.41 (s: 1H); 7.70(dd, J=9.5 and 3 Hz: 1H); 7.80 (s: 1H); 8.06 (dd, J=3 and 2.5 Hz: 1H);11.87 (unresolved peak: 1H).

Mass spectrum (EI): m/z=325 [M]⁺ (base peak); m/z=310 [M-CH₃]⁺; m/z=282[M-CO]⁺

b)3-(5,6-Dimethoxy-1-methyl-1H-indol-3-ylethynyl)-5-fluoropyridin-2-ylaminecan be prepared in the following way:

0.049 g of bis(triphenylphosphine) palladium(II) chloride is added to asuspension, degassed with argon for approximately 15 minutes, of 0.57 gof 3-ethynyl-5,6-dimethoxy-1-methyl-1H-indole, 0.316 g of5-fluoro-3-iodopyridin-2-ylamine and 0.06 g of copper iodide in 39.5 mlof triethylamine and 20 ml of dimethylformamide, and the mixture isagitated at a temperature in the region of 20° C. for 18 hours and thenconcentrated to dryness under reduced pressure (13 kPa). The residue istaken up with 150 ml of dichloromethane. The organic solution is washedwith five times 50 ml of water, dried on magnesium sulfate, filtered,and concentrated to dryness under reduced pressure (13 kPa). The residueis purified by flash chromatography on a silica column [eluent:cyclohexane/ethyl acetate (50/50 by volume)]. 0.14 g of3-(5,6-dimethoxy-1-methyl-1H-indol-3-ylethynyl)-5-fluoropyridin-2-ylamineis obtained in the form of a solid, the characteristics of which are asfollows:

Silica TLC [eluent: dichloromethane/methanol (98/2 by volume)] Rf=0.28

Mass spectrum (CI): m/z=326 [M+H]⁺ (base peak)

c) 5-Fluoro-3-iodopyridin-2-ylamine can be prepared as in example 103e:

But using 5 g of 5-fluoropyridin-2-ylamine and 11.04 g ofN-iodosuccinimide in 250 ml of glacial acetic acid. 6.1 g of5-fluoro-3-iodopyridin-2-ylamine are thus obtained in the form of asolid, the characteristics of which are as follows:

Melting point: 70° C. (Köfler bench)

Mass spectrum (CI): m/z=239 [M+H]⁺ (base peak)

d) 3-Ethynyl-5,6-dimethoxy-1-methyl-1H-indole can be prepared as inexample 103c:

But using 1.71 g of5,6-dimethoxy-1-methyl-3-trimethylsilanylethynyl-1H-indole and 1.04 g ofpotassium fluoride in 70 ml of methanol. 1 g of3-ethynyl-5,6-dimethoxy-1-methyl-1H-indole is thus obtained in the formof a solid, the characteristics of which are as follows:

Silica TLC (eluent: dichloromethane) Rf=0.49

Mass spectrum (EI): m/z=215 [M]⁺ (base peak); m/z=200 [M-CH₃]⁺m/z=172[M-CO]⁺

e) 5,6-Dimethoxy-1-methyl-3-trimethylsilanylethynyl-1H-indole can beprepared in the following way:

0.421 g of bis(triphenylphosphine) palladium(II) chloride is added to asuspension of 3.81 g of 3-iodo-5,6-dimethoxy-1-methyl-1H-indole, 2.36 gof ethynyltrimethylsilane and 0.457 g of copper iodide in 150 ml oftriethylamine, degassed under argon for 15 minutes. The mixture isagitated at a temperature in the region of 20° C. for approximately 18hours and then heated at around 50° C. for approximately 24 hours. Afterreturning to a temperature in the region of 20° C., the mixture isdiluted with 100 ml of ethyl acetate, and washed with 150 ml of water.The aqueous phase is re-extracted with two times 150 ml of ethylacetate; the combined organic phases are washed with 200 ml of asaturated aqueous sodium chloride solution, dried over magnesiumsulfate, filtered, and concentrated to dryness under reduced pressure(13 kPa). After filtration through silica and elution withdichloromethane, 1.71 g of5,6-dimethoxy-1-methyl-3-trimethylsilanylethynyl-1H-indole are obtainedin the form of a solid, the characteristics of which are as follows:

Melting point: 124° C. (Köfler bench)

Mass spectrum (EI): m/z=287 [M]⁺ (base peak); m/z=272 [M-CH₃]⁺m/z=214[M-SiMe₃]⁺

3-Iodo-5,6-dimethoxy-1-methyl-1H-indole is described in example 103f.

EXAMPLE 1052-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridine

a)2-[5,6-Dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A solution of 2.08 g of potassium hydroxide in 7 ml of water is added toa solution of 0.83 g of2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1-(toluene-4-sulfonyl)—1H-pyrrolo[2,3-b]pyridinein 100 ml of methanol brought to reflux. The mixture is agitated atreflux for 3 hours 30 minutes. After returning to around 20° C., themixture is concentrated to dryness under reduced pressure (13 kPa). Theresidue is taken up with 50 ml of water and extracted with three times80 ml of dichloromethane. The combined organic phases are dried overmagnesium sulfate, filtered, and concentrated to dryness under reducedpressure (13 kPa). The residue is purified by flash chromatography on asilica column [eluent: ethyl acetate/methanol (90/10 by volume)]. 0.37 gof2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3-b]pyridine is obtained in the form of a solid, the characteristics ofwhich are as follows:

Melting point: 205-210° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.49 (broad t, J=4.5Hz: 4H); 2.73 (t, J=6.5 Hz: 2H); 3.61 (broad t, J=4.5 Hz: 4H); 3.87 (s:3H); 3.89 (s: 3H); 4.32 (broad t, J=6.5 Hz: 2H); 6.78 (broad s: 1H);7.20 (s: 1H); 7.41 (s: 1H); 7.70 (dd, J=9.5 and 3 Hz: 1H); 7.89 (s: 1H);8.07 (dd, J=3 and 2.5 Hz: 1H); 11.88 (unresolved peak: 1H).

Mass spectrum (EI): m/z=424 [M]⁺; m/z=100 [C₅H₁₀NO]⁺ (base peak)

b)2-[5,6-Dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 10b:

But using 1 g of5-fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.223 g of potassium carbonate and 0.28 ml of morpholine in 100 ml ofacetonitrile. 0.83 g of2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 182° C. (Köfler bench)

Mass spectrum (CI): m/z=620 [M′+H)⁺; m/z=579[M+H)⁺ (base peak)

c)5-Fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 100c:

But using 2 g of5-fluoro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.85 g of sodium iodide in 100 ml of 2-butanone. 2.2 g of5-fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 176° C. (Köfler bench)

Mass spectrum (EI): m/z=619 [M]⁺; m/z=492 [M-I]⁺; m/z=464 [M-C₇H₇O₂S]⁺(base peak); m/z=337 [464-I]⁺

d)5-Fluoro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 100d:

But using 2 g of2-(5,6-dimethoxy-1H-indol-3-yl)-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.028 g of tetrabutylammonium bromide, 1.89 g of potassium hydroxide and1.38 g of potassium carbonate in 50 ml of 1,2-dichloroethane. Afterflash chromatography on a silica column [eluent:dichloromethane/methanol (98.5/1.5 by volume)], 2.05 g of5-fluoro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 150° C. (Köfler bench)

Mass spectrum (EI): m/z=527 [M]⁺; m/z=372 [M-C₇H₇O₂S]⁺(base peak)

e)2-(5,6-Dimethoxy-1H-indol-3-yl)-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

A mixture of 3.1 g of5-fluoro-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine, 2.4 gof 1-tert-butyloxycarbonyl-5,6-dimethoxy-1H-indole-3-boronic acid and20.3 ml of a saturated aqueous sodium hydrogen carbonate solution in 100ml of dimethylformamide is degassed with argon for approximately 15minutes and then 0.43 g of tetrakis(triphenylphosphine)palladium isadded. The mixture is heated at around 110° C. for approximately 2 hoursand then concentrated to dryness under reduced pressure (13 kPa). Theresidue is taken up with 500 ml of water, and extracted with three times250 ml of ethyl acetate. The combined organic phases are dried overmagnesium sulfate, filtered, and concentrated to dryness under reducedpressure. The residue is taken up with 100 ml of diisopropyl ether,filter-dried, washed with three times 20 ml of diisopropyl ether, anddried under reduced pressure (13 kPa) in the presence of potassiumhydroxide chips at a temperature in the region of 20° C. 2.66 g of2-(5,6-dimethoxy-1H-indol-3-yl)-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained in the form of a solid, the characteristics of which are asfollows:

Melting point: 218° C. (Köfler bench)

Mass spectrum (EI): m/z=465 [M]⁺; m/z=310 [M-C₇H₇O₂S]⁺(base peak)

1-Tert-butyloxycarbonyl-5,6-dimethoxy-1H-indole-3-boronic acid isprepared as described in patent WO 03000688A1.

f) 5-Fluoro-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine canbe prepared in the following way:

7.54 ml of a solution of N-butyllithium at 1.6 N in hexane is added,dropwise, maintaining the temperature of the medium in the region of−75° C., to a solution, cooled to approximately −78° C., of 3.5 g of5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine in 100 ml oftetrahydrofuran. After agitation for approximately one hour at the sametemperature, a solution of 6.12 g of bisublimated iodine in 50 ml oftetrahydrofuran is run in dropwise. After the temperature has returnedto around 20° C., the reaction mixture is diluted with 600 ml of ethylacetate, washed three times with 100 ml of a 5% aqueous sodiumthiosulfate solution, dried over magnesium sulfate, treated withvegetable black, filtered, and concentrated to dryness under reducedpressure (13 kPa). The residue is taken up with 30 ml of diisopropylether, filter-dried, washed with three times 5 ml of diisopropyl ether,and dried under reduced pressure (13 kPa). 3.6 g of5-fluoro-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine areobtained in the form of a solid, the characteristics of which are asfollows:

Melting point: 158° C. (Köfler bench)

Mass spectrum (EI): m/z=416 [M]⁺; m/z=352 [M-SO2]⁺; m/z=155 [C₇H₇O₂S]+;m/z=91 [C₇H₇]⁺ (base peak)

g) 5-Fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine can beprepared in the following way:

A mixture of 2.3 g of 5-fluoro-1H-pyrrolo[2,3-b]pyridine, 3.54 g of4-methylbenzenesulfonyl chloride, 7.56 g of sodium hydroxide dissolvedin 55 ml of water, and 0.115 g of tetrabutylammonium hydrogen sulfate in125 ml of toluene is agitated at around 20° C. for approximately 24hours. The mixture is diluted with 500 ml of ethyl acetate; the organicphase is washed with three times 200 ml of water, dried over magnesiumsulfate, filtered, and concentrated to dryness under reduced pressure(13 kPa). The residue is purified by flash chromatography on a silicacolumn [eluent: dichloromethane]. 3.85 g of5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine are obtainedin the form of a solid, the characteristics of which are as follows:

Melting point: 160° C. (Köfler bench)

Mass spectrum (EI): m/z=290 [M]⁺; m/z=226 [M-SO₂]⁺.; m/z=155 [C₇H₇O₂S]⁺;m/z=91 [C₇H₇]⁺ (base peak)

h) 5-Fluoro-1H-pyrrolo[2,3-b]pyridine can be prepared in the followingway:

A mixture of 3.8 g of5-fluoro-3-trimethylsilanylethynylpyridin-2-ylamine and 3.4 g ofpotassium tert-butoxide in 100 ml of 1-methylpyrrolidin-2-one is broughtto around 130° C. for approximately 4 hours. After returning to atemperature in the region of 20° C., the mixture is run into 1000 ml ofa saturated aqueous sodium chloride solution and extracted with fivetimes 250 ml of diethyl ether. The organic phases are combined, washedwith five times 100 ml of a saturated aqueous sodium chloride solution,dried over magnesium sulfate, filtered, and concentrated to drynessunder reduced pressure (13 kPa). 2.35 g of5-fluoro-1H-pyrrolo[2,3-b]pyridine are obtained in the form of a solid,the characteristics of which are as follows:

Melting point: 110° C. (Köfler bench)

Mass spectrum (EI): m/z=136 [M]⁺ (base peak); m/z=109 [M-HCN]⁺

i) 5-Fluoro-3-trimethylsilanylethynylpyridin-2-ylamine can be preparedas described in example 103d:

But using 14 g of 5-fluoro-3-iodopyridin-2-ylamine, 12.47 ml ofethynyltrimethylsilane, 2.24 g of copper iodide, 2.74 g of lithiumchloride, 41.33 ml of triethylamine and 2.15 g of[1,1′-bis(diphenylphosphino)ferrocene] palladium(II) chloride in 441 mlof dimethylformamide. After flash chromatography on a silica column(eluent: dichloromethane), 7.91 g of5-fluoro-3-trimethylsilanylethynylpyridin-2-ylamine are thus obtained inthe form of a solid, the characteristics of which are as follows:

Melting point: 65° C. (Köfler bench)

Mass spectrum (EI): m/z=208 [M]⁺; m/z=193 [M-CH₃]⁺ (base peak)

5-Fluoro-3-iodopyridin-2-ylamine is described in example 104c.

EXAMPLE 1062-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine

a)2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridinecan be prepared as in example 105a:

But using 0.82 g of2-[5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl]-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinedissolved in 100 ml of methanol and 2 g of potassium hydroxide dissolvedin 7 ml of water. After flash chromatography on a silica column [eluent:dichloromethane/methanol (70/30 by volume)], 0.37 g of2-{5,6-dimethoxy-1-[2-(4-methyl-piperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 210° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.16 (s: 3H); 2.32(unresolved peak: 4H); from 2.40 to 2.55 (mt: 4H); 2.73 (broad t, J=6.5Hz: 2H); 3.87 (s: 3H); 3.89 (s: 3H); 4.30 (broad t, J=6.5 Hz: 2H); 6.76(broad s: 1H); 7.18 (s: 1H); 7.42 (s: 1H); 7.71 (dd, J=9.5 and 3 Hz:1H); 7.88 (s: 1H); 8.07 (mt: 1H); 11.87 (unresolved peak: 1H).

Mass spectrum (EI): m/z=437 [M]⁺; m/z=113 [C₆H₁₃N₂]⁺ (base peak); m/z=70[C₄H₈N]⁺

b)2-[5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl]-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared as described in example 100b:

But using 1 g of5-fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,0.223 g of potassium carbonate and 0.323 g of 1-methylpiperazine in 100ml of acetonitrile. 0.83 g of2-[5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl]-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a solid, the characteristics of whichare as follows:

Melting point: 188° C. (Köfler bench)

Mass spectrum (EI): m/z=591 [M]⁺; m/z=491 [M-C₄H₈N]⁺; m/z=436[M-C₇H₇O₂S]⁺; m/z=113 [C₆H₁₃N₂]⁺ (base peak); m/z=70 [C₄H₈N]⁺

EXAMPLE 107[1-Carboxymethyl-5-methoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]aceticacid

a)[1-carboxymethyl-5-methoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]aceticacid is prepared in the following way:

0.3 ml of a methanolic potassium hydroxide solution (0.1 g/ml) is placedin a hemolysis tube containing{5-methoxy-1-methoxycarbonylmethyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacetate (0.056 g; 97.1 μmol), then the mixture is agitated at 20° C. for16 hours. Reverse-phase liquid chromatography mass spectrometry analysisshows that the expected product forms but is not in the majority.Purification attempts carried out at this stage of the reaction arefruitless and the compounds obtained, all containing mixtures ofstarting compound and of expected product, are evaporated and re-reactedwith 2 ml of methanolic potassium hydroxide (0.1 g/ml) for 20 hours. Thereaction mixture becomes milky in color. The mixture is evaporated todryness and taken up with a mixture of 1 ml of dimethyl sulfoxide and 1ml of a 6M aqueous hydrochloric acid solution. The solution thusobtained is purified by reverse-phase liquid chromatography massspectrometry (method C), after filtering-off the white precipitate whichis formed. After evaporation of the fractions, the tubes containing theexpected compound are combined so as to obtain[1-carboxymethyl-5-methoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]aceticacid (0.015 g; 31%) the characteristics of which are as follows:

LC/MS analysis: tr=2.9 min [M+H]⁺; m/z=396.17 [M+H]⁺

b) The methyl ester of{5-methoxy-1-methoxycarbonylmethyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacid is prepared in the following way:

A solution of5-methoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol(0.043 g; 100 μmol), in solution in dimethylformamide (10 ml), is placedin a 1.3×10 cm hemolysis tube, then potassium carbonate (0.027 g; 200μmol) is added and the mixture is agitated at ambient temperature for 5minutes. Methyl bromoacetate (0.028 ml; 300 μmol) is added and themixture is then heated at 50° C. for 4 hours, the TLC control (eluent:50/50 v/v cyclohexane/ethyl acetate) showing that the reaction has cometo an end. The reaction mixture is run into 5 ml of distilled water andthe reaction mixture is then extracted with ethyl acetate (15 ml). Thecombined extracts are washed with water (20 ml), dried over magnesiumsulfate, filtered, and evaporated to give a crude compound which ispurified by chromatography on silica gel, elution being carried out witha mixture of cyclohexane and ethyl acetate (60/40 v/v). The fractionscontaining the expected compound are combined and evaporated to give themethyl ester of{5-methoxy-1-methoxycarbonylmethyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacid (0.056 g; 97%), the characteristics of which are as follows:

LC/MS analysis: tr=4.1, m/z=578.1 [M+H]⁺

c)5-Methoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-olis prepared in the following way:

A solution of2-(6-benzyloxy-5-methoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.52 g; 993 μmol), in acetonitrile (40 ml) is treated with trimethylsilyl iodide (0.353 ml; 2.483 mmol; 2.5 eq.) at 50° C. for 2 hours andthen at 20° C. for 16 hours, in a 100 ml three-necked flask. Afterevaporation, the reaction mixture is taken up in a mixture ofdichloromethane (50 ml) and water (50 ml) and is then separated bysettling out. The aqueous phase is extracted with dichloromethane (250ml); the extracts are combined, dried over magnesium sulfate, andevaporated to give a compound which is purified by chromatography onsilica gel (10 g, 35 μm silica), elution being carried out with amixture of cyclohexane and ethyl acetate (60/40 vol/vol). The fractionscontaining the expected compound are combined and evaporated, resultingin a solid which is triturated in diisopropyl ether so as to obtain5-methoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol,(0.215 g; 50%), the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.30 (s: 3H); 3.75 (s:3H); 6.75 (s: 1H); 6.90 (s: 1H); 6.93 (broad s: 1H); 7.26 (broad d,J=8.5 Hz: 2H); 7.304 (dd, J=8 and 5 Hz: 1H); 7.42 (d, J=2.5 Hz: 1H);7.57 (broad d, J=8.5 Hz: 2H); 7.94 (dd, J=8 and 1.5 Hz: 1H); 8.34 (dd,J=5 and 1.5 Hz: 1H); 8.71 (broad s: 1H); 11.08 (broad s: 1H).

EXAMPLE 108{5-Methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacid

a)(5-Methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacid is prepared in the following way:

A solution of methyl{5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}acetate,(0.91 g; 1.751 mmol) in methanolic potassium hydroxide (74 ml at 1 g/ml)is placed in a 100 ml round-bottomed flask, at 20° C. for 16 hours withagitation. After reaction, the precipitate formed is filtered off, andrinsed with methanol (20 ml). A suspension of the above solid in water(30 ml) is placed in a 250 ml Erlenmeyer flask and the pH is thenadjusted to 4 with 2N aqueous hydrochloric acid. The yellow solid formedis triturated in the reaction mixture and is then filtered, rinsed withwater and dried under reduced pressure.{5-Methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacid (0.666 g; 98%) is isolated, the characteristics of which are asfollows:

Mass spectrum (IC): m/z=352 [M+H]⁺ (base peak)

b) The methyl ester of{5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}aceticacid is prepared in the following way:

A solution of5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol,(0.558 g; 1.247 mmol) dissolved in dimethylformamide (10 ml) is placedin a 25 ml three-necked flask, under argon, then sodium hydride (0.045g; 1.49 mmol) is added, and the mixture is agitated at ambienttemperature for 10 minutes. As soon as there is no more gas being givenoff, methyl bromoacetate (0.142 ml; 1.496 mmol) is added dropwise, andthe mixture is left at ambient temperature for 3 hours with agitation.The reaction mixture is run into 100 ml of distilled water and the solidformed is then filtered off and washed with water (30 ml). The solid isdissolved in dichloromethane (150 ml), and the solution thus obtained isthen washed with distilled water (50 ml), dried over magnesium sulfateand then evaporated under reduced pressure, resulting in methyl{5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-yloxy}acetate,in the form of a brown-colored oil (0.5 g; 77%), the characteristics ofwhich are as follows:

LC/MS analysis: tr=4.1 min; m/z=520.13 [M+H⁺)

c)5-Methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-olis prepared in the following way:

A solution of2-(6-benzyloxy-5-methoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(1.5 g; 2.79 mmol) in acetonitrile (120 ml) is placed in a 250 mlthree-necked flask at 20° C., and then trimethylsilyl iodide (0.956 ml;6.97 mmol) is added dropwise. The reaction mixture is heated at 50° C.for 4 hours and is then evaporated to dryness under reduced pressure.The evaporation residue is taken up in dichloromethane (200 ml) and thenwashed with distilled water (1×200 ml). The extracts are combined,washed with distilled water, dried over magnesium sulfate and evaporatedunder reduced pressure, to produce the crude compound which is purifiedby chromatography on a silica cartridge (AIT FlashSmart Pack,BP-0610300-093, 50 g silica), elution being carried out at 15 ml/minwith a dichloromethane/ethyl acetate (95/5 v/v) mixture. The fractionscontaining the expected product are combined and evaporated to give5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol(0.87 g; 70%) in the form of an ochre foam, which is used as it is forthe following step.

d)2-(6-Benzyloxy-5-methoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution of2-(6-benzyloxy-5-methoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(1 g, 1.9 mmol) in dimethylformamide (10 ml) is placed in a 25 mlthree-necked flask placed under argon, then sodium hydride (0.063 g;2.101 mmol) is added and the mixture is left to agitate for 15 minutes.When there is no longer any gas being given off, methyl iodide (0.131ml, 2.101 mmol) is added dropwise and the mixture is left to react at21° C. for 2 hours. The reaction medium is run into 100 ml of distilledwater, and then extracted with 2 times 100 ml of dichloromethane. Theorganic extracts are combined, dried over magnesium sulfate, filtered,and evaporated to dryness under reduced pressure. The evaporationcompound is triturated in diisopropyl ether. The pulverulent solidcompound thus obtained is filtered off and rinsed.2-(6-Benzyloxy-5-methoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.888 g; 86%) is isolated in the form of a beige-colored solid, thecharacteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.30 (s: 3H); 3.77 (s:3H); 3.87 (s: 3H); 5.21 (s: 2H); 6.76 (s: 1H); 7.00 (s: 1H); 7.27 (broadd, J=8.5 Hz: 2H); 7.29 (s: 1H); 7.31 (dd, J=8 and 5 Hz: 1H); 7.39 (broadt, J=7.5 Hz: 1H); 7.47 (broad t, J=7.5 Hz: 2H); 7.51 (s: 1H); from 7.55to 7.65 (mt: 4H); 7.95 (dd, J=8 and 1.5 Hz: 1H); 8.36 (dd, J=5 and 1.5Hz: 1H).

2-(6-Benzyloxy-5-methoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinewas prepared as described in patent WO 03000688 A1.

EXAMPLES 109 TO 146

Preparation of the Reagents:

A solution of[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]aceticacid, (prepared as in example 108), (0.228 g; 0.585 mmol) indimethylformamide (3.25 ml; Solution A) and also a solution ofN,N′-dicyclohexylcarbodiimide (0.465 g, 2.25 mmol) in dimethylformamide(3.75 ml; Solution C) and a mixture of 1-hydroxybenzotriazole (0.206 g;1.52 mmol) and dimethylaminopyridine (0.015 g; 0.12 mmol) indimethylformamide (3.75 ml; Solution D) are prepared and placed inreceptacles. Each amine in the table below can be weighed and diluted indimethylformamide.

TABLE 1 Reagents used Molecular weight Weight Ex. Entry Name Formula(g/mol) Equivalent (mg) 109 1 morpholine C4H9NO 87.12 3.000 13.069 110 2n-(2-hydroxyethyl)piperazine C6H14N2O 130.19 3.000 19.530 111 3n,n-dimethylethylenediamine C4H12N2 88.15 3.000 13.220 112 4diethylamine C4H11N 73.14 3.000 10.970 113 5 3-hydroxypiperidine C5H11NO101.15 3.000 15.170 114 6 n,n,n′-trimethylethylenediamine C5H14N2 102.183.000 15.330 115 7 1-cyclohexylpiperazine C10H20N2 168.28 3.000 25.240116 8 1-methylhomopiperazine C6H14N2 114.19 3.000 17.130 117 94-(4-methylpiperazino)aniline C11H17N3 191.28 3.000 28.690 118 10cis-perhydropyrrolo[3,4-c]- C6H8N2O2 140.14 3.000 21.020pyrrole-1,3-dione 119 11 2-(2-methylaminoethyl)pyridine C8H12N2 136.23.000 20.430 120 12 1-methylpiperazine C5H12N2 100.16 3.000 15.020 12113 1-(2-furoyl)piperazine C9H12N2O2 180.21 3.000 27.030 122 143-(n-acetyl-n-methylamino)- C7H14N2O 142.2 3.000 21.330 pyrrolidine 12315 1-hydroxyethylethoxypiperazine C8H18N2O2 174.24 3.000 26.140 124 164-piperidineethanol C7H15NO 129.2 3.000 19.380 125 173-(aminomethyl)pyridine C6H8N2 108.14 3.000 16.220 126 183-methylamino-1,2-propanediol C4H11NO2 105.14 3.000 15.770 127 192-methoxy-n-methylethylamine C4H11NO 89.14 3.000 13.370 128 20cis-perhydropyrrolo[3,4-c]- C6H10N2O 126.16 3.000 18.920 pyrrol-1-one129 21 2-(methylamino)ethanol C3H9NO 75.11 3.000 11.270 130 22diethanolamine C4H11NO2 105.14 3.000 15.770 131 23n,n-dimethyl-n′-ethylethylene- C6H16N2 116.21 3.000 17.430 diamine 13224 4-benzyl-4-hydroxypiperidine C12H17NO 191.28 3.000 28.690 133 254-(ethylaminomethyl)pyridine C8H12N2 136.2 3.000 20.430 134 26bis(2-methoxyethyl)amine C6H15NO2 133.19 3.000 19.980 135 271,1,7,7-tetraethyldiethylene- C12H29N3 215.39 3.000 32.310 triamine 13628 methyl-4-(aminomethyl) C9H12ClNO2 201.65 3.000 30.250 benzoatehydrochloride 137 29 (3aR,6aS)-2-phenyltetrahydro- C12H13ClN2O2 252.73.000 37.910 pyrrolo[3,4-c]pyrrole-1,3-dione hydrochloride 138 30(3aR,6aS)-2-benzyltetrahydro- C13H15ClN2O2 266.73 3.000 40.010pyrrolo[3,4-c]pyrrole-1,3-dione hydrochloride 139 314-Amino-1-benzopyran-8- C12H17NO3 223.27 3.000 33.490 carboxylic acidmethyl ester hydrochloride 140 32 2-aminopyridine C5H6N2 94.12 3.00014.120 141 33 4-aminopyridine C5H6N2 94.12 3.000 14.120 142 344-piperidinoaniline C11H16N2 176.26 3.000 26.440 143 35methyl-4-(aminomethyl) C9H12ClNO2 201.65 3.0 45.050 benzoatehydrochloride 144 36 2-amino-3-hydroxypyridine C5H6N2O 110.12 3.00037.66 145 37 2-amino-3-methylpyridine C6H8N2 108.14 3.000 37.00 146 38m-anisidine C7H9NO 123.16 3.000 42.12Preparation of the Non-Commercial Amines Used

Preparation of cis-perhydropyrrolo[3,4-c]pyrrole-1,3-dione (example 118)

a) Cis-perhydropyrrolo[3,4-c]pyrrole-1,3-dione is prepared in thefollowing way:

A solution 5-benzyl-tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione, (11.5 g;49.9 mmol) in ethanol (200 ml) is placed in a 1000 ml autoclave andpalladium-on-charcoal (5%; 2 g; 0.9 mmol) is then added. After havingpurged the reactor with nitrogen, the autoclave is placed under 58 barsof hydrogen at 70° C. for 16 hours. After returning to 20° C.,filtration and washing of the catalyst, evaporation is carried out underreduced pressure and the solid obtained is then recrystallized frommethanol (100 ml) and drying is carried out under reduced pressure atconstant weight. Perhydropyrrolo[3,4-c]pyrrole-1,3-dione, (3.6 g) isisolated, the characteristics of which are as follows:

Melting point: 222° C. (Köfler bench)

b) 5-Benzyl-tetrahydro-pyrrolo[3,4-c]pyrrole-1,3-dione is prepared inthe following way:

A suspension of2-acetyl-5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione, (107.7 g;395 mmol) in ethanol is placed in a 1000 ml round-bottomed flask and thesuspension is warmed while at the same time adding a 4N aqueous sodiumhydroxide solution (200 ml). The reaction mixture is agitated for 30minutes and then evaporated under reduced pressure. The evaporationresidue is taken up in a mixture of water (100 ml) and ethyl acetate(300 ml), which is acidified to pH 4 by adding 4N aqueous hydrochloricacid (100 ml). After separation by settling out and extraction withethyl acetate (2×200 ml), the organic extracts are combined, washed withbrine (100 ml), dried over magnesium sulfate, filtered, and evaporatedunder reduced pressure. The evaporation residue is crystallized fromethanol (100 ml) and then 7.5 g of the solid obtained are recrystallizedfrom acetonitrile (25 ml). The solid obtained is filtered off, washedwith acetonitrile (5 ml) and then dried under reduced pressure atconstant weight. 5-Benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione (5.8g) is isolated, the characteristics of which are as follows:

Melting point: 158° C. (Köfler bench).

c) 2-Acetyl-5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione isprepared in the following way:

A mixture of N-acetylmaleimide (64 g; 460 mmol) andn-butoxymethyl-n-trimethylsilylmethylbenzylamine (128 g; 460 mmol) indichloromethane (1000 ml) is placed in a 2000 ml three-necked flask andthe reaction mixture is then cooled to 10° C. Trifluoroacetic acid (0.5cm³) is run in while maintaining effective agitation. The temperature ofthe reaction mixture increases to 38° C. over 15 minutes. Potassiumcarbonate (100 g) is added and the reaction mixture is agitated at 20°C. for 48 hours. The solid is removed by filtration and the filtrate isthen evaporated under reduced pressure. The oil obtained is purified bychromatography on silica gel (silica, 40-63 μm, eluent: 65/35 v/vcyclohexane/ethyl acetate). The fractions containing the expectedcompound are combined and then evaporated under reduced pressure, giving2-acetyl-5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione, (107.7 g;86%), in the form of a brown oil which is used directly in the followingstep.

d) N-acetyl maleimide is prepared in the following way:

A solution of maleimide (68 g; 700 mmol) in acetic anhydride (500 ml) isplaced in a 1000 ml three-necked flask and the reaction mixture is thenbrought to reflux for 3 hours. After returning to 20° C., the reactionmixture is evaporated under reduced pressure, resulting in an oil, whichis crystallized from ethyl acetate (100 ml). After filtering-off thesolid and washing with ethyl acetate (25 ml) and diisopropyl ether (100ml), and drying under reduced pressure at constant weight,N-acetylmaleimide (64.1 g; 65.8%) is isolated, the characteristics ofwhich are as follows:

Melting point: 58° C. (Köfler bench)

Preparation of cis-perhydropyrrolo[3,4-c]pyrrole-1-one (example 128)

a) Hexahydropyrrolo[3,4-c]pyrrole-1-one is prepared in the followingway:

A solution of 5-benzylhexahydropyrrolo[3,4-c]pyrrole-1-one, (7.2 g; 33mmol) in absolute ethanol (100 ml) is placed in a 250 ml autoclave andpalladium-on-charcoal at 5% (1.5 g) is then added. After having purgedwith nitrogen, the autoclave is placed under 5-6 bar of hydrogen at 70°C. for 16 hours. After returning to 20° C., the catalyst is filtered offand the filtrate is evaporated under reduced pressure. The compoundobtained is taken up in acetonitrile (15 ml) at reflux, filtered, underhot conditions, through paper and then crystallized. Aftercrystallization, the solid obtained is filtered off, washed withacetonitrile (3 ml) and then with diethyl ether (20 ml) and, finally,dried under reduced pressure at constant weight.Hexahydropyrrolo[3,4-c]pyrrole-1-one, (1.3 g; 31%) is isolated, thecharacteristics of which are as follows:

Melting point: 145° C. (Köfler bench)

b) 5-Benzylhexahydropyrrolo[3,4-c]pyrrole-1-one is prepared in thefollowing way:

5-Benzyl-3-hydroxyhexahydropyrrolo[3,4-c]pyrrole-1-one, (7 g; 30 mmol)in suspension in dichloromethane (50 ml) is placed in a 1000 mlthree-necked flask and is then cooled in an ice bath. Trimethylsilane(7.1 g; 60 mmol) is run in slowly at 3° C. The reaction mixture ishomogeneous and is left to react at 25° C. for 10 minutes, and is thencooled to 3° C. in order to run in trifluoro-acetic acid (50 ml). Thereaction mixture is agitated at 20° C. for 16 hours and then evaporatedunder reduced pressure. The residue is taken up in a mixture of ethylacetate (100 ml) and 4 N aqueous sodium peroxide (50 ml), separated bysettling out and washed with water (100 ml). After drying over magnesiumsulfate and evaporation under reduced pressure, a yellow-colored oil isisolated, which is purified by chromatography on silica gel (silica:40-63 μm eluent: 90/10 ethyl acetate/methanol). The fractions containingthe expected compound are combined and then evaporated under reducedpressure, giving 5-benzylhexahydropyrrolo[3,4-c]pyrrole-1-one, (7.2 g)which is used directly in the following step.

c) 5-Benzyl-3-hydroxyhexahydropyrrolo[3,4-c]pyrrole-1-one is prepared inthe following way:

A solution of 5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione, (12.7g; 55 mmol) {preparation described for the preparation ofcis-perhydropyrrolo[3,4-c]pyrrole-1,3-dione (b)} is added to asuspension of lithium aluminum tetrahydride (2 g; 55 mmol) intetrahydrofuran, cooled to 3° C. in an ice bath, in a 500 mlthree-necked flask. The reaction mixture is agitated at this temperaturefor 25 minutes and then water (2 ml), 4 N aqueous sodium hydroxide (2ml) and water (6 ml) are successively added. The solid thus formed isremoved by filtration; the filtrate is dried over magnesium sulfate andthen evaporated under reduced pressure, resulting in a white solid whichis triturated in diisopropyl ether (50 ml). The solid formed is filteredoff, washed with diisopropyl ether (25 ml), and then dried under reducedpressure at constant weight.5-Benzyl-3-hydroxyhexahydropyrrolo[3,4-c]pyrrol-1-one (7 g; 55%) isisolated, the characteristics of which are as follows:

Melting point: 138° C. (Köfler bench).

EXAMPLE 137 Preparation(3aR,6aS)-2-phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dionehydrochloride

a) (3aR,6aS)-2-phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dionehydrochloride is prepared in the following way:

A suspension of 2-phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione (8 g;37 mmol) in ethanol (80 ml) is placed in a 250 ml three-necked flask andthe reaction mixture is then brought to 70° C. The solution thusobtained is treated under hot conditions with 4.9 N hydrochloric ethanol(37 mmol) and then left to return to 20° C. The solid formed is filteredoff, washed with ethanol (10 ml) and then with diethyl ether (25 ml),and dried under reduced pressure at constant weight.2-Phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione hydrochloride (6.85 g;73.1%) is isolated, the characteristics of which are as follows:

Melting point: 250° C. (Köfler bench)

b) 2-Phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione is prepared in thefollowing way:

A solution of5-benzyl-2-phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione, freed of itshydrochloride beforehand by treatment with 4 N sodium hydroxide (93.2 g;304 mmol), in absolute ethanol (1200 ml) is placed in a 5000 mlautoclave and palladium-on-charcoal at 5% (11 g) is then added. Afterhaving purged with nitrogen, the autoclave is placed under 64 bar ofhydrogen at 70° C. for 12 hours. After returning to 20° C., the catalystis filtered off and the filtrate is evaporated under reduced pressure.The compound obtained is triturated in diisopropyl ether (500 ml) andthe solid obtained is filtered off, washed with diisopropyl ether and,finally, dried under reduced pressure at constant weight.2-Phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione, (6.6 g; 92%) isisolated, the characteristics of which are as follows:

Melting point: 128° C. (Köfler bench)

c) 5-benzyl-2-phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione isprepared in the following way:

A mixture of phenylmaleimide (77.85 g; 450 mmol) andn-(buthoxymethyl)-n-(trimethylsilylmethyl)benzylamine (180 g; 450 mmol)in dichloromethane (1000 ml) is placed in a 2000 ml three-necked flaskand then trifluoroacetic acid (0.1 ml) is run in while maintainingeffective agitation. The temperature of the reaction mixture increasesto 36° C. during the 2 hours of reaction, and then potassium carbonate(100 g) is added and the reaction mixture is agitated for 15 minutes at20° C. The solid is removed by filtration and the filtrate is thenevaporated under reduced pressure. The oil obtained is dissolved inacetone (2000 ml) and then treated with 4.9 N hydrochloric ethanol (490mmol) and agitated at 20° C. for 16 hours. The solid formed is filteredoff, washed with acetone (150 ml) and with diethyl ether (250 ml), anddried under reduced pressure at constant weight.5-Benzyl-2-phenyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione hydrochloride(129 g) is isolated and is used directly in the following step.

EXAMPLE 138 Preparation of(3aR,6aS)-2-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dionehydrochloride

a) (3aR,6aS)-2-Benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dionehydrochloride is prepared in the following way:

A solution of 2,5-dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione (253g; 790 mmol) in ethanol (2000 ml) is placed in a 5000 ml autoclave andpalladium-on-activated charcoal at 5% (2 g; 0.9 mmol) is then added.After having purged the reactor with nitrogen, the autoclave is placedunder 59 bar of hydrogen at 70° C. for 16 hours. After returning to 20°C., and filtering off and washing the catalyst, the reaction mixture isconcentrated down to 2000 ml, under reduced pressure, and 9.6 Nhydrochloric ethanol (90 ml) is then added. The crystallized solidobtained is filtered off, then washed with ethanol (100 ml) and withdiethyl ether (250 ml) and, finally, dried under reduced pressure atconstant weight. 2-Benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dionehydrochloride (3.6 g) is isolated, the characteristics of which are asfollows:

Melting point: 240° C. (Köfler bench)

b) 2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione is prepared inthe following way:

A mixture of benzyl maleimide (70.4 g; 376 mmol) andn-(butoxymethyl)-n-(trimethylsilylmethyl)benzylamine (105 g; 376 mmol)in dichloromethane (1000 ml) is placed in a 2000 ml three-necked flask,and trifluoroacetic acid (1 ml) is then run in while maintainingeffective agitation. The temperature of the reaction mixture increasesto 33° C. over one hour of reaction, then potassium carbonate (50 g) isadded and the reaction mixture is agitated for 10 minutes at 20° C. Thesolid is removed by filtration, and the filtrate is then evaporatedunder reduced pressure. The oil obtained is taken up in diisopropylether (500 ml) and then triturated until crystallization occurs. Thesolid formed is filtered off, washed with diisopropyl ether (50 ml) anddried under reduced pressure at constant weight.2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione (70 g; 58%) isisolated, the characteristics of which are as follows:

Melting point: 100° C. (Köfler bench)

0.25 ml of solution A (50 μmol per reactor), 0.25 ml of solution B, eachamine solution in the table above, 0.25 ml of solution C and 0.035 ml oftriethylamine are successively distributed into a set of reactorssuitable for parallel synthesis. The reactors are closed and thenagitated and heated at 88° C. for 4 hours 30 minutes. After returning toambient temperature, the reactors are agitated for 48 hours. The contentof each reactor is filtered and then each filtrate is adsorbed onto asolid-phase extraction cartridge (2 g of SCX phase per cartridge at 0.8mmol/g, prior wetting with methanol: 5 volumes; first elution: 5 volumesmethanol) and then desorbed with a second elution of 5 volumes ofmethanol/ammonia, 2M. After evaporation of the ammoniacal methanol, thecompounds are diluted in 1 ml of dimethyl sulfoxide and purified byreverse-phase liquid chromatography mass spectrometry (method C). Thefractions containing the expected compounds are evaporated, weighed,diluted to 10 mM in dimethyl sulfoxide and analyzed by reverse-phaseliquid chromatography mass spectrometry.

-   -   1. The compounds thus purified are characterized by virtue of        their retention time and their molecular peak. (Table below).    -   2. The compounds derived from the coupling of        [5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetic        acid (prepared as in example 88) and the precursors mentioned in        lines 16, 17, 18 and 19 of the table above are subjected to a        further cycle of purification by reverse-phase liquid        chromatography mass spectrometry (method D). The fractions        containing the expected compounds are evaporated, weighed,        diluted to 10 mM in dimethyl sulfoxide and then analyzed by        reverse-phase liquid chromatography mass spectrometry. The        purified compounds are characterized by virtue of their        retention time and their molecular peak (table below).    -   3. The compounds derived from the coupling of        [5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetic        acid and the precursors mentioned on lines 21, 22, 23, 24, 25,        26, 27, 28, 29, 30, 31 and 35 are subjected to a further cycle        of purification by reverse-phase liquid chromatography mass        spectrometry (method D). The fractions containing the expected        compounds are evaporated, weighed, diluted to 10 mM and analyzed        by reverse-phase liquid chromatography mass spectrometry. The        purified compounds are characterized by virtue of their        retention time and their molecular peak (table below).    -   4. The compounds derived from the coupling of        [5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetic        acid and the precursors mentioned in lines 29 and 30 are        subjected to a further cycle of purification by reverse-phase        liquid chromatography mass spectrometry (method D). The        fractions containing the expected compounds are evaporated,        weighed, diluted to 10 mM and analyzed by reverse-phase liquid        chromatography mass spectrometry. The purified compounds are        characterized by virtue of their retention time and their        molecular peak (table below).

EXAMPLE 1394-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetylamino}-1-benzopyran-8-carboxylicacid

The methyl ester of4-{2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-acetylamino}-1-benzopyran-8-carboxylicacid derived from the coupling of[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]aceticacid (obtained as described in example 88) with the precursor mentionedin line 31 of the table above is dissolved in 1 ml of a methanolicpotassium hydroxide solution (0.1 g of potassium per ml of methanol) andthen agitated at ambient temperature for 16 hours. After evaporation,the compound is diluted in a mixture of dimethyl sulfoxide (0.75 ml) and12N aqueous hydrochloric acid (0.25 ml). The solution obtained isfiltered and purified by reverse-phase liquid chromatography massspectrometry (method F).4-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetylamino}-1-benzopyran-8-carboxylicacid (0.0016 g, 30%) is isolated, the characteristics of which are asfollows:

LC/MS analysis: tr=3.5 min, m/z=526.88 [M+H⁺)

MW RT Example Name (parent) EF (g/mol) (min) m/z % trace 1092-[5-Methoxy-1-methyl-3-(1H- C23H24N4O4 420.47 2.50 421.74 80 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]-1-morpholin-4-ylethanone110 1-[4-(2-Hydroxyethyl-piperazin-1-yl]- C25H29N5O4 463.54 2.31 464.3463 DAD 2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]ethanone 111N-(2-Dimethylaminoethyl)-2-[5- C23H27N5O3 421.50 2.69 422.32 100 DADmethoxy-1-methyl-3-(1H-4lambda- 4-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetamide 112 N,N-Diethyl-2-[5-methoxy-1-methyl-C23H26N4O3 406.49 3.01 407.31 100 DAD3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H- indol-6-yloxy]acetamide 1131-(3-Hydroxy-piperidin-1-yl)-2-[5- C24H26N4O4 434.50 2.58 435.30 84 DADmethoxy-1-methyl-3-(1H-pyrrolo- [2,3-b]pyridin-2-yl)-1H-indol-6-yl-oxy]ethanone 114 N-(2-Dimethylaminoethyl)-2-[5- C24H29N5O3 435.53 2.24436.35 97 DAD methoxy-1-methyl-3-(1H-pyrrolo-[2,3-b]pyridin-2-yl)-1H-indol-6-yl- oxy]-N-methylacetamide 1151-(4-Cyclohexylpiperazin-1-yl)-2-[5- C29H35N5O3 501.63 2.43 502.39 98DAD methoxy-1-methyl-3-(1H-pyrrolo- [2,3-b]pyridin-2-yl)-1H-indol-6-yl-oxy]ethanone 116 2-[5-Methoxy-1-methyl-3-(1H- C25H29N5O3 447.54 2.33448.35 97 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methyl-[1,4]diazepan- 1-yl)ethanone 1172-[5-Methoxy-1-methyl-3-(1H- C30H32N6O3 524.62 2.94 525.38 100 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1- yl)-phenyl]acetamide 1185-{2-[5-Methoxy-1-methyl-3-(1H- C25H23N5O5 473.49 2.58 474.29 98 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]acetyl}tetrahydro-pyrrolo-[3,4-c]pyrrole-1,3-dione 119 2-[5-Methoxy-1-methyl-3-(1H- C27H27N5O3469.54 2.53 470.45 84 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-methyl-N-(2-pyridin-2-yl- ethyl)acetamide 1202-[5-Methoxy-1-methyl-3-(1H- C24H27N5O3 433.51 2.46 435.42 97 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)- ethanone 1211-[4-(Furan-2-carbonyl)piperazin-1- C28H27N5O5 513.55 2.89 514.41 87 DADyl]-2-[5-methoxy-1-methyl-3-(1H- pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethanone 122 N-(1-{2-[5-Methoxy-1-methyl-3-(1H- C26H29N5O4475.55 2.67 476.44 78 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetyl}pyrrolidin-3-yl)-N- methylacetamide 1231-{4-[2-(2-Hydroxyethoxy)ethyl]- C27H33N5O5 507.59 2.45 508.46 96 DADpiperazin-1-yl}-2-[5-methoxy-1- methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethanone 1241-[4-(2-Hydroxyethyl)piperidin-1-yl]- 2-[5-methoxy-1-methyl-3-(1H-C26H30N4O4 462.55 2.76 463.45 100 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]ethanone 1252-[5-Methoxy-1-methyl-3-(1H- C25H23N5O3 441.49 2.50 442.41 100 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-pyridin-3-ylmethylacetamide 126 N-(2,3-Dihydroxypropyl)-2-[5-C23H26N4O5 438.48 2.53 439.41 100 DAD methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]-N-methylacetamide 127N-(2-Methoxyethyl)-2-[5-methoxy-1- C23H26N4O4 422.48 2.83 423.42 100 DADmethyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-methylacetamide 128(3aS,6aS)-5-{2-[5-Methoxy-1- C25H25N5O4 459.19 2.55 460.08 90 DADmethyl-3-(1H-pyrrolo[2,3-b]pyridin- 2-yl)-1H-indol-6-yloxy]acetyl}hexa-hydropyrrolo[3,4-c]pyrrol-1-one trifluoroacetate 129N-(2-Hydroxyethyl)-2-[5-methoxy-1- C22H24N4O4 408.18 2.59 409.06 89 DADmethyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-methylacetamide trifluoroacetate 130N,N-Bis-(2-hydroxyethyl)-2-[5- C23H26N4O5 438.19 2.50 439.21 87 DADmethoxy-1-methyl-3-(1H-pyrrolo- [2,3-b]pyridin-2-yl)-1H-indol-6-yl-oxy]acetamide trifluoroacetate 131 N-(2-Dimethylaminoethyl)-N-ethyl-C25H31N5O3 449.24 2.54 450.08 98 DAD 2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]acetamide trifluoroacetate132 1-(4-Benzyl-4-hydroxypiperidin-1- C31H32N4O4 524.24 3.14 525.83 100DAD yl)-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]ethanone trifluoroacetate133 N-Ethyl-2-[5-methoxy-1-methyl-3- C27H27N5O3 469.21 2.56 470.07 100DAD (1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-pyridin-4-ylmethylacetamide trifluoroacetate 134N,N-Bis-(2-methoxyethyl)-2-[5- C25H30N4O5 466.22 2.93 467.39 100 DADmethoxy-1-methyl-3-(1H-pyrrolo- [2,3-b]pyridin-2-yl)-1H-indol-6-yl-oxy]acetamide trifluoroacetate 135 N,N-Bis-(2-diethylaminoethyl)-2-[5-C31H44N6O3 548.35 2.43 549.02 90 DAD methoxy-1-methyl-3-(1H-pyrrolo-[2,3-b]pyridin-2-yl)-1H-indol-6-yl- oxy]acetamide trifluoroacetate 1364-({2-[5-Methoxy-1-methyl-3-(1H- C28H26N4O5 498.54 3.80 499.74 89 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]acetylamino}methyl)-benzoic acid methyl ester 137 (3aR,6aS)-5-{2-[5-Methoxy-1- C31H27N5O5549.58 3.70 550.81 100 DAD methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-acetyl}-2- phenyltetrahydropyrrolo[3,4-c]-pyrrole-1,3-dione 138 (3aR,6aS)-2-Benzyl-5-{2-[5- C32H29N5O5 563.61 3.80564.85 100 DAD methoxy-1-methyl-3-(1H-pyrrolo-[2,3-b]pyridin-2-yl)-1H-indol-6-yl- oxy]acetyl}tetrahydropyrrolo[3,4-c]-pyrrole-1,3-dione 139 4-{2-[5-Methoxy-1-methyl-3-(1H- C29H26N4O6 526.183.50 526.88 100 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetylamino}-1-benzopyran- 8-carboxylic acid 1402-[5-Methoxy-1-methyl-3-(1H- C24H21N5O3 427.20 2.87 428.13 86 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]-N-pyridin-2-ylacetamide141 2-[5-Methoxy-1-methyl-3-(1H- C24H21N5O3 427.50 2.52 428.63 100 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]-N-pyridin-4-ylacetamide142 2-[5-Methoxy-1-methyl-3-(1H- C30H31N5O3 509.61 2.68 510.75 100 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-(4-piperidin-1-yl-phenyl)- acetamide 1434-({2-[5-Methoxy-1-methyl-3-(1H- C27H24N4O5 484.51 3.8 485.34 85 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]acetylamino}methyl)-benzoic acid 144 N-(3-Hydroxypyridin-2-yl)-2-[5- C24H21N5O4 443.46 2.68444.59 83 DAD methoxy-1-methyl-3-(1H-pyrrolo-[2,3-b]pyridin-2-yl)-1H-indol-6-yl- oxy]acetamide 1452-[5-Methoxy-1-methyl-3-(1H- C25H23N5O3 441.49 2.67 442.34 85 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol- 6-yloxy]-N-(3-methylpyridin-2-yl)-acetamide 146 2-[5-Methoxy-1-methyl-3-(1H- C26H24N4O4 456.50 3.31 457.3084 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-(3-methoxyphenyl)- acetamide

EXAMPLE 1472-[1-Methyl-5-methoxy-6-(2-morpholin-4-yl-ethoxy)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine

a)2-[1-Methyl-5-methoxy-6-(2-morpholin-4-yl-ethoxy)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 0.24 g of2-[1-methyl-5-methoxy-6-(2-morpholin-4-ylethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.93 ml of a 5N aqueous potassium hydroxide solution. 0.116 g of2-[1-methyl-5-methoxy-6-(2-morpholin-4-ylethoxy)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 2.50 to 2.65 (mt:4H); 2.76 (t, J=6 Hz: 2H); 3.60 (broad t, J=5 Hz: 4H); 3.79 (s: 3H);3.87 (s: 3H); 4.16 (t, J=6 Hz: 2H); 6.73 (d, J=1.5 Hz: 1H); 6.99 (dd,J=8 and 5 Hz: 1H); 7.16 (s: 1H); 7.42 (s: 1H); 7.77 (s: 1H); 7.82 (broadd, J=8 Hz: 1H); 8.09 (dd, J=5 and 1.5 Hz: 1H); 11.71 (broad s: 1H).

Mass spectrum (EI): m/z=407 [M]⁺ (base peak)

b)2-[1-Methyl-5-methoxy-6-(2-morpholin-4-ylethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.11 g of potassium carbonate and 0.14 ml of morpholine are added to asolution of 0.24 g of2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 24 ml of acetonitrile, under an inert argon atmosphere at atemperature in the region of 20° C. The reaction medium is heated at 60°C. for 24 hours. After cooling, the reaction medium is concentratedunder reduced pressure. The oil obtained is taken up with 10 ml of waterand 10 ml of ethyl acetate. After separation by settling out, theorganic phase is dried over magnesium sulfate, filtered and thenconcentrated under reduced pressure. The residue obtained is purified byflash-pack chromatography (silica, 30/70 by volume ethylacetate/cyclohexane as eluents). The fractions containing the productare concentrated under reduced pressure. 0.24 g of2-[1-methyl-5-methoxy-6-(2-morpholin-4-ylethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=561 [M+H]⁺ (base peak)

c)2-[1-Methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.260 g of sodium iodide is added to a solution of 0.59 g of2-[1-methyl-5-methoxy-6-(2-chloroethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 42 ml of 2-butanone, under an inert argon atmosphere at a temperaturein the region of 20° C. The reaction medium is refluxed for 24 hours.After cooling, the reaction medium is concentrated under reducedpressure. The residue obtained is purified by flash-pack chromatography(silica, dichloromethane as eluent). The fractions containing theproduct are concentrated under reduced pressure. 0.565 g of2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=601 [M]⁺, m/z=446 (base peak)

d)2-[1-Methyl-5-methoxy-6-(2-chloroethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following manner:

0.101 g of sodium hydride (at 60% in oil) is added to a solution of 0.94g of2-[1-methyl-5-methoxy-6-hydroxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 22 ml of dimethylformamide, under an inert argon atmosphere at atemperature in the region of 20° C. The reaction medium is agitated atthis temperature for 15 minutes. 0.525 ml of 1-chloro-2-bromoethane issubsequently added. After agitating for 2 hours at the same temperature,0.1 g of sodium hydride (at 60% in oil) and 0.525 ml of1-chloro-2-bromoethane are again added. The reaction medium ismaintained at this temperature for 20 hours, with agitation. 20 ml ofwater and 20 ml of ethyl acetate are added; after separation by settlingout, the organic phase is dried over magnesium sulfate, filtered, andthen concentrated under reduced pressure. The residue obtained ispurified by flash-pack chromatography (silica, 35/65 by volume ethylacetate/cyclohexane as eluents). The fractions containing the productare concentrated under reduced pressure. 0.596 g of2-[1-methyl-5-methoxy-6-(2-chloroethoxy)-1H-indol-3-yl]-1-(toluene4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine is thus obtained, thecharacteristics of which are as follows:

Mass spectrum (EI): m/z=509 [M]⁺, m/z=354 (base peak)

e)2-[1-Methyl-5-methoxy-6-hydroxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.798 ml of iodotrimethylsilane is added to a solution of 1.2 g of2-[1-methyl-5-methoxy-6-benzyloxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 90 ml of acetonitrile, under an inert argon atmosphere at atemperature in the region of 20° C. The reaction medium is heated at 50°C. for 4 hours. After cooling, 60 ml of water and 60 ml of ethyl acetateare added; after separation by settling out, the organic phase is driedover magnesium sulfate, filtered, and then concentrated under reducedpressure. The residue obtained is purified by flash chromatography(silica, 40/60 by volumes ethyl acetate/cyclohexane as eluents, argon).The fractions containing the product are concentrated under reducedpressure. 0.825 g of2-[1-methyl-5-methoxy-6-hydroxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=447 [M]⁺, m/z=292 (base peak)

The compound2-[1-methyl-5-methoxy-6-benzyloxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared according to the process described in patent WO 03000688 A1.

EXAMPLE 1482-{1-Methyl-5-methoxy-6-[2-(4-methyl-piperazin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine

a)2-{1-Methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)-ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 0.195 g of2-[1-methyl-5-methoxy-6-(2-(4-methylpiperazin-4-ylethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.53 ml of a 5N aqueous potassium hydroxide solution. Afterpurification by flash-pack chromatography (silica, 90/10 by volumedichloromethane/methanol as eluents, argon), 0.086 g of2-[1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)-ethoxy]-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.18 (s: 3H); 2.37(unresolved peak: 4H) from 2.50 to 2.65 (mt: 4H); 2.78 (t, J=6 Hz: 2H);3.83 (s: 3H); 3.90 (s: 3H); 4.17 (t, J=6 Hz: 2H); 6.77 (d, J=2 Hz: 1H);7.03 (dd, J=8 and 5 Hz: 1H); 7.20 (s: 1H); 7.46 (s: 1H); 7.80 (s: 1H);7.86 (broad dd, J=8 and 1.5 Hz: 1H); 8.13 (dd, J=5 and 1.5 Hz: 1H);11.75 (broad s: 1H).

Mass spectrum (EI): m/z=419 [M]⁺, m/z=127 (base peak)

b)2-[1-Methyl-5-methoxy-6-(2-(4-methylpiperazin-4-yl-ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147b butusing 0.1 ml of N-methylpiperazine and 0.27 g of2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.After purification by flash-pack chromatography (silica, 90/10 by volumedichloromethane/methanol as eluents, argon), 0.197 g of 2-[1-methyl-5methoxy-6-(2-(4-methylpiperazin-4-yl-ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=573 [M]⁺, m/z=127 (base peak)

EXAMPLE 1491-{2-[1-Methyl-5-methoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}piperidin-4-ol

a) 1-{2-[1-Methyl-5-methoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol6-yloxy]ethyl}piperidin-4-ol is prepared by following the proceduredescribed in example 89a, but using 0.23 g of1-{2-[1-methyl-5-methoxy-3-(1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}piperidin-4-oland 1.8 ml of a 5N aqueous potassium hydroxide solution. Afterpurification by flash-pack chromatography (silica, 90/10 by volumedichloromethane/methanol as eluents, argon), 0.017 g of1-{2-[5-1-methylmethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}piperidin-4-olis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.41 (mt: 2H); 1.72(very broad d, J=12 Hz: 2H); 2.16 (broad t, J=11 Hz: 2H); 2.73 (t, J=6Hz: 2H); 2.84 (mt: 2H); 3.45 (mt: 1H); 3.81 (s: 3H); 3.88 (s: 3H); 4.13(t, J=6 Hz: 2H); 4.55 (d, J=4 Hz: 1H); 6.75 (broad d, J=2 Hz: 1H); 7.00(dd, J=8 and 5 Hz: 1H); 7.16 (s: 1H); 7.42 (s: 1H); 7.77 (s: 1H); 7.84(broad d, J=8 Hz: 1H); 8.12 (broad dd, J=5 and 1.5 Hz: 1H); 11.73 (broads: 1H).

Mass spectrum (EI): m/z=420 [M]⁺, m/z=128 (base peak)

b)1-{2-[1-methyl-5-methoxy-3-(1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}piperidin-4-olis prepared by following the procedure described in example 147b, butusing 0.089 g of 4-hydroxypiperidine and 0.265 g of2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.After purification by flash-pack chromatography (silica, 90/10 by volumedichloromethane/methanol as eluents, argon), 0.234 g of 1-{2-[1-methyl-5methoxy-3-(1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}piperidin-4-olis obtained, the characteristics of which are as follows:

Mass Spectrum (CI): m/z=575 [M+H]⁺ (base peak).

EXAMPLES 150 TO 159

a)2-[6-(2-Iodoethoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution of2-[6-(2-chloroethoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.660 g, 1,294 μmol) in methyl ethyl ketone (10 ml) is placed in a 50ml single-necked flask and sodium iodide (0.29 g; 1.941 mmol) is thenadded. The reaction mixture is refluxed for 16 hours. Analysis by thinlayer chromatography (50/50 cyclohexane/ethyl acetate) shows that thereaction has come to an end. After returning to 20° C., the reactionmixture is evaporated under reduced pressure and the residue is taken upin a mixture of water (50 ml) and dichloromethane (50 ml), which isseparated by settling out; the organic extract is washed with water (30ml) and dried over magnesium sulfate. After evaporation, the compoundobtained is purified by chromatography on silica gel (cartridgeFC-10-Si-BP-Sup, 10 g of silica with a particle size of 15-35 μm,elution being carried out with a 70/30 mixture of cyclohexane/ethylacetate). The fractions containing the expected: compound are combinedand then evaporated under reduced pressure, giving2-[6-(2-iodoethoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.695 g; 89%) the characteristics of which are as follows:

LC/MS analysis: tr=4.0, m/z=601.96 [M+H]⁺

b)2-[6-(2-Chloroethoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution of5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol(0.8 g; 1.788 mmol) in solution in dimethylformamide (5 ml) is placed ina 50 ml round-bottomed flask rendered inert with argon, and sodiumhydride (0.064 g; 2.146 mmol) is then added. The reaction mixturebecomes brown in color and 1-bromo-2-chloroethane (0.308 g; 2.146 mmol)is added. The reaction mixture is agitated for 1 hour 30 minutes at 20°C. and then sodium hydride (0.064 g; 2.146 mmol) and1-bromo-2-chloroethane (2×0.5 ml) are again added. Analysis by thinlayer chromatography (50/50 cyclohexane/ethyl acetate) shows that thereaction has come to an end. The reaction mixture is diluted with water(150 ml) and ethyl acetate (50 ml), and extracted with ethyl acetate(2×50 ml). The organic extracts are combined, dried over magnesiumsulfate, filtered, and evaporated under reduced pressure, resulting inthe crude compound, which is purified by chromatography on silica gel(AIT cartridge FC 25 Si-BP-Sup, eluent: 65/35 cyclohexane/ethyl acetateat 10 ml/min). The fractions containing the expected compound arecombined and then evaporated under reduced pressure, giving the expected2-[6-(2-chloroethoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.66 g; 72%) in the form of a powder, the characteristics of which areas follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.30 (s: 3H); 3.75 (s:3H); 3.87 (s: 3H); 4.04 (broad t, J=5 Hz: 2H); 4.36 (broad t, J=5 Hz:2H); 6.75 (s: 1H); 6.99 (s: 1H); 7.20 (s: 1H); 7.26 (broad d, J=9 Hz:2H); 7.30 (dd, J=8 and 5 Hz: 1H); 7.54 (d, J=9 Hz: 2H); 7.59 (broad s:1H); 7.94 (dd, J=8 and 1.5 Hz: 1H); 8.35 (dd, J=5 and 1.5 Hz: 1H).

c) Alkylation of Examples 150 to 159

Each amine in the table below is weighed and solubilized indimethylformamide (0.5 ml), in 10 glass reactors (1.3×10 cm).2-[6-(2-Iodoethoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.05 g/reactor, 83 μmol/reactor) in dimethylformamide (0.5 ml/reactor),followed by potassium carbonate (0.035 g/reactor, 249 μmol/reactor), areadded to this solution. The reactors are closed and then placed in anoil bath at 60° C. for 4 hours 30 minutes. The content of each reactoris filtered and then transferred onto a solid-phase extraction cartridge(Varian Mega BondElut-SCX, ref: 12256011, 1gr, 6 ml, Batch 1728002,UNRESOLVED PEAKG code 3102) pre-conditioned with methanol (12 ml). Thesolid-phase extraction cartridges are eluted with methanol (2×6 ml) andthen with methanol/2M ammonia (2×6 ml). The ammonia-containing elutionfractions are combined and evaporated to give the crude compounds. Thecrude compounds are purified by chromatography on silica gel (24 mlcartridge containing 10 g of 40-60 μm silica gel with dichloromethane),elution being carried out with a mixture of dichloromethane/methanol invarying proportions, but adapted to each case (from 97/3 to 80/20). Thefractions containing the expected compounds are combined and evaporated,resulting in the corresponding intermediate compounds, which are used inthe detosylation step.

MW Weight Name Formula (g/mol) Eq. (mg) 150 n-(2-hydroxyethyl)piperazineC6H14N2O 130.19 3.000 32.470 151 3-hydroxypiperidine C5H11NO 101.153.000 25.230 152 n,n,n′-trimethylethylenediamine C5H14N2 102.18 3.00025.480 153 1-(2-furoyl)piperazine C9H12N2O2 180.21 3.000 44.940 1543-(n-acetyl-n-methylamino)pyrrolidine C7H14N2O 142.2 3.000 35.460 1551-methylhomopiperazine C6H14N2 114.19 3.000 28.480 1561-hydroxyethylethoxypiperazine C8H18N2O2 174.24 3.000 43.460 1573-methylamino-1,2-propanediol C4H11NO2 105.14 3.000 26.220 1582-methoxy-n-methylethylamine C4H11NO 89.14 3.000 22.230 1594-(4-methylpiperazino)aniline C11H17N3 191.28 3.000 47.710

d) Deprotection of Examples 150 to 159 A methanolic potassium hydroxidesolution (1.5 ml per tube, 0.1 g of potassium hydroxide/ml of methanol)is added to 10 hemolysis tubes (1.3×10 cm) containing the compoundsderived from the reaction described above, and the tubes are thenagitated at 20° C. for 16 hours. After evaporation under reducedpressure, the residues are taken up in dimethylformamide (0.6 ml) andthe solutions thus obtained are then eluted on solid-phase extractioncartridges (Varian, Mega Bond Elut, SCX, 2 g, 6 ml, Ref. 19102),pre-conditioned with methanol (2×6 ml). After a first elution withmethanol (6 ml), the cartridges are eluted with 2N ammoniacal methanol(5 ml); the ammonia-containing eluate is evaporated to dryness. Thecompounds thus obtained are finally purified by chromatography on silicagel (cartridges of 2 g of 40-60 μm silica gel, dichloromethane), elutionbeing carried out with a mixture of dichloromethane and 2M ammoniacalmethanol (95/5) at 5 ml/min. The fractions containing the expectedcompound are combined and then evaporated under reduced pressure, givingthe expected compounds. Each of the compounds is solubilized indimethylformamide (0.6 ml) and then eluted on solid-phase extractioncartridges (Varian, Mega Bond Elut, SCX, 0.5 g, 3 ml) pre-conditionedwith methanol (2×3 ml). After a first elution with methanol (4.8 ml),the cartridges are eluted with 2N ammoniacal methanol (4.8 ml); theammonia-containing eluate is evaporated to dryness, giving the expectedcompounds, which are characterized by reverse-phase liquidchromatography mass spectrometry (method A). The retention times andmolecular ions are reported in the table below.

MW RT ex Name (parent) EF (g/mol) (min) M + H⁺ % Trace 1502-(4-{2-[5-Methoxy-1-methyl-3- C25H31N5O3 449.55 2.28 450.32 85.00 DAD(1H-pyrrolo[2,3-b]pyridin-2-yl)- 1H-indol-6-yloxy]ethyl}piperazin-1-yl)ethanol 151 1-{2-[5-N-Methoxy-1-methyl-3-(1H- C24H28N4O3 420.512.40 421.29 100.00 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}piperidin-3-ol 152 N-{2-[5-Methoxy-1-methyl-3-(1H-C24H31N5O2 421.54 2.26 422.32 94.00 DAD pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}-N,N′,N′- trimethylethane-1,2-diamine 153Furan-2-yl-(4-{2-[5-methoxy-1- C28H29N5O4 499.57 2.56 500.29 74.00 DADmethyl-3-(1H-pyrrolo[2,3-b]- pyridin-2-yl)-1H-indol-6-yloxy]-ethyl}piperazin-1-yl)methanone 154 N-(1-{2-[5-Methoxy-1-methyl-3-C26H31N5O3 461.57 2.45 462.32 96.00 DAD (1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethyl}-pyrrolidin- 3-yl)-N-methylacetamide 1552-{5-Methoxy-1-methyl-6-[2-(4- C25H31N5O2 433.56 2.26 434.31 100.00 DADmethylperhydro-1,4-diazepin- 1-yl)ethoxy]-1H-indol-3-yl}-1Hpyrrolo[2,3-b]pyridine 156 2-[2-(4-{2-[5-Methoxy-1-methyl- C27H35N5O4493.61 2.28 494.33 97.00 DAD 3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-ethyl}piperazin- 1-yl)ethoxy]ethanol 1573-({2-[5-Methoxy-1-methyl-3-(1H- C23H28N4O4 424.50 2.32 425.28 84.00 DADpyrrolo[2,3-b]pyridin-2-yl)-1H- indol-6-yloxy]ethyl}methyl-amino)propane-1,2-diol 158 (2-Methoxyethyl)-{2-[5-methoxy- C23H28N4O3408.50 2.47 409.28 100.00 DAD 1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]- ethyl}methylamine 159{2-[5-Methoxy-1-methyl-3-(1H- C30H34N6O2 510.64 2.39 511.32 100.00 DADpyrrolo[2,3-b]pyridin-2-yl)-1H- indol-6-yloxy]ethyl}-[4-(4-methyl-piperazin-1-yl)phenyl]amine

EXAMPLES 160 TO 164

a)2-[6-(3-Iodopropoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution of2-[6-(3-chloropropoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.415 g; 792 μmol) in methyl ethyl ketone (10 ml) is placed in a 50 mlsingle-necked flask and sodium iodide (0.178 g; 1.18 mmol) is thenadded. The reaction mixture is refluxed for 16 hours. Analysis by thinlayer chromatography (50/50 cyclohexane/ethyl acetate) shows that thestarting compound is still present. Additional sodium iodide (0.178 g;1.18 mmol) is introduced and the reflux is maintained for 3 hours. Afterreturning to 20° C., the precipitate is dissolved in dichloromethane(200 ml) and then washing with water (50 ml) and drying over magnesiumsulfate are carried out. After evaporation, the residue is taken up inethyl acetate (20 ml); the insoluble material is removed and thefiltrate is then evaporated under reduced pressure.2-[6-(3-Iodopropoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.367 g; 75%) is isolated, the characteristics of which are as follows:

LC/MS analysis: tr=4.32 min; m/z=615.96 [M+H]⁺

b)2-[6-(3-Chloropropoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution of5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol(0.45 g; 1.006 mmol) in solution in dimethylformamide (5 ml) is placedin a 50 ml round-bottomed flask rendered inert with argon, and sodiumhydride (0.06 g; 2.01 mmol) is then added. The reaction mixture becomesdark in color and 1-bromo-3-chloropropane (0.199 ml, 2.01 mmol) isadded. The reaction mixture is agitated for 30 minutes at 20° C. Thereaction mixture is diluted with dichloromethane (50 ml) and water (100ml), separated by settling out, and extracted with dichloromethane (2×50ml). The organic extracts are combined, dried over magnesium sulfate,filtered and evaporated under reduced pressure, resulting in an oil. Theoil is taken up in diisopropyl ether (10 ml) and then triturated,discarding crystals. After filtration, washing with diisopropyl etherand drying under reduced pressure,2-[6-(3-chloropropoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis isolated in the form of ochre-colored crystals (0.415 g; 79%), thecharacteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.27 (mt: 2H); 2.30(s: 3H); 3.75 (s: 3H); 3.87 (s: 3H); 3.89 (t, J=6.5 Hz: 2H); 4.20 (t,J=6.5 Hz: 2H); 6.74 (s: 1H); 6.97 (s: 1H); 7.19 (s: 1H); 7.26 (broad d,J=8.5 Hz: 2H); 7.29 (dd, J=8 and 5 Hz: 1H); 7.50 (s: 1H); 7.57 (d, J=8.5Hz: 2H); 7.93 (dd, J=8 and 1.5 Hz: 1H); 8.34 (dd, J=5 and 11.5 Hz: 1H).

c) Alkylation of Examples 160 to 164

The 5 amines described in the table below are weighed and aresolubilized in dimethyl formamide (0.5 ml), in five 1.2×10 cm hemolysistubes. A solution of2-[6-(3-iodopropoxy)-5-methoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(81.2 μmol/tube) in dimethylformamide (0.5 ml/tube) is placed in 5hemolysis tubes (1.2×10 cm), and the solutions of amines described beloware added to said solution. Potassium carbonate (0.035 g/tube) is addedusing a spatula. The reactors are closed and then heated at 65° C. for 3hours with agitation. After returning to ambient temperature, thecontents of each reactor is filtered and the filtrates are purified byreverse-phase liquid chromatography mass spectrometery (2 injections persample, method B). The fractions containing the expected compounds arecombined and then evaporated under reduced pressure, giving thecompounds which are used in the following step.

Equiv- Weight ex Name Formula MW alent mg 160 morpholine C4H9NO 87.123,010 21.300 161 1-methylpiperazine C5H12N2 100.16 3,000 24.410 1624-(4-methyl- C11H17N3 191.28 3,000 46.610 piperazino)- aniline 1631-methyl- C6H14N2 114.19 3,000 27.830 homopiperazine 1641-hydroxyethylethoxy- C8H18N2O2 174.24 3,000 42.460 piperazine

d) Detosylation of Examples 160 to 164

A methanolic potassium hydroxide solution (1.6 ml per tube, solution at0.1 g of potassium hydroxide per ml of methanol) is added to 5 hemolysistubes (1.2×10 cm) containing the compounds obtained above, and themixture is then agitated at 20° C. for 16 hours before being evaporatedto dryness. The evaporation residues are taken up in a mixture ofdimethylformamide (0.8 ml) and acetic acid (0.2 ml), and then purifiedby reverse-phase liquid chromatography mass spectrometry (method B, 2injections per sample). The fractions containing the expected compoundsare combined and then eluted on solid-phase extraction cartridges(Varian Mega BondElut-SCX cartridges, 1 gr, 6 ml) pre-conditioned withmethanol (2×6 ml). After elution with methanol (2×6 ml) and then elutionwith 2M ammoniacal methanol (2×6 ml), the ammonia-containing eluates arecombined and evaporated under reduced pressure. The dry extracts aretaken up in a mixture of dichloromethane and methanol (90/10), and thenfiltered through silica cartridges (Thermoquest, Hypersep Silica, 0.1 g,#60300-494). The eluates are evaporated under reduced pressure,resulting in the expected compounds, which are characterized by virtueof their retention time and molecular peak.

MW RT ex NAME EF (g/mol) (min) M + H⁺ Trace % 1602-[5-Methoxy-1-methyl-6- C24H28N4O3 420.51 2.47 421.32 DAD 96(3-morpholin-4-yl- propoxy)-1H-indol-3-yl]- 1H-pyrrolo[2,3-b]- pyridine161 2-{5-Methoxy-1-methyl-6- C25H31N5O2 433.56 2.32 434.34 DAD 100[3-(4-methylpiperazin-1- yl)-propoxy]-1H-indol-3- yl}-1H-pyrrolo[2,3-b]-pyridine 162 {3-[5-Methoxy-1-methyl- C31H36N6O2 524.67 2.41 525.38 DAD100 3-(1H-pyrrolo[2,3-b]- pyridin-2-yl)-1H-indol- 6-yloxy]propyl}-[4-(4-methylpiperazin-1-yl)- phenyl]amine 163 2-{5-Methoxy-1-methyl-6-C26H33N5O2 447.58 2.31 448.36 DAD 100 [3-(4-methylperhydro-1,4-diazepin-1-yl)- propoxy]-1H-indol-3-yl}- 1H-pyrrolo[2,3-b]- pyridine164 2-[2-(4-{3-[5-Methoxy-1- C28H37N5O4 507.63 2.33 508.37 DAD 100methyl-3-(1H-pyrrolo- [2,3-b]pyridin-2-yl)-1H- indol-6-yloxy]-propyl}-piperazin-1-yl)ethoxy]- ethanol

EXAMPLES 165 TO 167

a)2-{6-[2-(2-Chloroethoxy)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution2-{6-[2-(2-chloroethoxy)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.145 g, 261.7 μmol) in methyl ethyl ketone (3 ml) is placed in a 50 mlsingle-necked flask and sodium iodide (0.118 g; 785 μmol) is then added.The reaction mixture is refluxed for 16 hours. Analysis by thin layerchromatography (50/50 cyclohexane/ethyl acetate) shows that the startingcompound is still present. Additional sodium iodide (0.178 g; 1.18 mmol)is introduced and the reflux is maintained for 3 hours. After returningto 20° C., the precipitate is dissolved in dichloromethane (30 ml), thenwashing with water (10 ml) and drying over magnesium sulfate are carriedout. After evaporation, the residue is taken up in diisopropyl ether (10ml); the solid formed is removed and the filtrate is then evaporatedunder reduced pressure.2-{6-[2-(2-Chloroethoxy)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.137 g; 81%) is isolated, which is used as it is.

b)2-{6-[2-(2-Chloroethoxy)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

A solution of5-methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-6-ol(2.998 g; 670 μmol) in dimethylformamide (3 ml) is placed in a 10 mlround-bottomed flask, sodium hydride (0.603 g; 2.01 mmol) is then addedand the mixture is agitated for 5 minutes. The reaction mixture becomesgreen in color, and bis(2-chloroethyl) ether (0.235 ml; 2.01 mmol) isthen added. The reaction mixture is then agitated for 1 hour 30 minutesat 20° C. Analysis by thin layer chromatography (50/50 cyclohexane/ethylacetate) shows that the starting compound has been used up. The reactionmixture is run into water (30 ml) and then extracted withdichloromethane (20 ml). The organic extracts are combined, dried overmagnesium sulfate, filtered and evaporated under reduced pressure, togive the crude compound, which is purified by chromatography on silicagel (AIT cartridge, Flash Silica column, 20-40 μm, 25 g, ref:FC-25SI-BP-SUP, 10 ml/min, 70/30 to 50/50 cyclohexane/ethyl acetate).The fractions containing the expected compound are combined and thenevaporated under reduced pressure, giving2-{6-[2-(2-chloroethoxy)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.145 g; 39%), which is used as it is for the following step.

c) Alkylation of Examples 165 to 167

The amines described in the table below are placed in 3 hemolysis tubes(1.2×10 cm) and solubilized in dimethylformamide (1 ml per tube). Asolution of2-{6-[2-(2-chloroethoxy)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine(0.032 g per tube, 50 μmol per reactor) is placed in 4 hemolysis tubes)1.2×10 cm), and then each solution of amine described above, and alsopotassium carbonate (0.021 g; 150 μmol per tube), are then added. Thereactors are closed and then heated at 65° C. for 6 hours withagitation. After returning to 20° C., the content of each tube isfiltered and then diluted with acetic acid (0.2 ml). The solutions thusobtained are eluted on solid-phase extraction cartridges (Varian, MegaBond Elut, SCX, 2 g, 6 ml, #19102) pre-conditioned with methanol (2×6ml). After a first elution with methanol (6 ml), the cartridges areeluted with 2N ammoniacal methanol (5 ml); the ammonia-containing eluateis evaporated to dryness, so as to give the expected compounds, whichare used in the following step.

Mol Equiv- Weight Name Formula weight alent mg 165 1-methylpiperazineC5H12N2 100.16 3.000 15.020 166 4-piperidinopiperidine C10H20N2 168.283.000 25.240 167 1-methyl- C6H14N2 114.19 3.000 17.130 homopiperazine

d) Detosylation of Examples 165 to 167

A methanolic potassium hydroxide solution (1.5 ml, solution at 0.1 g ofpotassium hydroxide per ml of methanol) is added to 3 hemolysis tubes(1.2×10 cm) containing the compounds obtained above, and each reactionmixture is then agitated at 20° C. for 16 hours. The content of eachtube is diluted with acetic acid (0.2 ml) and then loaded onto anextraction cartridge (Varian, Mega Bond Elut, SCX, 2 g, 6 ml, Ref.19102, Batch 1706002) pre-conditioned with methanol (2×6 ml). After afirst elution with methanol (6 ml), the cartridges are eluted with 2Nammoniacal methanol (2×5 ml); the ammonia-containing eluate isevaporated to dryness and each sample is then diluted in dimethylsulfoxide (0.5 ml) and purified by reverse-phase liquid chromatographymass spectrometry (method G). The fractions containing the expectedcompound are combined and then evaporated under reduced pressure, givingthe expected compounds. The fractions are loaded onto SCX cartridges(Varian Mega BondElut-SCX cartridges, ref: 12256011, 1 g, 6 ml, Batch1728002, UNRESOLVED PEAKG code 3102) pre-conditioned with methanol (2×6ml). After elution with methanol (2×6 ml), the cartridges are elutedwith 2N ammoniacal methanol (2×6 ml) and the ammonia-containing eluatesare evaporated under reduced pressure to give the expected compounds,characterized by their retention time and peak (table below)

Formula Ex Name (parent) (parent) MW Rt M + H⁺ % trace 1652-(5-Methoxy-1-methyl-6-{2-[2-(4-methyl- C26H33N5O3 463.58 2.37 464 100DAD piperazin-1-yl)ethoxy]ethoxy}-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine 166 1′-(2-{2-[5-Methoxy-1-methyl-3-(1H-C31H41N5O3 531.70 2.4 532 100 DADpyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethoxy}ethyl)-[1,4′]bipiperidinyl 1672-(5-Methoxy-1-methyl-6-{2-[2-(4-methyl- C27H35N5O3 477.61 2.36 478 100DAD perhydro-1,4-diazepin-1-yl)ethoxy]- ethoxy}-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine

EXAMPLE 1682-[5-Methoxy-6-(2-methoxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine

a)2-[5-Methoxy-6-(2-methoxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 0.102 g of2-[5-methoxy-6-(2-methoxyethoxy)-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.80 ml of 5N potassium hydroxide. After purification by flash-packchromatography (silica, 92.5/7.5 by volume dichloromethane/methanol aseluents, argon), 0.033 g of2-[5-methoxy-6-(2-methoxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.39 (s: 3H); 3.76(mt: 2H); 3.83 (s: 3H); 3.91 (s: 3H); 4.21 (mt: 2H); 6.78 (d, J=2 Hz:1H); 7.04 (dd, J=8 and 5 Hz: 1H); 7.17 (s: 1H); 7.46 (s: 1H); 7.80 (s:1H); 7.88 (dd, J=8 and 1.5 Hz: 1H); 8.13 (dd, J=5 and 1.5 Hz: 1H); 11.75(broad s: 1H).

Mass spectrum (EI): m/z=351 [M]⁺ (base peak)

b)2-[5-Methoxy-6-(2-methoxyethoxy)-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147d, butusing 0.195 g of 1-bromo-2-methoxyethane instead of1-chloro-2-bromoethane used in example 147d, and 0.224 g of2-[1-methyl-5-methoxy-6-hydroxyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.After purification by flash-pack chromatography (silica, 80/20 by volumeethyl acetate/cyclohexane as eluents, argon), 0.121 g of2-[5-methoxy-6-(2-methoxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=505 [M]⁺ (base peak)

EXAMPLE 1692-[5-Methoxy-6-(2-hydroxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine

a)2-[5-Methoxy-6-(2-hydroxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure as described in example 89a, butusing 0.5 g of2-[5-methoxy-6-(2-acetyloxyethoxy)-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 8.43 ml of a 5N aqueous potassium hydroxide solution. Afterpurification by flash-pack chromatography (silica, 95/05 by volumedichloromethane/methanol as eluents, argon), 0.103 g of2-[5-methoxy-6-(2-hydroxyethoxy)-1-methyl-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 3.75 to 3.85 (mt:2H); 3.82 (s: 3H); 3.90 (s: 3H); 4.09 (t, J=5.5 Hz: 2H); 4.88 (broad t,J=5 Hz: 1H); 6.76 (d, J=2 Hz: 1H); 7.02 (dd, J=8 and 5 Hz: 1H); 7.15 (s:1H); 7.44 (s: 1H); 7.79 (s: 1H); 7.86 (broad dd, J=8 and 1.5 Hz: 1H);8.12 (dd, J=5 and 1.5 Hz: 1H); 12.24 (unresolved peak: 1H).

Mass spectrum (EI): m/z=337 [M]⁺ (base peak)

b)2-[5-Methoxy-6-(2-acetyloxyethoxy)-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147d, butusing 0.246 ml of 2-bromoethyl acetate and 0.5 g of2-[1-methyl-5-methoxy-6-hydroxyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.After purification by flash-pack chromatography (silica, 40/60 by volumeethyl acetate/cyclohexane as eluents), 0.506 g of2-[5-methoxy-6-(2-acetyloxyethoxy)-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=533 [M]⁺, m/z=292 (base peak)

EXAMPLE 170 2-(5-Methoxy-1,6-dimethyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine

a) 2-(5-Methoxy-1,6-dimethyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]-pyridineis prepared by following the procedure described in example 189a, butusing 0.028 g of2-(5-methoxy-1,6-dimethyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.283 ml of a 5N aqueous potassium hydroxide solution. 0.01 g of2-(5-methoxy-1,6-dimethyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]-pyridine isobtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.33 (s: 3H); 3.83 (s:3H); 3.94 (s: 3H); 6.78 (d, J=2 Hz: 1H); 7.03 (dd, J=8 and 5 Hz: 1H);7.35 (broad s: 1H); 7.40 (broad s: 1H); 7.84 (s: 1H); 7.87 (broad dd,J=8 and 1.5 Hz: 1H); 8.12 (dd, J=5 and 1.5 Hz: 1H); 11.78 (broad s: 1H).

Mass spectrum (ES⁺): m/z=292 [M+H]⁺ (base peak)

b)2-(5-Methoxy-1,6-dimethyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.012 g of methylboronic acid, 0.0715 g of potassium carbonate and 0.020g of tetrakis(triphenylphosphine)palladium are added to a solution of0.1 g of2-[1-methyl-5-methoxy-6-(trifluorosulfonyloxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 3 ml of anhydrous dioxane, under an inert argon atmosphere at atemperature in the region of 20° C. The reaction medium is heated at120° C. for 24 hours. After cooling, 5 ml of water and 5 ml of ethylacetate are added. After separation by settling out, the organic phaseis dried over sodium sulfate, filtered, and then concentrated underreduced pressure. The residue obtained is purified by flash-packchromatography (silica, 30/70 by volume ethyl acetate/cyclohexane aseluents). The fractions containing the products are concentrated underreduced pressure. 0.03 g of2-(5-methoxy-1,6-dimethyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=445 [M]⁺, m/z=290 (base peak)

c)2-[1-Methyl-5-methoxy-6-(trifluorosulfonyloxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared in the following way:

0.451 ml of triflic anhydride and 1.35 ml of pyridine are added to asolution of 1 g of2-[1-methyl-5-methoxy-6-hydroxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 30 ml of dichloromethane, under an inert argon atmosphere at atemperature in the region of 0° C. The reaction medium is agitated atthis temperature for 3 hours. The ice bath is removed. After returningto a temperature in the region of 20° C., 15 ml of water are added.After separation by settling out, the organic phase is dried over sodiumsulfate, filtered, and then concentrated under reduced pressure. Theresidue obtained is purified by flash-pack chromatography (silica,dichloromethane as eluent). The fractions containing the product areconcentrated under reduced pressure. 1.12 g of2-[1-methyl-5-methoxy-6-(trifluorosulfonyloxy)-1-H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=580 [M+H]⁺ (base peak)

The compound2-[1-methyl-5-methoxy-6-hydroxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared according to the process described in example 147e.

EXAMPLE 1714-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]-pyridine

a)4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 0.300 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-(4-methylpiperazin-4-yl-ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 2.22 ml of a 5N aqueous potassium hydroxide solution. 0.169 g of4-chloro-2-[1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.17 (s: 3H); 2.36(unresolved peak: 4H); from 2.45 to 2.60 (mt: 4H); 2.77 (t, J=6.5 Hz:2H); 3.84 (s: 3H); 3.90 (s: 3H); 4.16 (t, J=6.5 Hz: 2H); 6.71 (broad s:1H); 7.14 (d, J=5 Hz: 1H); 7.21 (s: 1H); 7.44 (s: 1H); 7.85 (s: 1H);8.08 (d, J=5 Hz: 1H); 12.16 (unresolved peak: 1H).

Mass spectrum (EI): m/z=453 [M]⁺, m/z=127 (base peak)

b)4-Chloro-2-[1-methyl-5-methoxy-6-(2-methoxyethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147b, butusing 0.087 ml of N-methylpiperazine and 0.25 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.0.303 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-(4-methylpiperazin-4-yl-ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=607 [M]⁺, m/z=127 (base peak)

c)4-Chloro-2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147c, butusing 1.15 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-chloroethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.950 g of sodium iodide. After purification by flash chromatography(silica, 40/60 by volume ethyl acetate/cyclohexane as eluents, argon),1.21 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=635 [M]⁺, m/z=480 (base peak)

d)4-Chloro-2-[1-methyl-5-methoxy-6-(2-chloroethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147d, butusing 1.3 g of4-chloro-2-[1-methyl-5-methoxy-6-hydroxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.675 cm³ of 1-bromo-2-chloroethane. After purification by flashchromatography (silica, 40/60 by volume ethyl acetate/cyclohexane aseluents, argon), 1.16 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-chloroethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=544 [M+H]⁺ (base peak)

e)4-chloro-2-[1-methyl-5-methoxy-6-hydroxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147e, butusing 1.8 g of4-chloro-2-[1-methyl-5-methoxy-6-benzyloxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.124 ml of iodotrimethylsilane. After purification by flashchromatography (silica, 40/60 by volume ethyl acetate/cyclohexane aseluents, argon), 1.3 g of4-chloro-2-[1-methyl-5-methoxy-6-hydroxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=482 [M+H]⁺ (base peak)

f)4-Chloro-2-[1-methyl-5-methoxy-6-benzyloxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89c, butusing 2.5 g of4-chloro-2-(5-methoxy-6-benzyloxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.335 ml of methyl iodide. After purification by flashchromatography (silica, 40/60 by volume ethyl acetate/cyclohexane aseluents, argon), 2.1 g of4-chloro-2-(1-methyl-5-methoxy-6-benzyloxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=571 [M]⁺, m/z=480 (base peak)

g)4-Chloro-2-(5-methoxy-6-benzyloxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 97c, butusing 2.75 g of1-tert-butyloxycarbonyl-5-methoxy-6-benzyloxy-indol-3-boronic acid and 3g of 1-(toluene-4-sulfonyl)-1H-2-iodo-4-chloro-pyrrolo-[2,3-b]pyridine.After purification by flash chromatography (silica, 40/60 by volumeethyl acetate/cyclohexane as eluents, argon), 2.53 g of4-chloro-2-(5-methoxy-6-benzyloxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare obtained, the characteristics of which are as follows:

Mass spectrum (EI): m/z=557 [M]⁺, m/z=466 (base peak)

The compounds1-(toluene-4-sulfonyl)-1H-2-iodo-4-chloropyrrolo[2,3-b]pyridine and1-tert-butyloxy-carbonyl-5-methoxy-6-benzyloxyindol-3-boronic acid areprepared according to the process described in patent WO 03000688 A1.

EXAMPLE 1724-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperidin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine

a)4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperidin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 0.41 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-(4-piperidylpiperidin-1-yl)ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 2.73 ml of a 5N aqueous potassium hydroxide solution. 0.272 g of4-chloro-2-{5-methoxy-1-methyl-6-[2-(4-piperidylpiperidin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 1.30 to 1.60 (mt:8H); 1.70 (broad d, J=12 Hz: 2H); 2.05 (broad t, J=11 Hz: 2H); 2.18(broad tt, J=12 and 3.5 Hz: 1H); 2.46 (mt: 4H); 2.75 (t, J=6 Hz: 2H);3.04 (broad d, J=11 Hz: 2H); 3.83 (s: 3H); 3.90 (s: 3H); 4.15 (t, J=6Hz: 2H); 6.71 (broad s: 1H); 7.15 (dd, J=5.5 Hz: 1H); 7.20 (s: 1H); 7.44(s: 1H); 7.85 (s: 1H); 8.19 (d, J=5.5 Hz: 1H); 12.14 (broad s: 1H).

Mass spectrum (EI): m/z=521 [M]⁺, m/z=195 (base peak)

b)4-Chloro-2-[1-methyl-5-methoxy-6-(2-(4-piperidylpiperidin-1-yl)ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147b, butusing 0.212 g of 4-piperidinopiperidine and 0.400 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.0.415 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-(4-piperidylpiperidin-1-yl)ethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=676 [M+H]⁺

EXAMPLE 1734-Chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]-pyridine

a)4-Chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a, butusing 0.22 g of4-chloro-2-{1-methyl-5-methoxy-6-(2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.6 ml of a 5N aqueous potassium hydroxide solution. Afterpurification by flash-pack chromatography (silica, 12/3/0.5 by volumechloroform/methanol/aqueous ammonia (28%) as eluents), 0.095 g of4-chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.70 (mt: 4H); from1.70 to 2.10 (very broad unresolved peak: 1H); 2.45 (mt: 4H); from 2.45to 2.55 (mt: 2H); 2.73 (t, J=6.5 Hz: 2H); 2.97 (t, J=6 Hz: 2H); 3.84 (s:3H); 3.91 (s: 3H); 4.13 (t, J=6 Hz: 2H); 6.72 (s large: 1H); 7.15 (d,J=5.5 Hz: 1H); 7.18 (s: 1H); 7.45 (s: 1H); 7.85 (s: 1H); 8.08 (d, J=5.5Hz: 1H); 12.14 (broad s: 1H).

Mass spectrum (CI): m/z=468 [M+H]⁺

b)4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147b, butusing 0.100 ml of N-(2-aminoethyl)pyrrolidine and 0.3 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.0.229 g of4-chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

Mass, spectrum (CI): m/z=622 [M+H]⁺ (base peak)

EXAMPLE 1744-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]-pyridine

a)4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 89a butusing 10.240 g of4-chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 1.7 ml of a 5N aqueous potassium hydroxide solution. Afterpurification by flash-pack chromatography (silica, 40/5/0.5 by volumedichloromethane/methanol/aqueous ammonia (28%) as eluents), 0.092 g of4-chloro-2-{1-methyl-5-methoxy-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.40 (mt: 2H); 1.51(mt: 4H); 1.88 (broad unresolved peak: 1H); 2.35 (mt: 4H); 2.39 (t,J=6.5 Hz: 2H); 2.71 (t, J=6.5 Hz: 2H); 2.96 (t, J=5.5 Hz: 2H); 3.83 (s:3H); 3.91 (s: 3H); 4.13 (t, J=5.5 Hz: 2H); 6.71 (broad s: 1H); 7.15 (dd,J=5.5 Hz: 1H); 7.17 (s: 1H); 7.45 (s: 1H); 7.85 (s: 1H); 8.08 (d, J=5.5Hz: 1H); 12.14 (broad s: 1H).

Mass spectrum (CI): m/z=482 [M+H]⁺ (base peak)

b)4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared by following the procedure described in example 147b, butusing 0.135 ml of N-(2-aminoethyl)piperidine and 0.3 g of4-chloro-2-[1-methyl-5-methoxy-6-(2-iodoethoxy)-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine.0.246 g of4-chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]-pyridineis obtained, the characteristics of which are as follows:

Mass spectrum (CI): m/z=636 [M+H]⁺ (base peak)

EXAMPLE 175 2-(5,7-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine

a) 2-(5,7-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

3.3 ml of a 5N aqueous potassium hydroxide solution are added to asolution of 0.31 g of2-(5,7-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 20 ml of methanol. The mixture is heated at around 80° C. forapproximately 18 hours. The reaction medium is run into a mixture of 100ml of ice plus, water, and extracted with three times 75 ml of ethylacetate. The combined organic phases are washed with 100 ml of water andthen with 100 ml of a saturated aqueous sodium chloride solution, driedover magnesium sulfate, filtered and concentrated to dryness underreduced pressure (13 kPa). The residue is purified by flashchromatography on a silica column [eluent: dichloromethane]. 0.073 g of2-(5,7-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine isobtained in the form of a solid, the characteristics of which are asfollows:

Melting point: 220° C. (Köfler bench)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.86 (s: 3H); 3.90 (s:3H); 4.01 (s: 3H); 6.43 (d, J=2 Hz: 1H); 6.71 (d, J=2 Hz: 1H); 6.99 (d,J=1.5 Hz: 1H); 7.01 (dd, J=8 and 5 Hz: 1H); 7.76 (s: 1H); 7.85 (broad d,J=8 Hz: 1H); 8.11 (dd, J=5 and 1.5 Hz: 1H); 11.74 (unresolved peak: 1H).

Mass spectrum (EI): m/z=307 [M]⁺ (base peak); m/z=292 [M-CH₃]⁺

b)2-(5,7-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared in the following way:

0.028 g of sodium hydride at 60% in oil is added, in small portions, tosolution of 0.26 g of2-(5,7-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 11.5 ml of dimethylformamide. The suspension is agitated forapproximately 1 hour at around 20° C. and then 0.04 ml of iodomethane isadded. After agitation for approximately 18 hours at around 20° C., themixture is run into 100 ml of a mixture of ice plus water, and extractedwith three times 75 ml of ethyl acetate. The combined organic phases aredried over magnesium sulfate, filtered and concentrated to dryness underreduced pressure. 0.3 g of2-(5,7-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained in the form of a foam, the characteristics of which are asfollows:

Mass spectrum (EI): m/z=461 [M]⁺ (base peak); m/z 306 [M-C₇H₇O₂S]⁺

c)2-(5,7-Dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinecan be prepared as described in example 105e:

But using 2.9 g of2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine, 2.34 g of1-tert-butyloxycarbonyl-5,7-dimethoxy-1H-indole-3 boronic acid and 19 mlof a saturated aqueous solution of sodium hydrogen carbonate in 63 ml ofdimethylformamide, and 0.42 g of tetrakis(triphenylphosphine)palladiumis added. After flash chromatography on a silica column [eluent:cyclohexane/ethyl acetate (70/30 by volume)], 0.26 g of2-(5,7-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a solid, the characteristics of whichare as follows:

silica TLC [eluent: cyclohexane/ethyl acetate (70/30 by volume)]

-   Rf=0.51

Mass spectrum (EI): m/z=447 [M]⁺ (base peak); m/z=292 [M-C₇H₇O₂S]⁺

The preparation of2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine is described inpatent WO 2003000688 A1.

d) 1-tert-Butyloxycarbonyl-5,7-dimethoxy-1H-indole-3-boronic acid can beprepared in the following way:

9.82 ml of a 2.5N solution of n-butyllithium in hexane are added,dropwise, while maintaining the temperature at around −100° C., to asolution of 2.2 g of tert-butyl ester of3-iodo-5,7-dimethoxyindole-1-carboxylic acid and 1.8 ml of tributylborate in 33 ml of tetrahydrofuran cooled to −100° C. The cooling bathis removed and, when the temperature of the reaction medium reachesapproximately −5° C., 2 g of ice are added. After agitation for one hourat a temperature in the region of 20° C., the mixture is concentrated todryness under reduced pressure (13 kPa). The residue is extracted with200 ml of ethyl acetate, and washed with 100 ml of a saturated aqueoussodium chloride solution The organic phase is dried over magnesiumsulfate, filtered and concentrated to dryness under reduced pressure (13kPa). 2.34 g of1-tert-butyloxycarbonyl-5,7-dimethoxy-1H-indole-3-boronic acid are thusobtained in the form of a solid, which is used as it is for thefollowing step.

e) The tert-butyl ester of 3-iodo-5,7-dimethoxy-indole-1-carboxylic acidcan be prepared in the following way:

0.94 g of powdered potassium hydroxide is added to a solution of 1.18 gof 5,7-dimethoxy-1H-indole in 34 ml of dimethylformamide. A solution of1.71 g of bisublimated iodine in 34 ml of dimethylformamide is addeddropwise to the above mixture. After agitation of the mixture for 3hours at a temperature in the region of 20° C., 0.062 g of4-dimethylaminopyridine is added, followed by a solution of 1.82 g ofdi-tert-butyl dicarbonate in 10 ml of dimethylformamide. After agitationfor approximately 18 hours at around 20° C., the mixture is run into 89ml of a 0.2% aqueous sodium thiosulfate solution. The mixture isextracted with three times 200 ml of ethyl acetate. The organic phasesare combined, dried over magnesium sulfate, filtered and concentrated todryness under reduced pressure (13 kPa). The residue is purified byflash chromatography on a silica column [eluent: cyclohexane/ethylacetate (90/10 by volume)]. 2.2 g of tert-butyl ester of3-iodo-5,7-dimethoxyindole-1-carboxylic acid are obtained in the form ofa solid, the characteristics of which are as follows:

silica TLC [eluent: cyclohexane/ethyl acetate (70/30 by volume)]

-   Rf=0.67

Mass spectrum (EI): m/z=403 [M]⁺; m/z=303 [M-CO₂tBu]⁺. (base peak)

5,7-Dimethoxy-1H-indole was prepared according to the method describedby P. J. Milligan and S La Berge, Journal of Medicinal Chemistry, 1970,Vol. 13, No. 6, 1248-1

EXAMPLE 1764-chloro-5-fluoro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine(A003364503 (P-32416-147-2))

a)4-Chloro-5-fluoro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridinemay be prepared by following the procedure described in Example 100a,but starting with 0.260 g of4-chloro-5-fluoro-2-[1-(2-morpholin-4-ylethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.62 g of 85% potassium hydroxide. After purification bycrystallization from 11 cm³ of acetonitrile, 0.115 g of4-chloro-5-fluoro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.47 (partially maskedm, 4H); 2.71 (broad t, J=6.5 Hz, 2H); 3.57 (m, 4H); 3.86 (s, 3H); 3.89(s, 3H); 4.31 (broad t, J=6.5 Hz, 2H); 6.74 (d, J=2.0 Hz, 1H); 7.19 (s,1H); 7.42 (s, 1H); 7.93 (s, 1H); 8.19 (d, J=2.0 Hz, 1H); 12.2 (broad s,1H).

Mass spectrum (EI): m/z=458 (M)⁺ (base peak)

b)4-Chloro-5-fluoro-2-[1-(2-morpholin-4-ylethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared by following the procedure described in Example 100b,but starting with 0.280 g of4-chloro-5-fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl]-1H-pyrrolo[2,3-b]pyridine,0.065 g of potassium carbonate and 0.075 g of morpholine. 0.270 g of4-chloro-5-fluoro-2-[1-(2-morpholin-4-ylethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of an orange-colored resin, thecharacteristics of which are as follows:

-   Rf TLC, silica [eluent: cyclohexane/methanol (95/5 by volume)]=0.52

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.27 (s, 3H); from2.45 to 2.55 (masked m, 4H); 2.77 (t, J=6.5 Hz, 2H); 3.58 (m, 4H); 3.70(s, 3H); 3.87 (s, 3H); 4.35 (t, J=6.5 Hz, 2H); 6.77 (s, 1H); 6.84 (s,1H); 7.17 (s, 1H); 7.20 (broad d, J=8.5 Hz, 2H); 7.49 (broad d, J=8.5Hz, 2H); 7.60 (s, 1H); 8.48 (d, J=2.0 Hz, 1H)

c)4-Chloro-5-fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared by following the procedure described in Example 100c,but starting with 0.260 g of4-chloro-5-fluoro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.104 g of sodium iodide. 0.283 g of4-chloro-5-fluoro-2-[1-(2-iodoethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of an orange-colored resin, thecharacteristics of which are as follows:

-   Rf TLC, silica [eluent: dichloromethane/ethyl acetate (95/5 by    volume)]=0.72

Mass spectrum (EI): m/z 653 (M)⁺ base peak

d)4-Chloro-5-fluoro-2-[1-(2-chloroethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared by following the procedure described in Example 100d,but starting with 0.390 g of4-chloro-5-fluoro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.005 g of tetrabutylammonium bromide in 30 cm³ of1,2-dichloroethane, 0.343 g of potassium hydroxide and 0.251 g ofpotassium carbonate. 0.260 g of4-chloro-5-fluoro-2-[1-(2-chloro-ethyl)-5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained in the form of an orange-colored resins the characteristicsof which are as follows:

TLC, silica [eluent: dichloromethane/ethyl acetate (95/5 by volume)]Rf=0.56

Mass spectrum (EI): m/z=562 (M)⁺

e)4-Chloro-5-fluoro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared by following the procedure described in Example 97c, butstarting with 0.750 g of1-(toluene-4-sulfonyl)-1H-2-iodo-4-chloro-5-fluoropyrrolo[2,3-b]pyridine,0.534 g of 1-tert-butyloxycarbonyl-5,6-dimethoxyindol-3-boronic acid and0.096 g of tetrakis(triphenylphosphine)palladium. 0.390 g of4-chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis thus obtained, the characteristics of which are as follows:

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.29 (s, 3H); 3.70 (s,3H); 3.82 (s, 3H); 6.79 (s, 1H); 6.92 (s, 1H); 7.00 (s, 1H); 7.26 (broadd, J=8.5 Hz, 2H); 7.52 (broad d, J=8.5 Hz, 2H); 7.53 (s, 1H); 8.47 (d,J=2.0 Hz, 1H); 11.3 (broad s, 1H).

Mass spectrum (EI): m/z=499 (M)⁺

1-tert-Butyloxycarbonyl-5,6-dimethoxyindol-3-boronic acid is preparedaccording to the process described in patent WO 03/000688 A1.

f)1-(Toluene-4-sulfonyl)-1H-2-iodo-4-chloro-5-fluoropyrrolo[2,3-b]pyridinemay be prepared in the following manner:

1.18 cm³ of tert-BuLi are added dropwise to a solution of 0.650 g of1-(toluene-4-sulfonyl)-1H-4-chloro-5-fluoropyrrolo[2,3-b]pyridine in 15cm³ of tetrahydrofuran at about −78° C. After stirring the reactionmedium for 30 minutes at about, −78° C., a solution of 1.01 g of iodinein 6 cm³ of tetrahydrofuran is added dropwise, and the temperature ismaintained at −78° C. for 2 h. The temperature is allowed to return toabout 0° C. After addition of 5 cm³ of saturated aqueous ammoniumchloride solution, the reaction mixture is extracted with 80 cm³ ofethyl acetate, the organic phase is then washed with 3 times 20 cm³ ofwater, and then dried over magnesium sulfate and concentrated underreduced pressure (13 kPa). 0.750 g of1-(toluene-4-sulfonyl)-1H-2-iodo-4-chloro-5-fluoropyrrolo[2,3-b]pyridineis thus obtained in the form of a cream-colored solid, thecharacteristics of which are as follows:

TLC, silica [eluent: dichloromethane] Rf=0.59

Mass spectrum (EI): m/z=451 (M)⁺

g) 1-(Toluene-4-sulfonyl)-1H-4-chloro-5-fluoropyrrolo[2,3-b]pyridine maybe prepared in the following manner:

A mixture of 1.30 g of 4-chloro-5-fluoro-1H-pyrrolo[2,3-b]pyridine, 1.6g of 4-methylbenzenesulfonyl chloride, 3.40 g of sodium hydroxidedissolved in 16 cm³ of water, and 0.052 g of tetrabutylammonium hydrogensulfate in 200 cm³ of toluene is stirred for about 24 hours in theregion of 20° C. The mixture is diluted with 500 cm³ of ethyl acetate;the organic phase is washed with three times 200 cm³ of water, driedover magnesium sulfate, filtered and concentrated to dryness underreduced pressure (13 kPa). The residue is purified by flashchromatography on a column of silica [eluent: dichloromethane]. 1.90 μgof 4-chloro-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained in the form of a powder, the characteristics of whichare as follows:

Melting point: melting at 125° C. (Köfler block)

¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm) 2.36 (s, 3H); 6.93 (d,J=3.0 Hz, 1H); 7.44 (broad d, J =8.0 Hz, 2H); 7.99 (broad d, J=8.0 Hz,2H); 8.12 (d, J =3.0 Hz, 1H); 8.52 (d, J=2.5 Hz, 1H)

Mass spectrum (EI): m/z=324 (M)⁺

h) 4-chloro-5-fluoro-1H-pyrrolo[2,3-b]pyridine may be prepared in thefollowing manner:

A solution of 1.7 g of 5-fluoro-1H-pyrrolo[2,3-b]pyridine-7-oxide in 10cm³ of phosphorus oxychloride is maintained at the reflux point of thePOCl₃ for 8 hours. After distilling off the POCl₃ under vacuum, theresidue is treated with 50 g of ice, and the pH of the solution obtainedis brought in the region of 8-9 by addition of sodium hydrogencarbonate. The aqueous phase is extracted with five times 80 cm³ ofethyl acetate. The combined organic phases are then dried over magnesiumsulfate, filtered and concentrated to dryness under reduced pressure (13kPa). 1.3 g of 4-chloro-5-fluoro-1H-pyrrolo[2,3-b]pyridine are thusobtained in the form of a solid, the characteristics of which are asfollows:

-   Rf TLC, silica (eluent: dichloromethane/methanol (98/2 by    volume)]=0.19

¹H NMR spectrum (400 MHz, (CD₃)₂SO d6, δ in ppm): 6.56 (m, 1H); 7.70 (m,1H); 8.35 (d, J=2.5 Hz, 1H); 12.15 (broad m, 1H)

Mass spectrum (EI): m/z=170 (M)⁺

i) 5-Fluoro-1H-pyrrolo[2,3-b]pyridine 7-oxide may be prepared in thefollowing manner:

6.22 g of 3-chloroperbenzoic acid are added to a solution of 2.7 g of5-fluoro-1H-pyrrolo[2,3-b]pyridine in 70 cm³ of dimethoxyethane. Thereaction medium is stirred in the region of 20° C. for 1 hour 30minutes. After addition of a solution of 2 g of potassium hydroxide in20 cm³ of methanol, the mixture is extracted with 5 times 100 cm³ ofethyl acetate. The organic phases are then washed with twice 15 cm³ ofsaturated ammonium chloride solution and then dried over magnesiumsulfate, filtered and concentrated to dryness under reduced pressure (13kPa) The residue is purified by flash chromatography on a column ofsilica [eluent: dichloromethane/methanol (95/5 by volume)], and 3.6 g ofa solid are obtained, which is washed with 25 cm³ of diethyl oxide andthen dewatered and dried. The residue is purified by flashchromatography on a column of silica [eluent: cyclohexane/ethyl acetate(50/50 by volume)], and 1.70 g of 5-fluoro-1H-pyrrolo[2,3-b]pyridine7-oxide are obtained in the form of a powder, the characteristics ofwhich are as follows:

Melting point: melting at 178° C. (Köfler block)

IR spectrum: KBr 3128; 3085; 2919; 2863; 2734; 2629; 2406; 1588; 1507;1349; 1256; 1206; 1129; 1077; 990; 804; 723; 670 and 466 cm⁻¹

j) 5-Fluoro-1H-pyrrolo[2,3-b]pyridine may be prepared in the followingmanner:

A mixture of 3.80 g of 5-fluoro-3-trimethylsilanylethynylpyrid-2-ylamineand 3.40 g of potassium tert-butoxide in 100 cm³ of1-methylpyrrolidin-2-one is maintained in the region of 130° C. forabout 4 hours. After cooling to a temperature in the region of 20° C.,the mixture is poured into 1000 cm³ of saturated aqueous sodium chloridesolution and extracted with 5 times 250 cm³ of diethyl oxide. Theorganic phases are combined, washed with 5 times 100 cm³ of saturatedaqueous sodium chloride solution, dried over magnesium sulfate, filteredand concentrated to dryness under reduced pressure (13 kPa). 2.35 g of5-fluoro-1H-pyrrolo[2,3-b]pyridine are obtained in the form of a solid,the characteristics of which are as follows:

Melting point: melting at 110° C. (Köfler block)

Mass spectrum (EI): m/z=136 (M)⁺ base peak m/z=109 (M-HCN)⁺

k) 5-Fluoro-3-trimethylsilanylethynylpyrid-2-ylamine may be prepared inthe following manner:

12.47 cm³ of ethynyltrimethylsilane, 2.24 g of copper iodide, 2.74 g oflithium chloride, 41.33 cm³ of triethylamine and 2.15 g of[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride are addedto a solution of 14 g of 5-fluoro-3-iodo-pyrid-2-ylamine in 440 cm³ ofdimethylformamide, degassed with argon. The solution obtained ismaintained at a temperature in the region of 55° C. for about 5 hours.After cooling to a temperature in the region of 20° C., the mixture isconcentrated under reduced pressure (13 kPa); the residue is taken up in300 cm³ of water and extracted with three times 100 cm³ of ethylacetate. The combined organic phases are washed with three times 100 cm³of water, dried over magnesium sulfate, filtered and concentrated underreduced pressure (13 kPa). 7.91 g of5-fluoro-3-trimethylsilanylethynylpyrid-2-ylamine are thus obtained,after flash chromatography on a column of silica (eluent;dichloromethane), in the form of a solid, the characteristics of whichare as follows:

Melting point: melting at 65° C. (Köfler block)

Mass spectrum (EI): m/z=208 (M)^(+m/z=)193 (M-CH₃)⁺ base peak

l) 5-Fluoro-3-iodo-pyrid-2-ylamine may be prepared in the followingmanner:

A mixture of 9.9 g of 5-fluoropyrid-3-ylamine and 21.85 g ofN-iodosuccinimide in 400 cm³ of acetic acid is stirred for about 6 hoursat a temperature in the region of 70° C. After concentrating to drynessunder reduced pressure (13 kPa), the residue is taken up in 250 cm³ ofwater; the pH is brought to about 8 by addition of sodium hydrogencarbonate. The aqueous phase is extracted with 5 times 150 cm³ ofdichloromethane. The combined organic phases are washed with three times100 cm³ of water and then with 5 times 50 cm³ of aqueous 10% sodiumthiosulfate solution, dried over sodium sulfate, filtered andconcentrated to dryness under reduced pressure (13 kPa). 11 g of5-fluoro-3-iodo-pyrid-2-ylamine are thus obtained, after flashchromatography on a column of silica (eluent: dichloromethane), in theform of a solid, the characteristics of which are as follows:

Melting point: melting at 76° C. (Köfler block)

1H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 5.98 (broad s, 2H);from 7.93 to 7.98 (m, 2H).

Mass spectrum (EI): m/z=238 (M)⁺

EXAMPLE 1772-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylamine(A003346712 (P-32441-067-1))

a)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylaminemay be prepared in the following manner:

1.05 cm³ of tetrabutylammonium fluoride are added to a solution of 0.1 gof2-(1-methyl)-5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylaminein 10 cm³ of tetrahydrofuran, degassed with argon. The solution obtainedis refluxed for about 24 hours. After cooling to a temperature in theregion of 20° C., the mixture is concentrated under reduced pressure (13kPa); the residue is taken up in 50 cm³ of saturated sodium hydrogencarbonate solution, extracted with three times 50 cm³ of ethyl acetateand then with three times 100 cm³ of dichloromethane. The combinedorganic phases are washed with three times 100 cm³ of water, dried overmagnesium sulfate, filtered and concentrated under reduced pressure (13kPa). 0.015 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylamineare thus obtained, after flash chromatography on a column of silica[eluent: dichloromethane/methanol (90/10 by volume)], in the form of awhite solid, the characteristics of which are as follows:

-   -   1H NMR spectrum (400 MHz, (CD₃)₂SO d6, δ in ppm): 3.79 (s, 3H);        3.87 (s, 3H); 3.89 (s, 3H); 6.07 (broad s, 2H); 6.13 (d, J=5.0        Hz, 1H); 6.82 (broad s, 1H); 7.09 (s, 1H); 7.43 (s, 1H); 7.63        (s, 1H); 7.67 (d, J=5.0 Hz, 1H); 11.2 (broad s, 1H).    -   Mass spectrum (EI): m/z=322 (M)⁺

b)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylaminemay be prepared in the following manner:

5.5 cm³ of aqueous 2N hydrochloric acid solution are added to a solutionof 0.7 g ofbenzhydrylidene-[2-(1-methyl)-5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]aminein 20 cm³ of tetrahydrofuran. The solution obtained is stirred in theregion of 20° C. for about 3 hours. The mixture is concentrated underreduced pressure (13 kPa); the residue is taken up in 50 cm³ ofsaturated sodium hydrogen carbonate solution and extracted with threetimes 50 cm³ of ethyl acetate and then with three times 25 cm³ ofdichloromethane. The combined organic phases are washed with three times50 cm³ of water, dried over magnesium sulfate, filtered and concentratedunder reduced pressure (13 kPa). 0.31 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylamineare thus obtained, after flash chromatography on a column of silica[eluent: dichloromethane/methanol (98/2 by volume)], in the form of apale pink solid, the characteristics of which are as follows:

-   -   TLC, silica [eluent: dichloromethane/methanol (98/2 by volume)]        Rf=0.125    -   Mass spectrum (EI): m/z=476 (M)⁺

c)benzhydrylidene-[2-(1-methyl)-5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]aminemay be prepared in the following manner:

1.7 g of cesium carbonate, 0.4 g of(R)-(+)-2,2-bis(diphenylphosphino)-1,1′-binaphthyl and 0.377 g ofbenzophenoneimine are added to a solution of 0.8 g of4-chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 80 cm³ of toluene, degassed with argon. The solution obtained isstirred in the region of 20° C. for about 15 minutes, and 0.144 g ofpalladium acetate is then added. The mixture is refluxed for 4 hoursand, after cooling to about 20° C., is then filtered through a sinterfunnel packed with Celite. The cake is washed with three times 20 cm³ ofdichloromethane, and the filtrate is then concentrated under reducedpressure (13 kPa). 1.3 g ofbenzhydrylidene-[2-(1-methyl)-5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]amineare thus obtained, after flash chromatography on a column of silica[eluent: cyclohexane/ethyl acetate (50/50 by volume)], in the form of ayellow solid, the characteristics of which are as follows:

-   -   1H NMR spectrum (400 MHz, (CD₃)₂SO d6, δ in ppm): 2.31 (s, 3H);        3.72 (s, 3H); 3.82 (s, 3H); 3.86 (s, 3H); 6.49 (s, 1H); 6.61 (d,        J=5.0 Hz, 1H); 6.88 (s, 1H); 7.08 (s, 1H); 7.20 (broad d, 8.5        Hz, 2H); 7.39 (broad d, J=8.5 Hz, 2H); 7.41 (s, 1H); from 7.05        to 7.75 (very broad m, 10H); 8.02 (d, J=5.0 Hz, 1H).    -   Mass spectrum (IC): m/z=641 (M+H)⁺

4-Chloro-2-(5,6-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained as described in Example 97b.

EXAMPLE 178Cyclohexyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amine(A003341949 (P-31916-162-1))

a)Cyclohexyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]aminemay be prepared in the following manner:

1 cm³ of a 1M solution of tetrabutylammonium fluoride (TBAF) intetrahydrofuran is added, at a temperature in the region of 20° C., to asolution of 0.14 g ofcyclohexyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]aminein 10 cm³ of tetrahydrofuran. The reaction medium is stirred at thissame temperature for 15 hours, and then refluxed for 24 hours. Aftercooling, the reaction medium is evaporated to dryness under reducedpressure. 4 cm³ of water are added. The solid formed is filtered off ona sinter funnel, and washed with water and then with ethyl ether. Thesolid obtained is taken up in water and the medium is basified to pH 10with 0.1N sodium hydroxide. The product is extracted five times withdichloromethane. The organic phases are combined, dried over magnesiumsulfate, filtered and then concentrated under reduced pressure. 0.029 gofcyclohexyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis thus obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.05 to 1.28        (m, 5H); from 1.48 to 1.76 (m, 3H); from 1.85 to 2.03 (m, 2H);        from 3.17 to 3.42 (masked m, 1H); 3.80 (s, 3H); 3.85 (s, 3H);        3.88 (s, 3H); 4.05 (broad s, 2H); 6.82 (d, J=2.0 Hz, 1H); 7.02        (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.45 (s, 1H); 7.75 (s, 1H);        8.03 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (EI): m/z=418 (M)⁺; m/z=321 (M-C₆H₁₁N)⁺ base peak

b)Cyclohexyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]aminemay be prepared in the following manner:

0.16 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.4 g of sodium sulfate are added to a solution of 0.24 g ofcyclohexylamine in 5 cm³ of dichloromethane, under an inert atmosphereof argon, at a temperature in the region of 20° C. Stirring ismaintained for 48 hours at room temperature. 5 cm³ of methanol and 0.023g of sodium borohydride are added. The reaction medium is stirred at thesame temperature for 6 hours. The reaction medium is concentrated underreduced pressure. The residue obtained is taken up in 10 cm³ ofdichloromethane. The precipitate formed is filtered off and the filtrateis concentrated under reduced pressure and then purified by column flashchromatography (SiO2, dichloromethane/methanol, 98/02 by volume aseluent). The fractions containing the product are combined andconcentrated to dryness under reduced pressure to give 0.143 g ofcyclohexyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)pyrrolo[2,3-b]pyrid-4-ylmethyl]amine.

-   -   Mass spectrum (EI): m/z=572 (M)⁺; m/z=417 (M-C₇H₇SO₂)⁺ base        peak; m/z=320 (m/z=417-C₆H₁₁N)⁺

c)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydemay be prepared in the following manner:

16.5 cm³ of 5N hydrochloric acid are added, at a temperature in theregion of 20° C., to a solution of 4.4 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 100 cm³ of tetrahydrofuran. The reaction medium is stirred at thissame temperature for 24 hours. 30 cm³ of water and 30 cm³ ofdichloromethane are added. After separation of the phases by settling,the organic phase is dried over magnesium sulfate, filtered,concentrated under reduced pressure and then purified on a column ofsilica, eluting with a 50/50 by volume mixture of cyclohexane and ethylacetate. The fractions containing the product are combined andconcentrated to dryness under reduced pressure to give 2.6 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehyde,the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=489 (M)⁺; m/z=334 (M-C₇H₇SO₂)⁺ base peak

d)2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be pre pared in the following manner:

0.462 g of a 60% suspension of sodium hydride in oil is added to asolution of 5 g of2-(5,6-dimethoxy-1H-indol-3-yl)-4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 185 cm³ of anhydrous dimethylformamide (DMF), under an inertatmosphere of argon at a temperature in the region of 20° C. Thereaction medium is stirred at the same temperature for 45 minutes. 0.719cm³ of methyl iodide is added dropwise. The reaction medium is stirredat this same temperature for 20 hours. 200 cm³ of water and 100 cm³ ofethyl acetate are added. After separation of the phases by settling, theorganic phase is dried over magnesium sulfate, filtered, concentratedunder reduced pressure and then purified on a column of silica, elutingwith a 98/02 by volume mixture of dichloromethane and methanol. Thefractions containing the product are combined and concentrated todryness under reduced pressure to give 4.42 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z =533 (M)⁺; m/z=378 (M-C₇H₇SO₂)⁺ base        peak

e)2-(5,6-Dimethoxy-1H-indol-3-yl)-4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared in the following manner:

41 cm³ of saturated sodium bicarbonate solution and 0.611 g oftetrakis(triphenylphosphine)palladium are added to a solution of 6.2 gof4-(1,3-dioxolan)-2-yl-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine,135 cm³ of anhydrous DMF and 7.42 g of1-t-butyloxycarbonyl-5,6-dimethoxyindol-3-boronic acid, under an inertatmosphere of argon at a temperature in the region of 20° C. Thereaction medium is heated at 130° C. for 3 hours. After cooling, thereaction medium is concentrated under reduced pressure. The oil obtainedis taken up in 80 cm³ of water and 100 cm³ of ethyl acetate. Afterseparation of the phases by settling, the organic phase is dried oversodium sulfate, filtered and then concentrated under reduced pressure.The residue obtained is purified by flash chromatography (SiO2, ethylacetate/cyclohexane 50/50 by volume as eluent, argon). The fractionscontaining the product are concentrated under reduced pressure. 5 g of2-(5,6-dimethoxy-1H-indol-3-yl)-4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=519 (M)⁺; m/z=364 (M-C₇H₇SO₂)⁺ base peak

1-t-Butyloxycarbonyl-5,6-dimethoxyindol-3-boronic acid is preparedaccording to the process described in patent WO 03/000688 A1.

f)4-(1,3-Dioxolan)-2-yl-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared in the following manner:

5.81 cm³ of n-BuLi (2.5M in hexane) are added dropwise to a solution of5 g of4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 100 cm³ of anhydrous tetrahydrofuran, under an inert atmosphere ofargon at a temperature in the region of −78° C. The reaction medium isstirred at this same temperature for 25 minutes, and a solution of 7.37g of iodine in 50 cm³ of tetrahydrofuran are then added dropwise. Thereaction medium is stirred at −78° C. for 15 minutes. The cooling bathis removed. The temperature rises to room temperature after stirring for2 hours. The reaction medium is stirred at room temperature for 20hours. 15 cm³ of water and 15 cm³ of ethyl acetate are added. Afterseparation of the phases by settling, the organic phase is dried oversodium sulfate, filtered and then concentrated under reduced pressure.The residue obtained is purified by flash chromatography (SiO2,dichloromethane as eluent, argon). The fractions containing the productare concentrated under reduced pressure. 6.28 g of4-(1,3-dioxolan)-2-yl-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=471 (M+H)⁺ base peak

g)4-(1,3-Dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared in the following manner:

2.15 cm³ of ethylene glycol and 0.735 g of para-toluenesulfonic acid areadded to a solution of 5.8 g of1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carboxaldehyde in 250cm³ of toluene, under an inert atmosphere of argon. The reaction mediumis heated at 120° C. for three hours. After cooling, 50 cm³ of water and50 cm³ of ethyl acetate are added. After separation of the phases bysettling, the organic phase is dried over sodium sulfate, filtered andthen concentrated under reduced pressure. The residue obtained istriturated in ethyl ether. The solid obtained is filtered off and thenwashed with 20 cm³ of ethyl ether. 5.3 g of4-(1,3-dioxolan)-2-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineare thus obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=344 (M)⁺; m/z=237 (M-C₇H₇SO₂)⁺ base        peak; m/z=91 (C₇H₇)⁺

h) 1-(Toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carboxaldehyde maybe prepared in the following manner:

50.5 cm³ of diisobutylaluminum hydride (DIBAH) as a 20% by weightsolution in toluene (1M) are added dropwise to a solution of 10 g of1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile in 400cm³ of toluene, under an inert atmosphere of argon at a temperature inthe region of −30° C. After stirring for 40 minutes at this sametemperature, the cooling bath is removed. The temperature is allowed torise to 20° C. The reaction medium is stirred at a temperature in theregion of 20° C. for 1 hour. The reaction medium is cooled to 4° C. 1Nhydrochloric acid is added dropwise to pH 6. The precipitate formed isfiltered off and then washed with 50 cm³ of water and 280 cm³ of ethylacetate. After separating out the filtrate by settling, the organicphase is dried over sodium sulfate, filtered, concentrated under reducedpressure and then purified by column flash chromatography (SiO2,dichloromethane as eluent, Ar). The fractions containing the product areconcentrated under reduced pressure. 4.3 g of1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carboxaldehyde arethus obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=300 (M)⁺; m/z=236 (M-SO₂)⁺; m/z=91;        (C₇H₇ ⁺) base peak

i) 1-(Toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile maybe prepared in the following manner:

6.9 g of zinc cyanide and 1.07 g of zinc powder are added to a solutionof 10 g of 4-chloro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine in200 cm³ of N,N-dimethylacetamide, under an inert atmosphere of argon.After stirring for 45 minutes at a temperature in the region of 20° C.,2.4 g of [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) (PdCl2,dppf) are added. The reaction medium is heated at a temperature in theregion of 140° C. for 90 minutes. After cooling, the reaction medium isfiltered through Celite and then rinsed with dichloromethane. 150 cm³ ofwater are added to the filtrate. After separation of the phases bysettling, the organic phase is dried over sodium sulfate, filtered andthen concentrated under reduced pressure. After purification by columnflash chromatography (SiO2, cyclohexane/ethyl acetate 75/25 by volume aseluent, Ar), 8.57 g of1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile areobtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=297 (M)⁺; m/z=233 (M-SO₂)⁺.; m/z=91        (C₇H₇)⁺ base peak

The compound 4-chloro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis prepared according to the process described in patent WO 03/000688A1.

EXAMPLE 179[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine(A003364149 (P-32520-098-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)aminemay be prepared in the following manner:

0.265 cm³ of 5N potassium hydroxide is added to a solution of 0.04 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)aminein 2 cm³ of methanol, at a temperature in the region of 20° C. Thereaction medium is refluxed for 6 hours. After cooling, the reactionmedium is concentrated under reduced pressure. The residue obtained istaken up in 4 cm³ of water. The solid formed is filtered off on a sinterfunnel, washed twice with 3 cm³ of water and then dried under vacuum togive 0.030 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine,the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 2.85 to        3.00 (broad m, 1H); 3.80 (s, 3H); 3.85 (s, 3H); 3.87 (s, 3H);        from 3.78 to 3.90 (masked m, 2H); 4.06 (broad s, 2H); 6.79        (broad s, 1H); 7.07 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.45 (s,        1H); 7.58 (broad d, J=8.5 Hz, 2H); 7.68 (broad d, J=8.5 Hz, 2H);        7.76 (s, 1H); 8.07 (d, J=5.0 Hz, 1H); 11.7 (broad s, 1H).    -   Mass spectrum (EI): m/z=526 (M)⁺; m/z=321 (M-C₈H₆SNF₃)⁺ base        peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)aminemay be prepared as described in Example 178b, starting with 0.065 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.08 cm³ of 4-trifluoromethylsulfanylbenzylamine instead of thecyclohexylamine used in Example 178b. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 98/02 by volume aseluent), 0.044 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=680 (M)⁺; m/z=525 (M-C₇H₇SO₂)⁺; m/z=320        (m/z=525 C₈H₆SNF₃)⁺ base peak

EXAMPLE 180Phenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amine(A003390480 (P-32520-140-4))

a)Phenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 179a and, starting with 0.120 g ofphenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,33-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a, and 0.95 cm³ of 5N potassium hydroxide. 0.010 g ofphenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.81 (s, 3H);        3.87 (s, 3H); 3.89 (s, 3H); 4.61 (d, J=6.0 Hz, 2H); 6.43 (t,        J=6.0 Hz, 1H); 6.49 (broad t, J=7.5 Hz, 1H); 6.61 (broad d,        J=7.5 Hz, 2H); 6.91 (d, J=2.0 Hz, 1H); from 6.96 to 7.05 (m,        3H); 7.11 (s, 1H); 7.47 (s, 1H); 7.76 (s, 1H); 8.02 (d, J=5.0        Hz, 1H); 11.7 (broad s, 1H).    -   Mass spectrum: (ES); m/z=413; (M+H)⁺ base peak

b)Phenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 178b starting with 0.1 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.037 cm³ of aniline instead of the cyclohexylamine used in Example178b. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.122 g ofphenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z 567 (M+H)⁺

EXAMPLE 181Benzyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amine(A003389983 (P-32520-141-1))

a)Benzyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 179a starting with 0.070 g ofbenzyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]-pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.54 cm³ of 5N potassium hydroxide. 0.038 g ofbenzyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 2.60 to        2.80 (broad m, 1H); 3.78 (broad s, 2H); 3.81 (s, 3H); 3.85 (s,        3H); 3.87 (s, 3H); 4.03 (broad s, 2H); 6.79 (d, J=2.0 Hz, 1H);        7.06 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.23 (broad t, J=7.5 Hz,        1H); 7.31 (broad t, J=7.5 Hz, 2H); 7.41 (broad d, J=7.5 Hz, 2H);        7.43 (s, 1H); 7.75 (s, 1H); 8.06 (d, J=5.0 Hz, 1H); 11.65 (broad        s, 1H).    -   Mass spectrum (EI): m/z=426 (M)⁺; m/z=321 (M-C₈H₆SNF₃)⁺ base        peak

b)Benzyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 178b starting with 0.1 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.045 cm³ of benzylamine instead of the cyclohexylamine used inExample 178b. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.071 g ofbenzyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=581 (M+H)⁺; m/z=474 (M+H—C₇H₉N)⁺ base        peak

EXAMPLE 182[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylethylamine(A003391552 (P-32520-158-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo-[2,3-b]pyrid-4-ylmethyl]phenylethylamineis prepared as described in Example 179a starting with 0.16 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylethylamineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 1.2 cm³ of 5N potassium hydroxide. 0.038 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-phenylethylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 2.10 to        2.25 (broad m, 1H); 2.75 to 2.86 (m, 4H); 3.81 (s, 3H); 3.87 (s,        6H); 4.07 (broad s, 2H); 6.80 (broad d, J=2.0 Hz, 1H); 6.99 (d,        J=5.0 Hz, 1H); 7.11 (s, 1H); from 7.12 to 7.30 (m, 5H); 7.46 (s,        1H); 7.74 (s, 1H); 8.03 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (EI): m/z=440 (M)⁺; m/z=320 (M-C₈H₁₀N)⁺ base peak

b)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylethylamineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.192 cm³ of phenylethylamine instead of the cyclohexylamine used inExample 178b. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 99/01 and then dichloromethane/methanol98.5/1.5 by volume as eluent), 0.17 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylethylamineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z 595 (M+H)⁺ base peak; m/z=474        (M+H—C₈H₁₁N)⁺

EXAMPLE 183[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylpropylamine(A003390226 (P-32520-144-1))

a)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylpropylamineis prepared as described in Example 179a starting with 0.115 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylpropylamineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.85 cm³ of 5N potassium hydroxide. 0.072 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-phenylpropylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.78 (m, 2H);        from 2.15 to 2.40 (broad m, 1H); 2.58 (broad t, J=6.5 Hz, 2H);        2.64 (broad t, J=7.5 Hz, 2H); 3.78 (s, 3H); 3.81 (s, 3H); 3.86        (s, 3H); 4.02 (broad s, 2H); 6.82 (broad s, 1H); 7.00 (d, J=5.0        Hz, 1H); 7.09 (s, 1H); from 7.06 to 7.28 (m, 5H); 7.45 (s, 1H);        7.75 (s, 1H); 8.03 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z=455 (M+H)⁺; m/z=320 (M+H—C₉H₁₃N)⁺ base        peak

b)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylpropylamineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.218 cm³ of phenylpropylamine instead of the cyclohexylamine usedin Example 178b. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.120 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]phenylpropylamineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=608 (M)⁺; m/z=453 (M-C₇H₇SO₂)⁺; m/z=320        (m/z=453-C₉H₁₁N)⁺ base peak

EXAMPLE 184[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylmethylamine(A003391639 (P-32520-162-1))

a)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylmethylamineis prepared as described in Example 179a starting with 0.11 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylmethylamineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine used in Example 179a and 0.85 cm³of 5N potassium hydroxide. 0.056 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylmethylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.87 (broad m,        1H); 3.81 (s, 3H); 3.87 (s, 6H); 3.95 (m, 2H); 4.04 (m, 2H);        6.81 (d, J=2.0 Hz, 1H); from 6.95 to 7.01 (m, 2H); 7.03 (d,        J=5.0 Hz, 1H); 7.11 (s, 1H); 7.39 (dd, J=2.0 and 5.0 Hz, 1H);        7.47 (s, 1H); 7.77 (s, 1H); 8.07 (d, J=5.0 Hz, 1H); 11.7 (broad        s, 1H).    -   Mass spectrum (ES): m/z=433 (M+H)⁺; m/z=337 (M+H—C₅H₄S)⁺ base        peak; m/z=320 (M+H—C₅H₇NS)⁺

b)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylmethylamineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.158 cm³ of thiophen-2-methylamine instead of the cyclohexylamineused in Example 178b. After purification by flash-pack chromatography(SiO2, dichloromethane/methanol 99/01 and then dichloromethane/methanol98.5/1.5 by volume as eluent), 0.11 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylmethylamineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=587 (M+H)⁺ base peak; m/z=474        (M+H—C₅H₇NS)⁺

EXAMPLE 185[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylethylamine(A003391615 (P-32520-160-1))

a)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylethylamineis prepared as described in Example 179a starting with 0.15 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylethylamineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine used in Example 179a and 1.12 cm³of 5N potassium hydroxide. 0.082 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylethylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 2.25 to        2.38 (broad m, 1H); 2.86 (broad t, J=6.5 Hz, 2H); 3.00 (t, J=6.5        Hz, 2H); 3.80 (s, 3H); 3.86 (s, 6H); 4.07 (broad s, 2H); 6.80        (broad d, J=2.0 Hz, 1H); 6.87 (broad d, J=3.5 Hz, 1H); 6.91 (dd,        J=3.5 and 5.0 Hz, 1H); 7.01 (d, J=5.0 Hz, 1H); 7.10 (s, 1H);        7.27 (broad d, J=5.0 Hz, 1H); 7.47 (s, 1H); 7.76 (s, 1H); 8.04        (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z=447 (M+H)⁺; m/z=320 (M+H—C₆H₉NS)⁺ base        peak

b)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylethylamineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.179 cm³ of thiophen-2-ethylamine instead of the cyclohexylamineused in Example 178b. After purification by flash-pack chromatography(SiO2, dichloromethane/methanol 99/01 and then dichloromethane/methanol98.5/1.5 by volume as eluent), 0.15 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]thiophen-2-ylethylamineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=60.1 (M+H)⁺; m/z=474 (MH—C₆H₉NS)⁺ base        peak

EXAMPLE 186[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methoxyethyl)amine(A003391652 (P-32520-163-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methoxyethyl)amineis prepared as described in Example 179a starting with 0.12 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methoxyethyl)amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.99 cm³ of 5N potassium hydroxide. 0.081 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methoxyethyl)amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 2.13 to        2.29 (broad m, 1H); 2.73 (broad t, J=6.5 Hz, 2H); 3.25 (s, 3H);        3.45 (t, J=6.5 Hz, 2H); 3.81 (s, 3H); 3.87 (s, 3H); 3.89 (s,        3H); 4.04 (broad s, 2H); 6.81 (broad d, J=2.0 Hz, 1H); 7.01 (d,        J=5.0 Hz, 1H); 7.11 (s, 1H); 7.47 (s, 1H); 7.74 (s, 1H); 8.04        (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z=395 (M+H)⁺; m/z=320 (M+H—C₃H₉NO)⁺ base        peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-ethoxyethyl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.134 cm³ of 2-methoxyethylamine instead of the cyclohexylamine usedin Example 178b. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 99/01 and then dichloromethane/methanol98.5/1.5 by volume as eluent), 0.11 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methoxyethyl)amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z 549 (M+H)⁺ base peak; m/z=474        (M+H—C₃H₉NO)⁺

EXAMPLE 1874-({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenylamine(A003393788 (P-33047-027-1))

4-({[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenylaminemay be prepared in the following manner:

1.6 cm³ of hydrochloric acid (4N in dioxane) are added to a solution of0.07 g of4-[({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenyl]carbamicacid tert-butyl ester in 1.5 cm³ of dioxane and 0.5 cm³ of DMF, at atemperature in the region of 20° C. The reaction medium is stirred atroom temperature for 24 hours. The reaction medium is concentrated underreduced pressure. The residue obtained is taken up in 4 cm³ of water andis then neutralized with triethylamine. 4 cm³ of dichloromethane areadded. After separation of the phases by settling, the organic phase isdried over magnesium sulfate, filtered and then concentrated underreduced pressure. The residue obtained is taken up in 5 cm³ of water.The solid formed is filtered off on a sinter funnel, washed twice with 3cm³ of water and then dried under vacuum to give 0.036 g of4-({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenylamine,the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 3.60 to        3.78 (broad m, 2H); 3.81 (s, 3H); 3.87 (s, 6H); from 4.02 to        4.13 (broad m, 2H); from 4.85 to 5.02 (broad m, 2H); 6.53 (broad        d, J=8.5 Hz, 2H); 6.80 (broad s, 1H); from 7.01 to 7.10 (m, 3H);        7.12 (s, 1H); 7.45 (s, 1H); 7.77 (s, 1H); 8.09 (d, J=5.0 Hz,        1H); 11.7 (broad m, 1H).    -   Mass spectrum (EI): m/z=441 (M)⁺; m/z 321 (M-C₇H₈N₂)⁺ base peak

EXAMPLE 1884-[({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenyl]carbamicacid tert-butyl ester (A003393158 (P-33047-016-1))

a)4-[({[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenyl]carbamicacid tert-butyl ester is prepared as described in Example 179a startingwith 0.16 g of4-[({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenyl]carbamicacid tert-butyl ester instead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 1.04 cm³ of 5N potassium hydroxide. 0.093 g of4-[({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenyl]carbamicacid tert-butyl ester is obtained, the characteristics of which are asfollows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.48 (s, 9H);        2.60 (broad m, 1H); 3.69 (m, 2H); 3.81 (s, 3H); 3.86 (s, 3H);        3.87 (s, 3H); 4.00 (m, 2H); 6.78 (broad d, J=2.0 Hz, 1H); 7.05        (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.25 (broad d, J=8.5 Hz, 2H);        7.40 (broad d, J=8.5 Hz, 2H); 7.42 (s, 1H); 7.74 (s, 1H); 8.06        (d, J=5.0 Hz, 1H); 9.22 (broad s, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z=542 (M+H)⁺ base peak; m/z=337        (M+H—C₁₂H₁₅NO₂)⁺

b)4-[({[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-amino}methyl)phenyl]carbamicacid tert-butyl ester is prepared as described in Example 178b startingwith 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.340 cm³ of (4-(aminomethyl)phenyl)carbamic acid tert-butyl esterinstead of the cyclohexylamine used in Example 178b. After purificationby flash-pack chromatography (SiO2, dichloromethane/methanol 99/01 andthen dichloromethane/methanol 98.5/1.5 by volume as eluent), 0.16 g of4-[({[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amino}methyl)phenyl]carbamicacid tert-butyl ester is obtained, the characteristics of which are asfollows:

-   -   Mass spectrum (ES): m/z=696 (M+H)⁺; m/z=337 (M+H—C₁₂H₁₅NO₂)⁺        base peak

EXAMPLE 189 [2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1Hpyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylphenyl)amine(A003403451 (P-33047-052-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylphenyl)amineis prepared as described in Example 179a starting with 0.08 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylphenyl)amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.53 cm³ of 5N potassium hydroxide. 0.068 g ofphenyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylphenyl)amine is obtained, the characteristicsof which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.80 (s, 3H);        3.86 (s, 3H); 3.88 (s, 3H); 4.67 (d, J=6.0 Hz, 2H); 6.70 (broad        d, J=8.5 Hz, 2H); 6.90 (broad s, 1H); 6.97 (d, J=5.0 Hz, 1H);        7.10 (s, 1H); 7.23 (broad t, J=6.0 Hz, 1H); 7.32 (broad d, J=8.5        Hz, 2H); 7.47 (s, 1H); 7.77 (s, 1H); 8.04 (d, J=5.0 Hz, 1H);        11.75 (broad m, 1H).    -   Mass spectrum (EI): m/z=512 (M)⁺; m/z=320 (M-C₇H₅SNF₃) base peak

b)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylphenyl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.219 cm³ of 4-(trifluoromethylsulfanyl)aniline instead of thecyclohexylamine used in Example 178b. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 98/02 by volume aseluent), 0.084 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylphenyl)amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=667 (M+H)⁺ base peak

EXAMPLE 190Cyclopropyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amine(A003403453 (P-33047-058-1))

a)Cyclopropyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 179a starting with 0.06 g ofcyclopropyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.5 cm³ of 5N potassium hydroxide. 0.034 g ofcyclopropyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 0.30 to        0.42 (m, 4H); 2.13 (m, 1H); from 2.72 to 2.86 (broad m, 1H);        3.80 (s, 3H); 3.86 (s, 3H); 3.88 (s, 3H); 4.06 (broad s, 2H);        6.81 (d, J=2.0 Hz, 1H); 7.00 (d, J=5.0 Hz, 1H); 7.11 (s, 1H);        7.47 (s, 1H); 7.75 (s, 1H); 8.04 (d, J=5.0 Hz, 1H); 11.65 (broad        m, 1H).    -   Mass spectrum (EI): m/z=376 (M)⁺; m/z=320 (M-C₃H₆N)⁺ base peak

b)Cyclopropyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.107 cm³ of cyclopropylamine instead of the cyclohexylamine used inExample 178b. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.075 g ofcyclopropyl[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=530 (M)⁺; m/z=375 (M-C₇H₇SO₂) base peak;        m/z=320 (m/z=375-C₃H₅N)⁺

EXAMPLE 191[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-morpholin-4-ylphenyl)amine(A003403814 (P-33047-056-2))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-morpholin-4-ylphenyl)amineis prepared as described in Example 179a starting with 0.16 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-morpholin-4-ylphenyl)amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine used in Example 179a and 1.08 cm³of 5N potassium hydroxide. 0.068 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-morpholin-4-ylphenyl)amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.83 (m, 4H);        3.67 (m, 4H); 3.80 (s, 3H); 3.85 (s, 3H); 3.89 (s, 3H); 4.58 (d,        J=6.0 Hz, 2H); 6.02 (t, J=6.0 Hz, 1H); 6.56 (broad d, J=8.5 Hz,        2H); 6.70 (broad d, J=8.5 Hz, 2H); 6.91 (d, J=2.0 Hz, 1H); 6.98        (d, J=5.0 Hz, 1H); 7.10 (s, 1H); 7.48 (s, 1H); 7.75 (s, 1H);        8.01 (d, J=5.0 Hz, 1H); 11.7 (broad m, 1H).    -   Mass spectrum (EI): m/z=497 (M)⁺; m/z=320 (M-C₁₀H₁₃N₂O)⁺ base        peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-morpholin-4-ylphenyl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.273 g of 4-morpholin-4-ylphenylamine instead of thecyclohexylamine used in Example 178b. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 98/02 by volume aseluent), 0.164 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-morpholin-4-ylphenyl)amine is obtained, the characteristics of whichare as follows:

-   -   Mass spectrum (EI): m/z=651 (M)⁺; m/z=496 (M-C₇H₇SO₂)⁺; m/z=177        (C₁₀H₁₃N₂O)⁺ base peak

EXAMPLE 192[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methyl-2H-pyrazol-3-yl)amine(A003405576 (P-33047-062-1))

a)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methyl-2H-pyrazol-3-yl)amineis prepared as described in Example 179a starting with 0.08 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methyl-2H-pyrazol-3-yl)aminetrifluoroacetate instead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.62 cm³ of 5N potassium hydroxide. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.024 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methyl-2H-pyrazol-3-yl)amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.60 (s, 3H);        3.81 (s, 3H); 3.86 (s, 3H); 3.88 (s, 3H); 4.53 (d, J=6.0 Hz,        2H); 5.28 (d, J=2.0 Hz, 1H); 6.24 (broad t, J=6.0 Hz, 1H); 6.90        (d, J=2.0 Hz, 1H); 7.00 (d, J=2.0 Hz, 1H); 7.02 (d, J=5.0 Hz,        1H); 7.11 (s, 1H); 7.47 (s, 1H); 7.77 (s, 1H); 8.04 (d, J=5.0        Hz, 1H); 11.7 (broad s, 1H).    -   Mass spectrum (EI): m/z=416 (M)⁺; m/z=320 (M-C₄H₆N₃)⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methyl-2H-pyrazol-3-yl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.149 g of 1-methyl-1H-pyrazol-5-ylamine instead of thecyclohexylamine used in Example 178b. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 98/02 by volume aseluent), followed by chromatography on a column of Kromasil C8 10 μm,eluents: water/acetonitrile/TFA 70/30/0.1 by volume, 0.08 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](2-methyl-2H-pyrazol-3-yl)aminetrifluoroacetate is obtained, the characteristics of which are asfollows:

-   -   Mass spectrum (EI): m/z=570 (M)⁺; m/z=415 (M-C₇H₇SO₂)⁺ base        peak; m/z=320 (m/z=415-C₄H₅N₃)⁺

EXAMPLE 193[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](1-methylpiperid-4-yl)amine(A003440113 (P-33047-137-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](1-methylpiperid-4-yl)amineis prepared as described in Example 179a starting with 0.07 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](1-methylpiperid-4-yl)amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.48 cm³ of 5N potassium hydroxide. 0.042 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](1-methylpiperid-4-yl)amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.34 (m, 2H);        1.85 (m, 4H); 2.11 (s, 3H); 2.42 (m, 1H); 2.69 (m, 2H); 3.81 (s,        3H); 3.87 (s, 3H); 3.88 (s, 3H); 4.05 (s, 2H); 6.81 (d, J=2.0        Hz, 1H); 7.02 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.44 (s, 1H);        7.75 (s, 1H); 8.03 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES: m/z=434 (M+H)⁺; m/z=218 (M+2H)²⁺/2; base peak

b)[2-(5,6-Dimethoxy-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](1-methylpiperid-4-yl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.175 g of 1-methyl-4-aminopiperidine instead of the cyclohexylamineused in Example 178b. After purification by flash-pack chromatography(SiO2, dichloromethane/methanol 90/10 by volume as eluent), 0.070 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](1-methylpiperid-4-yl)amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (IC): m/z=588 (M+H)⁺ base peak

EXAMPLE 194 (2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amine(A003408775 (P-32989-041-1))

a)(2,4-Dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 179a starting with 0.05 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.36 cm³ of 5N potassium hydroxide. 0.03 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.67 (broad s,        2H); 3.72 (s, 3H); 3.73 (s, 3H); 3.81 (s, 3H); 3.85 (s, 3H);        3.87 (s, 3H); 4.04 (broad s, 2H); 6.49 (dd, J=2.5 and 8.5 Hz,        1H); 6.52 (d, J=2.5 Hz, 1H); 6.76 (d, J=2.0 Hz, 1H); 7.06 (d,        J=5.0 Hz, 1H); 7.11 (s, 1H); 7.28 (d, J=8.5 Hz, 1H); 7.42 (s,        1H); 7.75 (s, 1H); 8.06 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z=487 (M+H)⁺ base peak

b)(2,4-Dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineis prepared as described in Example 178b starting with 2 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 3.39 g of 2,4-dimethoxybenzylamine instead of the cyclohexylamineused in Example 178b. After purification by flash-pack chromatography(SiO2, dichloromethane/methanol 98/02 by volume as eluent), 1.2 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineare obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=641 (M+H)⁺; m/z=486 (M+H—C₇H₇SO₂)⁺

EXAMPLE 195[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amine(A003425429 (P-333047-107-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,33-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amineis prepared as described in Example 179a starting with 0.09 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine used in Example 179a and 0.55 cm³of 5N potassium hydroxide. 0.016 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.45 (m, 2H);        1.59 (m, 4H); 2.83 (m, 4H); 3.82 (s, 3H); 3.88 (s, 3H); 3.90 (s,        3H); 4.57 (broad m, 2H); 6.00 (broad m, 1H); 6.55 (broad d,        J=8.5 Hz, 2H); 6.70 (broad d, J=8.5 Hz, 2H); 6.92 (broad s, 1H);        7.00 (broad d, J=5.0 Hz, 1H); 7.11 (broad s, 1H); 7.49 (broad s,        1H); 7.78 (broad s, 1H); 8.02 (broad d, J=5.0 Hz, 1H); 11.7        (broad s, H).    -   Mass spectrum (EI): m/z=495 (M)⁺; m/z=320 (M-C₁₁H₁₅N₂)⁺; m/z=175        (C₁₁H₁₅N₂ ⁺) base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.27 g of (4-piperid-1-ylphenyl)amine instead of the cyclohexylamineused in Example 178b. After purification by flash-pack chromatography(SiO2, dichloromethane/methanol 99/01 by volume as eluent), 0.12 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amineis obtained as a mixture (60/40) with[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)imine.

This mixture is dissolved in 7 cm³ of ethanol, at a temperature in theregion of 20° C. 0.016 g of sodium borohydride is added. The reactionmedium is stirred at room temperature for 24 hours. The reaction mediumis concentrated under reduced pressure. The residue obtained is taken upin 3 cm³ of water and 4 cm³ of dichloromethane. After separation of thephases by settling, the organic phase is dried over magnesium sulfate,filtered and then concentrated under reduced pressure. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/methanol 99.5/0.5 by volume as eluent), 0.095 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-piperid-1-ylphenyl)amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=649 (M)⁺; m/z=175 (C₁₁H₁₅N₂) base peak

EXAMPLE 196[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amine(A003425496 (P-333047-113-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amineis prepared as described in Example 179a starting with 0.08 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 1 cm³ of 5N potassium hydroxide. 0.017 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.09 (d, J=7.0        Hz, 6H); 2.08 (m, 2H); 3.21 (m, 2H); 3.63 (m, 2H); 3.80 (s, 3H);        3.87 (s, 3H); 3.89 (s, 3H); 4.56 (broad d, J=6.0 Hz, 2H); 6.00        (broad t, J=6.0 Hz, 1H); 6.55 (broad d, J=8.5 Hz, 2H); 6.69        (broad d, J=8.5 Hz, 2H); 6.91 (broad s, 1H); 6.98 (d, J=5.0 Hz,        1H); 7.11 (s, 1H); 7.47 (s, 1H); 7.75 (s, 1H); 8.01 (d, J=5.0        Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (EI): m/z=525 (M)⁺; m/z=320 (M-C₁₂H₁₇N₂O) base        peak; m/z=206 (C₁₂H₁₈N₂O)⁺

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amineis prepared as described in Example 178b starting with 0.15 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydeand 0.316 g of 4-(2,6-dimethylmorpholin-4-ylphenyl)amine instead of thecyclohexylamine used in Example 178b. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 99/01 by volume aseluent), 0.1 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amineis obtained as a mixture (50/50) with[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)imine.

This mixture is dissolved in 7 cm³ of ethanol, at a temperature in theregion of 20° C. 0.016 g of sodium borohydride is added. The reactionmedium is stirred at room temperature for 24 hours. The reaction mediumis concentrated under reduced pressure. The residue obtained is taken upin 3 cm³ of water and 4 cm³ of dichloromethane. After separation of thephases by settling, the organic phase is dried over magnesium sulfate,filtered and then concentrated under reduced pressure. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/dethanol 99/01 by volume as eluent), 0.08 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][4-(2,6-dimethylmorpholin-4-ylphenyl)amineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=679 (M)⁺; m/z=206 (C₁₂H₁₈N₂O⁺); m/z=120        (C₇H₈N₂ ⁺) base peak

EXAMPLE 197[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanol(A003377259 (P-32520-113-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolis prepared as described in Example 179a starting with 0.08 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amine used in Example 179a and 0.55 cm³of 5N potassium hydroxide. 0.036 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 3.72 to        3.97 (broad m, 9H); 4.85 (broad s, 2H); 5.32 (broad s, 1H); 6.75        (broad s, 1H); 7.03 (broad s, 1H); 7.11 (broad s, 1H); 7.45        (broad s, 1H); 7.75 (broad s, 1H); 8.08 (broad s, 1H); 11.65        (broad s, 1H).    -   Mass spectrum (EI): m/z=337 (M)⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolmay be prepared in the following manner:

0.054 mg of sodium borohydride is added to a solution of 0.47 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydein 10 cm³ of methanol, at a temperature in the region of 20° C. Thereaction medium is stirred at room temperature for 4 hours. The reactionmedium is concentrated under reduced pressure. The residue obtained istaken up in 10 cm³ of water and 20 cm³ of ethyl acetate. Afterseparation of the phases by settling, the organic phase is dried overmagnesium sulfate, filtered and then concentrated under reducedpressure. After purification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.45 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=492 (M+H)⁺ base peak

EXAMPLE 1981′-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][1,4′]bipiperidyl:(A003408597 (P-33047-074-1))

a)1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][1,4′]bipiperidylis prepared as described in Example 179a starting with 0.025 g of1′-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][1,4′]bipiperidylinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.17 cm³ of 5N potassium hydroxide. 0.01 g of1′-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][1,4′]bipiperidylis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): from 1.30 to        1.56 (m, 8H); 1.71 (m, 2H); 2.01 (m, 2H); 2.17 (m, 1H); 2.42 (m,        4H); 2.94 (m, 2H); 3.78 (s, 2H); 3.80 (s, 3H); 3.86 (s, 3H);        3.88 (s, 3H); 6.87 (d, J=2.0 Hz, 1H); 6.93 (d, J=5.0 Hz, 1H);        7.11 (s, 1H); 7.41 (s, 1H); 7.76 (s, 1H); 8.04 (d, J=5.0 Hz,        1H); 11.70 (broad s, 1H).    -   Mass spectrum (EI): m/z=487 (M)⁺; m/z=320 (M-C₁₀H₁₉N₂)⁺ base        peak

b)1′-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][1,4′]bipiperidylmay be prepared in the following manner:

0.003 g of sodium hydride is added to a solution of 0.008 g of4-piperidinopiperidine in 0.5 cm³ of THF, at a temperature in the regionof 20° C. The reaction medium is stirred at room temperature for 20minutes. 0.04 g of methanesulfonic acid2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethylester is added. The reaction medium is heated at 60° C. for 3 hours.After cooling, the reaction medium is concentrated under reducedpressure. The residue obtained is taken up in 2 cm³ of water and 3 cm³of ethyl acetate. After separation of the phases by settling, theorganic phase is dried over magnesium sulfate, filtered and thenconcentrated under reduced pressure. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 90/10 by volume aseluent), 0.026 g of1′-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl][1,4′]bipiperidylis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=642 (M+H)⁺; m/z=244 (M+H—C₇H₇SO₂+H)²⁺/2        base peak

c) Methanesulfonic acid2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethylester may be prepared in the following manner:

0.064 g of pyridine and 0.092 g of methanesulfonic anhydride are addedto a solution of 0.13 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolin 5 cm³ of dichloromethane, at a temperature in the region of −10° C.The reaction medium is stirred at this same temperature for one hour,and then at room temperature for 24 hours. Ice and 15 cm³ ofdichloromethane are added. After separation of the phases by settling,the organic phase is dried over magnesium sulfate, filtered and thenconcentrated under reduced pressure. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 98/02 by volume aseluent), 0.044 g of methanesulfonic acid2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethylester is obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=570 (M+H)⁺ base peak

EXAMPLE 199[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]diethylamine(A003416358 (P-33047-091-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]diethylamineis prepared as described in Example 179a starting with 0.060 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]diethylamineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.44 cm³ of 5N potassium hydroxide. 0.034 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]diethylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.06 (t, J=7.0        Hz, 6H); 2.53 (partially masked m, 4H); 3.81 (s, 3H); 3.83 (s,        2H); 3.87 (s, 6H); 6.86 (d, J=2.0 Hz, 1H); 6.99 (d, J=5.0 Hz,        1H); 7.11 (s, 1H); 7.41 (s, 1H); 7.74 (s, 1H); 8.03 (d, J=5.0        Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (EI): m/z=392 M⁺; m/z=321 (M-C₄H₉N)⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]diethylaminemay be prepared in the following manner:

0.022 cm³ of thionyl chloride is added to a solution of 0.15 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolin 3 cm³ of dichloromethane, at a temperature in the region of 20° C.,followed by addition of two drops of DMF. The reaction medium is stirredat this same temperature for 4 hours.

Next, 8 cm³ of acetonitrile, 0.160 cm³ of diethylamine, 0.211 g ofpotassium carbonate and 0.1 g of sodium iodide are added. The reactionmedium is heated at 50° C. for 24 hours. After cooling, the reactionmedium is filtered through a sinter funnel and the filtrate isconcentrated under reduced pressure. The residue obtained is taken up in3 cm³ of water and 4 cm³ of ethyl acetate. After separation of thephases by settling, the organic phase is dried over magnesium sulfate,filtered and then concentrated under reduced pressure. Afterpurification by flash-pack chromatography (SiO2, dichloromethane/ethylacetate 80/20 by volume as eluent), 0.036 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]diethylamineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=547 (M+H)⁺ base peak; m/z=474        ((M+H)—C₄H₁₁N)⁺

EXAMPLE 200[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]piperid-4-ol(A003435835 (P-33047-129-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]piperid-4-olis prepared as described in Example 179a starting with 0.045 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]piperid-4-olinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.44 cm³ of 5N potassium hydroxide. 0.031 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]piperid-4-olis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.46 (m, 2H);        1.74 (m, 2H); 2.13 (m, 2H); 2.78 (m, 2H); 3.48 (m, 1H); 3.78 (s,        2H); 3.81 (s, 3H); 3.87 (s, 3H); 3.89 (s, 3H); 4.56 (broad m,        1H); 6.89 (broad s, 1H); 6.93 (d, J=5.0 Hz, 1H); 7.12 (s, 1H);        7.42 (s, 1H); 7.76 (s, 1H); 8.03 (d, J=5.0 Hz, 1H); 11.7 (broad        s, 1H). Mass spectrum (EI): m/z=420 M⁺; m/z=321 (M-C₅H₉NO)⁺ base        peak

b)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]piperid-4-olmay be prepared in the following manner:

0.027 g of piperid-4-ol, 0.075 g of potassium carbonate and 0.016 g ofsodium iodide are added to a solution of 0.055 g of4-chloromethyl-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinein 3 cm³ of acetonitrile, at a temperature in the region of 20° C. Thereaction medium is heated at 80° C. for one hour. After cooling, thereaction medium is filtered through a sinter funnel and the filtrate isconcentrated under reduced pressure. The residue obtained is taken up in3 cm³ of water and 4 cm³ of ethyl acetate. After separation of thephases by settling, the organic phase is dried over magnesium sulfate,filtered and then concentrated under reduced pressure. 0.049 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]piperid-4-olis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=575 (M+H)⁺ base peak

c)4-Chloromethyl-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridinemay be prepared in the following manner:

0.089 cm³ of thionyl chloride and five drops of DMF are added to asolution of 0.4 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methanolin 4 cm³ of dichloromethane, at a temperature in the region of 20° C.The reaction medium is stirred at this same temperature for 4 hours. Iceis added and the reaction medium is then neutralized with saturatedsodium hydrogen carbonate solution. After separation of the phases bysettling, the organic phase is dried over magnesium sulfate, filteredand then concentrated under reduced pressure. After purification byflash-pack chromatography (SiO2, dichloromethane/ethyl acetate 97.5/2.5by volume as eluent), 0.234 g of4-chloromethyl-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=509 M⁺; m/z=354 M-C₇H₇SO₂)⁺ base peak

EXAMPLE 2011-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylamine(A003453957 (P-33047-148-1))

1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylaminemay be prepared in the following manner:

0.27 cm³ of hydrochloric acid (4N in dioxane) is added to a solution of0.051 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester in 3 cm³ of methanol and 0.5 cm³ ofdichloromethane, at a temperature in the region of 20° C. The reactionmedium is stirred at room temperature for 24 hours. The reaction mediumis concentrated under reduced pressure. The residue obtained is taken upin 4 cm³ of water and is then neutralized with 1N sodium hydroxide to pH10. 12 cm³ of dichloromethane are added. After separation of the phasesby settling, the organic phase is dried over magnesium sulfate, filteredand then concentrated under reduced pressure. 0.008 g of1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.73 (m, 2H);        3.44 (m, 1H); 3.59 (m, 2H); 3.81 (s, 3H); 3.87 (s, 5H); 3.89 (s,        3H); 6.73 (d, J=2.0 Hz, 1H); 6.92 (d, J=5.0 Hz, 1H); 7.11 (s,        1H); 7.44 (s, 1H); 7.73 (s, 1H); 8.03 (d, J=5.0 Hz, 1H); 11.65        (broad s, 1H).    -   Mass spectrum (ES): m/z=392 (M+H)⁺

EXAMPLE 202{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester (A003452988 (P-33047-143-1))

a){1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester is prepared as described in Example 179a startingwith 0.13 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester instead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.805 cm³ of 5N potassium hydroxide. 0.07 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester is obtained, the characteristics of which are asfollows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.37 (s, 9H);        2.97 (t, J=7.0 Hz, 2H); 3.58 (t, J=7.0 Hz, 2H); 3.81 (s, 3H);        3.88 (s, 3H); 3.90 (s, 5H); 4.10 (m, 1H); 6.73 (d, J=2.0 Hz,        1H); 6.91 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.31 (broad d, J=7.0        Hz, 1H); 7.44 (s, 1H); 7.74 (s, 1H); 8.03 (d, J=5.0 Hz, 1H);        11.7 (broad s, 1H).    -   Mass spectrum (ES): m/z=492 (M+H)⁺ base peak; m/z=436 (MH—C₄H₈)⁺

b){1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester is prepared as described in Example 200b startingwith 0.14 g of4-chloromethyl-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.118 g of azetidin-3-ylcarbamic acid tert-butyl ester instead ofthe piperid-4-ol used in Example 200b. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 95/5 by volume aseluent), 0.135 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester is obtained, the characteristics of which are asfollows:

-   -   Mass spectrum (ES): m/z=646 (M+H)⁺ base peak; m/z=590 (MH—C₄H₈)⁺

EXAMPLE 203{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}methylaminedihydrochloride (A003453945A (P-33047-150-1))

a){1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}methylaminedihydrochloride is prepared as described in Example 201 starting with0.027 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester instead of the{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}carbamicacid tert-butyl ester used in Example 201 and 1.35 cm³ of hydrochloricacid (4N in dioxane). 0.005 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-yl}methylaminedihydrochloride is obtained, the characteristics of which are asfollows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.83 (s, 3H);        3.88 (s, 3H); 3.92 (broad s, 3H); from 2.90 to 4.35 (partially        masked very broad m, 7H in total); 4.75 (m, 2H); from 7.05 to        7.10 (m, 3H); 7.60 (s, 1H); 7.81 (s, 1H); from 7.85 to 8.03        (broad m, 3H); 8.17 (broad d, J=5.0 Hz, 1H); from 140.7 to 11.2        (very broad m, 1H); 12.0 (broad m, 1H)    -   Mass spectrum (ES): m/z=406 (M+H)⁺ base peak

EXAMPLE 204{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester (A003453144 (P-33047-145-1))

a){1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester is prepared as described in Example 179a startingWith 0.15 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester instead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.909 cm³ of 5N potassium hydroxide. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/methanol 95/5 by volume as eluent), 0.037 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester is obtained, the characteristics of which are asfollows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 1.36 (s, 9H);        2.97 (t, J=7.0 Hz, 2H); 3.14 (m, 3H); from 3.19 to 3.35 (masked        m, 2H); 3.81 (s, 3H); 3.87 (s, 5H); 3.89 (s, 3H); 6.75 (d, J=2.0        Hz, 1H); 6.90 (broad m, 1H); 6.92 (d, J=5.0 Hz, 1H); 7.11 (s,        1H); 7.44 (s, 1H); 7.74 (s, 1H); 8.02 (d, J=5.0 Hz, 1H); 11.65        (broad s, 1H). Mass spectrum (EI): m/z=505 M⁺; m/z=321        (M-C₉H₁₆N₂O₂)⁺ base peak

b){1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester is prepared as described in Example 200b startingwith 0.14 g of4-chloromethyl-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.123 g of azetidin-3-ylmethylcarbamic acid tert-butyl ester insteadof the piperid-4-ol used in Example 200b. After purification byflash-pack chromatography (SiO2, dichloromethane/methanol 95/5 by volumeas eluent), 0.154 g of{1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]azetidin-3-ylmethyl}carbamicacid tert-butyl ester is obtained, the characteristics of which are asfollows:

-   -   Mass spectrum (EI): m/z=659 M⁺; m/z=505 (M-C₇H₆SO₂)⁺; m/z=320        (m/z=505-C₉H₁₇N₂O₂)⁺ base peak

EXAMPLE 205[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-4-(4-methylpiperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine(A003438870 (P-33047-131-2))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-4-(4-methylpiperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridineis prepared as described in Example 179a starting with 0.040 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.28 cm³ of 5N potassium hydroxide. 0.014 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-4-(4-methylpiperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.15 (s, 3H);        from 2.30 to 2.54 (partially masked m, 8H); 3.79 (s, 2H); 3.81        (s, 3H); 3.87 (s, 3H); 3.89 (s, 3H); 6.89 (d, J=2.0 Hz, 1H);        6.93 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.42 (s, 1H); 7.75 (s,        1H); 8.03 (d, J=5.0 Hz, 1H); 11.7 (broad s, 1H).    -   Mass spectrum (EI): m/z=419 M⁺; m/z=320 (M-C₅H₁₁N₂)⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridineis prepared as described in Example 200b starting with 0.055 g of4-chloromethyl-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridineand 0.03 cm³ of 1-methylpiperazine instead of the piperid-4-ol used inExample 200b. 0.043 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=574 (M+H)⁺; m/z=308        (M+acetonitrile+2H)²⁺/2; m/z=231 (MH+acetonitrile-C₇H₇SO₂+H)²⁺/2        base peak

EXAMPLE 206[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]phenylmethanol(A003403794 (P-32989-031-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]phenylmethanolis prepared as described in Example 179a starting with 0.105 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]phenylmethanolinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.85 cm³ of 5N potassium hydroxide. 0.070 g Of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]phenylmethanolis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.80 (s, 3H);        3.86 (s, 3H); 3.89 (s, 3H); 6.11 (s, 1H); 6.69 (broad s, 1H);        7.10 (s, 1H); from 7.15 to 7.24 (m, 2H); from 7.26 to 7.33 (m,        3H); 7.53 (broad d, J=7.5 Hz, 2H); 7.70 (s, 1H); 8.09 (d, J=5.0        Hz, 1H); 11.65 (broad m, 1H).    -   Mass spectrum (EI) (IC): m/z=413 M⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]phenylmethanolmay be prepared in the following manner:

0.45 cm³ of phenylmagnesium bromide, 1M in THF, is added to a solutionof 0.1 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-carboxaldehydein 5 cm³ of THF, at a temperature in the region of 6° C. The reactionmedium is stirred at this same temperature for 30 minutes and then for24 hours at room temperature. 5 cm³ of saturated ammonium chloridesolution and 10 cm³ of dichloromethane are added. After separation ofthe phases by settling, the organic phase is dried over magnesiumsulfate, filtered and then concentrated under reduced pressure. 0.105 gof[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]phenylmethanolis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=567 M⁺; m/z=412 (M-C₇H₇SO₂)⁺ base peak

EXAMPLE 207[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]propan-1-ol(A003408773 (P-32989-039-1))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]propan-1-olis prepared as described in Example 179a starting with 0.090 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]propan-1-olinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.80 cm³ of 5N potassium hydroxide. 0.060 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]-pyrid-4-yl]propan-1-olis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 0.90 (t, J=7.0        Hz, 3H); 1.80 (m, 2H); 3.81 (s, 3H); 3.87 (s, 3H); 3.88 (s, 3H);        4.96 (m, 1H); 5.25 (d, J=5.0 Hz, 1H); 6.75 (d, J=2.0 Hz, 1H);        7.01 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.44 (s, 1H); 7.74 (s,        1H); 8.07 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z 366 (M+H)⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]propan-1-olmay be prepared in the following manner:

0.45 cm³ of ethylmagnesium bromide, 1M in THF, is added to a solution of0.1 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-carboxaldehydein 5 cm³ of THF, at a temperature in the region of 6° C. The reactionmedium is stirred at this same temperature for 30 minutes and then for24 hours at room temperature. 5 cm³ of saturated ammonium chloridesolution and 10 cm³ of dichloromethane are added. After separation ofthe phases by settling, the organic phase is dried over magnesiumsulfate, filtered and then concentrated under reduced pressure. Afterpurification by flash-pack chromatography (SiO2, dichloromethane/ethylacetate 80/20 by volume as eluent), 0.154 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]propan-1-olis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=519 M⁺; m/z=364 (M-C₇H₇SO₂)⁺ base peak

EXAMPLE 208[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methylamine(A003435888 (P-32989-101-2))

a)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methylamineis prepared as described in Example 179a starting with 0.080 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methylamineinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4ylmethyl](4-trifluoromethylsulfanylbenzyl)amine used in Example 179a and0.80 cm³ of 5N potassium hydroxide. After purification by flash-packchromatography (SiO2, dichloromethane/methanol 95/05 by volume aseluent), 0.015 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methylamineis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.80 (s, 3H);        3.86 (s, 3H); 3.88 (s, 3H); 4.04 (s, 2H); 6.79 (d, J=2.0 Hz,        1H); 7.07 (d, J=5.0 Hz, 1H); 7.11 (s, 1H); 7.48 (s, 1H); 7.75        (s, 1H); 8.06 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (EI): m/z=336 M⁺ base peak

b)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methylaminemay be prepared in the following manner:

0.040 g of zinc and 2 cm³ of concentrated formic acid are added to asolution of 0.1 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime in 6 cm³ of ethanol and 5 cm³ of water, at a temperature in theregion of 20° C. The reaction medium is stirred at this same temperaturefor 24 hours at room temperature. The reaction medium is filteredthrough Celite and the filtrate is concentrated under reduced pressure.5 cm³ of water and 10 cm³ of dichloromethane are added. The reactionmedium is basified to pH 10 with 1N sodium hydroxide. After separationof the phases by settling, the organic phase is dried over magnesiumsulfate, filtered and then concentrated under reduced pressure. 0.06 gof[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-yl]methylamineis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z 490 M⁺; m/z=335 (M-C₇H₇SO₂)⁺ base peak

c)[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime may be prepared in the following manner:

0.2107 g of hydroxylamine hydrochloride is added to a solution of 0.5 gof[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carboxaldehydein 25 cm³ of pyridine, at a temperature in the region of 20° C. Thereaction medium is heated at 50° C. for 24 hours. The reaction medium isconcentrated under reduced pressure. The residue obtained is taken up in10 cm³ of water and 10 cm³ of dichloromethane. After separation of thephases by settling, the organic phase is dried over magnesium sulfate,filtered and then concentrated under reduced pressure. 0.510 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime is obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=350 M⁺ base peak; m/z=332 (M-H₂O)⁺;        m/z=306 (M-CH₂NO)⁺

EXAMPLE 209[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime (A003425653 (P-32989-091-2))

[2(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime is prepared as described in Example 179a starting with 0.060 g of2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime instead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.60 cm³ of 5N potassium hydroxide. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.010 g of[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-carbaldehydeoxime is obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.82 (s, 3H);        3.87 (s, 3H); 3.89 (s, 3H); 7.07 (d, J=2.0 Hz, 1H); 7.12 (s,        1H); 7.09 (d, J=5.0 Hz, 1H); 7.45 (s, 1H); 7.80 (s, 1H); 8.11        (d, J=5.0 Hz, 1H); 8.54 (s, 1H); 11.58 (s, 1H); 11.9 (broad s,        1H).    -   Mass spectrum (EI): m/z=350 M⁺ base peak; m/z=332 (M-H₂O)⁺;        m/z=306 (M-CH₂NO)⁺

EXAMPLE 210N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamide(A003453139 (P-32989-120-2))

N-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamidemay be prepared in the following manner:

0.053 g of para-toluenesulfonic acid is added to a solution of 0.050 gofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamidein 2 cm³ of dichloromethane and 5 cm³ of toluene, at a temperature inthe region of 20° C. The reaction medium is stirred at this sametemperature for 24 hours, at room temperature, and then heated at atemperature in the region of 60° C. for 24 hours. After cooling, thereaction medium is concentrated under reduced pressure. 5 cm³ of waterand 10 cm³ of dichloromethane are added. The reaction medium is basifiedto pH 9 with 1N sodium hydroxide. After separation of the phases bysettling, the organic phase is dried over magnesium sulfate, filteredand then concentrated under reduced pressure. The residue obtained ispurified on preparative LC/MS (water/acetonitrile/TFA). The solidobtained is taken up in 5 cm³ of dichloromethane and 2 cm³ of water, andthen basified with 1N sodium hydroxide to pH 9. 0.008 g ofN-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.82 (s, 3H);        3.88 (s, 3H); 3.90 (s, 3H); 4.38 (broad s, 2H); 6.87 (d, J=5.0        Hz, 1H); 6.95 (d, J=2.0 Hz, 1H); 7.13 (s, 1H); 7.50 (s, 1H);        7.55 (broad d, J=8.5 Hz, 2H); 7.78 (s, 1H); 7.96 (broad d, J=8.5        Hz, 2H); 8.00 (d, J=5.0 Hz, 1H); 8.50 (m, 1H); 11.75 (broad s,        1H).    -   Mass spectrum (EI): m/z=560 M⁺ base peak; m/z=335 (M-C₇H₄SO₃F₃)⁺

EXAMPLE 211N-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamide(A003423534 (P-32989-083-2))

a)N-(2,4-Dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideis prepared as described in Example 179a starting with 0.070 g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.40 cm³ of 5N potassium hydroxide. 0.030 g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.46 (s, 3H);        3.63 (s, 3H); 3.83 (s, 3H); 3.87 (s, 6H); 4.28 (broad s, 2H);        4.79 (broad s, 2H); from 6.20 to 6.26 (m, 2H); 6.78 (d, J=5.0        Hz, 1H); 6.88 (d, J=8.5 Hz, 1H); 6.99 (broad s, 1H); 7.12 (s,        1H); 7.48 (s, 1H); 7.50 (broad d, J=8.5 Hz, 2H); 7.78 (s, 1H);        7.88 (broad d, J=8.5 Hz, 2H); 7.98 (d, J=5.0 Hz, 1H); 11.75        (broad s, 1H).    -   Mass spectrum (ES): m/z=711 (M+H)⁺ base peak

b)N-(2,4-Dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamidemay be prepared in the following manner:

0.052 cm³ of triethylamine and 0.265 cm³ of4-(trifluoromethoxy)benzenesulfonyl chloride are added to a solution of0.200 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]aminein 6 cm³ of dichloromethane, under an argon atmosphere, at a temperaturein the region of 20° C. The reaction medium is stirred at this sametemperature for 24 hours. 2 cm³ of water are added. After separation ofthe phases by settling, the organic phase is dried over magnesiumsulfate, filtered and then concentrated under reduced pressure. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.210 g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=865 (M+H)⁺ base peak

EXAMPLE 212 Thiophene-2-sulfonic acid[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-amide(A0013453971 (P-32989-122-3))

a) Thiophene-2-sulfonic acid[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideis prepared as described in Example 210 starting with 0.1 g ofthiophene-2-sulfonic acid(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideinstead of theN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideused in Example 210 and 0.110 g of para-toluenesulfonic acid. 0.025 g ofthiophene-2-sulfonic acid[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideis obtained, the characteristics of which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.81 (s, 3H);        3.87 (s, 3H); 3.89 (s, 3H); 4.40 (broad s, 2H); 6.89 (d, J=5.0        Hz, 1H); 6.91 (d, J=2.0 Hz, 1H); 7.11 (s, 1H); 7.19 (dd, J=3.5        and 5.0 Hz, 1H); 7.48 (s, 1H); 7.66 (dd, J=1.0 and 3.5 Hz, 1H);        7.77 (s, 1H); 7.92 (dd, J=1.0 and 5.0 Hz, 1H); 8.02 (d, J=5.0        Hz, 1H); 8.51 (broad m, 1H); 11.75 (broad s, 1H).    -   Mass spectrum (EI): m/z=482 M⁺; m/z=320 (M-C₄H₄NO₂S₂)⁺ base peak

b) Thiophene-2-sulfonic acid(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideis prepared as described in Example 179a starting with 0.150 g ofthiophene-2-sulfonic acid(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 1 cm³ of 5N potassium hydroxide. 0.100 g ofthiophene-2-sulfonic acid(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=633 (M+H)⁺ base peak

c) Thiophene-2-sulfonic acid (2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideis prepared as described in Example 211b starting with 0.80 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineand 0.114 g of 2-thiophenesulfonyl chloride instead of the4-(trifluoromethoxy)benzenesulfonyl chloride used in Example 211b. 0.150g of thiophene-2-sulfonic acid(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amideis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=786 M⁺; m/z=631 (M-C₇H₇SO₂)⁺ base peak;        m/z=320 (m/z=631-C₁₃H₁₃NO₄S₂)⁺

EXAMPLE 213N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamidetrifluoroacetate (A003454170A (P-32989-126-3))

a)N-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamidetrifluoroacetate is prepared as described in Example 210 starting with0.04 g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamideinstead of theN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideused in Example 210 and 0.045 g of para-toluenesulfonic acid. 0.011 g ofN-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamidetrifluoroacetate is obtained, the characteristics of which are asfollows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.81 (s, 3H);        3.87 (s, 3H); 3.89 (s, 3H); 4.33 (d, J=6.5 Hz, 2H); 6.91 (d,        J=5.0 Hz, 1H); 6.93 (d, J=2.0 Hz, 1H); 7.11 (s, 1H); 7.49 (s,        1H); from 7.52 to 7.68 (m, 3H); 7.78 (s, 1H); 7.87 (broad d,        J=7.5 Hz, 2H); 8.01 (d, J=5.0 Hz, 1H); 8.31 (broad t, J=6.5 Hz,        1H); 11.8 (broad s, 1H).    -   Mass spectrum (ES): m/z=477; (M+H)⁺

b)N-(2,4-Dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-benzenesulfonamideis prepared as described in Example 179a starting with 0.090 g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamideinstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 0.6 cm³ of 5N potassium hydroxide. 0.100 g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamideis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=627 (M+H)⁺ base peak

c)N-(2,4-Dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamideis prepared as described in Example 211b starting with 0.80 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]amineand 0.110 g of benzenesulfonyl chloride instead of the4-(trifluoromethoxy)benzenesulfonyl chloride used in Example 211b. 0.060g ofN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]benzenesulfonamideis obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z 781 (M+H)⁺ base peak

EXAMPLE 2141-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureatrifluoroacetate (A003454230A (P-32989-128′-2))

a)1-[2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureatrifluoroacetate is prepared as described in Example 210 starting with0.04 g of1-(2,4-dimethoxybenzyl)-1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureainstead of theN-(2,4-dimethoxybenzyl)-N-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-4-trifluoromethoxybenzenesulfonamideused in Example 210 and 0.045 g of para-toluenesulfonic acid. 0.0015 gof1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureatrifluoroacetate is obtained, the characteristics of which are asfollows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 3.78 (s, 3H);        3.80 (s, 3H); 3.86 (s, 3H); 4.63 (broad d, J=6.5 Hz, 2H); 6.78        (broad t, J=6.5 Hz, 1H); 6.83 (broad s, 1H); 6.93 (d, J=5.0 Hz,        1H); 7.10 (s, 1H); 7.22 (broad d, J=8.5 Hz, 2H); 7.43 (s, 1H);        7.52 (broad d, J=8.5 Hz, 2H); 7.77 (s, 1H); 8.06 (d, J=5.0 Hz,        1H); 8.82 (s, 1H); 11.75 (broad s, 1H).    -   Mass spectrum (ES): m/z=540 (M+H)⁺ base peak

b)1-(2,4-Dimethoxybenzyl)-1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureais prepared as described in Example 179a starting with 0.150 g of1-(2,4-dimethoxybenzyl)-1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureainstead of the[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl](4-trifluoromethylsulfanylbenzyl)amineused in Example 179a and 1 cm³ of 5N potassium hydroxide. 0.040 g of1-(2,4-dimethoxybenzyl)-1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureais obtained, the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=690 (M+H)⁺ base peak

c)1-(2,4-Dimethoxybenzyl)-1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureamay be prepared in the following manner:

0.094 cm³ of 4-(trifluoromethoxy)phenyl isocyanate is added to asolution of 0.080 g of(2,4-dimethoxybenzyl)[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]aminein 6 cm³ of dichloromethane, under an argon atmosphere, at a temperaturein the region of 20° C. The reaction medium is stirred at this sametemperature for 24 hours. 2 cm³ of water are added. After separation ofthe phases by settling, the organic phase is dried over magnesiumsulfate, filtered and then concentrated under reduced pressure. Afterpurification by flash-pack chromatography (SiO2,dichloromethane/methanol 98/02 by volume as eluent), 0.150 g of1-(2,4-dimethoxybenzyl)-1-[2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-4-ylmethyl]-3-(4-trifluoromethoxyphenyl)ureais obtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=843 (M)⁺; m/z=640 (M-C₈H₄NO₂F₃)⁺;        m/z=485 (m/z=640-C₇H₇SO₂)⁺; m/z=203 (C₈H₄NO₂F₃ ⁺) base peak

EXAMPLE 2152-[5,6-dimethoxy-1-methyl-1H-indol-3-yl]-4-methyl-1H-pyrrolo[2,3-b]pyridine(A003338710 (P-31376-043-1))

a)2-[5,6-Dimethoxy-1-methyl-1H-indol-3-yl]-4-methyl-1H-pyrrolo[2,3-b]pyridineis prepared in the following manner:

1.3 cm³ of aqueous 5N potassium hydroxide solution are added to asolution of 0.13 g of2-[5,6-dimethoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-4-methyl-1H-pyrrolo[2,3-b]pyridinein 15 cm³ of methanol, at a temperature in the region of 20° C. Thereaction medium is refluxed for about 18 hours. The reaction mixture isevaporated under reduced pressure and the residue thus obtained isdissolved in 100 cm³ of ethyl acetate, transferred into a separatingfunnel and washed with 50 cm³ of distilled water. The aqueous phase isre-extracted with twice 50 cm³ of ethyl acetate, and the combinedorganic phases are washed successively with 50 cm³ of saturated aqueoussodium chloride solution and 50 cm³ of distilled water. The organicextract is dried over magnesium sulfate, filtered and evaporated underreduced pressure to give the crude compound, which is purified bychromatography on a Flash Chromabond RS 6 SiOH cartridge (3 g ofsilica). The elution was performed at a flow rate of 10 cm³/min with aheptane/isopropanol mixture (70/30 by volume). The fractions containingthe expected compound are combined and evaporated to give2-[5,6-dimethoxy-1-methyl-1H-indol-3-yl]-4-methyl-1H-pyrrolo[2,3-b]pyridinein the form of a pasty yellow solid (0.008 g, 8%), the characteristicsof which are as follows:

-   -   ¹H NMR spectrum (300 MHz, (CD₃)₂SO d6, δ in ppm): 2.55 (s, 3H);        3.81 (s, 3H); 3.86 (s, 3H); 3.89 (s, 3H); 6.73 (d, J=2.0 Hz,        1H); 6.82 (d, J=5.0 Hz, 1H); 7.10 (s, 1H); 7.47 (s, 1H); 7.75        (s, 1H); 7.98 (d, J=5.0 Hz, 1H); 11.65 (broad s, 1H).    -   Mass spectrum (ES): m/z=322 (M+H)⁺

b)2-[5,6-Dimethoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-4-methyl-1H-pyrrolo[2,3-b]pyridineis prepared in the following manner:

0.017 g of sodium hydride (60%) is added to a solution of 0.17 g of2-[5,6-dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-4-methyl-1H-pyrrolo[2,3-b]pyridinein 7 cm³ of anhydrous dimethylformamide, under an inert atmosphere ofargon at a temperature in the region of 20° C. After stirring for onehour at the same temperature, 0.025 cm³ of methyl iodide is added.Stirring is continued at this temperature for 4 hours. The reactionmixture is taken up in 50 cm³ of water and then extracted with 100 cm³of ethyl acetate, and the aqueous phase is re-extracted with 2×50 cm³ ofethyl acetate. The combined organic phases are washed successively with50 cm³ of saturated aqueous sodium chloride solution and then with 50cm³ of distilled water. After separation of the phases by settling, theorganic phase is dried over magnesium sulfate, filtered and thenconcentrated under reduced pressure. The residue obtained is purified ona Flash Chromabond RS 6 SiOH cartridge (3 g of silica). The elution wasperformed at a flow rate of 10 cm³/min with a dichloromethane/methanolmixture (95/05 by volume). The fractions containing the expectedcompound are combined and evaporated to give2-[5,6-dimethoxy-1-methyl-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-4-methyl-1H-pyrrolo[2,3-b]pyridinein the form of a beige-colored solid (0.130 g, 72%), the characteristicsof which are as follows:

-   -   Mass spectrum (ES): m/z=476 (M+H)⁺

c)2-[5,6-Dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-4-methyl-1H-pyrrolo[2,3-b]pyridineis prepared in the following manner:

0.475 g of 1-tert-butyloxycarbonyl-5,6-dimethoxyindol-3-boronic acid and4.5 cm³ of saturated aqueous sodium bicarbonate solution are addedsuccessively to a solution of 0.61 g of1-(toluene-4-sulfonyl)-1H-2-iodo-4-methylpyrrolo[2,3-b]pyridine in 14cm³ of anhydrous dimethylformamide. The reaction mixture is purged withargon using a sparge tube for 30 minutes, and 0.085 g oftetrakis(triphenylphosphine)palladium is added. The reaction medium isheated at 120° C. for 4 hours. After cooling, the reaction medium isfiltered through Celite and the filtrate is concentrated under reducedpressure. The oil obtained is taken up in 100 cm³ of water and extractedwith 2×100 cm³ of ethyl acetate, the organic phase is washedsuccessively with 2×50 cm³ of distilled water, 50 cm³ of saturatedaqueous sodium chloride solution and 50 cm³ of distilled water. Theorganic phase is dried over magnesium sulfate in the presence of animalcharcoal, filtered through Celite and then concentrated under reducedpressure. The residue obtained is purified on a Flash Chromabond RS 70SiOH cartridge (35 g of silica). The elution was performed at a flowrate of 10 cm³/minute with a heptane/isopropanol mixture (90/10 byvolume). The fractions containing the expected compound are combined andevaporated under reduced pressure.2-[5,6-Dimethoxy-1H-indol-3-yl]-1-(toluene-4-sulfonyl)-4-methyl-1H-pyrrolo[2,3-b]pyridineis thus obtained in the form of a beige-colored powder (0.17 g, 25%),the characteristics of which are as follows:

-   -   Mass spectrum (ES): m/z=462 (M+H)⁺

1-tert-Butyloxy-carbonyl-5,6-dimethoxyindol-3-boronic acid is preparedaccording to the process described in patent WO 03/000688 A1.

d) 1-(Toluene-4-sulfonyl)-1H-2-iodo-4-methylpyrrolo[2,3-b]pyridine isprepared in the following manner:

1.1 cm³ of n-BuLi (2.5 M in hexane) are added dropwise to a solution of0.5 g of 1-(toluene-4-sulfonyl)-1H-4-methylpyrrolo[2,3-b]pyridine in 8cm³ of anhydrous tetrahydrofuran, under an inert atmosphere of argon ata temperature in the region of −70° C. The reaction medium is stirred atthis same temperature for 1 hour, and a solution of 0.8 g of iodine in 4cm³ of tetrahydrofuran is then added dropwise. The reaction medium isstirred at −78° C. for 15 minutes. The reaction medium is stirred for 20hours. 50 cm³ of water are added and the reaction medium is extractedwith 3×100 cm³ of ethyl acetate. The organic phase is washedsuccessively with 100 cm³ of distilled water, 100 cm³ of saturatedaqueous sodium chloride solution, and 100 cm³ of distilled water. Theorganic phase is dried over magnesium sulfate, filtered and thenconcentrated under reduced pressure. The residue obtained is purified ona Macherey-Nagel cartridge (15 g of silica). The elution was performedat a flow rate of 10 cm³/minute with a (cyclohexane/ethyl acetate)mixture (75/25, V/V). The fractions containing the expected compound arecombined and evaporated under reduced pressure.1-(Toluene-4-sulfonyl)-1H-2-iodo-4-methylpyrrolo[2,3-b]pyridine is thusobtained in the form of a brown oil (0.61 g, 43%), the characteristicsof which are as follows:

-   -   Mass spectrum (EI): m/z=412 (M)⁺; m/z=348 (M-SO₂)⁺; m/z=221        (m/z=348-I)⁺; m/z=91; (C₇H₇)⁺ base peak

e) 1-(Toluene-4-sulfonyl)-1H-4-methylpyrrolo[2,3-b]pyridine is preparedin the following manner:

4.020 g of triphenylphosphine, 5.4 g of lithium chloride, 2.115 g ofbis(triphenylphosphine)palladium(II) chloride and 18.19 g oftetramethyltin are added to a solution of 10 g of1-(toluene-4-sulfonyl)-1H-4-iodo-pyrrolo[2,3-b]pyridine in 120 cm³ ofdimethylformamide, under an inert atmosphere of argon at a temperaturein the region of 20° C. The reaction medium is heated at a temperaturein the region of 120° C. for 20 hours. After cooling, the reactionmedium is concentrated under reduced pressure. The residue obtained istaken up in 200 cm³ of ethyl acetate and extracted with 2×50 cm³ ofwater. The organic phase is dried over magnesium sulfate in the presenceof animal charcoal, filtered through Celite and then concentrated underreduced pressure. The residue obtained is taken up in 50 ml of methanol.The solid obtained is filtered off through a sinter funnel. 5.1 g of1-(toluene-4-sulfonyl)-1H-4-methylpyrrolo[2,3-b]pyridine are thusobtained in the form of a yellow solid, the characteristics of which areas follows:

-   -   Mass spectrum (EI): m/z=286 (M)⁺; m/z=222 (M-SO₂)⁺ base peak;        m/z=91; (C₇H₇)⁺

f) 1-(Toluene-4-sulfonyl)-1H-4-iodo-pyrrolo[2,3-b]pyridine is preparedin the following manner:

10.6 g of para-toluenesulfonyl chloride and 0.331 g oftetrabutylammonium hydrogen sulfate are added to a solution of 12 g of1H-4-iodo-pyrrolo[2,3-b]pyridine in 425 cm³ of toluene, under an inertatmosphere of argon at a temperature in the region of 20° C., followedby dropwise addition of a 3.1N sodium hydroxide solution. The reactionmedium is stirred at a temperature in the region of 20° C. for 16 hours.After separation of the phases by settling, the organic phase is driedover sodium sulfate, filtered and then concentrated under reducedpressure. 19.3 g of1-(toluene-4-sulfonyl)-1H-4-iodo-pyrrolo[2,3-b]pyridine are thusobtained, the characteristics of which are as follows:

-   -   Mass spectrum (EI): m/z=398; (M)⁺; m/z=334 (M-S₂)⁺ base peak;        m/z=91 (C₇H₇)⁺

The compound 1H-4-iodo-pyrrolo[2,3-b]pyridine is prepared according tothe process described in Synlett, 2001, 5, 609-612.

EXAMPLE 216 Pharmaceutical Composition

Tablets corresponding to the following formula were prepared:

Compound of Example 94 0.2 g Excipient for a finished tablet weighing  1 g (excipient details: lactose, talc, starch, magnesium stearate).

EXAMPLE 217 Pharmaceutical Composition

Tablets corresponding to the following formula were prepared:

Compound of Example 101 0.2 g Excipient for a finished tablet weighing  1 g (excipient details: lactose, talc, starch, magnesium stearate).

EXAMPLE 218 Pharmaceutical Composition

Tablets corresponding to the following formula were prepared:

Compound of Example 193 0.2 g Excipient for a finished tablet weighing  1 g (excipient details: lactose, talc, starch, magnesium stearate)

1. A compound of formula (I):

wherein: R represents hydrogen or is selected from the values of R2 andR3, R1 represents alkenyl or alkyl substituted with —CO—NR7R8, —NR7R8,hydroxyl, or a halogen atom, R2 and R3, which may be identical ordifferent, represent alkyl or —O—alkyl optionally substituted with—CO—NR7R8, —NR7R8, alkoxy, alkoxy-NR7R8, free or esterified carboxyl, orphenyl, which is itself optionally substituted, R4, R5 and R6, which maybe identical or different, are selected from a hydrogen atom, a halogenatom and cyano, amino, and optionally substituted alkoxy or alkylradicals, R4 also being selected from the group consisting ofcarboxaldehyde —CH═O, formaldoxime —CH═N—OH and methylhydroxylamine—CH2NHOH; R7 and R8, which may be identical or different, are selectedfrom hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl,heterocycloalkyl, aryl and heteroaryl, which may be monocyclic orbicyclic, all these radicals being optionally substituted, oralternatively R7 and R8 form, with the nitrogen atom to which they areattached, an unsaturated or partially or totally saturated 3- to10-membered heterocyclic radical containing one or more hetero atomsselected from O, S, N and NR14, this radical being optionallysubstituted, all the above alkyl, alkenyl, cycloalkyl, cycloalkenyl,heterocycloalkyl, aryl and heteroaryl radicals, which may be monocyclicor bicyclic, and also the heterocyclic radical formed by R7 and R8 withthe nitrogen atom to which they are attached, being optionallysubstituted with one or more radicals, which may be identical ordifferent, selected from a halogen atom and cyano, hydroxyl, alkyl,alkoxy, alkylthio, nitro, oxo, cycloalkyl, heterocycloalkyl, aryl,heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl,heteroarylalkyl, —C(═O)—R9, —C(═O)—OR10, —N(R11)—C(═O)—R9,—N(R11)—C(═O)—OR10, —NR12R13, —C(═O)—NR12R13, —N(R11)—C(═O)—NR12R13,—S(O)n—R9, —N(R11)—S(O)n—R9, —S(O)n—NR12R13 and —N(R1 1)—S(O)n—NR12R13radicals, n represents an integer from 0 to 2, the latter alkyl, alkoxy,cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,heterocycloalkylalkyl, arylalkyl and heteroarylalkyl radicals themselvesbeing optionally substituted with one or more radicals, which may beidentical or different, selected from a halogen atom and hydroxyl,alkyl, alkoxy, —NR12R13, free or esterified carboxyl, CF3, nitro, cyano,phenyl and phenylalkyl radicals in which the phenyl radical is itselfoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and hydroxyl, alkyl, alkoxy,free or esterified carboxyl, CF3, nitro, cyano and pyridyl radicals; R9represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl,heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl orheteroarylalkyl, all these radicals being optionally substituted, R10represents the values of R9 or hydrogen, R11 represents hydrogen oroptionally substituted alkyl, R12 and R13, which may be identical ordifferent, represent hydrogen, acyl, alkyl, cycloalkyl,heterocycloalkyl, heteroaryl, SO2-heteroaryl, —SO2-alkyl, —SO2-phenyl,—CO—NH-phenyl and phenyl radicals, all these radicals being optionallysubstituted, or alternatively R12 and R13 form, with the nitrogen atomto which they are attached, an unsaturated or partially or totallysaturated 3- to 10-membered heterocyclic radical containing one or morehetero atoms selected from O, S, N and NR14, this radical beingoptionally substituted, R14 represents the values of R9, hydrogen, acylor free or esterified carboxyl, the radicals R9, R10, R11, R12, R13 andR14 above, and also the cyclic radical that may be formed by R12 and R13with the nitrogen atom to which they are attached, being optionallysubstituted with one or more radicals, which may be identical ordifferent, selected from a halogen atom and alkyl, alkyl-NH2,alkyl-NHCO2alkyl, NH2, NHCO2alkyl, hydroxyl, alkoxy, hydroxyalkoxy, freeor esterified carboxyl, CF3, SCF3, OCF3, OCHF2, SO2CF3, nitro, cyano,heterocycloalkyl, heteroaryl and phenyl radicals, the latter cyclicradicals themselves being optionally substituted with one or moreradicals, which may be identical or different, selected from a halogenatom and alkyl, hydroxyl, alkoxy, free or esterified carboxyl, CF3,SCF3, OCF3, OCHF2, SO2CF3, NH2, NHCO2alkyl, nitro and cyano radicals,all the above aryl, heteroaryl and heterocycloalkyl radicals being, inaddition, optionally substituted with an alkylenedioxy radical, all theabove alkyl, alkenyl, alkoxy or —O-alkyl and alkylthio radicals beinglinear or branched and containing no more than 6 carbon atoms, all theabove cycloalkyl radicals containing no more than 7 carbon atoms, allthe above aryl, heteroaryl and heterocycloalkyl radicals containing nomore than 10 carbon atoms; or a stereoisomer, a racemate, an enantiomeror a diastereoisomer of said compound of formula (I), or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 2. Thecompound of formula (I) according to claim 1, wherein: R representshydrogen or is selected from the values of R2 and R3, R1 representsalkenyl or alkyl substituted with —CO—NR7R8, —NR7R8, hydroxyl,or ahalogen atom, R2 and R3, which may be identical or different, representalkyl or —O-alkyl optionally substituted with —CO—NR7R8, —NR7R8, alkoxy,alkoxy-NR7R8, free or esterified carboxyl, or phenyl, which is itselfoptionally substituted, R4, R5 and R6, which may be identical ordifferent, are selected from a hydrogen atom, a halogen atom and cyano,amino, and optionally substituted alkoxy or alkyl radicals, R4 alsobeing selected from the group consisting of carboxaldehyde —CH═O,formaldoxime —CH═N—OH and methylhydroxylamine —CH2NHOH; R7 and R8, whichmay be identical or different, are selected from hydrogen, alkyl,alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl andheteroaryl, which may be monocyclic or bicyclic, all these radicalsbeing optionally substituted, or alternatively R7 and R8 form, with thenitrogen atom to which they are attached, an unsaturated or partially ortotally saturated 3- to 10-membered heterocyclic radical containing oneor more hetero atoms selected from O, S, N and NR14, this radical beingoptionally substituted, all the above alkyl, alkenyl, cycloalkyl,cycloalkenyl, heterocycloalkyl, aryl and heteroaryl radicals, which maybe monocyclic or bicyclic, and also the heterocyclic radical formed byR7 and R8 with the nitrogen atom to which they are attached, beingoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and cyano, hydroxyl, alkyl,alkoxy, alkylthio, nitro, oxo, cycloalkyl, heterocycloalkyl, aryl,heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl,heteroarylalkyl, —C(═O)—R9, —C(═O)—OR10, —N(R11)—C(═O)—R9,—N(R11)—C(═O)—OR10, —NR12R13, —C(═O)—NR12R13, —N(R11)—C(═O)—NR12R13,—S(O)n—R9, —N(R11)—S(O)n—R9, —S(O)n—NR12R13 and —N(R11)—S(O)n—NR12R13radicals, n represents an integer from 0 to 2, the latter alkyl, alkoxy,cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,heterocycloalkylalkyl, arylalkyl and heteroarylalkyl radicals themselvesbeing optionally substituted with one or more radicals, which may beidentical or different, selected from a halogen atom and hydroxyl,alkyl, alkoxy, —NR12R13, free or esterified carboxyl, CF3, nitro, cyano,phenyl and phenylalkyl radicals in which the phenyl radical is itselfoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and hydroxyl, alkyl, alkoxy,free or esterified carboxyl, CF3, nitro, cyano and pyridyl radicals; R9represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl,heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl orheteroarylalkyl, all these radicals being optionally substituted, R10represents the values of R9 or hydrogen, R11 represents hydrogen oroptionally substituted alkyl, R12 and R13, which may be identical ordifferent, represent hydrogen, acyl, alkyl, cycloalkyl, piperidyl,piperazinyl, pyrrolidinyl, azetidinyl, pyrazolyl, pyridyl, imidazolyl,pyrimidyl, thiazolyl, thiazolidinyl, —SO2-thienyl, —SO2-pyridyl,—SO2-alkyl, —SO2-phenyl, —CO—NH-phenyl and phenyl radicals, all theseradicals being optionally substituted, or alternatively R12 and R13form, with the nitrogen atom to which they are attached, an unsaturatedor partially or totally saturated 3- to 10-membered heterocyclic radicalcontaining one or more hetero atoms selected from O, S, N and NR14, thisradical being optionally substituted, R14 represents the values of R9 orhydrogen, acyl or free or esterified carboxyl, the radicals R9, R10,R11, R12, R13 and R14 above, and also the cyclic radical that may beformed by R12 and R13 with the nitrogen atom to which they are attached,being optionally substituted with one or more radicals, which may beidentical or different, selected from a halogen atom and alkyl,—CH2—NH2, —CH2—NHCO2alkyl, NH2, NHCO2alkyl, hydroxyl, alkoxy,hydroxyalkoxy, free or esterified carboxyl, CF3, SCF3, OCF3, OCHF2,SO2CF3, nitro, cyano, piperidyl, morpholinyl, piperazinyl, thienyl,pyridyl, imidazolyl, thiazolyl, thiazolidinyl and phenyl radicals, thelatter cyclic radicals themselves being optionally substituted with oneor more radicals, which may be identical or different, selected from ahalogen atom and alkyl, hydroxyl, alkoxy, free or esterified carboxyl,CF3, SCF3, OCF3, OCHF2, SO2CF3, NH2, NHCO2alkyl, nitro and cyanoradicals, all the above aryl, heteroaryl and heterocycloalkyl radicalsbeing, in addition, optionally substituted with an alkylenedioxyradical, all the above alkyl, alkenyl, alkoxy or —O-alkyl and alkylthioradicals being linear or branched and containing no more than 6 carbonatoms, all the above cycloalkyl radicals containing no more than 7carbon atoms, all the above aryl, heteroaryl and heterocycloalkylradicals containing no more than 10 carbon atoms; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.3. The compound of formula (I):

wherein: R represents hydrogen or is selected from the values for R2 andR3, R1 represents alkenyl or alkyl optionally substituted with—CO—NR7R8, —NR7R8, free or esterified carboxyl, hydroxyl, alkoxy or ahalogen atom, one of R2 and R3represents alkyl or —O-alkyl optionallysubstituted with —CO—NR7R8, —NR7R8, alkoxy, alkoxy—NR7R8, free oresterified carboxyl, or phenyl which is itself optionally substituted,and the other of R2 and R3 independently represents alkyl or —O-alkylsubstituted with —CO—NR7R8, —NR7R8. alkoxy. alkoxy-NR7R8. free oresterified carboxyl. or phenyl which is itself optionally substituted;R4, R5 and R6, which may be identical or different, are selected from ahydrogen atom, a halogen atom and the radicals: cyano, amino, andoptionally substituted alkoxy or alkyl, R7 and R8, which may beidentical or different, are selected from hydrogen, alkyl, alkenyl,cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, whichmay be monocyclic or bicyclic, all these radicals being optionallysubstituted, or alternatively R7 and R8 form, with the nitrogen atom towhich they are attached, an unsaturated or partially or totallysaturated 3- to 10-membered heterocyclic radical containing one or morehetero atoms selected from O, S, N and NR14, this radical beingoptionally substituted, all the above radicals: alkyl, alkenyl,cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, whichmay be monocyclic or bicyclic, and also the heterocyclic radical formedby R7 and R8 with the nitrogen atom to which they are attached, beingoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and the radicals: cyano,hydroxyl, alkyl, alkoxy, alkylthio, nitro, oxo, cycloalkyl,heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl,heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, —C(═O)—R9,—C(═O)—OR10, —N(R11)—C(═O)—R9, —N(R11)—C(═O)—OR10, —NR12R13,—C(═O)—NR12R13, —N(R11)—C(═O)—NR12R13, —S(O)n—R9, —N(R11)—S(O)n—R9,—S(O)n—NR12R13 and —N(R11)—S(O)n—NR12R13, n represents an integer from 0to 2, the latter alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl,heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl andheteroarylalkyl radicals themselves being optionally substituted withone or more radicals, which may be identical or different, selected froma halogen atom and hydroxyl, alkyl, alkoxy, —NR12R13, pyrrolidinyl, freeor esterified carboxyl, CF₃, nitro, cyano, and phenyl and phenylalkylradicals in which the phenyl radical is itself optionally substitutedwith one or more radicals, which may be identical or different, selectedfrom a halogen atom and hydroxyl, alkyl, alkoxy, free or esterifiedcarboxyl, CF₃, nitro, cyano and pyridyl radicals, R9 represents alkyl,alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, or heteroarylalkyl,all these radicals being optionally substituted, R10 represents thevalues of R9 or hydrogen, R11 represents hydrogen or optionallysubstituted alkyl, R12 and R13, which may be identical or different,represent hydrogen, acyl, alkyl, cycloalkyl and phenyl radicals, theseradicals being optionally substituted, or alternatively R12 and R13form, with the nitrogen atom to which they are attached, an unsaturatedor partially or totally saturated 3- to 10-membered heterocyclic radicalcontaining one or more hetero atoms selected from O, S, N and NR14, thisradical being optionally substituted, R14 represents the values for R9or hydrogen, acyl or free or esterified carboxyl, the radicals R9, R10,R11, R12, R13 and R14 above being optionally substituted with one ormore radicals, which may be identical or different, selected from ahalogen atom and the radicals: alkyl, hydroxyl, alkoxy, hydroxyalkoxy,free or esterified carboxyl, CF₃, nitro, cyano and phenyl, itselfoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and the radicals: alkyl,hydroxyl, alkoxy, free or esterified carboxyl, CF₃, nitro and cyano, allthe above aryl, heteroaryl and heterocycloalkyl radicals above being, inaddition, optionally substituted with an alkylenedioxy radical, all thealkyl, alkenyl, alkoxy or —O-alkyl and alkylthio radicals above beinglinear or branched and containing no more than 6 carbon atoms, all thecycloalkyl radicals above containing no more than 7 carbon atoms, allthe above aryl, heteroaryl and heterocycloalkyl radicals containing nomore than 10 carbon atoms; or a stereoisomer, a racemate, an enantiomeror a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 4. Thecompound of formula (I) according to claim 1, wherein R2 and R3, whichmay be identical or different, represent —O-alkyl containing no morethan 4 carbon atoms, optionally substituted with —CO—NR7R8, —NR7R8,alkoxy, alkoxy- NR7R8 or free or esterified carboxyl; R, R1, R4, R5, R6,R7 and R8 are as defined in claim 1; or a stereoisomer, a racemate, anenantiomer or a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 5. Thecompound of formula (I) according to claim 1, wherein R2 and R3, whichmay be identical or different, represent —O-alkyl containing no morethan 4 carbon atoms, optionally substituted with —CO—NR7R8, —NR7R8,alkoxy, or alkoxy-NR7R8; R, R1, R4, R5, R6, R7 and R8 are as defined inclaim 1; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 6. The compound of formula(I) according to claim 1, wherein R2 and R3, which may be identical ordifferent, represent —O-alkyl containing no more than 4 carbon atoms,optionally substituted with —CO—NR7R8 or —NR7R8; R, R1, R4, R5, R6, R7and R8 are as defined in claim l; or a stereoisomer, a racemate, anenantiomer or a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 7. Thecompound of formula (I) according to claim 1, wherein R1 representsalkyl substituted with —CO—NR7R8, —NR7R8, hydroxyl, or a halogen atom;R, R2, R3, R4, R5, R6, R7 and R8 are as defined in claim 1; or astereoisomer, a racemate, an enantiomer or a diastereoisomer of saidcompound of formula (I); or a pharmaceutically acceptable addition saltof said compound of formula (I) with a mineral or organic acid or amineral or organic base.
 8. The compound of formula (I) according toclaim 1, wherein R1 represents alkyl containing no more than 4 carbonatoms, substituted with —CO—NR7R8, —NR7R8, or hydroxyl; R, R2, R3, R4,R5, R6, R7, and R8 are as defined in claim 1; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.9. The compound of formula (I) according to claim 1, wherein R1represents alkyl containing no more than 4 carbon atoms, substitutedwith —CO—NR7R8, —NR7R8 or hydroxyl; R, R2, R3, R4, R5, R6, R7, and R8are as defined in claim 1; or a stereoisomer, a racemate, an enantiomeror a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 10. Thecompound of formula (I) according to claim 1, wherein R1 representsalkyl containing no more than 4 carbon atoms, substituted with —CO—NR7R8or —NR7R8; R, R2, R3, R4, R5, R6, R7, and R8 are as defined in claim 1;or a stereoisomer, a racemate, an enantiomer or a diastereoisomer ofsaid compound of formula (I); or a pharmaceutically acceptable additionsalt of said compound of formula (I) with a mineral or organic acid or amineral or organic base.
 11. The compound of formula (I) according toclaim 1, wherein R1 represents alkyl containing no more than 4 carbonatoms, substituted with NR7R8, R, R2, R3, R4, R5, R6, R7, and R8 are asdefined in claim 1; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 12. The compound offormula (I) according to claim 1, wherein R4, R5 and R6 are such thatone represents hydrogen and the others, which may be identical ordifferent, are selected from a hydrogen atom, a halogen atom and theradicals: cyano, amino or alkyl which may be optionally substituted; R,R1, R2, and R3 are as defined in claim 1; or a stereoisomer, a racemate,an enantiomer or a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 13. Thecompound of formula (I) according to claim 1, wherein R5 and R6, whichmay be identical or different, are selected from a hydrogen atom and ahalogen atom, R4, which may be identical to or different from R5 and R6,is selected from a halogen atom and amino, carboxaldehyde —CH═O,formaldoxime —CH═N—OH, methylhydroxylamine —CH2NHOH and alkyl radicals,optionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and cyano, hydroxyl, alkoxy,cycloalkyl, heterocycloalkyl, phenyl, heteroaryl and —NR12R13 radicals;R, R1, R2, R3, R12 and R13 are as defined in claim 1; or a stereoisomer,a racemate, an enantiomer or a diastereoisomer of said compound offormula (I); or a pharmaceutically acceptable addition salt of saidcompound of formula (I) with a mineral or organic acid or a mineral ororganic base.
 14. The compound of formula (I) according to claim 1,wherein R4, R5 and R6 represent hydrogen or are such that two of themrepresent hydrogen and the third represents a halogen atom or a cyanoradical; R, R1, R2, and R3 are as defined in claim 1; or a stereoisomer,a racemate, an enantiomer or a diastereoisomer of said compound offormula (I); or a pharmaceutically acceptable addition salt of saidcompound of formula (I) with a mineral or organic acid or a mineral ororganic base.
 15. The compound of formula (I) according to claim 1,wherein R4, R5 and R6 represent hydrogen; R, R1, R2, and R3 are asdefined in claim 1; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 16. The compound offormula (I) according to claim 1, wherein R4, R5 and R6 are such thattwo of them represent hydrogen and the third represents a halogen atomor a cyano radical; R, R1, R2, and R3 are as defined in claim 1; or astereoisomer, a racemate, an enantiomer or a diastereoisomer of saidcompound of formula (I); or a pharmaceutically acceptable addition saltof said compound of formula (I) with a mineral or organic acid or amineral or organic base.
 17. The compound of formula (I) according toclaim 1, wherein R4, R5 and R6 are such that two of them representhydrogen and the third represents a halogen atom; R, R1, R2, and R3 areas defined in claim 1; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 18. The compound offormula (I) according to claim 1, wherein R4, R5 and R6 are such thattwo of them represent hydrogen and the third represents a chlorine orfluorine atom; R, R1, R2, and R3 are as defined in claim 1; or astereoisomer, a racemate, an enantiomer or a diastereoisomer of saidcompound of formula (I); or a pharmaceutically acceptable addition saltof said compound of formula (I) with a mineral or organic acid or amineral or organic base.
 19. The compound of formula (I) according toclaim 1, wherein R4, R5 and R6 are such that two of them representhydrogen and the third represents a cyano radical; R, R1, R2, and R3 areas defined in claim 1; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 20. The compound offormula (I) according to claim 1, wherein R6 represents hydrogen; R, R1,R2, R3, R4, and R5 are as defined in claim 1; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.21. The compound of formula (I) according to claim 1, wherein R5 and R6represent hydrogen and R4 represents a halogen atom or a cyano radical;R, R1, R2, and R3 are as defined in claim 1; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.22. The compound of formula (I) according to claim 1, wherein R4 and R6represent hydrogen and R5 represents a fluorine atom; R, R1, R2, and R3are as defined in claim 1; or a stereoisomer, a racemate, an enantiomeror a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 23. Thecompound of formula (I) according to claim 1, wherein R, R1, R2, R3, R4,R5 and R6 are as defined in claim 1, wherein the radical —NR12R13 issuch that R12 and R13, which may be identical or different, represent ahydrogen atom; and acyl, alkyl, cycloalkyl, piperidyl, piperazinyl,pyrrolidinyl, azetidinyl, pyrazolyl, pyridyl, imidazolyl, pyrimidyl,thiazolyl, thiazolidinyl, —SO2-thienyl, —SO2-pyridyl, —SO2-alkyl,—SO2-phenyl, —CO—NH-phenyl and phenyl radicals, all these radicals beingoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and the following radicals:alkyl; CH2—NH2; CH2—NHCO2alkyl; NH2; NHCO2alkyl; hydroxyl; alkoxy;hydroxyalkoxy; free or esterified carboxyl; CF3; SCF3; OCF3; OCHF2;SO2CF3; nitro; cyano; thienyl; piperidyl; morpholino, which is itselfoptionally substituted with one or two alkyl radicals; and phenyl, whichis itself optionally substituted with one or more radicals, which may beidentical or different, selected from a halogen atom and alkyl,hydroxyl, alkoxy, free or esterified carboxyl, CF3, SCF3, OCH3, OCHF2,SO2CF3, NH2, NHCO2alkyl, nitro and cyano radicals; or alternatively R12and R13 form, with the nitrogen atom to which they are attached, anunsaturated or partially or totally saturated 3- to 10-memberedheterocyclic radical containing one or more hetero atoms selected fromO, S, N and NR11, this radical being optionally substituted with one ormore radicals, which may be identical or different, selected from ahalogen atom and the following radicals: alkyl; —CH2—NH2;CH2—NHCO2alkyl; NH2; NHCO2alkyl; hydroxyl; alkoxy; hydroxyalkoxy; freeor esterified carboxyl; CF3; SCF3; OCF3; OCHF2; SO2CF3; nitro; cyano;piperidyl; morpholinyl; piperazinyl; thienyl; pyridyl, imidazolyl,thiazolyl, thiazolidinyl and phenyl radicals, which are themselvesoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and alkyl, hydroxyl, alkoxy,free or esterified carboxyl, CF3, SCF3, NH2, NHCO2alkyl, nitro and cyanoradicals; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 24. The compound offormula (I) according to claim 1, wherein R, R1, R2, R3, R4, R5 and R6are as defined in claim 1, and R7 and R8, which may be identical ordifferent, are selected from hydrogen, alkyl, cycloalkyl, phenyl,heterocycloalkyl and heteroaryl, which may be monocyclic or bicyclic,all these radicals being optionally substituted, or alternatively R7 andR8 form, with the nitrogen atom to which they are attached, anunsaturated or partially or totally saturated 3- to 10-memberedheterocyclic radical containing one or more hetero atoms selected fromO, S, N and NR14, this radical being optionally substituted, all theabove radicals: alkyl, cycloalkyl, phenyl, heterocycloalkyl andheteroaryl, which may be monocyclic or bicyclic, and also theheterocyclic radical formed by R7 and R8 with the nitrogen atom to whichthey are attached, being optionally substituted with one or moreradicals, which may be identical or different, selected from a halogenatom and the radicals: hydroxyl, alkyl, alkoxy, alkylthio, nitro, oxo,cycloalkyl, phenyl, heterocycloalkyl, heteroaryl, —C(═O)—R9,—C(═O)—OR10, —N(R11)—C(═O)—R9, —N(R11)—C(═O)—OR10, —NR12R13,—C(═O)—NR12R13, and —N(R11)—C(═O)—NR12R13, the latter alkyl, alkoxy,cycloalkyl, phenyl, heterocycloalkyl and heteroaryl radicals themselvesbeing optionally substituted with one or more radicals, which may beidentical or different, selected from a halogen atom and the radicals:hydroxyl, alkyl, alkoxy, —NR12R13, free or esterified carboxy,pyrrolidinyl, phenyl and phenylalkyl in which the phenyl radical isitself optionally substituted with one or more radicals, which may beidentical or different, selected from a halogen atom and the radicals:hydroxyl, alkyl, alkoxy, free or esterified carboxy, CF₃, nitro, cyanoand pyridyl, R9 represents alkyl, cycloalkyl, phenyl, heterocycloalkylor heteroaryl, all these radicals being optionally substituted, R10represents the values of R9 or hydrogen, R11 represents hydrogen oroptionally substituted alkyl, R12 and R13, which may be identical ordifferent, represent hydrogen, acyl, alkyl, cycloalkyl and phenyl, theseradicals being optionally substituted, or alternatively R12 and R13form, with the nitrogen atom to which they are attached, an unsaturatedor partially or totally saturated 3- to 10-membered heterocyclic radicalcontaining one or more hetero atoms selected from O, S, N and NR11, theradical being optionally substituted, R14 represents hydrogen, acyl,free or esterified carboxyl, alkyl, cycloalkyl or phenyl, optionallysubstituted, the radicals R9, R10, R11, R12, R13 and R14 above beingoptionally substituted with one or more radicals, which may be identicalor different, selected from a halogen atom and the radicals: alkyl,hydroxyl, alkoxy, hydroxyalkoxy, free or esterified carboxyl, CF₃,nitro, cyano and phenyl, itself optionally substituted with one or moreradicals, which may be identical or different, selected from a halogenatom and the radicals: alkyl, hydroxyl, alkoxy, free or esterifiedcarboxyl, CF₃, nitro and cyano, all the phenyl and heteroaryl radicalsabove being, in addition, optionally substituted by a dioxol radical,all the above alkyl, alkenyl, alkoxy or —O-alkyl and alkylthio radicalsbeing linear or branched and containing no more than 4 carbon atoms, allthe above cycloalkyl radicals containing no more than 7 carbon atoms,all the above heteroaryl and heterocycloalkyl radicals containing nomore than 10 carbon atoms; or a stereoisomer, a racemate, an enantiomeror a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 25. Thecompound of formula (I) according to claim 1, wherein R, R1, R2, R3, R4,R5 and R6 are as defined in claim 1; and R7 and R8, which may beidentical or different, are selected from hydrogen, cycloalkyl,optionally substituted alkyl, optionally substituted phenyl,heterocycloalkyl and monocyclic or bicyclic heteroaryl, which may beoptionally substituted, or alternatively R7 and R8 form, with thenitrogen atom to which they are attached, an optionally substitutedheterocyclic radical containing one or more hetero atoms, all the alkyl,phenyl and heterocyclic radicals above, and also the heterocyclicradical that R7 and R8 may form with the nitrogen atom to which they areattached, being optionally substituted with one or more radicalsselected from a halogen atom and the radicals: hydroxyl; oxo; nitro;cycloalkyl; alkoxy; OCF₃; hydroxyalkoxy; alkylthio; acyl; free oresterified carboxyl; optionally substituted phenyl; optionallysubstituted amino; alkyl optionally substituted with one or moreradicals selected from a halogen atom and the radicals: hydroxyl,alkoxy, pyrrolidinyl, phenyl and amino, themselves optionallysubstituted; and pyrrolidinyl, piperidyl, pyridyl and piperazinyl,themselves optionally substituted with one or more radicals selectedfrom the radicals: hydroxyl, alkyl, alkoxy, free or esterified carboxyl,phenyl and phenylalkyl, themselves optionally substituted, the aminoradicals being optionally substituted with one or two radicals, whichmay be identical or different, selected from alkyl, hydroxyalkyl,alkoxyalkyl, acyl, phenyl and phenylalkyl, themselves optionallysubstituted, the phenyl and phenylalkyl radicals being optionallysubstituted with one or more radicals selected from a halogen atom andthe radicals: hydroxyl, alkyl, alkoxy, CF₃, free or esterified carboxyl,pyridyl and dioxol, all the alkyl and alkoxy radicals being linear orbranched and containing no more than 4 carbon atoms; or a stereoisomer,a racemate, an enantiomer or a diastereoisomer of said compound offormula (I); or a pharmaceutically acceptable addition salt of saidcompound of formula (I) with a mineral or organic acid or a mineral ororganic base.
 26. The compound of formula (I) according to claim 1,wherein R, R1, R2, R3, R4, R5 and R6 are as defined in claim 1, and R7and R8, which may be identical or different, are selected from hydrogenand alkyl, cycloalkyl, phenyl and heterocyclic radicals selected fromthe group consisting of pyrrolidinyl, piperidyl, pyrimidinyl, thienyl,thiazolyl, pyran, furyl, tetrahydrofuryl, tetrahydrofuran-2-yl,imidazolinyl, piperazinyl, indolyl, pyrrole, benzopyran, quinolyl,pyridyl, purinyl and morpholinyl, these radicals being optionallysubstituted, or alternatively R7 and R8 form, with the nitrogen atom towhich they are attached, a heterocyclic radical selected frompyrrolidinyl, imidazolyl, morpholinyl, piperazinyl, piperidyl,thiazolyl, diazepine, spiro [4.5]decane, pyrrolyl, dihydropyrrolyl,tetrahydropyrrolyl, tetrahydropyrrolo [3,4-c]pyrrolyl, piperidinyl,indolinyl, pyrindolinyl, tetrahydroquinolyl, thiazolidinyl,naphthyridyl, azetidine or quinazolinyl radicals, these radicals allbeing optionally substituted, all the above alkyl, phenyl andheterocyclic radicals being optionally substituted with one or moreradicals selected from a halogen atom and the radicals: hydroxyl; oxo;nitro; cycloalkyl; alkoxy; OCF₃; hydroxyalkoxy; alkylthio; acyl; free oresterified carboxyl; optionally substituted phenyl; optionallysubstituted amino; alkyl optionally substituted with one or moreradicals selected from a halogen atom and the radicals: hydroxyl,alkoxy, pyrrolidinyl, phenyl and amino, themselves optionallysubstituted; and pyrrolidinyl, piperidyl, pyridyl and piperazinyl,themselves optionally substituted with one or more radicals selectedfrom the radicals: hydroxyl, alkyl, alkoxy, free or esterified carboxyl,phenyl and phenylalkyl, themselves optionally substituted, the aminoradicals being optionally substituted with one or two radicals, whichmay be identical or different, selected from alkyl, hydroxyalkyl,alkoxyalkyl, acyl, phenyl and phenylalkyl, themselves optionallysubstituted, the phenyl and phenylalkyl radicals being optionallysubstituted with one or more radicals selected from a halogen atom andthe radicals: hydroxyl, alkyl, alkoxy, CF₃, free or esterified carboxyl,pyridyl and dioxol, all the alkyl and alkoxy radicals being linear orbranched and containing no more than 4 carbon atoms; or a stereoisomer,a racemate, an enantiomer or a diastereoisomer of said compound offormula (I); or a pharmaceutically acceptable addition salt of saidcompound of formula (I) with a mineral or organic acid or a mineral ororganic base.
 27. The compound of formula (I) according to claim 1,wherein R, R1, R2, R3, R4, R5 and R6 are as defined in claim 1, and R7and R8, which may be identical or different, are selected from hydrogen,cycloalkyl radicals and alkyl, phenyl and heterocyclic radicals selectedfrom the group consisting of pyrrolidinyl, piperidyl, furyl,tetrahydrofuryl, tetrahydrofuran-2-yl, imidazolinyl, piperazinyl,indolyl, pyrrolyl, benzopyranyl, benzopyran-8-carboxylic, pyridyl,purinyl and morpholinyl, all these radicals being optionallysubstituted, or alternatively R7 and R8 form, with the nitrogen atom towhich they are attached, a heterocyclic radical selected frompyrrolidinyl, imidazolyl, morpholinyl, piperazinyl, piperidyl,thiazolyl, diazepine, spiro [4.5]decane, pyrrolyl, dihydropyrrolyl,tetrahydropyrrolyl and tetrahydropyrrolo [3,4-c]pyrrolyl radicals, allthese radicals being optionally substituted, all the above alkyl, phenyland heterocyclic radicals that R7 and R8 represent or that R7 and R8 mayform with the nitrogen atom to which they are attached being optionallysubstituted with one or more radicals selected from the radicals:hydroxyl; oxo; cycloalkyl; alkoxy; hydroxyalkoxy; alkylthio; CO-alkyl;—CO-furyl; free or esterified carboxyl; optionally substituted phenyl;alkyl optionally substituted with a radical selected from hydroxyl,alkoxy, pyrrolidinyl, optionally substituted phenyl and amino optionallysubstituted with one or two radicals selected from alkyl and optionallysubstituted phenyl; amino optionally substituted with one or tworadicals, which may be identical or different, selected from alkyl,hydroxyalkyl, alkoxyalkyl, CO-alkyl and phenyl, itself optionallysubstituted; pyrrolidinyl, piperidyl, pyridyl and piperazinyl,optionally substituted with one or more radicals selected from hydroxyl,alkyl, alkoxy, free or esterified carboxyl, phenylalkyl and optionallysubstituted phenyl, all the phenyl radicals being optionally substitutedwith one or more radicals, which may be identical or different, selectedfrom a halogen atom and the radicals: hydroxyl, alkyl, alkoxy, CF₃, freeor esterified carboxyl, pyridyl and dioxol; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.28. The compound of formula (I) according to claim 1, wherein R, R1, R2,R3, R4, R5 and R6 are as defined in claim 1, and R7 and R8, which may beidentical or different, are selected from the following radicals:hydrogen; benzopyran; pyridyl itself optionally substituted withhydroxyl; piperidyl optionally substituted with alkyl, itself optionallysubstituted with phenyl; purinyl; alkyl optionally substituted with oneor more radicals selected from hydroxyl; alkoxy; alkylthio; pyridyl;imidazolinyl, indolyl; pyrrolyl; furyl; tetrahydrofuryl; aminooptionally substituted with one or two radicals, which may be identicalor different, selected from alkyl, hydroxyalkyl, alkoxyalkyl and phenyl,itself optionally substituted with alkyl; pyrrolidinyl, itselfoptionally substituted with an alkyl radical; piperidyl, itselfoptionally substituted with alkyl or phenylalkyl; piperazinyl, itselfoptionally substituted with alkyl; phenyl optionally substituted withdioxol or free or esterified carboxyl; phenyl optionally substitutedwith one or more radicals selected from alkoxy, piperidyl andpiperazinyl, itself optionally substituted with an alkyl radical; oralternatively R7 and R8 form, with the nitrogen atom to which they areattached, a heterocyclic radical selected from the following radicals:imidazolyl; dihydropyrrolyl; 1,4-dioxa-8-azaspiro [4.5]decane;thiazolyl; tetrahydropyrrolo [3,4-c]pyrrol-2-one; tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione; pyrrolidinyl optionally substituted with aradical selected from pyridyl; amino, itself optionally substituted withan alkyl radical and an acyl radical; and alkyl, itself optionallysubstituted with a radical selected from hydroxyl, alkoxy, pyrrolidinyland amino, itself optionally substituted with a phenyl radical;morpholinyl optionally substituted with one or more alkyl radicals;piperazinyl optionally substituted with one or more radicals, which maybe identical or different, selected from the radicals: oxo; cycloalkyl;acyl; carboxyl; pyridyl; alkyl containing no more than 4 carbon atoms,itself optionally substituted with a radical: hydroxyl, alkoxy,hydroxyalkoxy containing no more than 4 carbon atoms and phenyl, itselfoptionally substituted with a dioxol radical; phenyl, itself optionallysubstituted with one or more radicals selected from a halogen atom andhydroxyl, alkoxy and CF₃ radicals; piperidyl optionally substituted withone or more substituents selected from hydroxyl, alkyl, hydroxyalkyl andpiperidyl; diazepine or perhydro-1,4-diazepine optionally substitutedwith an alkyl radical; itself optionally substituted with pyrrolidinyl;or a stereoisomer, a racemate, an enantiomer or a diastereoisomer ofsaid compound of formula (I); or a pharmaceutically acceptable additionsalt of said compound of formula (I) with a mineral or organic acid or amineral or organic base.
 29. The compound of formula (I) according toclaim 1, wherein R, R1, R2, R3, R4, R5 and R6 are as defined in claim 1,and R7 and R8, which may be identical or different, are selected fromthe radicals: hydrogen, alkyl, itself optionally substituted with apyrrolidinyl or piperidyl radical and phenyl, itself optionallysubstituted with one or more radicals selected from the piperazinylradical, itself optionally substituted with an alkyl radical, oralternatively R7 and R8 form, together with the nitrogen atom to whichthey are attached, a radical selected from the following radicals:morpholinyl; thiazolyl; diazepine or perhydro-1,4-diazepine optionallysubstituted with an alkyl radical;1-tetrahydropyrrolo[3,4-c]pyrrol-2-one; piperazinyl optionallysubstituted with one or more radicals, which may be identical ordifferent, selected from the radicals: oxo and alkyl, itself optionallysubstituted with a hydroxyl, alkoxy or hydroxyalkoxy radical; piperidyloptionally substituted with hydroxyl, alkyl, hydroxyalkyl or piperidyl;the alkyl and alkoxy radicals containing no more than 4 carbon atoms; ora stereoisomer, a racemate, an enantiomer or a diastereoisomer of saidcompound of formula (I); or a pharmaceutically acceptable addition saltof said compound of formula (I) with a mineral or organic acid or amineral or organic base.
 30. The compound of formula (I) according toclaim 26, wherein: R and R6 represent a hydrogen atom, R1 representsalkyl containing no more than 2 carbon atoms, substituted with —CO—NR7R8or —NR7R8, R2 and R3, which may be identical or different, represent—O-alkyl containing no more than 3 carbon atoms, optionally substitutedwith —CO—NR7R8 or —NR7R8, R4 and R5 are such that one representshydrogen and the other represents a halogen atom or a cyano radical, R7and R8 are as defined in claim 26; or a stereoisomer, a racemate, anenantiomer or a diastereoisomer of said compound of formula (I); or apharmaceutically acceptable addition salt of said compound of formula(I) with a mineral or organic acid or a mineral or organic base.
 31. Thecompound of formula (I) according to claim 1, wherein R, R1, R2, R3, R4,R5, R6, R7 and R8 are as defined in claim 1, wherein R7 and R8 do notboth represent hydrogen; or a stereoisomer, a racemate, an enantiomer ora diastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 32. The compound offormula (I) according to claim 1, wherein R, R1, R2, R3, R4, R5 and R6are as defined in claim 1, and R7 and R8 are such that either one of R7and R8 represents hydrogen or alkyl and the other is selected from thevalues for R7 and R8 as defined in claim 1, or R7 and R8 form, with thenitrogen atom to which they are attached, a heterocyclic radical asdefined in claim 1; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 33. A compound selectedfrom the group consisting of: 2—{5,6-dimethoxy-1-[2-(4-methylpiperazin-1 -yl)ethyl]-1H-indol-3 -yl}-1H-pyrrolo[2,3- b]pyridine; 2-(4-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperazin-1-yl)ethanol; 2-(1-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperid-4-yl)ethanol;1′-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}-[1,4′]bipiperidyl;1-{2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]ethyl}piperid-3-ol;2-{5,6-dimethoxy-1-[2-(4-methylperhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]-1-(4-hydroxypiperid-1-yl)ethanone;2-[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone;4-{[5,6-dimethoxy-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one;4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine;2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile;4-chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3-b]pyridine;2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyrid-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperid-4-yl)ethanol; 4-chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H- pyrrolo[2,3-b]pyridine;2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile;2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine;2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3 -b]pyridine; 2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridine;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-morpholin-4-ylethanone;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-(4-methyl[1,4]diazepan-1-yl)ethanone;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]acetamide;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)ethanone;1-{4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl}-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]ethanone;(3aS,6aS)-5-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyrid-2-yl)-1H-indol-6-yloxy]acetyl}hexahydropyrrolo[3,4-c]pyrrol-1-one trifluoroacetate;2-{5-Methoxy-1-methyl-6-[3-(4-methylperhydro-1,4-diazepin-1-yl)propoxy]-1H-indol-3-yl}- 1H-pyrrolo[2,3-b]pyridine;4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperid-1-yl)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;4-Chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine; and4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine; or a stereoisomer, a racemate, an enantiomer ora diastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 34. A compound selectedfrom the group consisting of:2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;2-(4-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperazin-1-yl)ethanol; 2-(1-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-4- yl)ethanol;1′-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}-[1,4′]bipiperidinyl;1-{2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl}piperidin-3-ol;2-{5,6-Dimethoxy-1-[2-(4-methylperhydro-1,4-diazepin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(4-hydroxypiperidin-1-yl)ethanone;2-[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiazolidin-3-ylethanone;4-{[5,6-Dimethoxy-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl}-1-methylpiperazin-2-one; 4-Chloro-2-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine;2-(5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile;4-Chloro-2-[5,6-dimethoxy-1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-1H-pyrrolo[2,3 -b]pyridine;2-(1-{2-[3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxyindol-1-yl]ethyl}piperidin-4-yl)ethanol;4-Chloro-2-{5,6-dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H- pyrrolo[2,3-b]pyridine;2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-1H-pyrrolo[2,3 -b]pyridine-4-carbonitrile;2-{5,6-Dimethoxy-1-methyl-1H-indol-3-yl)-5-fluoro-1H-pyrrolo[2,3-b]pyridine;2-[5,6-Dimethoxy-1-[2-morpholin-4-ylethyl)-1H-indol-3-yl]-5-fluoro-1H-pyrrolo[2,3 -b]pyridine;2-{5,6-Dimethoxy-1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indol-3-yl}-5-fluoro-1H-pyrrolo[2,3-b]pyridine;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-morpholin-4-ylethanone;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methyl-[1,4]diazepan-1-yl)ethanone; 2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]acetamide;2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]-1-(4-methylpiperazin-1-yl)ethanone; 1-{4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl}-2-[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]ethanone;(3aS,6aS)-5-{2-[5-Methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yloxy]acetyl}hexahydropyrrolo[3,4-c]pyrrol-1-one trifluoroacetate;2-{5-Methoxy-1-methyl-6-[3-(4-methylperhydro-1,4-diazepin-1-yl)propoxy]-1H-indol-3-yl}- 1H-pyrrolo[2,3-b]pyridine;4-Chloro-2-{1-methyl-1-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;4-Chloro-2-{1-methyl-5-methoxy-6-[2-(4-piperidylpiperidin-1-yl)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine;4-Chloro-2-{5-methoxy-1-methyl-6-[2-(2-pyrrolidinethylamino)ethoxy]-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine; and4-Chloro-2-{1-methyl-5-methoxy-6-[2-(2-piperidinethylamino)ethoxy-1H-indol-3-yl}-1H-pyrrolo[2,3-b]pyridine; or a stereoisomer, a racemate, an enantiomer ora diastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 35. A pharmaceuticalcomposition comprising at least one compound according to claim 1 andone or more pharmaceutically acceptable excipients.
 36. A pharmaceuticalcomposition comprising at least one compound according to claim 33 andone or more pharmaceutically acceptable excipients.
 37. A pharmaceuticalcomposition comprising at least one compound according to claim 34 andone or more pharmaceutically acceptable excipients.
 38. Thepharmaceutical composition according to claim 35 further comprising oneor more antiproliferative agents.
 39. The compound of formula (I)according to claim 3, wherein one of R2 and R3 represents —O-alkylcontaining no more than 4 carbon atoms, substituted with —CO—NR7R8,—NR7R8, alkoxy, alkoxy-NR7R8 or free or esterified carboxyl; R, R1, R4,R5, R6, R7 and R8 are as defined in claim 3; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.40. The compound of formula (I) according to claim 3, wherein one of R2and R3 represents —O-alkyl containing no more than 4 carbon atoms,substituted with —CO—NR7R8, —NR7R8, alkoxy, or alkoxy—NR7R8; R, R1, R4,R5, R6, R7 and R8 are as defined in claim 3; or a stereoisomer, aracemate, an enantiomer or a diastereoisomer of said compound of formula(I); or a pharmaceutically acceptable addition salt of said compound offormula (I) with a mineral or organic acid or a mineral or organic base.41. The compound of formula (I) according to claim 3, wherein one R2 andR3 represents —O-alkyl containing no more than 4 carbon atoms,substituted with —CO—NR7R8 or —NR7R8; R, R1, R4, R5, R6, R7 and R8 areas defined in claim 3; or a stereoisomer, a racemate, an enantiomer or adiastereoisomer of said compound of formula (I); or a pharmaceuticallyacceptable addition salt of said compound of formula (I) with a mineralor organic acid or a mineral or organic base.
 42. A pharmaceuticalcomposition comprising at least one compound according to claim 3 andone or more pharmaceutically acceptable excipients.